{"matching_results": 30823, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1603, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1259}, {"key": "negative", "matching_results": 334}, {"key": "neutral", "matching_results": 9}]}]}, {"key": "watchlistnews.com", "matching_results": 731, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 556}, {"key": "negative", "matching_results": 175}]}]}, {"key": "tickerreport.com", "matching_results": 720, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 613}, {"key": "negative", "matching_results": 104}, {"key": "neutral", "matching_results": 3}]}]}, {"key": "dailypolitical.com", "matching_results": 709, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 578}, {"key": "negative", "matching_results": 131}]}]}, {"key": "freelancer.com.co", "matching_results": 700, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 654}, {"key": "negative", "matching_results": 43}, {"key": "neutral", "matching_results": 3}]}]}, {"key": "zolmax.com", "matching_results": 616, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 449}, {"key": "negative", "matching_results": 166}]}]}, {"key": "marketscreener.com", "matching_results": 594, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 404}, {"key": "negative", "matching_results": 188}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "thelincolnianonline.com", "matching_results": 565, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 422}, {"key": "negative", "matching_results": 142}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "theolympiareport.com", "matching_results": 454, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 316}, {"key": "negative", "matching_results": 138}]}]}, {"key": "findmarketresearch.org", "matching_results": 424, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 340}, {"key": "negative", "matching_results": 84}]}]}]}], "results": [{"id": "f-x5CyrUTCF9YbeWSBBQguzntUFP4hju6N57DWO1iKhB20x1IKNh0YTBhY9cVzQ6", "result_metadata": {"score": 37.682297}, "author": "Swapna", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.545752, "label": "negative"}, "text": "Mn", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}], "sentiment": {"document": {"score": -0.372922, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Dengue Vaccine", "keywords": [{"text": "Dengue Vaccine"}]}, "sentence": "Dengue Vaccine is projected to be valued at more than US$ 1250 Mn by 2027 |", "object": {"text": "projected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Dengue Vaccine", "keywords": [{"text": "Dengue Vaccine"}]}, "sentence": "Dengue Vaccine is projected to be valued at more than US$ 1250 Mn by 2027 |", "object": {"text": "valued at more than US$ 1250 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Dengue Vaccine", "keywords": [{"text": "Dengue Vaccine"}]}, "sentence": "Dengue Vaccine is projected to be valued at more than US$ 1250 Mn by 2027 |", "object": {"text": "at more than US$ 1250 Mn by 2027 |", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "value", "tense": "past"}, "text": "is projected to be valued", "normalized": "be project to be value"}}], "concepts": [{"text": "Dengue fever", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Dengue_fever"}], "categories": [{"score": 0.918287, "label": "/health and fitness/disease"}, {"score": 0.908342, "label": "/health and fitness/disease/epidemic"}, {"score": 0.809989, "label": "/health and fitness/disease/cold and flu"}], "relations": [], "keywords": [{"text": "Dengue Vaccine", "sentiment": {"score": -0.372922, "label": "negative"}, "relevance": 0.998229, "count": 1}, {"text": "US", "sentiment": {"score": -0.372922, "label": "negative"}, "relevance": 0.755544, "count": 1}, {"text": "Mn", "sentiment": {"score": -0.372922, "label": "negative"}, "relevance": 0.036753, "count": 1}]}, "crawl_date": "2018-11-19T22:54:21Z", "url": "https://www.findmarketresearch.org/2018/11/dengue-vaccine-market-is-projected-to-be-valued-at-more-than-us-1250-mn-by-2027/", "host": "findmarketresearch.org", "text": "Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-19T11:33:00+05:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": -0.5609, "label": "negative"}, "text": "dengue", "relevance": 0.806153, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Dengue fever", "dbpedia_resource": "http://dbpedia.org/resource/Dengue_fever"}}, {"count": 3, "sentiment": {"score": -0.128492, "label": "negative"}, "text": "Mn", "relevance": 0.423342, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 2, "sentiment": {"score": -0.616433, "label": "negative"}, "text": "Asia-Pacific", "relevance": 0.35689, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi S.A.", "relevance": 0.342797, "type": "Company", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.248827, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.245269, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": -0.750475, "label": "negative"}, "text": "Latin America", "relevance": 0.219897, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biological E. Limited", "relevance": 0.217826, "type": "Company", "disambiguation": {"subtype": [], "name": "Biological E. Limited", "dbpedia_resource": "http://dbpedia.org/resource/Biological_E._Limited"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Panacea Biotech Ltd.", "relevance": 0.216431, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Butantan Institute", "relevance": 0.208575, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck & Co. Inc.", "relevance": 0.198472, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.193294, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "17.3%", "relevance": 0.193294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "17.4%", "relevance": 0.193294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "70.3%", "relevance": 0.193294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.193294, "type": "TwitterHandle"}], "sentiment": {"document": {"score": -0.574775, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Burdening occurrence of dengue fever across the Asia-Pacific region", "keywords": [{"text": "dengue fever"}, {"text": "Asia-Pacific region"}, {"text": "occurrence"}]}, "sentence": "Burdening occurrence of dengue fever across the Asia-Pacific region has prompted the demand for effective vaccines and medications to supress this viral malaise.", "object": {"text": "the demand for effective vaccines and medications", "keywords": [{"text": "effective vaccines"}, {"text": "demand"}, {"text": "medications"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has prompted", "normalized": "have prompt"}}, {"subject": {"text": "Burdening occurrence of dengue fever across the Asia-Pacific region", "keywords": [{"text": "dengue fever"}, {"text": "Asia-Pacific region"}, {"text": "occurrence"}]}, "sentence": "Burdening occurrence of dengue fever across the Asia-Pacific region has prompted the demand for effective vaccines and medications to supress this viral malaise.", "object": {"text": "the demand for effective vaccines and medications to supress this viral malaise", "keywords": [{"text": "viral malaise"}, {"text": "effective vaccines"}, {"text": "demand"}, {"text": "medications"}]}, "action": {"verb": {"text": "prompt", "tense": "past"}, "text": "has prompted", "normalized": "have prompt"}}, {"subject": {"text": "several pharmaceutical companies", "keywords": [{"text": "pharmaceutical companies"}], "entities": []}, "sentence": " While several pharmaceutical companies are striving to develop a cure for dengue, the fever\u2019s incidence rate in Asia-Pacific is rising at an alarming rate.", "object": {"text": "to develop a cure for dengue", "keywords": [{"text": "dengue"}, {"text": "cure"}], "entities": [{"type": "HealthCondition", "text": "dengue", "disambiguation": {"subtype": [], "name": "Dengue fever", "dbpedia_resource": "http://dbpedia.org/resource/Dengue_fever"}}]}, "action": {"verb": {"text": "strive", "tense": "present"}, "text": "striving", "normalized": "strive"}}, {"subject": {"text": "several pharmaceutical companies", "keywords": [{"text": "pharmaceutical companies"}], "entities": []}, "sentence": " While several pharmaceutical companies are striving to develop a cure for dengue, the fever\u2019s incidence rate in Asia-Pacific is rising at an alarming rate.", "object": {"text": "a cure for dengue", "keywords": [{"text": "dengue"}, {"text": "cure"}], "entities": [{"type": "HealthCondition", "text": "dengue", "disambiguation": {"subtype": [], "name": "Dengue fever", "dbpedia_resource": "http://dbpedia.org/resource/Dengue_fever"}}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "are striving to develop", "normalized": "be strive to develop"}}, {"subject": {"text": "the fever\u2019s incidence rate in Asia-Pacific", "keywords": [{"text": "incidence rate"}, {"text": "Asia-Pacific"}, {"text": "fever"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " While several pharmaceutical companies are striving to develop a cure for dengue, the fever\u2019s incidence rate in Asia-Pacific is rising at an alarming rate.", "object": {"text": "rising at an alarming rate", "keywords": [{"text": "rate"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the fever\u2019s incidence rate in Asia-Pacific", "keywords": [{"text": "incidence rate"}, {"text": "Asia-Pacific"}, {"text": "fever"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " While several pharmaceutical companies are striving to develop a cure for dengue, the fever\u2019s incidence rate in Asia-Pacific is rising at an alarming rate.", "object": {"text": "at an alarming rate", "keywords": [{"text": "rate"}]}, "action": {"verb": {"text": "rise", "tense": "present"}, "text": "is rising", "normalized": "be rise"}}, {"subject": {"text": "by Future Market Insights", "keywords": [{"text": "Future Market Insights"}]}, "sentence": " A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "object": {"text": "A recent report", "keywords": [{"text": "recent report"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "A recent report published by Future Market Insights", "keywords": [{"text": "Future Market Insights"}, {"text": "recent report"}]}, "sentence": " A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "object": {"text": "that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific", "keywords": [{"text": "global dengue vaccines"}, {"text": "Asia-Pacific"}, {"text": "70.3"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "Quantity", "text": "70.3"}]}, "action": {"verb": {"text": "predict", "tense": "present"}, "text": "predicts", "normalized": "predict"}}, {"subject": {"text": "by Asia-Pacific", "keywords": [{"text": "Asia-Pacific"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "object": {"text": "an estimated 70.3% of global dengue vaccines market", "keywords": [{"text": "global dengue vaccines"}, {"text": "70.3"}, {"text": "market"}], "entities": [{"type": "Quantity", "text": "70.3"}]}, "action": {"verb": {"text": "dominate", "tense": "future"}, "text": "will be dominated", "normalized": "will be dominate"}}, {"subject": {"text": "the region", "keywords": [{"text": "region"}]}, "sentence": " Through 2027, the region will continue to be the largest market for dengue vaccines, procuring a majority revenue share and projecting revenue growth at a 17.4% CAGR.", "action": {"verb": {"text": "continue", "tense": "future"}, "text": "will continue to be", "normalized": "will continue to be"}}, {"subject": {"text": "the region", "keywords": [{"text": "region"}]}, "sentence": " Through 2027, the region will continue to be the largest market for dengue vaccines, procuring a majority revenue share and projecting revenue growth at a 17.4% CAGR.", "object": {"text": "the largest market", "keywords": [{"text": "largest market"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will continue to be", "normalized": "will continue to be"}}, {"subject": {"text": "$ 288.7 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$ 288.7"}]}, "sentence": " Future Market Insights also observes Latin America as the second-largest market for dengue vaccines, and is expected to rake in US$ 288.7 Mn towards the end of 2027.", "object": {"text": "in US", "entities": []}, "action": {"verb": {"text": "rake", "tense": "future"}, "text": "is expected to rake", "normalized": "be expect to rake"}}, {"subject": {"text": "The report, titled \u201cDengue Vaccines Market: Global Industry Analysis and Opportunity Assessment, 2017-2027,\u201d", "keywords": [{"text": "Dengue Vaccines Market"}, {"text": "Global Industry Analysis"}, {"text": "Opportunity Assessment"}]}, "sentence": " The report, titled \u201cDengue Vaccines Market: Global Industry Analysis and Opportunity Assessment, 2017-2027,\u201d expects that more and more pharmaceutical giants from across the globe will be partaking in the market\u2019s growth in the years to come.", "object": {"text": "that more and more pharmaceutical giants from across the globe will be partaking in the market\u2019s growth in the years to come", "keywords": [{"text": "pharmaceutical giants"}, {"text": "globe"}, {"text": "market"}, {"text": "growth"}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "expects", "normalized": "expect"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "object": {"text": "witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd.", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "Biological E. Limited"}, {"text": "Panacea Biotech"}, {"text": "Sanofi S.A."}], "entities": [{"type": "Company", "text": "Sanofi S.A.", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"type": "Company", "text": "Biological E. Limited", "disambiguation": {"subtype": [], "name": "Biological E. Limited", "dbpedia_resource": "http://dbpedia.org/resource/Biological_E._Limited"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Organization", "text": "Butantan Institute"}, {"type": "Company", "text": "Panacea Biotech Ltd."}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "object": {"text": "active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development", "keywords": [{"text": "Panacea Biotech Ltd."}, {"text": "Takeda Pharmaceutical Company"}, {"text": "Biological E. Limited"}, {"text": "Sanofi S.A."}], "entities": [{"type": "Company", "text": "Sanofi S.A.", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"type": "Company", "text": "Biological E. Limited", "disambiguation": {"subtype": [], "name": "Biological E. Limited", "dbpedia_resource": "http://dbpedia.org/resource/Biological_E._Limited"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Organization", "text": "Butantan Institute"}, {"type": "Company", "text": "Panacea Biotech Ltd."}]}, "action": {"verb": {"text": "witness", "tense": "present"}, "text": "is witnessing", "normalized": "be witness"}}, {"subject": {"text": "by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "GlaxoSmithKline plc"}, {"text": "Biological E. Limited"}, {"text": "Co. Inc."}], "entities": [{"type": "Company", "text": "Biological E. Limited", "disambiguation": {"subtype": [], "name": "Biological E. Limited", "dbpedia_resource": "http://dbpedia.org/resource/Biological_E._Limited"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Organization", "text": "Butantan Institute"}]}, "sentence": " Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "object": {"text": "vaccines", "keywords": [{"text": "vaccines"}]}, "action": {"verb": {"text": "formulate", "tense": "past"}, "text": "being formulated", "normalized": "be formulate"}}, {"subject": {"text": "government institutes", "keywords": [{"text": "government institutes"}]}, "sentence": " The report further reveals that government institutes will remain the largest end-users of dengue vaccines in the world.", "action": {"verb": {"text": "remain", "tense": "future"}, "text": "will remain", "normalized": "will remain"}}, {"subject": {"text": "a little less than US$ 650 Mn worth of revenues", "keywords": [{"text": "Mn worth"}, {"text": "revenues"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": " Through 2027, a little less than US$ 650 Mn worth of revenues is expected to arise from sales of dengue vaccines across government institutes.", "object": {"text": "from sales of dengue vaccines across government institutes", "keywords": [{"text": "dengue vaccines"}, {"text": "sales"}, {"text": "government"}]}, "action": {"verb": {"text": "arise", "tense": "future"}, "text": "is expected to arise", "normalized": "be expect to arise"}}, {"subject": {"text": "hospitals", "keywords": [{"text": "hospitals"}]}, "sentence": " Meanwhile, hospitals will also dominate the market by registering a 17.3% revenue CAGR.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "dominate", "tense": "future"}, "text": "will also dominate", "normalized": "will also dominate"}}, {"subject": {"text": "hospitals", "keywords": [{"text": "hospitals"}]}, "sentence": " Meanwhile, hospitals will also dominate the market by registering a 17.3% revenue CAGR.", "object": {"text": "a 17.3% revenue CAGR", "keywords": [{"text": "revenue CAGR"}], "entities": [{"type": "Quantity", "text": "17.3"}]}, "action": {"verb": {"text": "register", "tense": "present"}, "text": "registering", "normalized": "register"}}, {"subject": {"text": "The market", "keywords": [{"text": "market"}]}, "sentence": " The market, at present, will witness sales of the sole of vaccine, Dengvaxia, developed by Sanofi.", "object": {"text": "sales of the sole of vaccine, Dengvaxia, developed by Sanofi", "keywords": [{"text": "Sanofi"}, {"text": "sole"}, {"text": "vaccine"}, {"text": "sales"}], "entities": [{"type": "Company", "text": "Sanofi S.A.", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}]}, "action": {"verb": {"text": "witness", "tense": "future"}, "text": "will witness", "normalized": "will witness"}}, {"subject": {"text": "factors shaping up the dynamics of global dengue vaccines market", "keywords": [{"text": "global dengue vaccines"}, {"text": "factors"}, {"text": "dynamics"}, {"text": "market"}], "entities": []}, "sentence": " Furthermore, factors shaping up the dynamics of global dengue vaccines market, also compiled in the report, are:", "action": {"verb": {"text": "compile", "tense": "past"}, "text": "compiled", "normalized": "compile"}}, {"subject": {"text": "the economic turmoil in Latin America", "keywords": [{"text": "economic turmoil"}, {"text": "Latin America"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "sentence": " Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market\u2019s growth at a macroeconomic level", "object": {"text": "projected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global market\u2019s growth", "keywords": [{"text": "global market"}, {"text": "growth"}], "entities": []}, "sentence": " Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market\u2019s growth at a macroeconomic level", "object": {"text": "at a macroeconomic level", "keywords": [{"text": "macroeconomic level"}]}, "action": {"verb": {"text": "impact", "tense": "future"}, "text": "is projected to impact", "normalized": "be project to impact"}}, {"subject": {"text": "growth", "keywords": [{"text": "growth"}]}, "sentence": " Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market\u2019s growth at a macroeconomic level", "object": {"text": "the global market", "keywords": [{"text": "global market"}], "entities": []}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "lack of skilled professionals and unavailability of optimum diagnostic systems", "keywords": [{"text": "optimum diagnostic systems"}, {"text": "skilled professionals"}, {"text": "lack"}, {"text": "unavailability"}]}, "sentence": " However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease", "object": {"text": "rise", "keywords": [{"text": "rise"}]}, "action": {"verb": {"text": "give", "tense": "past"}, "text": "has given", "normalized": "have give"}}, {"subject": {"text": "dengue fever", "keywords": [{"text": "dengue fever"}]}, "sentence": " However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease", "object": {"text": "being treated as an undistinguished febrile disease", "keywords": [{"text": "undistinguished febrile disease"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "dengue fever", "keywords": [{"text": "dengue fever"}]}, "sentence": " However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease", "object": {"text": "treated as an undistinguished febrile disease", "keywords": [{"text": "undistinguished febrile disease"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "being", "normalized": "be"}}, {"subject": {"text": "dengue fever", "keywords": [{"text": "dengue fever"}]}, "sentence": " However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease", "object": {"text": "as an undistinguished febrile disease", "keywords": [{"text": "undistinguished febrile disease"}]}, "action": {"verb": {"text": "treat", "tense": "past"}, "text": "is being treated", "normalized": "be be treat"}}, {"subject": {"text": "The global market for dengue vaccines", "keywords": [{"text": "dengue vaccines"}, {"text": "global market"}], "entities": []}, "sentence": " The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group", "object": {"text": "an opportunistic breakthrough", "keywords": [{"text": "opportunistic breakthrough"}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "holds", "normalized": "hold"}}, {"subject": {"text": "drugmakers", "keywords": [{"text": "drugmakers"}]}, "sentence": " The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group", "object": {"text": "effective vaccines", "keywords": [{"text": "effective vaccines"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "develop", "normalized": "develop"}}, {"subject": {"text": "dengue vaccines", "keywords": [{"text": "dengue vaccines"}]}, "sentence": " On the long run, the global market for dengue vaccines, which is presently valued at close to US$ 250 Mn, will soar vigorously to rake in US$ 1,250.6 Mn revenues by the end of 2027.", "object": {"text": "presently valued at close to US$ 250 Mn,", "keywords": [{"text": "Mn"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "dengue vaccines", "keywords": [{"text": "dengue vaccines"}]}, "sentence": " On the long run, the global market for dengue vaccines, which is presently valued at close to US$ 250 Mn, will soar vigorously to rake in US$ 1,250.6 Mn revenues by the end of 2027.", "object": {"text": "at close to US$ 250 Mn", "keywords": [{"text": "Mn"}]}, "action": {"verb": {"text": "value", "tense": "past"}, "text": "valued", "normalized": "value"}}, {"subject": {"text": "the global market for dengue vaccines, which is presently valued at close to US$ 250 Mn,", "keywords": [{"text": "dengue vaccines"}, {"text": "global market"}, {"text": "Mn"}], "entities": []}, "sentence": " On the long run, the global market for dengue vaccines, which is presently valued at close to US$ 250 Mn, will soar vigorously to rake in US$ 1,250.6 Mn revenues by the end of 2027.", "action": {"verb": {"text": "soar", "tense": "future"}, "text": "will soar", "normalized": "will soar"}}], "concepts": [{"text": "Fever", "relevance": 0.972167, "dbpedia_resource": "http://dbpedia.org/resource/Fever"}, {"text": "Dengue fever", "relevance": 0.759806, "dbpedia_resource": "http://dbpedia.org/resource/Dengue_fever"}, {"text": "Malaria", "relevance": 0.730133, "dbpedia_resource": "http://dbpedia.org/resource/Malaria"}, {"text": "GlaxoSmithKline", "relevance": 0.723071, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Pharmaceutical industry", "relevance": 0.710269, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Economics", "relevance": 0.659496, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}, {"text": "Revenue", "relevance": 0.625078, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.612347, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Asia-Pacific", "relevance": 0.591665, "dbpedia_resource": "http://dbpedia.org/resource/Asia-Pacific"}, {"text": "Dengue", "relevance": 0.57362, "dbpedia_resource": "http://dbpedia.org/resource/Dengue"}, {"text": "Biotechnology", "relevance": 0.522927, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology"}, {"text": "Sanofi-Aventis", "relevance": 0.51673, "dbpedia_resource": "http://dbpedia.org/resource/Sanofi-Aventis"}, {"text": "Macroeconomics", "relevance": 0.493112, "dbpedia_resource": "http://dbpedia.org/resource/Macroeconomics"}, {"text": "Aspirin", "relevance": 0.455566, "dbpedia_resource": "http://dbpedia.org/resource/Aspirin"}, {"text": "Pharmacology", "relevance": 0.453272, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Vaccine", "relevance": 0.438429, "dbpedia_resource": "http://dbpedia.org/resource/Vaccine"}, {"text": "HPV vaccine", "relevance": 0.41898, "dbpedia_resource": "http://dbpedia.org/resource/HPV_vaccine"}], "categories": [{"score": 0.975514, "label": "/health and fitness/disease"}, {"score": 0.904593, "label": "/health and fitness/disease/epidemic"}, {"score": 0.774834, "label": "/health and fitness/disease/cold and flu"}], "relations": [{"type": "agentOf", "sentence": "A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "score": 0.711673, "arguments": [{"text": "Future Market Insights", "location": [347, 369], "entities": [{"type": "Organization", "text": "Future Market Insights"}]}, {"text": "published", "location": [334, 343], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "agentOf", "sentence": "A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "score": 0.85028, "arguments": [{"text": "Future Market Insights", "location": [347, 369], "entities": [{"type": "Organization", "text": "Future Market Insights"}]}, {"text": "predicts", "location": [370, 378], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.617823, "arguments": [{"text": "Merck & Co. Inc.", "location": [1283, 1299], "entities": [{"type": "Organization", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1182, 1191], "entities": [{"type": "Organization", "text": "pharmaceutical companies"}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.564008, "arguments": [{"text": "Vabiotech", "location": [1301, 1310], "entities": [{"type": "Organization", "text": "Vabiotech", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1182, 1191], "entities": [{"type": "Organization", "text": "pharmaceutical companies"}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.537026, "arguments": [{"text": "Butantan Institute", "location": [1312, 1330], "entities": [{"type": "Organization", "text": "Butantan Institute", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1182, 1191], "entities": [{"type": "Organization", "text": "pharmaceutical companies"}]}]}, {"type": "employedBy", "sentence": "The report further reveals that government institutes will remain the largest end-users of dengue vaccines in the world.", "score": 0.943342, "arguments": [{"text": "institutes", "location": [1442, 1452], "entities": [{"type": "Person", "text": "institutes"}]}, {"text": "government", "location": [1431, 1441], "entities": [{"type": "GeopoliticalEntity", "text": "government", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Through 2027, a little less than US$ 650 Mn worth of revenues is expected to arise from sales of dengue vaccines across government institutes.", "score": 0.931626, "arguments": [{"text": "institutes", "location": [1651, 1661], "entities": [{"type": "Person", "text": "institutes"}]}, {"text": "government", "location": [1640, 1650], "entities": [{"type": "GeopoliticalEntity", "text": "government", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "The report further reveals that government institutes will remain the largest end-users of dengue vaccines in the world.", "score": 0.748367, "arguments": [{"text": "institutes", "location": [1442, 1452], "entities": [{"type": "Person", "text": "institutes"}]}, {"text": "dengue vaccines", "location": [1490, 1505], "entities": [{"type": "HealthCondition", "text": "dengue vaccines"}]}]}, {"type": "hasAttribute", "sentence": "Through 2027, a little less than US$ 650 Mn worth of revenues is expected to arise from sales of dengue vaccines across government institutes.", "score": 0.821245, "arguments": [{"text": "institutes", "location": [1651, 1661], "entities": [{"type": "Person", "text": "institutes"}]}, {"text": "dengue vaccines", "location": [1617, 1632], "entities": [{"type": "HealthCondition", "text": "dengue vaccines"}]}]}, {"type": "agentOf", "sentence": "Through 2027, a little less than US$ 650 Mn worth of revenues is expected to arise from sales of dengue vaccines across government institutes.", "score": 0.59603, "arguments": [{"text": "Mn", "location": [1561, 1563], "entities": [{"type": "Person", "text": "Mn"}]}, {"text": "arise", "location": [1597, 1602], "entities": [{"type": "EventCommunication", "text": "arise"}]}]}, {"type": "instrumentOf", "sentence": "Furthermore, factors shaping up the dynamics of global dengue vaccines market, also compiled in the report, are: Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market's growth at a macroeconomic level Live attenuated vaccines are being developed & produced economically, thereby comforting vaccine makers as well as patients However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group Request for Report customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-1763 On the long run, the global market for dengue vaccines, which is presently valued at close to US$ 250 Mn,", "score": 0.244216, "arguments": [{"text": "dengue", "location": [2000, 2006], "entities": [{"type": "HealthCondition", "text": "dengue fever"}]}, {"text": "outbreak", "location": [1988, 1996], "entities": [{"type": "NaturalDisaster", "text": "outbreak"}]}]}, {"type": "locatedAt", "sentence": "Furthermore, factors shaping up the dynamics of global dengue vaccines market, also compiled in the report, are: Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market's growth at a macroeconomic level Live attenuated vaccines are being developed & produced economically, thereby comforting vaccine makers as well as patients However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group Request for Report customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-1763 On the long run, the global market for dengue vaccines, which is presently valued at close to US$ 250 Mn,", "score": 0.390575, "arguments": [{"text": "outbreak", "location": [1988, 1996], "entities": [{"type": "NaturalDisaster", "text": "outbreak"}]}, {"text": "countries", "location": [2018, 2027], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Furthermore, factors shaping up the dynamics of global dengue vaccines market, also compiled in the report, are: Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market's growth at a macroeconomic level Live attenuated vaccines are being developed & produced economically, thereby comforting vaccine makers as well as patients However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group Request for Report customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-1763 On the long run, the global market for dengue vaccines, which is presently valued at close to US$ 250 Mn,", "score": 0.581907, "arguments": [{"text": "countries", "location": [2018, 2027], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Latin America", "location": [2053, 2066], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "Furthermore, factors shaping up the dynamics of global dengue vaccines market, also compiled in the report, are: Apart from the burdening outbreak of dengue in several countries, the economic turmoil in Latin America is projected to impact the global market's growth at a macroeconomic level Live attenuated vaccines are being developed & produced economically, thereby comforting vaccine makers as well as patients However, lack of skilled professionals and unavailability of optimum diagnostic systems has given rise to cases where dengue fever is being treated as an undistinguished febrile disease The global market for dengue vaccines holds an opportunistic breakthrough when drugmakers will be able to successfully develop effective vaccines for all age group Request for Report customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-1763 On the long run, the global market for dengue vaccines, which is presently valued at close to US$ 250 Mn,", "score": 0.75557, "arguments": [{"text": "drugmakers", "location": [2531, 2541], "entities": [{"type": "Person", "text": "drugmakers"}]}, {"text": "dengue vaccines", "location": [2474, 2489], "entities": [{"type": "HealthCondition", "text": "dengue vaccines"}]}]}, {"type": "timeOf", "sentence": "A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "score": 0.781182, "arguments": [{"text": "2017", "location": [387, 391], "entities": [{"type": "Date", "text": "2017"}]}, {"text": "predicts", "location": [370, 378], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "populationOf", "sentence": "will soar vigorously to rake in US$ 1,250.6 Mn revenues by the end of 2027.", "score": 0.580184, "arguments": [{"text": "1,250.6", "location": [2866, 2873], "entities": [{"type": "Cardinal", "text": "1,250.6"}]}, {"text": "US$", "location": [2862, 2865], "entities": [{"type": "GeopoliticalEntity", "text": "US$"}]}]}, {"type": "locatedAt", "sentence": "A recent report published by Future Market Insights predicts that in 2017, an estimated 70.3% of global dengue vaccines market will be dominated by Asia-Pacific.", "score": 0.550537, "arguments": [{"text": "Pacific", "location": [471, 478], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}, {"text": "Asia", "location": [466, 470], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "Future Market Insights also observes Latin America as the second-largest market for dengue vaccines, and is expected to rake in US$ 288.7 Mn towards the end of 2027.", "score": 0.508396, "arguments": [{"text": "Mn", "location": [785, 787], "entities": [{"type": "Person", "text": "Mn"}]}, {"text": "dengue vaccines", "location": [731, 746], "entities": [{"type": "HealthCondition", "text": "dengue vaccines"}]}]}, {"type": "hasAttribute", "sentence": "Through 2027, a little less than US$ 650 Mn worth of revenues is expected to arise from sales of dengue vaccines across government institutes.", "score": 0.556831, "arguments": [{"text": "Mn", "location": [1561, 1563], "entities": [{"type": "Person", "text": "Mn"}]}, {"text": "dengue vaccines", "location": [1617, 1632], "entities": [{"type": "HealthCondition", "text": "dengue vaccines"}]}]}, {"type": "populationOf", "sentence": "Future Market Insights also observes Latin America as the second-largest market for dengue vaccines, and is expected to rake in US$ 288.7 Mn towards the end of 2027.", "score": 0.574871, "arguments": [{"text": "288.7", "location": [779, 784], "entities": [{"type": "Cardinal", "text": "288.7"}]}, {"text": "US$", "location": [775, 778], "entities": [{"type": "GeopoliticalEntity", "text": "US$"}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.816563, "arguments": [{"text": "drugmaker", "location": [1123, 1132], "entities": [{"type": "Person", "text": "Sanofi S.A."}]}, {"text": "French", "location": [1116, 1122], "entities": [{"type": "GeopoliticalEntity", "text": "French", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.703763, "arguments": [{"text": "Biological E. Limited", "location": [1200, 1221], "entities": [{"type": "Organization", "text": "Biological E. Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1182, 1191], "entities": [{"type": "Organization", "text": "pharmaceutical companies"}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.829056, "arguments": [{"text": "Takeda Pharmaceutical Company Limited", "location": [1223, 1260], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1182, 1191], "entities": [{"type": "Organization", "text": "pharmaceutical companies"}]}]}, {"type": "partOfMany", "sentence": "Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under multiple phases of development.", "score": 0.579328, "arguments": [{"text": "GlaxoSmithKline plc", "location": [1262, 1281], "entities": [{"type": "Organization", "text": "GlaxoSmithKline plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1182, 1191], "entities": [{"type": "Organization", "text": "pharmaceutical companies"}]}]}], "keywords": [{"text": "Future Market Insights", "sentiment": {"score": -0.67407, "label": "negative"}, "relevance": 0.81618, "count": 2}, {"text": "occurrence of dengue fever", "sentiment": {"score": -0.519307, "label": "negative"}, "relevance": 0.750249, "count": 1}, {"text": "global dengue vaccines market", "sentiment": {"score": -0.689106, "label": "negative"}, "relevance": 0.742915, "count": 1}, {"text": "effective vaccines", "sentiment": {"score": -0.525263, "label": "negative"}, "relevance": 0.720067, "count": 2}, {"text": "recent report", "sentiment": {"score": -0.689106, "label": "negative"}, "relevance": 0.702708, "count": 1}, {"text": "dengue", "sentiment": {"score": -0.829124, "label": "negative"}, "relevance": 0.660601, "count": 1}, {"text": "largest market", "sentiment": {"score": 0.697686, "label": "positive"}, "relevance": 0.657464, "count": 1}, {"text": "pharmaceutical companies", "sentiment": {"score": -0.829124, "label": "negative"}, "relevance": 0.623678, "count": 1}, {"text": "Asia-Pacific region", "sentiment": {"score": -0.519307, "label": "negative"}, "relevance": 0.61729, "count": 1}, {"text": "Latin America", "sentiment": {"score": -0.819279, "label": "negative"}, "relevance": 0.599493, "count": 2}, {"text": "report", "sentiment": {"score": -0.596426, "mixed": "1", "label": "negative"}, "relevance": 0.593935, "count": 3}, {"text": "dengue vaccines", "sentiment": {"score": -0.384248, "mixed": "1", "label": "negative"}, "relevance": 0.562886, "count": 4}, {"text": "lack of skilled professionals", "sentiment": {"score": -0.531179, "label": "negative"}, "relevance": 0.55478, "count": 1}, {"text": "economic turmoil", "sentiment": {"score": -0.93683, "label": "negative"}, "relevance": 0.553588, "count": 1}, {"text": "companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.552781, "count": 1}, {"text": "market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.552708, "count": 3}, {"text": "vaccines", "sentiment": {"score": -0.93683, "label": "negative"}, "relevance": 0.550064, "count": 2}, {"text": "burdening outbreak of dengue", "sentiment": {"score": -0.93683, "label": "negative"}, "relevance": 0.548845, "count": 1}, {"text": "global market", "sentiment": {"score": -0.531179, "label": "negative"}, "relevance": 0.547718, "count": 2}, {"text": "region", "sentiment": {"score": 0.697686, "label": "positive"}, "relevance": 0.543012, "count": 1}, {"text": "factors", "sentiment": {"score": -0.93683, "label": "negative"}, "relevance": 0.54165, "count": 1}, {"text": "Global Industry Analysis", "sentiment": {"score": 0.553906, "label": "positive"}, "relevance": 0.541326, "count": 1}, {"text": "Dengue Vaccines Market", "sentiment": {"score": 0.553906, "label": "positive"}, "relevance": 0.540775, "count": 1}, {"text": "dengue fever", "sentiment": {"score": -0.531179, "label": "negative"}, "relevance": 0.538687, "count": 1}, {"text": "US", "sentiment": {"score": -0.630184, "label": "negative"}, "relevance": 0.536865, "count": 4}, {"text": "second-largest market", "sentiment": {"score": -0.658804, "label": "negative"}, "relevance": 0.534147, "count": 1}, {"text": "Biological E. Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53311, "count": 1}, {"text": "dynamics of global dengue vaccines market", "sentiment": {"score": -0.93683, "label": "negative"}, "relevance": 0.527557, "count": 1}, {"text": "Sanofi", "sentiment": {"score": -0.93683, "label": "negative"}, "relevance": 0.522306, "count": 1}, {"text": "countries", "sentiment": {"score": -0.93683, "label": "negative"}, "relevance": 0.521047, "count": 1}, {"text": "alarming rate", "sentiment": {"score": -0.829124, "label": "negative"}, "relevance": 0.518822, "count": 1}, {"text": "Merck", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516461, "count": 1}, {"text": "hospitals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516373, "count": 1}, {"text": "cure", "sentiment": {"score": -0.829124, "label": "negative"}, "relevance": 0.515567, "count": 1}, {"text": "active participation of French drugmaker", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51522, "count": 1}, {"text": "globe", "sentiment": {"score": 0.553906, "label": "positive"}, "relevance": 0.515163, "count": 1}, {"text": "cases", "sentiment": {"score": -0.531179, "label": "negative"}, "relevance": 0.515152, "count": 1}, {"text": "end", "sentiment": {"score": -0.658804, "label": "negative"}, "relevance": 0.514609, "count": 2}, {"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513691, "count": 1}, {"text": "demand", "sentiment": {"score": -0.519307, "label": "negative"}, "relevance": 0.513291, "count": 1}, {"text": "long run", "sentiment": {"score": -0.531179, "label": "negative"}, "relevance": 0.512974, "count": 1}, {"text": "medications", "sentiment": {"score": -0.519307, "label": "negative"}, "relevance": 0.509625, "count": 1}, {"text": "largest end-users of dengue vaccines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507928, "count": 1}, {"text": "unavailability of optimum diagnostic systems", "sentiment": {"score": -0.531179, "label": "negative"}, "relevance": 0.507287, "count": 1}, {"text": "sales of dengue vaccines", "sentiment": {"score": -0.760372, "label": "negative"}, "relevance": 0.506761, "count": 1}, {"text": "patients", "sentiment": {"score": -0.531179, "label": "negative"}, "relevance": 0.5054, "count": 1}, {"text": "world", "sentiment": {"score": -0.760372, "label": "negative"}, "relevance": 0.5054, "count": 1}, {"text": "Opportunity Assessment", "sentiment": {"score": 0.553906, "label": "positive"}, "relevance": 0.497334, "count": 1}, {"text": "Sanofi S.A.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.496339, "count": 1}, {"text": "majority revenue share", "sentiment": {"score": 0.697686, "label": "positive"}, "relevance": 0.495862, "count": 1}]}, "extracted_metadata": {"sha1": "fbbeb6d614c229167e9f7479c8bcbceebacde9e1", "filename": "1542668061375.zip-46923b82503efd0215a9569cdc427614.xml", "file_type": "json"}, "external_links": ["https://www.futuremarketinsights.com/reports/dengue-vaccines-market", "https://www.futuremarketinsights.com/customization-available/rep-gb-1763"], "title": "Dengue Vaccine is projected to be valued at more than US$ 1250 Mn by 2027 |", "forum_title": "Research Insights | Find Market Research - Part 16"}, {"id": "dsizZATbAwYh-ma6F1Wdye22MZiaxy7MZlpObKVF1Ew-28iymwTDUZPcLm2HYgr3", "result_metadata": {"score": 37.11242}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "European Commission", "relevance": 0.33, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MarketScreener", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "clearance from the European Commission", "keywords": [{"text": "clearance"}, {"text": "European Commission"}], "entities": [{"type": "Organization", "text": "European Commission"}]}, "sentence": "Takeda Pharmaceutical : receives clearance from the European Commission for the proposed acquisition of Shire plc | MarketScreener", "object": {"text": "for the proposed acquisition of Shire plc | MarketScreener", "keywords": [{"text": "proposed acquisition"}, {"text": "Shire plc"}, {"text": "MarketScreener"}], "entities": [{"type": "Company", "text": "Shire plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"type": "Company", "text": "MarketScreener"}]}, "action": {"verb": {"text": "receive", "tense": "present"}, "text": "receives", "normalized": "receive"}}], "concepts": [{"text": "European Commission", "relevance": 0.971008, "dbpedia_resource": "http://dbpedia.org/resource/European_Commission"}, {"text": "European Union", "relevance": 0.937672, "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}, {"text": "European Parliament", "relevance": 0.858258, "dbpedia_resource": "http://dbpedia.org/resource/European_Parliament"}, {"text": "European Council", "relevance": 0.852116, "dbpedia_resource": "http://dbpedia.org/resource/European_Council"}], "categories": [{"score": 0.934212, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.864158, "label": "/business and industrial/pharmaceutical industry"}], "relations": [{"type": "agentOf", "sentence": "Takeda Pharmaceutical : receives clearance from the European Commission for the proposed acquisition of Shire plc | MarketScreener", "score": 0.772422, "arguments": [{"text": "European Commission", "location": [52, 71], "entities": [{"type": "Organization", "text": "European Commission", "disambiguation": {"subtype": ["Multigov"]}}]}, {"text": "acquisition", "location": [89, 100], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "Takeda Pharmaceutical : receives clearance from the European Commission for the proposed acquisition of Shire plc | MarketScreener", "score": 0.760582, "arguments": [{"text": "Shire plc", "location": [104, 113], "entities": [{"type": "Organization", "text": "Shire plc"}]}, {"text": "acquisition", "location": [89, 100], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}], "keywords": [{"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.994296, "count": 1}, {"text": "European Commission", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.970551, "count": 1}, {"text": "clearance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.805238, "count": 1}, {"text": "acquisition of Shire plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.324083, "count": 1}, {"text": "MarketScreener", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.057927, "count": 1}]}, "crawl_date": "2018-11-20T14:43:31Z", "url": "https://www.marketscreener.com/TAKEDA-PHARMACEUTICAL-CO-6491073/news/Takeda-Pharmaceutical-receives-clearance-from-the-European-Commission-for-the-proposed-acquisition-27639295/", "host": "marketscreener.com", "text": "February 2018. # # # Attachments Original document Permalink Disclaimer Takeda Pharmaceutical Co.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-20T00:00:00Z", "enriched_text": {"entities": [{"count": 21, "sentiment": {"score": 0.115469, "label": "positive"}, "text": "Takeda", "relevance": 0.917196, "type": "Person"}, {"count": 12, "sentiment": {"score": -0.0287704, "label": "negative"}, "text": "Takeda", "relevance": 0.774659, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.544087, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 12, "sentiment": {"score": -0.483046, "label": "negative"}, "text": "Vedolizumab", "relevance": 0.457438, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and Chief Executive Officer of Takeda", "relevance": 0.420931, "type": "JobTitle"}, {"count": 8, "sentiment": {"score": -0.325145, "label": "negative"}, "text": "Shire", "relevance": 0.411146, "type": "Organization"}, {"count": 4, "sentiment": {"score": -0.646413, "label": "negative"}, "text": "bowel disease", "relevance": 0.391495, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd.", "relevance": 0.390803, "type": "Company"}, {"count": 4, "sentiment": {"score": -0.736207, "label": "negative"}, "text": "ulcerative colitis", "relevance": 0.332178, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.307519, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 3, "sentiment": {"score": -0.758918, "label": "negative"}, "text": "Crohn", "relevance": 0.294924, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Crohn's disease", "dbpedia_resource": "http://dbpedia.org/resource/Crohn's_disease"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States", "relevance": 0.287201, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.282042, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Securities and Exchange Commission", "relevance": 0.278955, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "solicitation", "relevance": 0.27809, "type": "Crime"}, {"count": 3, "sentiment": {"score": 0.529623, "label": "positive"}, "text": "EC", "relevance": 0.276355, "type": "Organization", "disambiguation": {"subtype": [], "name": "European Economic Community", "dbpedia_resource": "http://dbpedia.org/resource/European_Economic_Community"}}, {"count": 6, "sentiment": {"score": 0.0777938, "label": "positive"}, "text": "Dealing Disclosures", "relevance": 0.268574, "type": "Company"}, {"count": 4, "sentiment": {"score": 0.238306, "label": "positive"}, "text": "Shire", "relevance": 0.260818, "type": "Company"}, {"count": 3, "sentiment": {"score": 0.579111, "label": "positive"}, "text": "European Commission", "relevance": 0.259315, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "EGM", "relevance": 0.259184, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.74301, "label": "positive"}, "text": "Takashi Okubo", "relevance": 0.259118, "type": "Person"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.257994, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0.485501, "label": "positive"}, "text": "Tokyo", "relevance": 0.257093, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Entyvio", "relevance": 0.251645, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.248563, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "progressive multifocal leukoencephalopathy", "relevance": 0.248165, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Progressive multifocal leukoencephalopathy", "dbpedia_resource": "http://dbpedia.org/resource/Progressive_multifocal_leukoencephalopathy"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazilian Administrative Council for Economic Defense", "relevance": 0.247894, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.428323, "label": "negative"}, "text": "Entyvio", "relevance": 0.246119, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.437544, "label": "negative"}, "text": "IBD", "relevance": 0.241943, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Inflammatory bowel disease", "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "INTEX Osaka", "relevance": 0.240811, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Investor Relations", "relevance": 0.240775, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jersey court", "relevance": 0.240236, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "gastrointestinal tract", "relevance": 0.239381, "type": "Anatomy"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "EU", "relevance": 0.239128, "type": "Organization", "disambiguation": {"subtype": ["BuildingFunction"], "name": "University", "dbpedia_resource": "http://dbpedia.org/resource/University"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "European Union", "relevance": 0.238267, "type": "Organization", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kazumi Kobayashi", "relevance": 0.23821, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tsuyoshi Tada", "relevance": 0.23801, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.639078, "label": "positive"}, "text": "Elissa Johnsen", "relevance": 0.237532, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Christophe Weber", "relevance": 0.237285, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.213998, "label": "negative"}, "text": "celiac disease", "relevance": 0.234749, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Coeliac disease", "dbpedia_resource": "http://dbpedia.org/resource/Coeliac_disease"}}, {"count": 1, "sentiment": {"score": -0.837916, "label": "negative"}, "text": "Crohn's disease", "relevance": 0.233809, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan Fair Trade Commission", "relevance": 0.233776, "type": "Organization", "disambiguation": {"subtype": [], "name": "Fair Trade Commission (Japan)", "dbpedia_resource": "http://dbpedia.org/resource/Fair_Trade_Commission_(Japan)"}}, {"count": 2, "sentiment": {"score": -0.464166, "label": "negative"}, "text": "epinephrine", "relevance": 0.232794, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.227738, "label": "negative"}, "text": "UC", "relevance": 0.231163, "type": "Organization", "disambiguation": {"subtype": ["Location", "Company", "PeriodicalPublisher", "CollegeUniversity"], "name": "University of Chicago", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Chicago"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States Federal Trade Commission", "relevance": 0.230818, "type": "Organization", "disambiguation": {"subtype": [], "name": "Federal Trade Commission", "dbpedia_resource": "http://dbpedia.org/resource/Federal_Trade_Commission"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.230693, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.336475, "label": "negative"}, "text": "paracetamol", "relevance": 0.227788, "type": "Drug"}, {"count": 2, "sentiment": {"score": -0.737746, "label": "negative"}, "text": "tuberculosis", "relevance": 0.226097, "type": "HealthCondition"}], "sentiment": {"document": {"score": -0.315208, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Takeda Pharmaceutical Company Limited (' Takeda ')", "keywords": [{"text": "Takeda"}, {"text": "Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Takeda"}]}, "sentence": "Takeda Pharmaceutical Company Limited (' Takeda ') announces that it has received clearance from the European Commission (the ' EC ') for the proposed acquisition of Shire plc (' Shire ') announced on May 8, 2018 (the ' Acquisition ').", "object": {"text": "that it has received clearance from the European Commission (the ' EC ') for the proposed acquisition of Shire plc (' Shire ') announced on May 8, 2018 (the ' Acquisition ')", "keywords": [{"text": "Shire plc"}, {"text": "proposed acquisition"}, {"text": "European Commission"}, {"text": "EC"}], "entities": [{"type": "Organization", "text": "European Commission"}, {"type": "Organization", "text": "EC", "disambiguation": {"subtype": ["Organization"], "name": "European Economic Community", "dbpedia_resource": "http://dbpedia.org/resource/European_Economic_Community"}}, {"type": "Company", "text": "Shire plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"type": "Person", "text": "Shire"}]}, "action": {"verb": {"text": "announce", "tense": "present"}, "text": "announces", "normalized": "announce"}}, {"subject": {"text": "Shire plc (' Shire ')", "keywords": [{"text": "Shire plc"}], "entities": [{"type": "Company", "text": "Shire plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"type": "Person", "text": "Shire"}]}, "sentence": "Takeda Pharmaceutical Company Limited (' Takeda ') announces that it has received clearance from the European Commission (the ' EC ') for the proposed acquisition of Shire plc (' Shire ') announced on May 8, 2018 (the ' Acquisition ').", "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "The EC's approval", "keywords": [{"text": "EC"}, {"text": "approval"}], "entities": [{"type": "Organization", "text": "EC", "disambiguation": {"subtype": ["Organization"], "name": "European Economic Community", "dbpedia_resource": "http://dbpedia.org/resource/European_Economic_Community"}}]}, "sentence": " The EC's approval is conditional on Takeda and Shire fulfilling commitments given to the EC in connection with the clearance.", "object": {"text": "conditional on Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "commitments", "keywords": [{"text": "commitments"}]}, "sentence": " The EC's approval is conditional on Takeda and Shire fulfilling commitments given to the EC in connection with the clearance.", "object": {"text": "to the EC", "keywords": [{"text": "EC"}], "entities": [{"type": "Organization", "text": "EC", "disambiguation": {"subtype": ["Organization"], "name": "European Economic Community", "dbpedia_resource": "http://dbpedia.org/resource/European_Economic_Community"}}]}, "action": {"verb": {"text": "give", "tense": "past"}, "text": "given", "normalized": "give"}}, {"subject": {"text": "Takeda and Shire", "keywords": [{"text": "Takeda"}, {"text": "Shire"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Shire"}]}, "sentence": " Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "object": {"text": "committed to divest the pipeline compound SHP647 and certain associated rights", "keywords": [{"text": "pipeline compound"}, {"text": "rights"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Takeda and Shire", "keywords": [{"text": "Takeda"}, {"text": "Shire"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Shire"}]}, "sentence": " Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "object": {"text": "the pipeline compound SHP647 and certain associated rights", "keywords": [{"text": "pipeline compound"}, {"text": "rights"}]}, "action": {"verb": {"text": "divest", "tense": "future"}, "text": "have committed to divest", "normalized": "have commit to divest"}}, {"subject": {"text": "rights", "keywords": [{"text": "rights"}]}, "sentence": " The divestment of SHP647 and certain associated rights is not a condition to the completion of the Acquisition.", "object": {"text": "to the completion of the Acquisition", "keywords": [{"text": "completion"}, {"text": "Acquisition"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "The divestment of SHP647 and certain associated rights", "keywords": [{"text": "divestment"}, {"text": "SHP647"}, {"text": "rights"}]}, "sentence": " The divestment of SHP647 and certain associated rights is not a condition to the completion of the Acquisition.", "object": {"text": "not a condition to the completion of the Acquisition", "keywords": [{"text": "completion"}, {"text": "Acquisition"}, {"text": "condition"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "SHP647", "keywords": [{"text": "SHP647"}]}, "sentence": " SHP647 is an exciting pipeline compound and Takeda expects the asset to attract interest from a number of potential buyers.", "object": {"text": "an exciting pipeline compound", "keywords": [{"text": "exciting pipeline compound"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an exciting pipeline compound and Takeda", "keywords": [{"text": "exciting pipeline compound"}, {"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " SHP647 is an exciting pipeline compound and Takeda expects the asset to attract interest from a number of potential buyers.", "object": {"text": "the asset to attract interest from a number of potential buyers", "keywords": [{"text": "potential buyers"}, {"text": "asset"}, {"text": "number"}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "expects", "normalized": "expect"}}, {"subject": {"text": "Entyvio", "keywords": [{"text": "Entyvio"}], "entities": [{"type": "Location", "text": "Entyvio", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Takeda remains committed to Entyvio, which has been granted marketing authorization in more than 60 countries and is the cornerstone of Takeda's diverse specialty gastrointestinal portfolio.", "object": {"text": "been granted marketing authorization in more than 60 countries", "keywords": [{"text": "authorization"}, {"text": "countries"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Entyvio", "keywords": [{"text": "Entyvio"}], "entities": [{"type": "Location", "text": "Entyvio", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Takeda remains committed to Entyvio, which has been granted marketing authorization in more than 60 countries and is the cornerstone of Takeda's diverse specialty gastrointestinal portfolio.", "object": {"text": "granted marketing authorization in more than 60 countries", "keywords": [{"text": "marketing authorization"}, {"text": "countries"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "marketing authorization in more than 60 countries", "keywords": [{"text": "marketing authorization"}, {"text": "countries"}]}, "sentence": " Takeda remains committed to Entyvio, which has been granted marketing authorization in more than 60 countries and is the cornerstone of Takeda's diverse specialty gastrointestinal portfolio.", "object": {"text": "Entyvio", "keywords": [{"text": "Entyvio"}], "entities": [{"type": "Location", "text": "Entyvio", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "grant", "tense": "past"}, "text": "granted", "normalized": "grant"}}, {"subject": {"text": "Entyvio", "keywords": [{"text": "Entyvio"}], "entities": [{"type": "Location", "text": "Entyvio", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Takeda remains committed to Entyvio, which has been granted marketing authorization in more than 60 countries and is the cornerstone of Takeda's diverse specialty gastrointestinal portfolio.", "object": {"text": "authorization", "keywords": [{"text": "authorization"}]}, "action": {"verb": {"text": "market", "tense": "present"}, "text": "has been granted marketing", "normalized": "have be grant market"}}, {"subject": {"text": "'We", "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " 'We are very pleased to have secured clearance from the European Commission, the final regulatory approval required to proceed with our acquisition of Shire,' said Christophe Weber, President and Chief Executive Officer of Takeda.", "object": {"text": "clearance", "keywords": [{"text": "clearance"}]}, "action": {"verb": {"text": "secure", "tense": "past"}, "text": "to have secured", "normalized": "to have secure"}}, {"subject": {"text": "Christophe Weber, President and Chief Executive Officer of Takeda", "keywords": [{"text": "Chief Executive Officer"}, {"text": "Christophe Weber"}, {"text": "Takeda"}, {"text": "President"}], "entities": [{"type": "Person", "text": "Christophe Weber"}, {"type": "JobTitle", "text": "President and Chief Executive Officer of Takeda"}]}, "sentence": " 'We are very pleased to have secured clearance from the European Commission, the final regulatory approval required to proceed with our acquisition of Shire,' said Christophe Weber, President and Chief Executive Officer of Takeda.", "object": {"text": "'We are very pleased to have secured clearance from the European Commission, the final regulatory approval required to proceed with our acquisition of Shire", "keywords": [{"text": "final regulatory approval"}, {"text": "European Commission"}, {"text": "clearance"}, {"text": "Shire"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Organization", "text": "European Commission"}, {"type": "Person", "text": "Shire"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "'We", "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "sentence": " 'We are another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader, and after several months of constructive dialogue, we are optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.'", "object": {"text": "another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader,", "keywords": [{"text": "R&D-driven biopharmaceutical leader"}, {"text": "step"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "'We", "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "sentence": " 'We are another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader, and after several months of constructive dialogue, we are optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.'", "object": {"text": "a global, values-based, R&D-driven biopharmaceutical leader,", "keywords": [{"text": "R&D-driven biopharmaceutical leader"}]}, "action": {"verb": {"text": "create", "tense": "future"}, "text": "creating", "normalized": "create"}}, {"subject": {"text": "we"}, "sentence": " 'We are another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader, and after several months of constructive dialogue, we are optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.'", "object": {"text": "optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination", "keywords": [{"text": "significant long-term value"}, {"text": "powerful combination"}, {"text": "creation potential"}, {"text": "shareholders"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The Acquisition", "keywords": [{"text": "Acquisition"}]}, "sentence": " The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "object": {"text": "now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities", "keywords": [{"text": "Brazilian Administrative Council"}, {"text": "Japan Fair Trade"}, {"text": "United States Federal"}, {"text": "Trade Commission"}], "entities": [{"type": "Organization", "text": "European Commission"}, {"type": "Organization", "text": "United States Federal Trade Commission", "disambiguation": {"subtype": [], "name": "Federal Trade Commission", "dbpedia_resource": "http://dbpedia.org/resource/Federal_Trade_Commission"}}, {"type": "Organization", "text": "Japan Fair Trade Commission", "disambiguation": {"subtype": [], "name": "Fair Trade Commission (Japan)", "dbpedia_resource": "http://dbpedia.org/resource/Fair_Trade_Commission_(Japan)"}}, {"type": "Organization", "text": "State Administration"}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Country"]}}, {"type": "Organization", "text": "Brazilian Administrative Council for Economic Defense"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The Acquisition", "keywords": [{"text": "Acquisition"}]}, "sentence": " The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "object": {"text": "clearances", "keywords": [{"text": "clearances"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " As announced on November 12, 2018, Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the ' EGM ') to vote on the necessary matters relating to the proposed Acquisition.", "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " As announced on November 12, 2018, Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the ' EGM ') to vote on the necessary matters relating to the proposed Acquisition.", "object": {"text": "published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the ' EGM ') to vote on the necessary matters relating to the proposed Acquisition", "keywords": [{"text": "Extraordinary General Meeting"}, {"text": "necessary matters"}, {"text": "EGM"}, {"text": "Shareholders"}], "entities": [{"type": "Company", "text": "EGM"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " As announced on November 12, 2018, Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the ' EGM ') to vote on the necessary matters relating to the proposed Acquisition.", "object": {"text": "a circular"}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "has published", "normalized": "have publish"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " As announced on November 12, 2018, Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the ' EGM ') to vote on the necessary matters relating to the proposed Acquisition.", "object": {"text": "an Extraordinary General Meeting of Shareholders (the ' EGM ')", "keywords": [{"text": "Extraordinary General Meeting"}, {"text": "EGM"}, {"text": "Shareholders"}], "entities": [{"type": "Company", "text": "EGM"}]}, "action": {"verb": {"text": "hold", "tense": "future"}, "text": "to hold", "normalized": "to hold"}}, {"subject": {"text": "The EGM", "keywords": [{"text": "EGM"}], "entities": [{"type": "Company", "text": "EGM"}]}, "sentence": " The EGM is to be convened at 10:00 a.m. (Tokyo time) on December 5, 2018 at INTEX Osaka, Hall 6B Zone.", "object": {"text": "convened"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019.", "object": {"text": "its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019", "keywords": [{"text": "previously announced expectation"}, {"text": "necessary shareholder approvals"}, {"text": "Jersey court"}, {"text": "sanction"}], "entities": [{"type": "Organization", "text": "Jersey court"}]}, "action": {"verb": {"text": "confirm", "tense": "present"}, "text": "confirms", "normalized": "confirm"}}, {"subject": {"text": "its"}, "sentence": " Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019.", "object": {"text": "expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019", "keywords": [{"text": "necessary shareholder approvals"}, {"text": "Jersey court"}, {"text": "expectation"}, {"text": "sanction"}], "entities": [{"type": "Organization", "text": "Jersey court"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "by the Jersey court", "keywords": [{"text": "Jersey court"}], "entities": [{"type": "Organization", "text": "Jersey court"}]}, "sentence": " Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019.", "object": {"text": "the necessary shareholder approvals and sanction of the scheme of arrangement", "keywords": [{"text": "necessary shareholder approvals"}, {"text": "sanction"}, {"text": "arrangement"}, {"text": "scheme"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "receiving", "normalized": "receive"}}, {"subject": {"text": "Further announcements", "keywords": [{"text": "announcements"}]}, "sentence": " Further announcements will be made as appropriate.", "object": {"text": "made as appropriate"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Further announcements", "keywords": [{"text": "announcements"}]}, "sentence": " Further announcements will be made as appropriate.", "object": {"text": "as appropriate"}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "will be made", "normalized": "will be make"}}, {"subject": {"text": "Vedolizumab", "keywords": [{"text": "Vedolizumab"}], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, "sentence": " Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation.", "object": {"text": "a gut-selective biologic", "keywords": [{"text": "gut-selective biologic"}], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Vedolizumab", "keywords": [{"text": "Vedolizumab"}], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, "sentence": " Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation.", "object": {"text": "approved as an intravenous (IV) formulation", "keywords": [{"text": "formulation"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Vedolizumab", "keywords": [{"text": "Vedolizumab"}], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, "sentence": " Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation.", "object": {"text": "as an intravenous (IV) formulation", "keywords": [{"text": "formulation"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "is approved", "normalized": "be approve"}}, {"subject": {"text": "1 It"}, "sentence": " 1 It is a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not vascular cell adhesion molecule 1 (VCAM-1). 2 MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.", "object": {"text": "a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin", "keywords": [{"text": "humanized monoclonal antibody"}, {"text": "alpha4beta7 integrin"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a humanized monoclonal antibody", "keywords": [{"text": "humanized monoclonal antibody"}]}, "sentence": " 1 It is a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not vascular cell adhesion molecule 1 (VCAM-1). 2 MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.", "object": {"text": "the binding of alpha4beta7 integrin", "keywords": [{"text": "integrin"}, {"text": "binding"}]}, "action": {"verb": {"text": "inhibit", "tense": "present"}, "text": "inhibiting", "normalized": "inhibit"}}, {"subject": {"text": "not vascular cell adhesion molecule 1 (VCAM-1). 2 MAdCAM-1", "keywords": [{"text": "cell adhesion molecule"}]}, "sentence": " 1 It is a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not vascular cell adhesion molecule 1 (VCAM-1). 2 MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.", "action": {"verb": {"text": "express", "tense": "past"}, "text": "expressed", "normalized": "express"}}, {"subject": {"text": "3 The alpha4beta7 integrin", "keywords": [{"text": "alpha4beta7 integrin"}]}, "sentence": " 3 The alpha4beta7 integrin is expressed on a subset of circulating white blood cells.These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn's disease (CD). 4 5 By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.", "action": {"verb": {"text": "express", "tense": "past"}, "text": "is expressed", "normalized": "be express"}}, {"subject": {"text": "white blood cells.These cells", "keywords": [{"text": "blood cells.These cells"}]}, "sentence": " 3 The alpha4beta7 integrin is expressed on a subset of circulating white blood cells.These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn's disease (CD). 4 5 By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.", "object": {"text": "shown to play a role in mediating the inflammatory process", "keywords": [{"text": "inflammatory process"}, {"text": "role"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "the inflammatory process", "keywords": [{"text": "inflammatory process"}]}, "sentence": " 3 The alpha4beta7 integrin is expressed on a subset of circulating white blood cells.These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn's disease (CD). 4 5 By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.", "object": {"text": "in ulcerative colitis (UC) and Crohn's disease (CD)", "keywords": [{"text": "ulcerative colitis"}, {"text": "Crohn"}, {"text": "UC"}, {"text": "disease"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"type": "Organization", "text": "UC", "disambiguation": {"subtype": ["Location", "Company", "PeriodicalPublisher", "CollegeUniversity"], "name": "University of Chicago", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Chicago"}}, {"type": "HealthCondition", "text": "Crohn", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Crohn's disease", "dbpedia_resource": "http://dbpedia.org/resource/Crohn's_disease"}}]}, "action": {"verb": {"text": "mediate", "tense": "present"}, "text": "mediating", "normalized": "mediate"}}, {"subject": {"text": "vedolizumab", "keywords": [{"text": "vedolizumab"}], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, "sentence": " 3 The alpha4beta7 integrin is expressed on a subset of circulating white blood cells.These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn's disease (CD). 4 5 By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.", "object": {"text": "alpha4beta7 integrin", "keywords": [{"text": "integrin"}]}, "action": {"verb": {"text": "inhibit", "tense": "present"}, "text": "inhibiting", "normalized": "inhibit"}}, {"subject": {"text": "vedolizumab", "keywords": [{"text": "vedolizumab"}], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, "sentence": " 3 The alpha4beta7 integrin is expressed on a subset of circulating white blood cells.These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn's disease (CD). 4 5 By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.", "object": {"text": "the ability of certain white blood cells to infiltrate gut tissues", "keywords": [{"text": "gut tissues"}, {"text": "certain white blood"}, {"text": "cells"}, {"text": "ability"}]}, "action": {"verb": {"text": "limit", "tense": "future"}, "text": "may limit", "normalized": "may limit"}}, {"subject": {"text": "Vedolizumab IV", "keywords": [{"text": "Vedolizumab"}]}, "sentence": " Vedolizumab IV is approved for the treatment of adult patients with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "approved"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Vedolizumab IV", "keywords": [{"text": "Vedolizumab"}]}, "sentence": " Vedolizumab IV is approved for the treatment of adult patients with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist", "keywords": [{"text": "severely active UC"}, {"text": "tumor necrosis factor-alpha"}, {"text": "inadequate response"}, {"text": "conventional therapy"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "is approved", "normalized": "be approve"}}, {"subject": {"text": "active UC and CD", "keywords": [{"text": "active UC"}, {"text": "CD"}]}, "sentence": " Vedolizumab IV is approved for the treatment of adult patients with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "an inadequate response", "keywords": [{"text": "inadequate response"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "have had", "normalized": "have have"}}, {"subject": {"text": "Vedolizumab IV", "keywords": [{"text": "Vedolizumab"}]}, "sentence": " Vedolizumab IV has been granted marketing authorization in over 60 countries, including the United States and European Union, with over 200,000 patient years of exposure to date.", "object": {"text": "been granted marketing authorization in over 60 countries", "keywords": [{"text": "authorization"}, {"text": "countries"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Vedolizumab IV", "keywords": [{"text": "Vedolizumab"}]}, "sentence": " Vedolizumab IV has been granted marketing authorization in over 60 countries, including the United States and European Union, with over 200,000 patient years of exposure to date.", "object": {"text": "granted marketing authorization in over 60 countries, including the United States and European Union,", "keywords": [{"text": "marketing authorization"}, {"text": "United States"}, {"text": "European Union"}, {"text": "countries"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Organization", "text": "European Union", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "the United States and European Union", "keywords": [{"text": "United States"}, {"text": "European Union"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Organization", "text": "European Union", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "sentence": " Vedolizumab IV has been granted marketing authorization in over 60 countries, including the United States and European Union, with over 200,000 patient years of exposure to date.", "object": {"text": "60 countries", "keywords": [{"text": "countries"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist", "keywords": [{"text": "active ulcerative colitis"}, {"text": "tumor necrosis factor-alpha"}, {"text": "inadequate response"}, {"text": "conventional therapy"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "sentence": " Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "Vedolizumab", "keywords": [{"text": "Vedolizumab"}], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, "action": {"verb": {"text": "indicate", "tense": "past"}, "text": "is indicated", "normalized": "be indicate"}}, {"subject": {"text": "active ulcerative colitis", "keywords": [{"text": "colitis"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "sentence": " Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u03b1) antagonist.", "object": {"text": "an inadequate response", "keywords": [{"text": "inadequate response"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "have had", "normalized": "have have"}}], "concepts": [{"text": "Ulcerative colitis", "relevance": 0.984381, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "Inflammatory bowel disease", "relevance": 0.726194, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "Crohn's disease", "relevance": 0.684553, "dbpedia_resource": "http://dbpedia.org/resource/Crohn's_disease"}, {"text": "U.S. Securities and Exchange Commission", "relevance": 0.546638, "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}, {"text": "Inflammation", "relevance": 0.517925, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Immune system", "relevance": 0.423132, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.420525, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Opportunistic infection", "relevance": 0.360985, "dbpedia_resource": "http://dbpedia.org/resource/Opportunistic_infection"}], "categories": [{"score": 0.979859, "label": "/health and fitness/disease"}, {"score": 0.905464, "label": "/health and fitness/therapy"}, {"score": 0.773156, "label": "/health and fitness/disorders"}], "relations": [{"type": "agentOf", "sentence": "Takeda Pharmaceutical Company Limited (' Takeda ') announces that it has received clearance from the European Commission (the ' EC ') for the proposed acquisition of Shire plc (' Shire ') announced on May 8, 2018 (the ' Acquisition ').", "score": 0.624053, "arguments": [{"text": "Takeda Pharmaceutical Company Limited", "location": [0, 37], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announces", "location": [51, 60], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Takeda Pharmaceutical Company Limited (' Takeda ') announces that it has received clearance from the European Commission (the ' EC ') for the proposed acquisition of Shire plc (' Shire ') announced on May 8, 2018 (the ' Acquisition ').", "score": 0.503556, "arguments": [{"text": "Takeda", "location": [41, 47], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announces", "location": [51, 60], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "ownerOf", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.385469, "arguments": [{"text": "SHP647", "location": [549, 555], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "compound", "location": [540, 548], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "ownerOf", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.351216, "arguments": [{"text": "SHP647", "location": [621, 627], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "compound", "location": [612, 620], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "affectedBy", "sentence": "The divestment of SHP647 and certain associated rights is not a condition to the completion of the Acquisition.", "score": 0.371696, "arguments": [{"text": "SHP647", "location": [677, 683], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "Acquisition", "location": [758, 769], "entities": [{"type": "EventLegal", "text": "Acquisition"}]}]}, {"type": "locatedAt", "sentence": "SHP647 is an exciting pipeline compound and Takeda expects the asset to attract interest from a number of potential buyers.", "score": 0.806393, "arguments": [{"text": "SHP647", "location": [771, 777], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "compound", "location": [802, 810], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "affectedBy", "sentence": "Takeda remains committed to Entyvio, which has been granted marketing authorization in more than 60 countries and is the cornerstone of Takeda's diverse specialty gastrointestinal portfolio.", "score": 0.630817, "arguments": [{"text": "Takeda", "location": [895, 901], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "granted", "location": [947, 954], "entities": [{"type": "EntertainmentAward", "text": "granted"}]}]}, {"type": "agentOf", "sentence": "'We are very pleased to have secured clearance from the European Commission, the final regulatory approval required to proceed with our acquisition of Shire,' said Christophe Weber, President and Chief Executive Officer of Takeda.", "score": 0.50667, "arguments": [{"text": "our", "location": [1218, 1221], "entities": [{"type": "Person", "text": "our"}]}, {"text": "acquisition", "location": [1222, 1233], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "'We are very pleased to have secured clearance from the European Commission, the final regulatory approval required to proceed with our acquisition of Shire,' said Christophe Weber, President and Chief Executive Officer of Takeda.", "score": 0.818686, "arguments": [{"text": "Christophe Weber", "location": [1250, 1266], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [1245, 1249], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "managerOf", "sentence": "'We are very pleased to have secured clearance from the European Commission, the final regulatory approval required to proceed with our acquisition of Shire,' said Christophe Weber, President and Chief Executive Officer of Takeda.", "score": 0.638112, "arguments": [{"text": "Chief Executive Officer", "location": [1282, 1305], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "Takeda", "location": [1309, 1315], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "' The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "score": 0.617892, "arguments": [{"text": "European Commission", "location": [1654, 1673], "entities": [{"type": "Organization", "text": "European Commission", "disambiguation": {"subtype": ["Multigov"]}}]}, {"text": "Acquisition", "location": [1605, 1616], "entities": [{"type": "EventLegal", "text": "Acquisition"}]}]}, {"type": "partOf", "sentence": "' The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "score": 0.976358, "arguments": [{"text": "Federal Trade Commission", "location": [1693, 1717], "entities": [{"type": "Organization", "text": "Federal Trade Commission", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "United States", "location": [1679, 1692], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "' The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "score": 0.668326, "arguments": [{"text": "Trade Commission", "location": [1734, 1750], "entities": [{"type": "Organization", "text": "Trade Commission", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Japan Fair", "location": [1723, 1733], "entities": [{"type": "Organization", "text": "Japan Fair", "disambiguation": {"subtype": ["Sports"]}}]}]}, {"type": "affectedBy", "sentence": "Takeda Pharmaceutical Company Limited (' Takeda ') announces that it has received clearance from the European Commission (the ' EC ') for the proposed acquisition of Shire plc (' Shire ') announced on May 8, 2018 (the ' Acquisition ').", "score": 0.593828, "arguments": [{"text": "Shire plc", "location": [166, 175], "entities": [{"type": "Organization", "text": "Shire plc"}]}, {"text": "acquisition", "location": [151, 162], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "locatedAt", "sentence": "' The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "score": 0.735959, "arguments": [{"text": "State Administration", "location": [1756, 1776], "entities": [{"type": "Organization", "text": "State Administration"}]}, {"text": "Market Regulation", "location": [1781, 1798], "entities": [{"type": "Facility", "text": "Market Regulation"}]}]}, {"type": "locatedAt", "sentence": "' The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "score": 0.559683, "arguments": [{"text": "Market Regulation", "location": [1781, 1798], "entities": [{"type": "Facility", "text": "Market Regulation"}]}, {"text": "China", "location": [1802, 1807], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "' The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "score": 0.915483, "arguments": [{"text": "Administrative Council", "location": [1826, 1848], "entities": [{"type": "Person", "text": "Administrative Council"}]}, {"text": "Brazilian", "location": [1816, 1825], "entities": [{"type": "GeopoliticalEntity", "text": "Brazilian", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "' The Acquisition has now received clearances from the European Commission, the United States Federal Trade Commission, the Japan Fair Trade Commission, the State Administration for Market Regulation in China and the Brazilian Administrative Council for Economic Defense, among other regulatory authorities.", "score": 0.544314, "arguments": [{"text": "Administrative Council", "location": [1826, 1848], "entities": [{"type": "Person", "text": "Administrative Council"}]}, {"text": "Economic Defense", "location": [1853, 1869], "entities": [{"type": "Organization", "text": "Economic Defense"}]}]}, {"type": "timeOf", "sentence": "As announced on November 12, 2018, Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the ' EGM ') to vote on the necessary matters relating to the proposed Acquisition.", "score": 0.989633, "arguments": [{"text": "November 12, 2018", "location": [1923, 1940], "entities": [{"type": "Date", "text": "November 12, 2018"}]}, {"text": "announced", "location": [1910, 1919], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "As announced on November 12, 2018, Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the ' EGM ') to vote on the necessary matters relating to the proposed Acquisition.", "score": 0.920704, "arguments": [{"text": "Takeda", "location": [1942, 1948], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "announced", "location": [1910, 1919], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019.", "score": 0.962786, "arguments": [{"text": "Takeda", "location": [2255, 2261], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "confirms", "location": [2267, 2275], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019.", "score": 0.585287, "arguments": [{"text": "Takeda", "location": [2255, 2261], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "announced", "location": [2291, 2300], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Takeda aspires to advance how patients manage their disease.", "score": 0.996234, "arguments": [{"text": "Takeda", "location": [10146, 10152], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "aspires", "location": [10153, 10160], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOf", "sentence": "As announced on November 12, 2018, Takeda has published a circular containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the ' EGM ') to vote on the necessary matters relating to the proposed Acquisition.", "score": 0.459684, "arguments": [{"text": "Extraordinary General Meeting of Shareholders", "location": [2021, 2066], "entities": [{"type": "Organization", "text": "Extraordinary General Meeting of Shareholders"}]}, {"text": "its", "location": [1997, 2000], "entities": [{"type": "Organization", "text": "State Administration"}]}]}, {"type": "locatedAt", "sentence": "The EGM is to be convened at 10:00 a.m. (Tokyo time) on December 5, 2018 at INTEX Osaka, Hall 6B Zone.", "score": 0.688963, "arguments": [{"text": "INTEX Osaka", "location": [2228, 2239], "entities": [{"type": "Facility", "text": "INTEX Osaka"}]}, {"text": "Tokyo", "location": [2193, 2198], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "locatedAt", "sentence": "The EGM is to be convened at 10:00 a.m. (Tokyo time) on December 5, 2018 at INTEX Osaka, Hall 6B Zone.", "score": 0.549389, "arguments": [{"text": "Hall 6B Zone", "location": [2241, 2253], "entities": [{"type": "Person", "text": "Hall 6B Zone"}]}, {"text": "INTEX Osaka", "location": [2228, 2239], "entities": [{"type": "Facility", "text": "INTEX Osaka"}]}]}, {"type": "agentOf", "sentence": "Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019.", "score": 0.487964, "arguments": [{"text": "its", "location": [2276, 2279], "entities": [{"type": "Organization", "text": "State Administration"}]}, {"text": "announced", "location": [2291, 2300], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "timeOf", "sentence": "Takeda Pharmaceutical Company Limited (' Takeda ') announces that it has received clearance from the European Commission (the ' EC ') for the proposed acquisition of Shire plc (' Shire ') announced on May 8, 2018 (the ' Acquisition ').", "score": 0.697184, "arguments": [{"text": "May 8, 2018", "location": [201, 212], "entities": [{"type": "Date", "text": "May 8, 2018"}]}, {"text": "acquisition", "location": [151, 162], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "basedIn", "sentence": "Takeda also confirms its previously announced expectation that, subject to receiving the necessary shareholder approvals and sanction of the scheme of arrangement by the Jersey court, completion of the Acquisition will take place on January 8, 2019.", "score": 0.864715, "arguments": [{"text": "court", "location": [2432, 2437], "entities": [{"type": "Organization", "text": "court", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Jersey", "location": [2425, 2431], "entities": [{"type": "GeopoliticalEntity", "text": "Jersey"}]}]}, {"type": "managerOf", "sentence": "Takeda (Investor Relations) Takashi Okubo takeda.ir.contact@takeda.com +81 3 3278 2306 Takeda (Media - inside Japan) Kazumi Kobayashi Kazumi.Kobayashi@takeda.com +81 3 3278 2095 Takeda (Media - outside Japan) Tsuyoshi Tada Tsuyoshi.Tada@takeda.com +1 617 551 2933 Elissa Johnsen Elissa.Johnsen@takeda.com +1 312 285 3203 About Entyvio \u00ae (vedolizumab) Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation.", "score": 0.263344, "arguments": [{"text": "Takeda", "location": [2643, 2649], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "Media -", "location": [2651, 2658], "entities": [{"type": "Organization", "text": "Media -"}]}]}, {"type": "managerOf", "sentence": "Takeda (Investor Relations) Takashi Okubo takeda.ir.contact@takeda.com +81 3 3278 2306 Takeda (Media - inside Japan) Kazumi Kobayashi Kazumi.Kobayashi@takeda.com +81 3 3278 2095 Takeda (Media - outside Japan) Tsuyoshi Tada Tsuyoshi.Tada@takeda.com +1 617 551 2933 Elissa Johnsen Elissa.Johnsen@takeda.com +1 312 285 3203 About Entyvio \u00ae (vedolizumab) Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation.", "score": 0.310051, "arguments": [{"text": "Takeda", "location": [2734, 2740], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "Media", "location": [2742, 2747], "entities": [{"type": "Organization", "text": "Media -"}]}]}, {"type": "basedIn", "sentence": "Takeda (Investor Relations) Takashi Okubo takeda.ir.contact@takeda.com +81 3 3278 2306 Takeda (Media - inside Japan) Kazumi Kobayashi Kazumi.Kobayashi@takeda.com +81 3 3278 2095 Takeda (Media - outside Japan) Tsuyoshi Tada Tsuyoshi.Tada@takeda.com +1 617 551 2933 Elissa Johnsen Elissa.Johnsen@takeda.com +1 312 285 3203 About Entyvio \u00ae (vedolizumab) Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation.", "score": 0.367559, "arguments": [{"text": "Media -", "location": [2651, 2658], "entities": [{"type": "Organization", "text": "Media -"}]}, {"text": "Japan", "location": [2666, 2671], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "timeOf", "sentence": "2 MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.", "score": 0.905683, "arguments": [{"text": "MAdCAM-1", "location": [3271, 3279], "entities": [{"type": "Date", "text": "MAdCAM-1"}]}, {"text": "expressed", "location": [3298, 3307], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "hasAttribute", "sentence": "6 Therapeutic Indications Ulcerative colitis Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u0251) antagonist.", "score": 0.856623, "arguments": [{"text": "patients", "location": [4268, 4276], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "ulcerative colitis", "location": [4312, 4330], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "hasAttribute", "sentence": "6 Therapeutic Indications Ulcerative colitis Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u0251) antagonist.", "score": 0.376044, "arguments": [{"text": "who", "location": [4331, 4334], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "ulcerative colitis", "location": [4312, 4330], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "partOfMany", "sentence": "Crohn's disease Vedolizumab is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF\u0251) antagonist.", "score": 0.602843, "arguments": [{"text": "Crohn", "location": [4605, 4610], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "who", "location": [4621, 4624], "entities": [{"type": "Person", "text": "patients"}]}]}, {"type": "hasAttribute", "sentence": "Infections Vedolizumab is a gut-selective integrin antagonist with no identified systemic immunosuppressive activity.", "score": 0.917841, "arguments": [{"text": "Vedolizumab", "location": [6154, 6165], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, {"text": "Infections", "location": [6143, 6153], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.719148, "arguments": [{"text": "Vedolizumab", "location": [6404, 6415], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, {"text": "infections", "location": [6481, 6491], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.55785, "arguments": [{"text": "Vedolizumab", "location": [6404, 6415], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, {"text": "tuberculosis", "location": [6500, 6512], "entities": [{"type": "HealthCondition", "text": "tuberculosis"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.493412, "arguments": [{"text": "Vedolizumab", "location": [6404, 6415], "entities": [{"type": "Person", "text": "Vedolizumab"}]}, {"text": "sepsis", "location": [6514, 6520], "entities": [{"type": "HealthCondition", "text": "sepsis"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.613335, "arguments": [{"text": "patients", "location": [6452, 6460], "entities": [{"type": "Person", "text": "Patients"}]}, {"text": "infections", "location": [6481, 6491], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Patients should be monitored closely for infections before, during and after treatment.", "score": 0.950673, "arguments": [{"text": "Patients", "location": [6927, 6935], "entities": [{"type": "Person", "text": "Patients"}]}, {"text": "infections", "location": [6968, 6978], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "agentOf", "sentence": "Takeda Pharmaceutical Company Limited (' Takeda ') announces that it has received clearance from the European Commission (the ' EC ') for the proposed acquisition of Shire plc (' Shire ') announced on May 8, 2018 (the ' Acquisition ').", "score": 0.729861, "arguments": [{"text": "Shire", "location": [179, 184], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "announced", "location": [188, 197], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.959491, "arguments": [{"text": "Shire", "location": [14695, 14700], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Report", "location": [14722, 14728], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.605086, "arguments": [{"text": "patients", "location": [6452, 6460], "entities": [{"type": "Person", "text": "Patients"}]}, {"text": "tuberculosis", "location": [6500, 6512], "entities": [{"type": "HealthCondition", "text": "tuberculosis"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.540018, "arguments": [{"text": "patients", "location": [6452, 6460], "entities": [{"type": "Person", "text": "Patients"}]}, {"text": "sepsis", "location": [6514, 6520], "entities": [{"type": "HealthCondition", "text": "sepsis"}]}]}, {"type": "hasAttribute", "sentence": "Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab.", "score": 0.628185, "arguments": [{"text": "who", "location": [6683, 6686], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "infection", "location": [6704, 6713], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Caution should be exercised when considering the use of vedolizumab in patients with a controlled chronic severe infection or a history of recurring severe infections.", "score": 0.593938, "arguments": [{"text": "patients", "location": [6830, 6838], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "infection", "location": [6872, 6881], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Some integrin antagonists and some systemic immunosuppressive agents have been associated with progressive multifocal leukoencephalopathy (PML), which is a rare and often fatal opportunistic infection caused by the John Cunningham (JC) virus.", "score": 0.88926, "arguments": [{"text": "John Cunningham", "location": [7348, 7363], "entities": [{"type": "Person", "text": "John Cunningham"}]}, {"text": "infection", "location": [7324, 7333], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Although no systemic immunosuppressive effect was noted in healthy subjects, the effects on systemic immune system function in patients with inflammatory bowel disease are not known.", "score": 0.844701, "arguments": [{"text": "patients", "location": [7631, 7639], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "inflammatory bowel disease", "location": [7645, 7671], "entities": [{"type": "HealthCondition", "text": "inflammatory bowel disease"}]}]}, {"type": "hasAttribute", "sentence": "Healthcare professionals should monitor patients on vedolizumab for any new onset or worsening of neurological signs and symptoms, and consider neurological referral if they occur.", "score": 0.789071, "arguments": [{"text": "patients", "location": [7727, 7735], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "neurological signs", "location": [7785, 7803], "entities": [{"type": "HealthCondition", "text": "neurological signs"}]}]}, {"type": "hasAttribute", "sentence": "Malignancies The risk of malignancy is increased in patients with ulcerative colitis and Crohn's disease.", "score": 0.590675, "arguments": [{"text": "patients", "location": [8424, 8432], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "ulcerative colitis", "location": [8438, 8456], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "hasAttribute", "sentence": "Malignancies The risk of malignancy is increased in patients with ulcerative colitis and Crohn's disease.", "score": 0.475228, "arguments": [{"text": "patients", "location": [8424, 8432], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "disease", "location": [8469, 8476], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "hasAttribute", "sentence": "Malignancies The risk of malignancy is increased in patients with ulcerative colitis and Crohn's disease.", "score": 0.791504, "arguments": [{"text": "Crohn", "location": [8461, 8466], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "disease", "location": [8469, 8476], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "managerOf", "sentence": "Please consult with your local regulatory agency for approved labeling in your country .", "score": 0.421848, "arguments": [{"text": "your", "location": [9532, 9536], "entities": [{"type": "Person", "text": "your"}]}, {"text": "regulatory agency", "location": [9543, 9560], "entities": [{"type": "Organization", "text": "regulatory agency"}]}]}, {"type": "employedBy", "sentence": "For U.S. audiences, please see the full Prescribing Information including Medication Guide for ENTYVIO \u00ae .", "score": 0.958765, "arguments": [{"text": "audiences", "location": [9610, 9619], "entities": [{"type": "Person", "text": "audiences"}]}, {"text": "U.S.", "location": [9605, 9609], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "timeOf", "sentence": "Takeda Pharmaceutical Company Limited (' Takeda ') announces that it has received clearance from the European Commission (the ' EC ') for the proposed acquisition of Shire plc (' Shire ') announced on May 8, 2018 (the ' Acquisition ').", "score": 0.969331, "arguments": [{"text": "May 8, 2018", "location": [201, 212], "entities": [{"type": "Date", "text": "May 8, 2018"}]}, {"text": "announced", "location": [188, 197], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "employedBy", "sentence": "7 For EU audiences, please see the Summary of Product Characteristics (SmPC) for ENTYVIO \u00ae .", "score": 0.646657, "arguments": [{"text": "audiences", "location": [9717, 9726], "entities": [{"type": "Person", "text": "audiences"}]}, {"text": "EU", "location": [9714, 9716], "entities": [{"type": "GeopoliticalEntity", "text": "European Union", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "Takeda's Commitment to Gastroenterology Gastrointestinal (GI) diseases can be complex, debilitating and life-changing.", "score": 0.996669, "arguments": [{"text": "Takeda", "location": [9801, 9807], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "Commitment", "location": [9810, 9820], "entities": [{"type": "EventCommunication", "text": "Commitment"}]}]}, {"type": "affectedBy", "sentence": "Takeda's Commitment to Gastroenterology Gastrointestinal (GI) diseases can be complex, debilitating and life-changing.", "score": 0.394161, "arguments": [{"text": "Gastroenterology\nGastrointestinal", "location": [9824, 9857], "entities": [{"type": "Organization", "text": "Gastroenterology\nGastrointestinal", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Commitment", "location": [9810, 9820], "entities": [{"type": "EventCommunication", "text": "Commitment"}]}]}, {"type": "hasAttribute", "sentence": "Additionally, Takeda is leading in areas of gastroenterology associated with high unmet need, such as inflammatory bowel disease, acid-related diseases and motility disorders.", "score": 0.468927, "arguments": [{"text": "Takeda", "location": [10221, 10227], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "inflammatory bowel disease", "location": [10309, 10335], "entities": [{"type": "HealthCondition", "text": "inflammatory bowel disease"}]}]}, {"type": "hasAttribute", "sentence": "Our GI Research & Development team is also exploring solutions in celiac disease and liver diseases, as well as scientific advancements through microbiome therapies.", "score": 0.931421, "arguments": [{"text": "team", "location": [10413, 10417], "entities": [{"type": "Person", "text": "team"}]}, {"text": "celiac disease", "location": [10449, 10463], "entities": [{"type": "HealthCondition", "text": "celiac disease"}]}]}, {"type": "hasAttribute", "sentence": "Our GI Research & Development team is also exploring solutions in celiac disease and liver diseases, as well as scientific advancements through microbiome therapies.", "score": 0.761418, "arguments": [{"text": "team", "location": [10413, 10417], "entities": [{"type": "Person", "text": "team"}]}, {"text": "liver diseases", "location": [10468, 10482], "entities": [{"type": "HealthCondition", "text": "liver diseases"}]}]}, {"type": "colleague", "sentence": "Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "score": 0.265518, "arguments": [{"text": "Takeda", "location": [11225, 11231], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "employees", "location": [11232, 11241], "entities": [{"type": "Person", "text": "employees"}]}]}, {"type": "colleague", "sentence": "Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "score": 0.361207, "arguments": [{"text": "Takeda", "location": [11312, 11318], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "partners", "location": [11321, 11329], "entities": [{"type": "Person", "text": "partners"}]}]}, {"type": "agentOf", "sentence": "Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this Announcement.", "score": 0.880516, "arguments": [{"text": "you", "location": [14477, 14480], "entities": [{"type": "Person", "text": "you"}]}, {"text": "cautioned", "location": [14495, 14504], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "timeOf", "sentence": "Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this Announcement.", "score": 0.545758, "arguments": [{"text": "date", "location": [14596, 14600], "entities": [{"type": "Date", "text": "date"}]}, {"text": "Announcement", "location": [14609, 14621], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "hasAttribute", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.6036, "arguments": [{"text": "Shire", "location": [523, 528], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "diseases", "location": [454, 462], "entities": [{"type": "HealthCondition", "text": "liver diseases"}]}]}, {"type": "timeOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.865986, "arguments": [{"text": "10-K", "location": [14737, 14741], "entities": [{"type": "Date", "text": "10-K"}]}, {"text": "Report", "location": [14722, 14728], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.984957, "arguments": [{"text": "Shire", "location": [14749, 14754], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Reports", "location": [14778, 14785], "entities": [{"type": "EventCommunication", "text": "Reports"}]}]}, {"type": "hasAttribute", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.548308, "arguments": [{"text": "Securities and Exchange Commission", "location": [14927, 14961], "entities": [{"type": "Organization", "text": "Securities and Exchange Commission", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "www.Shire.com", "location": [14984, 14997], "entities": [{"type": "Web", "text": "www.Shire.com"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.413159, "arguments": [{"text": "they", "location": [15085, 15089], "entities": [{"type": "Person", "text": "their"}]}, {"text": "Announcement", "location": [15109, 15121], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "These risk factors expressly qualify all forward-looking statements contained in this Announcement and should also be considered by the reader.", "score": 0.492954, "arguments": [{"text": "reader", "location": [15259, 15265], "entities": [{"type": "Person", "text": "reader"}]}, {"text": "Announcement", "location": [15209, 15221], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.865201, "arguments": [{"text": "Takeda", "location": [15314, 15320], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "their", "location": [15405, 15410], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.958817, "arguments": [{"text": "Shire", "location": [15324, 15329], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "their", "location": [15405, 15410], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.803988, "arguments": [{"text": "person", "location": [15337, 15343], "entities": [{"type": "Person", "text": "person"}]}, {"text": "their", "location": [15405, 15410], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "agentOf", "sentence": "Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.", "score": 0.834273, "arguments": [{"text": "Readers", "location": [15450, 15457], "entities": [{"type": "Person", "text": "Readers"}]}, {"text": "cautioned", "location": [15462, 15471], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOf", "sentence": "Publication on Website In accordance with Rule 26.1 of the Code, a copy of this Announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on November 20, 2018.", "score": 0.576713, "arguments": [{"text": "Rule", "location": [16803, 16807], "entities": [{"type": "Organization", "text": "Code\nUnder Rule"}]}, {"text": "Code", "location": [16820, 16824], "entities": [{"type": "Organization", "text": "Code"}]}]}, {"type": "hasAttribute", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.460457, "arguments": [{"text": "Takeda", "location": [557, 563], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "diseases", "location": [454, 462], "entities": [{"type": "HealthCondition", "text": "liver diseases"}]}]}, {"type": "hasAttribute", "sentence": "Takeda's Commitment to Gastroenterology Gastrointestinal (GI) diseases can be complex, debilitating and life-changing.", "score": 0.58672, "arguments": [{"text": "Takeda", "location": [9801, 9807], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "diseases", "location": [9863, 9871], "entities": [{"type": "HealthCondition", "text": "liver diseases"}]}]}, {"type": "agentOf", "sentence": "Publication on Website In accordance with Rule 26.1 of the Code, a copy of this Announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on November 20, 2018.", "score": 0.485232, "arguments": [{"text": "Code", "location": [16820, 16824], "entities": [{"type": "Organization", "text": "Code"}]}, {"text": "Announcement", "location": [16841, 16853], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "hasAttribute", "sentence": "If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.", "score": 0.824036, "arguments": [{"text": "Rule", "location": [19698, 19702], "entities": [{"type": "Organization", "text": "Code\nUnder Rule"}]}, {"text": "8.3", "location": [19703, 19706], "entities": [{"type": "Money", "text": "8.3", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "participantIn", "sentence": "Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).", "score": 0.508911, "arguments": [{"text": "persons", "location": [19889, 19896], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "concert", "location": [19907, 19914], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "locatedAt", "sentence": "You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.", "score": 0.457452, "arguments": [{"text": "Panel", "location": [20368, 20373], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "Market Surveillance Unit", "location": [20376, 20400], "entities": [{"type": "Facility", "text": "Market Surveillance Unit"}]}]}, {"type": "employedBy", "sentence": "1 Entyvio\u00ae Summary of Product Characteristics.", "score": 0.606684, "arguments": [{"text": "\u00ae Summary", "location": [20552, 20561], "entities": [{"type": "Person", "text": "\u00ae Summary"}]}, {"text": "Product Characteristics", "location": [20565, 20588], "entities": [{"type": "Organization", "text": "Summary of Product Characteristics"}]}]}, {"type": "timeOf", "sentence": "Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue.", "score": 0.862359, "arguments": [{"text": "molecule-1", "location": [20920, 20930], "entities": [{"type": "Date", "text": "molecule-1"}]}, {"text": "expressed", "location": [20949, 20958], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "# # # Attachments Original document Permalink Disclaimer Takeda Pharmaceutical Co. Ltd. published this content on 20 November 2018 and is solely responsible for the information contained herein.", "score": 0.982494, "arguments": [{"text": "Takeda Pharmaceutical Co. Ltd.", "location": [21473, 21503], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "published", "location": [21504, 21513], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "timeOf", "sentence": "# # # Attachments Original document Permalink Disclaimer Takeda Pharmaceutical Co. Ltd. published this content on 20 November 2018 and is solely responsible for the information contained herein.", "score": 0.62975, "arguments": [{"text": "November 2018", "location": [21533, 21546], "entities": [{"type": "Date", "text": "November 2018"}]}, {"text": "published", "location": [21504, 21513], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "employedBy", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.535642, "arguments": [{"text": "Shire", "location": [523, 528], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "pipeline", "location": [531, 539], "entities": [{"type": "Organization", "text": "pipeline", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "ownerOf", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.581049, "arguments": [{"text": "pipeline", "location": [531, 539], "entities": [{"type": "Organization", "text": "pipeline", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "compound", "location": [540, 548], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "ownerOf", "sentence": "Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights.", "score": 0.458079, "arguments": [{"text": "pipeline", "location": [603, 611], "entities": [{"type": "Organization", "text": "pipeline", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "compound", "location": [612, 620], "entities": [{"type": "Facility", "text": "compound"}]}]}, {"type": "ownerOf", "sentence": "SHP647 is an exciting pipeline compound and Takeda expects the asset to attract interest from a number of potential buyers.", "score": 0.650891, "arguments": [{"text": "pipeline", "location": [793, 801], "entities": [{"type": "Organization", "text": "pipeline", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "compound", "location": [802, 810], "entities": [{"type": "Facility", "text": "compound"}]}]}], "keywords": [{"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": 0.52781, "label": "positive"}, "relevance": 0.678744, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0.362506, "mixed": "1", "label": "positive"}, "relevance": 0.592768, "count": 25}, {"text": "acquisition of Shire plc", "sentiment": {"score": 0.52781, "label": "positive"}, "relevance": 0.578335, "count": 1}, {"text": "treatment of adult patients", "sentiment": {"score": -0.811548, "label": "negative"}, "relevance": 0.57154, "count": 3}, {"text": "alpha4beta7 integrin", "sentiment": {"score": -0.434911, "mixed": "1", "label": "negative"}, "relevance": 0.556778, "count": 3}, {"text": "vedolizumab", "sentiment": {"score": -0.530003, "mixed": "1", "label": "negative"}, "relevance": 0.554979, "count": 14}, {"text": "Disclosure requirements of the Code", "sentiment": {"score": 0.734496, "label": "positive"}, "relevance": 0.54585, "count": 1}, {"text": "possible combination", "sentiment": {"score": -0.604767, "label": "negative"}, "relevance": 0.54424, "count": 5}, {"text": "Shire", "sentiment": {"score": -0.329159, "mixed": "1", "label": "negative"}, "relevance": 0.542928, "count": 12}, {"text": "Further announcements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542381, "count": 1}, {"text": "Opening Position Disclosure", "sentiment": {"score": 0.619727, "label": "positive"}, "relevance": 0.537216, "count": 5}, {"text": "securities exchange offeror", "sentiment": {"score": 0.548479, "mixed": "1", "label": "positive"}, "relevance": 0.536003, "count": 9}, {"text": "risk of opportunistic infections", "sentiment": {"score": -0.776276, "label": "negative"}, "relevance": 0.535839, "count": 1}, {"text": "such patients", "sentiment": {"score": 0.853863, "label": "positive"}, "relevance": 0.534307, "count": 1}, {"text": "European Commission", "sentiment": {"score": 0.80719, "label": "positive"}, "relevance": 0.53381, "count": 3}, {"text": "securities", "sentiment": {"score": 0.513134, "label": "positive"}, "relevance": 0.533797, "count": 1}, {"text": "Statements", "sentiment": {"score": 0.707653, "label": "positive"}, "relevance": 0.533195, "count": 1}, {"text": "statements", "sentiment": {"score": 0.280919, "mixed": "1", "label": "positive"}, "relevance": 0.533195, "count": 14}, {"text": "Vedolizumab", "sentiment": {"score": 0.730593, "label": "positive"}, "relevance": 0.533073, "count": 1}, {"text": "ordinary shares", "sentiment": {"score": -0.604767, "label": "negative"}, "relevance": 0.532204, "count": 1}, {"text": "tumor necrosis factor-alpha", "sentiment": {"score": -0.772139, "label": "negative"}, "relevance": 0.532105, "count": 3}, {"text": "Shire's pipeline compound SHP647", "sentiment": {"score": -0.769706, "label": "negative"}, "relevance": 0.530842, "count": 1}, {"text": "binding of alpha4beta7 integrin", "sentiment": {"score": 0.730593, "label": "positive"}, "relevance": 0.53024, "count": 1}, {"text": "Special warnings", "sentiment": {"score": -0.493739, "label": "negative"}, "relevance": 0.530119, "count": 1}, {"text": "hypersensitivity reactions", "sentiment": {"score": -0.573836, "label": "negative"}, "relevance": 0.529805, "count": 2}, {"text": "pharmaceutical company", "sentiment": {"score": 0.947101, "label": "positive"}, "relevance": 0.529339, "count": 1}, {"text": "Announcement", "sentiment": {"score": 0.434506, "mixed": "1", "label": "positive"}, "relevance": 0.526445, "count": 10}, {"text": "transfer of securities of Shire", "sentiment": {"score": 0.513134, "label": "positive"}, "relevance": 0.525425, "count": 1}, {"text": "person", "sentiment": {"score": 0.582482, "label": "positive"}, "relevance": 0.525132, "count": 5}, {"text": "patient years of exposure", "sentiment": {"score": -0.77705, "label": "negative"}, "relevance": 0.525128, "count": 1}, {"text": "clinical studies", "sentiment": {"score": -0.648864, "label": "negative"}, "relevance": 0.524844, "count": 1}, {"text": "Securities", "sentiment": {"score": -0.761779, "label": "negative"}, "relevance": 0.522551, "count": 1}, {"text": "Market Regulation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521489, "count": 1}, {"text": "area of inflammatory bowel diseases", "sentiment": {"score": -0.769706, "label": "negative"}, "relevance": 0.521149, "count": 1}, {"text": "infections", "sentiment": {"score": -0.877453, "label": "negative"}, "relevance": 0.520607, "count": 3}, {"text": "Infusion-related reactions", "sentiment": {"score": -0.648864, "label": "negative"}, "relevance": 0.520294, "count": 1}, {"text": "monoclonal antibody", "sentiment": {"score": 0.730593, "label": "positive"}, "relevance": 0.520037, "count": 1}, {"text": "product Entyvio", "sentiment": {"score": -0.769706, "label": "negative"}, "relevance": 0.520009, "count": 1}, {"text": "severe IRR", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519634, "count": 1}, {"text": "companies", "sentiment": {"score": -0.604767, "label": "negative"}, "relevance": 0.519135, "count": 1}, {"text": "exchange", "sentiment": {"score": 0.513134, "label": "positive"}, "relevance": 0.519105, "count": 2}, {"text": "Development team", "sentiment": {"score": 0.985792, "label": "positive"}, "relevance": 0.518976, "count": 1}, {"text": "Dealing Disclosure", "sentiment": {"score": 0.527581, "label": "positive"}, "relevance": 0.518262, "count": 5}, {"text": "progressive multifocal leukoencephalopathy", "sentiment": {"score": -0.706252, "label": "negative"}, "relevance": 0.517487, "count": 1}, {"text": "Appropriate monitoring", "sentiment": {"score": 0.778665, "label": "positive"}, "relevance": 0.517231, "count": 1}, {"text": "risks", "sentiment": {"score": -0.900205, "label": "negative"}, "relevance": 0.517173, "count": 3}, {"text": "appropriate treatment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516254, "count": 2}, {"text": "markets", "sentiment": {"score": 0.85793, "label": "positive"}, "relevance": 0.515939, "count": 1}, {"text": "Vedolizumab IV", "sentiment": {"score": -0.75942, "label": "negative"}, "relevance": 0.515923, "count": 2}, {"text": "EC's approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515649, "count": 1}]}, "extracted_metadata": {"sha1": "ce74825e58ac66ffba56af876bd51e8cb16654ea", "filename": "1542725011984.zip-3709c23d23312dd860c3de593d4fc5b5.xml", "file_type": "json"}, "external_links": ["https://general.takedapharm.com/entyviopi/", "https://www.takeda.com/investors/", "https://www.takeda.com/newsroom/newsreleases/2018/takeda-receives-clearance-from-the-european-commission-for-the-proposed-acquisition-of-shire-plc2/", "https://general.takedapharm.com/entyviomg/", "https://www.takeda.com/newsroom/", "http://www.publicnow.com/view/20F2210C5A53F3609066F2480F54DFD5ACEA6FA5", "http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002782/WC500168528.pdf"], "title": "Takeda Pharmaceutical : receives clearance from the European Commission for the proposed acquisition of Shire plc | MarketScreener", "forum_title": "Stock market news - Company News  - MarketScreener.com"}, {"id": "C_uUkqDpwcp6cFO7NnKpMkTvrrusY5A6ee77uBobIZ1Mn7U--eoUF8yANuM-q0hJ", "result_metadata": {"score": 36.45837}, "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0.520402, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Cardiovascular Drugs Market", "keywords": [{"text": "Cardiovascular Drugs"}, {"text": "Market"}]}, "sentence": "Valuable Foresights on How Cardiovascular Drugs Market will Grow During 2015-2021", "action": {"verb": {"text": "Grow", "tense": "future"}, "text": "will Grow", "normalized": "will Grow"}}], "concepts": [], "categories": [{"score": 0.974521, "label": "/health and fitness"}, {"score": 0.839423, "label": "/health and fitness/disease/heart disease"}, {"score": 0.760141, "label": "/health and fitness/drugs"}], "relations": [], "keywords": [{"text": "Valuable Foresights", "sentiment": {"score": 0.520402, "label": "positive"}, "relevance": 0.961217, "count": 1}, {"text": "Cardiovascular Drugs Market", "sentiment": {"score": 0.520402, "label": "positive"}, "relevance": 0.038783, "count": 1}]}, "crawl_date": "2018-11-19T17:05:22Z", "url": "https://industrytoday.co.uk/market-research-industry-today/valuable-foresights-on-how-cardiovascular-drugs-market-will-grow-during-2015-2021/168233/168233", "host": "industrytoday.co.uk", "text": "Some of the major companies operating in the global cardiovascular drugs market are Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co.", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-19T12:19:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": -0.867064, "label": "negative"}, "text": "hypertensive heart disease", "relevance": 0.823624, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Hypertensive heart disease", "dbpedia_resource": "http://dbpedia.org/resource/Hypertensive_heart_disease"}}, {"count": 2, "sentiment": {"score": -0.911619, "label": "negative"}, "text": "inflammatory heart disease", "relevance": 0.776364, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Cardiovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}}, {"count": 3, "sentiment": {"score": -0.75901, "label": "negative"}, "text": "Cerebrovascular disease", "relevance": 0.67417, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Cerebrovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cerebrovascular_disease"}}, {"count": 3, "sentiment": {"score": -0.787412, "label": "negative"}, "text": "rheumatic fever", "relevance": 0.513896, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Persistence Market Research", "relevance": 0.476343, "type": "Company"}, {"count": 6, "sentiment": {"score": -0.375028, "label": "negative"}, "text": "Japan", "relevance": 0.471907, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 3, "sentiment": {"score": -0.0134332, "label": "negative"}, "text": "Asia", "relevance": 0.361988, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 1, "sentiment": {"score": -0.832513, "label": "negative"}, "text": "kawasaki disease", "relevance": 0.355477, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Kawasaki disease", "dbpedia_resource": "http://dbpedia.org/resource/Kawasaki_disease"}}, {"count": 2, "sentiment": {"score": -0.767521, "label": "negative"}, "text": "group A streptococcal infection", "relevance": 0.339014, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "InfectiousDisease", "RiskFactor"], "name": "Group A streptococcal infection", "dbpedia_resource": "http://dbpedia.org/resource/Group_A_streptococcal_infection"}}, {"count": 2, "sentiment": {"score": -0.450286, "label": "negative"}, "text": "North America", "relevance": 0.327842, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": -0.306977, "label": "negative"}, "text": "subarachnoid hemorrhage", "relevance": 0.287859, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Subarachnoid hemorrhage", "dbpedia_resource": "http://dbpedia.org/resource/Subarachnoid_hemorrhage"}}, {"count": 1, "sentiment": {"score": -0.337861, "label": "negative"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.254399, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tredaptive", "relevance": 0.246222, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eliquis", "relevance": 0.245132, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.244156, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.241252, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.23569, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": -0.292396, "label": "negative"}, "text": "Solvay SA", "relevance": 0.233367, "type": "Company", "disambiguation": {"subtype": [], "name": "Solvay (company)", "dbpedia_resource": "http://dbpedia.org/resource/Solvay_(company)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca PLC", "relevance": 0.232619, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.230889, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": -0.224413, "label": "negative"}, "text": "Bayer AG", "relevance": 0.229566, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Forest Laboratories Inc.", "relevance": 0.222553, "type": "Company", "disambiguation": {"subtype": [], "name": "Forest Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Forest_Laboratories"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.215534, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": -0.292396, "label": "negative"}, "text": "Pfizer Inc.", "relevance": 0.215128, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiichi Sankyo Co. Ltd.", "relevance": 0.21299, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.210933, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott Laboratories Inc.", "relevance": 0.205561, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.204768, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Spain", "relevance": 0.201599, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Kingdom of Spain (Napoleonic)", "dbpedia_resource": "http://dbpedia.org/resource/Kingdom_of_Spain_(Napoleonic)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd.", "relevance": 0.200988, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.200537, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.K.", "relevance": 0.197055, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.195098, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche Ltd.", "relevance": 0.1926, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Italy", "relevance": 0.180056, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@IndustryToday", "relevance": 0.180056, "type": "TwitterHandle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "five years", "relevance": 0.180056, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2021", "relevance": 0.180056, "type": "Quantity"}], "sentiment": {"document": {"score": -0.680416, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Cardiovascular Drugs Market", "keywords": [{"text": "Cardiovascular Drugs"}, {"text": "Market"}]}, "sentence": "Valuable Foresights on How Cardiovascular Drugs Market will Grow During 2015-2021", "action": {"verb": {"text": "Grow", "tense": "future"}, "text": "will Grow", "normalized": "will Grow"}}, {"subject": {"text": "Persistence Market Research", "keywords": [{"text": "Persistence Market Research"}], "entities": [{"type": "Company", "text": "Persistence Market Research"}]}, "sentence": " Persistence Market Research has announced the addition of the \u201cCardiovascular Drugs Market: Global Industry Analysis and Opportunity Assessment 2015- 2021\" report to their offering.", "object": {"text": "announced the addition of the \u201cCardiovascular Drugs Market: Global Industry Analysis and Opportunity Assessment 2015- 2021\" report to their offering", "keywords": [{"text": "Cardiovascular Drugs Market"}, {"text": "Global Industry Analysis"}, {"text": "Opportunity Assessment"}, {"text": "addition"}], "entities": [{"type": "Quantity", "text": "2021\""}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Persistence Market Research", "keywords": [{"text": "Persistence Market Research"}], "entities": [{"type": "Company", "text": "Persistence Market Research"}]}, "sentence": " Persistence Market Research has announced the addition of the \u201cCardiovascular Drugs Market: Global Industry Analysis and Opportunity Assessment 2015- 2021\" report to their offering.", "object": {"text": "the addition of the \u201cCardiovascular Drugs Market: Global Industry Analysis and Opportunity Assessment 2015- 2021\" report to their offering", "keywords": [{"text": "Cardiovascular Drugs Market"}, {"text": "Global Industry Analysis"}, {"text": "Opportunity Assessment"}, {"text": "addition"}], "entities": [{"type": "Quantity", "text": "2021\""}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "has announced", "normalized": "have announce"}}, {"subject": {"text": "us"}, "sentence": " Follow us on Twitter @IndustryToday", "object": {"text": "on Twitter @IndustryToday", "keywords": [{"text": "Twitter"}], "entities": [{"type": "TwitterHandle", "text": "@IndustryToday"}]}, "action": {"verb": {"text": "Follow", "tense": "present"}, "text": "Follow", "normalized": "Follow"}}, {"subject": {"text": "Cardiovascular diseases,", "keywords": [{"text": "Cardiovascular diseases"}]}, "sentence": " Cardiovascular diseases, also known as heart diseases, are diseases of heart and circulatory system.", "object": {"text": "as heart diseases", "keywords": [{"text": "heart diseases"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "also known", "normalized": "also know"}}, {"subject": {"text": "Cardiovascular diseases, also known as heart diseases,", "keywords": [{"text": "Cardiovascular diseases"}, {"text": "heart diseases"}]}, "sentence": " Cardiovascular diseases, also known as heart diseases, are diseases of heart and circulatory system.", "object": {"text": "diseases of heart and circulatory system", "keywords": [{"text": "diseases"}, {"text": "heart"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Some of the most common cardiovascular diseases", "keywords": [{"text": "common cardiovascular diseases"}]}, "sentence": " Some of the most common cardiovascular diseases are hypertensive heart disease, rheumatic heart disease, cerebrovascular heart disease, ischemic heart disease and inflammatory heart disease.", "object": {"text": "hypertensive heart disease", "keywords": [{"text": "hypertensive heart disease"}], "entities": [{"type": "HealthCondition", "text": "hypertensive heart disease", "disambiguation": {"subtype": [], "name": "Hypertensive heart disease", "dbpedia_resource": "http://dbpedia.org/resource/Hypertensive_heart_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Major problems", "keywords": [{"text": "Major problems"}]}, "sentence": " Major problems associated with hypertensive heart disease include heart failure, hypertrophy, coronary heart disease and angina.", "object": {"text": "with hypertensive heart disease", "keywords": [{"text": "hypertensive heart disease"}], "entities": [{"type": "HealthCondition", "text": "hypertensive heart disease", "disambiguation": {"subtype": [], "name": "Hypertensive heart disease", "dbpedia_resource": "http://dbpedia.org/resource/Hypertensive_heart_disease"}}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "heart failure, hypertrophy, coronary heart disease and angina", "keywords": [{"text": "coronary heart disease"}, {"text": "heart failure"}, {"text": "hypertrophy"}, {"text": "angina"}]}, "sentence": " Major problems associated with hypertensive heart disease include heart failure, hypertrophy, coronary heart disease and angina.", "object": {"text": "Major problems associated with hypertensive heart disease", "keywords": [{"text": "hypertensive heart disease"}, {"text": "Major problems"}], "entities": [{"type": "HealthCondition", "text": "hypertensive heart disease", "disambiguation": {"subtype": [], "name": "Hypertensive heart disease", "dbpedia_resource": "http://dbpedia.org/resource/Hypertensive_heart_disease"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Rheumatic heart disease", "keywords": [{"text": "Rheumatic heart disease"}]}, "sentence": " Rheumatic heart disease is caused by rheumatic fever.", "object": {"text": "by rheumatic fever", "keywords": [{"text": "rheumatic fever"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is caused", "normalized": "be cause"}}, {"subject": {"text": "by rheumatic fever", "keywords": [{"text": "rheumatic fever"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}]}, "sentence": " Rheumatic heart disease is caused by rheumatic fever.", "object": {"text": "Rheumatic heart disease", "keywords": [{"text": "Rheumatic heart disease"}]}, "action": {"verb": {"text": "cause", "tense": "past"}, "text": "is caused", "normalized": "be cause"}}, {"subject": {"text": "by preceding group A streptococcal infection", "keywords": [{"text": "streptococcal infection"}, {"text": "group"}], "entities": [{"type": "HealthCondition", "text": "group A streptococcal infection", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "InfectiousDisease", "RiskFactor"], "name": "Group A streptococcal infection", "dbpedia_resource": "http://dbpedia.org/resource/Group_A_streptococcal_infection"}}]}, "sentence": " Rheumatic fever occurs by preceding group A streptococcal infection.", "object": {"text": "Rheumatic fever", "keywords": [{"text": "Rheumatic fever"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}]}, "action": {"verb": {"text": "occur", "tense": "present"}, "text": "occurs", "normalized": "occur"}}, {"subject": {"text": "It"}, "sentence": " It is one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries.", "object": {"text": "one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries", "keywords": [{"text": "heart diseases"}, {"text": "countries"}, {"text": "children"}, {"text": "world"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Cerebrovascular disease", "keywords": [{"text": "Cerebrovascular disease"}], "entities": [{"type": "HealthCondition", "text": "Cerebrovascular disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Cerebrovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cerebrovascular_disease"}}]}, "sentence": " Cerebrovascular disease affects blood vessels of the brain.", "object": {"text": "blood vessels of the brain", "keywords": [{"text": "blood vessels"}, {"text": "brain"}], "entities": []}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affects", "normalized": "affect"}}, {"subject": {"text": "Most common types of cerebrovascular disease", "keywords": [{"text": "cerebrovascular disease"}, {"text": "common types"}], "entities": [{"type": "HealthCondition", "text": "Cerebrovascular disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Cerebrovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cerebrovascular_disease"}}]}, "sentence": " Most common types of cerebrovascular disease are vascular dementia, stroke, subarachnoid hemorrhage and transient ischemic attack (TIA).", "object": {"text": "vascular dementia", "keywords": [{"text": "vascular dementia"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Ischemic heart disease", "keywords": [{"text": "Ischemic heart disease"}]}, "sentence": " Ischemic heart disease is characterized by reduced blood supply to the heart.", "object": {"text": "by reduced blood supply to the heart", "keywords": [{"text": "blood supply"}, {"text": "heart"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is characterized", "normalized": "be characterize"}}, {"subject": {"text": "by reduced blood supply to the heart", "keywords": [{"text": "blood supply"}, {"text": "heart"}]}, "sentence": " Ischemic heart disease is characterized by reduced blood supply to the heart.", "object": {"text": "Ischemic heart disease", "keywords": [{"text": "Ischemic heart disease"}]}, "action": {"verb": {"text": "characterize", "tense": "past"}, "text": "is characterized", "normalized": "be characterize"}}, {"subject": {"text": "It"}, "sentence": " It is one of the most common causes of death in western parts of the world.", "object": {"text": "one of the most common causes of death in western parts of the world", "keywords": [{"text": "common causes"}, {"text": "western parts"}, {"text": "death"}, {"text": "world"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Inflammatory heart disease", "keywords": [{"text": "Inflammatory heart disease"}], "entities": [{"type": "HealthCondition", "text": "inflammatory heart disease", "disambiguation": {"subtype": ["Disease"], "name": "Cardiovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}}]}, "sentence": " Inflammatory heart disease occurs due to the infection of bacteria and virus.", "object": {"text": "due to the infection of bacteria and virus", "keywords": [{"text": "bacteria"}, {"text": "infection"}, {"text": "virus"}], "entities": [{"type": "HealthCondition", "text": "group A streptococcal infection", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "InfectiousDisease", "RiskFactor"], "name": "Group A streptococcal infection", "dbpedia_resource": "http://dbpedia.org/resource/Group_A_streptococcal_infection"}}]}, "action": {"verb": {"text": "occur", "tense": "present"}, "text": "occurs", "normalized": "occur"}}, {"subject": {"text": "This type of inflammation", "keywords": [{"text": "inflammation"}, {"text": "type"}]}, "sentence": " This type of inflammation is often associated with episodes of rheumatic fever and kawasaki disease.", "object": {"text": "often associated with episodes of rheumatic fever and kawasaki disease", "keywords": [{"text": "rheumatic fever"}, {"text": "kawasaki disease"}, {"text": "episodes"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}, {"type": "HealthCondition", "text": "kawasaki disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Kawasaki disease", "dbpedia_resource": "http://dbpedia.org/resource/Kawasaki_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "This type of inflammation", "keywords": [{"text": "inflammation"}, {"text": "type"}]}, "sentence": " This type of inflammation is often associated with episodes of rheumatic fever and kawasaki disease.", "object": {"text": "with episodes of rheumatic fever and kawasaki disease", "keywords": [{"text": "rheumatic fever"}, {"text": "kawasaki disease"}, {"text": "episodes"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}, {"type": "HealthCondition", "text": "kawasaki disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Kawasaki disease", "dbpedia_resource": "http://dbpedia.org/resource/Kawasaki_disease"}}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "The global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " The global cardiovascular drugs market is categorized based on various anti-hypertensive drugs, anti-dyslipidemics drugs and anti-thrombotics drugs.", "object": {"text": "based on various anti-hypertensive drugs, anti-dyslipidemics drugs and anti-thrombotics drugs", "keywords": [{"text": "various anti-hypertensive drugs"}, {"text": "anti-dyslipidemics drugs"}, {"text": "anti-thrombotics drugs"}]}, "action": {"verb": {"text": "categorize", "tense": "past"}, "text": "is categorized", "normalized": "be categorize"}}, {"subject": {"text": "The global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " The global cardiovascular drugs market is categorized based on various anti-hypertensive drugs, anti-dyslipidemics drugs and anti-thrombotics drugs.", "object": {"text": "on various anti-hypertensive drugs, anti-dyslipidemics drugs and anti-thrombotics drugs", "keywords": [{"text": "various anti-hypertensive drugs"}, {"text": "anti-dyslipidemics drugs"}, {"text": "anti-thrombotics drugs"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "based", "normalized": "base"}}, {"subject": {"text": "Anti-hypertensive drug segment", "keywords": [{"text": "Anti-hypertensive drug segment"}]}, "sentence": " Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "object": {"text": "further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL", "keywords": [{"text": "Benicar/Benicar HCT"}, {"text": "Micardis/Micardis HCT"}, {"text": "Exforge/Exforge HCT"}, {"text": "Norvasc"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Lipitor, Crestor, Niaspan, TriCor/Trilipix, Zetia/Vytorin and Tredaptive", "keywords": [{"text": "Niaspan"}, {"text": "Crestor"}, {"text": "Lipitor"}, {"text": "TriCor/Trilipix"}], "entities": [{"type": "Location", "text": "Tredaptive", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Anti-dyslipidemics drug segment includes Lipitor, Crestor, Niaspan, TriCor/Trilipix, Zetia/Vytorin and Tredaptive.", "object": {"text": "Anti-dyslipidemics drug segment", "keywords": [{"text": "Anti-dyslipidemics drug segment"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "Anti-thrombotics drug segment", "keywords": [{"text": "Anti-thrombotics drug segment"}]}, "sentence": " Anti-thrombotics drug segment is further sub-segmented into Plavix, Lovenox, Pradaxa, Xarelto, Brilique/Brilinta and Eliquis.", "object": {"text": "further sub-segmented into Plavix, Lovenox, Pradaxa, Xarelto, Brilique/Brilinta and Eliquis", "keywords": [{"text": "Plavix"}, {"text": "Lovenox"}, {"text": "Pradaxa"}, {"text": "Xarelto"}], "entities": [{"type": "Location", "text": "Eliquis", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " In terms of geographic, North America dominates the global cardiovascular drugs market.", "object": {"text": "the global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "market"}]}, "action": {"verb": {"text": "dominate", "tense": "present"}, "text": "dominates", "normalized": "dominate"}}, {"subject": {"text": "The U.S.", "keywords": [{"text": "U.S"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " The U.S. represents the largest market for cardiovascular drugs followed by Canada in North America.", "object": {"text": "the largest market for cardiovascular drugs followed by Canada in North America", "keywords": [{"text": "cardiovascular drugs"}, {"text": "largest market"}, {"text": "North America"}, {"text": "Canada"}], "entities": [{"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "action": {"verb": {"text": "represent", "tense": "present"}, "text": "represents", "normalized": "represent"}}, {"subject": {"text": "by Canada in North America", "keywords": [{"text": "North America"}, {"text": "Canada"}], "entities": [{"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " The U.S. represents the largest market for cardiovascular drugs followed by Canada in North America.", "object": {"text": "cardiovascular drugs", "keywords": [{"text": "cardiovascular drugs"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "the U.K., Spain, Italy and France", "keywords": [{"text": "U.K."}, {"text": "Spain"}, {"text": "Italy"}, {"text": "France"}], "entities": [{"type": "Location", "text": "U.K.", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"type": "Location", "text": "Spain", "disambiguation": {"subtype": ["Country"], "name": "Kingdom of Spain (Napoleonic)", "dbpedia_resource": "http://dbpedia.org/resource/Kingdom_of_Spain_(Napoleonic)"}}, {"type": "Location", "text": "Italy", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "France", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}]}, "sentence": " In Europe, Germany, the U.K., Spain, Italy and France holds major share of cardiovascular drugs market.", "object": {"text": "major share of cardiovascular drugs market", "keywords": [{"text": "cardiovascular drugs"}, {"text": "major share"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "holds", "normalized": "hold"}}, {"subject": {"text": "Asia", "keywords": [{"text": "Asia"}], "entities": [{"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "sentence": " However, Asia is expected to show high growth rates in the next five years in global cardiovascular drugs market.", "object": {"text": "high growth rates", "keywords": [{"text": "high growth rates"}]}, "action": {"verb": {"text": "show", "tense": "future"}, "text": "is expected to show", "normalized": "be expect to show"}}, {"subject": {"text": "many companies", "keywords": [{"text": "companies"}]}, "sentence": " This is due to many companies constructing their R&D facilities in the region.", "object": {"text": "their R&D facilities in the region", "keywords": [{"text": "R&D facilities"}, {"text": "region"}]}, "action": {"verb": {"text": "construct", "tense": "present"}, "text": "constructing", "normalized": "construct"}}, {"subject": {"text": "Less stringent wages and availability of skilled labor", "keywords": [{"text": "stringent wages"}, {"text": "skilled labor"}, {"text": "availability"}]}, "sentence": " Less stringent wages and availability of skilled labor attracts manufacturing companies to invest in Asia.", "object": {"text": "manufacturing companies", "keywords": [{"text": "manufacturing companies"}]}, "action": {"verb": {"text": "attract", "tense": "present"}, "text": "attracts", "normalized": "attract"}}, {"subject": {"text": "increasing awareness about heart related problems", "keywords": [{"text": "awareness"}, {"text": "heart"}, {"text": "problems"}]}, "sentence": " In addition, increasing awareness about heart related problems is also supporting in the growth of cardiovascular drugs market in the region.", "action": {"verb": {"text": "support", "tense": "present"}, "text": "is also supporting", "normalized": "be also support"}}, {"subject": {"text": "Japan, China and India", "keywords": [{"text": "Japan"}, {"text": "China"}, {"text": "India"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}]}, "sentence": " Japan, China and India are expected to be the fastest growing cardiovascular drugs markets in Asia.", "object": {"text": "the fastest growing cardiovascular drugs markets in Asia", "keywords": [{"text": "cardiovascular drugs"}, {"text": "markets"}, {"text": "Asia"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "increasing prevalence of heart diseases and extensive pipeline drugs", "keywords": [{"text": "extensive pipeline drugs"}, {"text": "prevalence"}, {"text": "heart diseases"}]}, "sentence": " In recent time, increasing prevalence of heart diseases and extensive pipeline drugs are some of the major drivers of global cardiovascular drugs market.", "object": {"text": "some of the major drivers of global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "major drivers"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Rising number of diabetic patients", "keywords": [{"text": "diabetic patients"}, {"text": "number"}]}, "sentence": " Rising number of diabetic patients holds immense potential to the growth of global cardiovascular drugs market.Request TOC@ https://www.persistencemarketresearch.com/methodology/3776", "object": {"text": "immense potential to the growth of global cardiovascular drugs market.Request TOC", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "immense potential"}, {"text": "market.Request TOC"}, {"text": "growth"}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "holds", "normalized": "hold"}}, {"subject": {"text": "stringent regulations and side-effects of cardiovascular drugs", "keywords": [{"text": "cardiovascular drugs"}, {"text": "stringent regulations"}, {"text": "side-effects"}]}, "sentence": " However, stringent regulations and side-effects of cardiovascular drugs hamper the growth of global cardiovascular drugs market.", "object": {"text": "the growth of global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "hamper", "tense": "present"}, "text": "hamper", "normalized": "hamper"}}, {"subject": {"text": "patent expiry of various blockbuster drugs", "keywords": [{"text": "various blockbuster drugs"}, {"text": "patent expiry"}]}, "sentence": " Moreover, patent expiry of various blockbuster drugs also obstructs the growth of the global cardiovascular drugs market.", "object": {"text": "the growth of the global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "obstruct", "tense": "present"}, "text": "obstructs", "normalized": "obstruct"}}, {"subject": {"text": "the major companies", "keywords": [{"text": "major companies"}]}, "sentence": " Some of the major companies operating in the global cardiovascular drugs market are Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co. Ltd., Novartis AG, Forest Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Pfizer Inc. and Solvay SA.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "Some of the major companies operating in the global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "major companies"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Some of the major companies operating in the global cardiovascular drugs market are Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co. Ltd., Novartis AG, Forest Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Pfizer Inc. and Solvay SA.", "object": {"text": "Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co. Ltd., Novartis AG, Forest Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Pfizer Inc. and Solvay SA", "keywords": [{"text": "Bristol-Myers Squibb Company"}, {"text": "Forest Laboratories Inc."}, {"text": "F. Hoffmann-La Roche"}, {"text": "AstraZeneca PLC"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "Abbott Laboratories Inc."}, {"type": "Company", "text": "AstraZeneca PLC", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co. Ltd."}, {"type": "Company", "text": "Novartis AG", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Forest Laboratories Inc.", "disambiguation": {"subtype": [], "name": "Forest Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Forest_Laboratories"}}, {"type": "Company", "text": "Bayer AG", "disambiguation": {"subtype": ["Organization", "Brand", "Company"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"type": "Company", "text": "Roche Ltd."}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Daiichi Sankyo Co. Ltd."}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Solvay SA", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Solvay (company)", "dbpedia_resource": "http://dbpedia.org/resource/Solvay_(company)"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}], "concepts": [{"text": "Hypertension", "relevance": 0.951266, "dbpedia_resource": "http://dbpedia.org/resource/Hypertension"}, {"text": "Heart", "relevance": 0.768204, "dbpedia_resource": "http://dbpedia.org/resource/Heart"}, {"text": "Cardiology", "relevance": 0.763788, "dbpedia_resource": "http://dbpedia.org/resource/Cardiology"}, {"text": "Heart disease", "relevance": 0.761355, "dbpedia_resource": "http://dbpedia.org/resource/Heart_disease"}, {"text": "Blood", "relevance": 0.645019, "dbpedia_resource": "http://dbpedia.org/resource/Blood"}, {"text": "Circulatory system", "relevance": 0.6048, "dbpedia_resource": "http://dbpedia.org/resource/Circulatory_system"}, {"text": "Blood vessel", "relevance": 0.593518, "dbpedia_resource": "http://dbpedia.org/resource/Blood_vessel"}, {"text": "Myocardial infarction", "relevance": 0.559648, "dbpedia_resource": "http://dbpedia.org/resource/Myocardial_infarction"}, {"text": "Bristol-Myers Squibb", "relevance": 0.551373, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Genetic disorder", "relevance": 0.536268, "dbpedia_resource": "http://dbpedia.org/resource/Genetic_disorder"}, {"text": "Ischaemic heart disease", "relevance": 0.536197, "dbpedia_resource": "http://dbpedia.org/resource/Ischaemic_heart_disease"}, {"text": "Hoffmann\u2013La Roche", "relevance": 0.524243, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Ischemia", "relevance": 0.521214, "dbpedia_resource": "http://dbpedia.org/resource/Ischemia"}, {"text": "Cardiovascular system", "relevance": 0.501223, "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_system"}, {"text": "Aspirin", "relevance": 0.492895, "dbpedia_resource": "http://dbpedia.org/resource/Aspirin"}, {"text": "Cardiovascular diseases", "relevance": 0.492717, "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_diseases"}, {"text": "Pfizer", "relevance": 0.480082, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}, {"text": "Diseases and disorders", "relevance": 0.470777, "dbpedia_resource": "http://dbpedia.org/resource/Diseases_and_disorders"}, {"text": "Stroke", "relevance": 0.455585, "dbpedia_resource": "http://dbpedia.org/resource/Stroke"}, {"text": "Circulatory System", "relevance": 0.427173, "dbpedia_resource": "http://dbpedia.org/resource/Circulatory_System"}, {"text": "Streptococcus", "relevance": 0.421092, "dbpedia_resource": "http://dbpedia.org/resource/Streptococcus"}, {"text": "Rheumatic fever", "relevance": 0.419609, "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}, {"text": "Heart failure", "relevance": 0.411061, "dbpedia_resource": "http://dbpedia.org/resource/Heart_failure"}, {"text": "Coronary artery disease", "relevance": 0.366044, "dbpedia_resource": "http://dbpedia.org/resource/Coronary_artery_disease"}, {"text": "Clopidogrel", "relevance": 0.35913, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "Infection", "relevance": 0.351716, "dbpedia_resource": "http://dbpedia.org/resource/Infection"}, {"text": "Blood pressure", "relevance": 0.350305, "dbpedia_resource": "http://dbpedia.org/resource/Blood_pressure"}, {"text": "Atherosclerosis", "relevance": 0.348132, "dbpedia_resource": "http://dbpedia.org/resource/Atherosclerosis"}, {"text": "Pharmaceutical industry", "relevance": 0.346119, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Rheumatism", "relevance": 0.336972, "dbpedia_resource": "http://dbpedia.org/resource/Rheumatism"}, {"text": "Pulmonary vein", "relevance": 0.324188, "dbpedia_resource": "http://dbpedia.org/resource/Pulmonary_vein"}, {"text": "Medicine", "relevance": 0.319804, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Arthralgia", "relevance": 0.313346, "dbpedia_resource": "http://dbpedia.org/resource/Arthralgia"}, {"text": "Disease", "relevance": 0.313159, "dbpedia_resource": "http://dbpedia.org/resource/Disease"}, {"text": "Infectious disease", "relevance": 0.30799, "dbpedia_resource": "http://dbpedia.org/resource/Infectious_disease"}, {"text": "Immune system", "relevance": 0.305842, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Genentech", "relevance": 0.299442, "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}, {"text": "Streptococcus pyogenes", "relevance": 0.296819, "dbpedia_resource": "http://dbpedia.org/resource/Streptococcus_pyogenes"}, {"text": "Inflammation", "relevance": 0.29676, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Cerebral hemorrhage", "relevance": 0.294615, "dbpedia_resource": "http://dbpedia.org/resource/Cerebral_hemorrhage"}, {"text": "Amlodipine", "relevance": 0.291471, "dbpedia_resource": "http://dbpedia.org/resource/Amlodipine"}, {"text": "Transient ischemic attack", "relevance": 0.290835, "dbpedia_resource": "http://dbpedia.org/resource/Transient_ischemic_attack"}, {"text": "Hypercholesterolemia", "relevance": 0.287857, "dbpedia_resource": "http://dbpedia.org/resource/Hypercholesterolemia"}, {"text": "Pharmaceutical drug", "relevance": 0.285251, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Cardiovascular disease", "relevance": 0.281888, "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}, {"text": "Rheumatology", "relevance": 0.281173, "dbpedia_resource": "http://dbpedia.org/resource/Rheumatology"}, {"text": "AstraZeneca", "relevance": 0.278915, "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}, {"text": "Cardiac muscle", "relevance": 0.273698, "dbpedia_resource": "http://dbpedia.org/resource/Cardiac_muscle"}, {"text": "Irbesartan", "relevance": 0.269219, "dbpedia_resource": "http://dbpedia.org/resource/Irbesartan"}, {"text": "Multinational companies", "relevance": 0.264462, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}], "categories": [{"score": 0.999938, "label": "/health and fitness/disease/heart disease"}], "relations": [{"type": "agentOf", "sentence": "Valuable Foresights on How Cardiovascular Drugs Market will Grow During 2015-2021 Persistence Market Research has announced the addition of the \"Cardiovascular Drugs Market: Global Industry Analysis and Opportunity Assessment 2015- 2021\" report to their offering.", "score": 0.5012, "arguments": [{"text": "Grow", "location": [60, 64], "entities": [{"type": "Person", "text": "Grow"}]}, {"text": "announced", "location": [114, 123], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "Most common types of cerebrovascular disease are vascular dementia, stroke, subarachnoid hemorrhage and transient ischemic attack (TIA).", "score": 0.50584, "arguments": [{"text": "TIA", "location": [1258, 1261], "entities": [{"type": "Person", "text": "TIA"}]}, {"text": "attack", "location": [1250, 1256], "entities": [{"type": "EventViolence", "text": "attack"}]}]}, {"type": "locatedAt", "sentence": "It is one of the most common causes of death in western parts of the world.", "score": 0.506713, "arguments": [{"text": "western", "location": [1390, 1397], "entities": [{"type": "Location", "text": "western"}]}, {"text": "parts", "location": [1398, 1403], "entities": [{"type": "Location", "text": "parts"}]}]}, {"type": "locatedAt", "sentence": "It is one of the most common causes of death in western parts of the world.", "score": 0.780669, "arguments": [{"text": "parts", "location": [1398, 1403], "entities": [{"type": "Location", "text": "parts"}]}, {"text": "world", "location": [1411, 1416], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.68216, "arguments": [{"text": "Co-Diovan", "location": [1892, 1901], "entities": [{"type": "GeopoliticalEntity", "text": "Co-Diovan"}]}, {"text": "Blopress", "location": [1903, 1911], "entities": [{"type": "GeopoliticalEntity", "text": "Blopress"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.676207, "arguments": [{"text": "Benicar HCT", "location": [1921, 1932], "entities": [{"type": "GeopoliticalEntity", "text": "Benicar HCT"}]}, {"text": "Micardis", "location": [1934, 1942], "entities": [{"type": "GeopoliticalEntity", "text": "Micardis HCT"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.676207, "arguments": [{"text": "Micardis HCT", "location": [1943, 1955], "entities": [{"type": "GeopoliticalEntity", "text": "Micardis HCT"}]}, {"text": "Aprovel", "location": [1957, 1964], "entities": [{"type": "GeopoliticalEntity", "text": "CoAprovel"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.623328, "arguments": [{"text": "CoAprovel", "location": [1965, 1974], "entities": [{"type": "GeopoliticalEntity", "text": "CoAprovel"}]}, {"text": "Tekturna", "location": [1976, 1984], "entities": [{"type": "GeopoliticalEntity", "text": "Tekturna"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.829898, "arguments": [{"text": "Rasilez", "location": [1985, 1992], "entities": [{"type": "GeopoliticalEntity", "text": "Rasilez"}]}, {"text": "Edarbi", "location": [1994, 2000], "entities": [{"type": "GeopoliticalEntity", "text": "Edarbi"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.529909, "arguments": [{"text": "Edarbi", "location": [1994, 2000], "entities": [{"type": "GeopoliticalEntity", "text": "Edarbi"}]}, {"text": "Cozaar", "location": [2002, 2008], "entities": [{"type": "GeopoliticalEntity", "text": "Cozaar"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.92593, "arguments": [{"text": "Hyzaar", "location": [2009, 2015], "entities": [{"type": "GeopoliticalEntity", "text": "Hyzaar"}]}, {"text": "Norvasc", "location": [2017, 2024], "entities": [{"type": "GeopoliticalEntity", "text": "Norvasc"}]}]}, {"type": "timeOf", "sentence": "Valuable Foresights on How Cardiovascular Drugs Market will Grow During 2015-2021 Persistence Market Research has announced the addition of the \"Cardiovascular Drugs Market: Global Industry Analysis and Opportunity Assessment 2015- 2021\" report to their offering.", "score": 0.737847, "arguments": [{"text": "2015", "location": [226, 230], "entities": [{"type": "Date", "text": "2015"}]}, {"text": "report", "location": [238, 244], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "locatedAt", "sentence": "The U.S. represents the largest market for cardiovascular drugs followed by Canada in North America.", "score": 0.840381, "arguments": [{"text": "drugs", "location": [2545, 2550], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "Canada", "location": [2563, 2569], "entities": [{"type": "GeopoliticalEntity", "text": "Canada", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "The U.S. represents the largest market for cardiovascular drugs followed by Canada in North America.", "score": 0.637932, "arguments": [{"text": "drugs", "location": [2545, 2550], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "North America", "location": [2573, 2586], "entities": [{"type": "GeopoliticalEntity", "text": "North America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "In Europe, Germany, the U.K., Spain, Italy and France holds major share of cardiovascular drugs market.", "score": 0.954556, "arguments": [{"text": "Europe", "location": [2591, 2597], "entities": [{"type": "GeopoliticalEntity", "text": "Europe"}]}, {"text": "Germany", "location": [2599, 2606], "entities": [{"type": "GeopoliticalEntity", "text": "Germany", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "In Europe, Germany, the U.K., Spain, Italy and France holds major share of cardiovascular drugs market.", "score": 0.704525, "arguments": [{"text": "U.K.", "location": [2612, 2616], "entities": [{"type": "GeopoliticalEntity", "text": "U.K."}]}, {"text": "Spain", "location": [2618, 2623], "entities": [{"type": "GeopoliticalEntity", "text": "Spain", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "ownerOf", "sentence": "This is due to many companies constructing their R&D facilities in the region.", "score": 0.268793, "arguments": [{"text": "companies", "location": [2826, 2835], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "facilities", "location": [2859, 2869], "entities": [{"type": "Facility", "text": "facilities"}]}]}, {"type": "locatedAt", "sentence": "This is due to many companies constructing their R&D facilities in the region.", "score": 0.950849, "arguments": [{"text": "facilities", "location": [2859, 2869], "entities": [{"type": "Facility", "text": "facilities"}]}, {"text": "region", "location": [2877, 2883], "entities": [{"type": "GeopoliticalEntity", "text": "Tredaptive"}]}]}, {"type": "locatedAt", "sentence": "Less stringent wages and availability of skilled labor attracts manufacturing companies to invest in Asia.", "score": 0.397101, "arguments": [{"text": "companies", "location": [2963, 2972], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Asia", "location": [2986, 2990], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Japan, China and India are expected to be the fastest growing cardiovascular drugs markets in Asia.", "score": 0.602137, "arguments": [{"text": "drugs", "location": [3211, 3216], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "Asia", "location": [3228, 3232], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "In recent time, increasing prevalence of heart diseases and extensive pipeline drugs are some of the major drivers of global cardiovascular drugs market.", "score": 0.744416, "arguments": [{"text": "drivers", "location": [3341, 3348], "entities": [{"type": "Person", "text": "drivers"}]}, {"text": "cardiovascular", "location": [3359, 3373], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "hasAttribute", "sentence": "Increasing aging population and rising number of life-style diseases are also contributing in the growth of global cardiovascular drugs market.", "score": 0.743664, "arguments": [{"text": "population", "location": [3405, 3415], "entities": [{"type": "Person", "text": "population"}]}, {"text": "diseases", "location": [3448, 3456], "entities": [{"type": "HealthCondition", "text": "heart diseases"}]}]}, {"type": "affectedBy", "sentence": "Valuable Foresights on How Cardiovascular Drugs Market will Grow During 2015-2021 Persistence Market Research has announced the addition of the \"Cardiovascular Drugs Market: Global Industry Analysis and Opportunity Assessment 2015- 2021\" report to their offering.", "score": 0.351983, "arguments": [{"text": "their", "location": [248, 253], "entities": [{"type": "Person", "text": "their"}]}, {"text": "report", "location": [238, 244], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "hasAttribute", "sentence": "Rising number of diabetic patients holds immense potential to the growth of global cardiovascular drugs market.", "score": 0.909393, "arguments": [{"text": "patients", "location": [3558, 3566], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "diabetic", "location": [3549, 3557], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "locatedAt", "sentence": "Moreover, patent expiry of various blockbuster drugs also obstructs the growth of the global cardiovascular drugs market.", "score": 0.499794, "arguments": [{"text": "drugs", "location": [3891, 3896], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "blockbuster", "location": [3879, 3890], "entities": [{"type": "Facility", "text": "blockbuster"}]}]}, {"type": "affectedBy", "sentence": "Increasing mergers and acquisitions between drug manufacturing companies and rapid product launches are key trends of the global cardiovascular drugs market.", "score": 0.48594, "arguments": [{"text": "companies", "location": [4029, 4038], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisitions", "location": [3989, 4001], "entities": [{"type": "EventBusiness", "text": "acquisitions"}]}]}, {"type": "partOfMany", "sentence": "Some of the major companies operating in the global cardiovascular drugs market are Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co. Ltd., Novartis AG, Forest Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Pfizer Inc. and Solvay SA.", "score": 0.432917, "arguments": [{"text": "Bristol-Myers Squibb Company", "location": [4208, 4236], "entities": [{"type": "Organization", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [4142, 4151], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the major companies operating in the global cardiovascular drugs market are Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co. Ltd., Novartis AG, Forest Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Pfizer Inc. and Solvay SA.", "score": 0.494633, "arguments": [{"text": "Abbott Laboratories Inc.", "location": [4238, 4262], "entities": [{"type": "Organization", "text": "Abbott Laboratories Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [4142, 4151], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the major companies operating in the global cardiovascular drugs market are Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co. Ltd., Novartis AG, Forest Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Pfizer Inc. and Solvay SA.", "score": 0.647762, "arguments": [{"text": "AstraZeneca PLC", "location": [4264, 4279], "entities": [{"type": "Organization", "text": "AstraZeneca PLC", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [4142, 4151], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the major companies operating in the global cardiovascular drugs market are Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co. Ltd., Novartis AG, Forest Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Pfizer Inc. and Solvay SA.", "score": 0.578518, "arguments": [{"text": "Takeda Pharmaceutical Co. Ltd.", "location": [4281, 4311], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [4142, 4151], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the major companies operating in the global cardiovascular drugs market are Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co. Ltd., Novartis AG, Forest Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Pfizer Inc. and Solvay SA.", "score": 0.475912, "arguments": [{"text": "Novartis AG", "location": [4313, 4324], "entities": [{"type": "Organization", "text": "Novartis AG", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [4142, 4151], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the major companies operating in the global cardiovascular drugs market are Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co. Ltd., Novartis AG, Forest Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Pfizer Inc. and Solvay SA.", "score": 0.490063, "arguments": [{"text": "Forest Laboratories Inc.", "location": [4326, 4350], "entities": [{"type": "Organization", "text": "Forest Laboratories Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [4142, 4151], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Follow us on Twitter @IndustryToday Cardiovascular diseases, also known as heart diseases, are diseases of heart and circulatory system.", "score": 0.569351, "arguments": [{"text": "us", "location": [299, 301], "entities": [{"type": "Person", "text": "their"}]}, {"text": "diseases", "location": [343, 351], "entities": [{"type": "HealthCondition", "text": "heart diseases"}]}]}, {"type": "affectedBy", "sentence": "Rheumatic fever occurs by preceding group A streptococcal infection.", "score": 0.668725, "arguments": [{"text": "group", "location": [901, 906], "entities": [{"type": "Person", "text": "group"}]}, {"text": "preceding", "location": [891, 900], "entities": [{"type": "EventCommunication", "text": "preceding"}]}]}, {"type": "hasAttribute", "sentence": "Rheumatic fever occurs by preceding group A streptococcal infection.", "score": 0.881228, "arguments": [{"text": "group", "location": [901, 906], "entities": [{"type": "Person", "text": "group"}]}, {"text": "infection", "location": [923, 932], "entities": [{"type": "HealthCondition", "text": "cerebrovascular disease"}]}]}, {"type": "hasAttribute", "sentence": "It is one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries.", "score": 0.927547, "arguments": [{"text": "children", "location": [990, 998], "entities": [{"type": "Person", "text": "children"}]}, {"text": "heart diseases", "location": [972, 986], "entities": [{"type": "HealthCondition", "text": "heart diseases"}]}]}, {"type": "locatedAt", "sentence": "It is one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries.", "score": 0.463019, "arguments": [{"text": "children", "location": [990, 998], "entities": [{"type": "Person", "text": "children"}]}, {"text": "countries", "location": [1007, 1016], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "It is one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries.", "score": 0.466845, "arguments": [{"text": "countries", "location": [1007, 1016], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "world", "location": [1024, 1029], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}], "keywords": [{"text": "Cardiovascular Drugs Market", "sentiment": {"score": 0.896601, "label": "positive"}, "relevance": 0.772795, "count": 2}, {"text": "Cardiovascular diseases", "sentiment": {"score": -0.927467, "label": "negative"}, "relevance": 0.725892, "count": 1}, {"text": "heart diseases", "sentiment": {"score": -0.887359, "label": "negative"}, "relevance": 0.687729, "count": 2}, {"text": "recent time", "sentiment": {"score": -0.908696, "label": "negative"}, "relevance": 0.64804, "count": 1}, {"text": "hypertensive heart disease", "sentiment": {"score": -0.889217, "label": "negative"}, "relevance": 0.612941, "count": 2}, {"text": "various anti-hypertensive drugs", "sentiment": {"score": -0.888288, "label": "negative"}, "relevance": 0.602722, "count": 1}, {"text": "common cardiovascular diseases", "sentiment": {"score": -0.957113, "label": "negative"}, "relevance": 0.591755, "count": 1}, {"text": "diseases of heart", "sentiment": {"score": -0.927467, "label": "negative"}, "relevance": 0.590502, "count": 1}, {"text": "rheumatic heart disease", "sentiment": {"score": -0.957113, "label": "negative"}, "relevance": 0.584611, "count": 1}, {"text": "global cardiovascular drugs market", "sentiment": {"score": -0.671298, "label": "negative"}, "relevance": 0.575466, "count": 4}, {"text": "Major problems", "sentiment": {"score": -0.809269, "label": "negative"}, "relevance": 0.575346, "count": 1}, {"text": "Anti-hypertensive drug segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.572963, "count": 1}, {"text": "Global Industry Analysis", "sentiment": {"score": 0.896601, "label": "positive"}, "relevance": 0.570861, "count": 1}, {"text": "Takeda Pharmaceutical Co. Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.56962, "count": 1}, {"text": "stringent wages", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.566351, "count": 1}, {"text": "Persistence Market Research", "sentiment": {"score": 0.896601, "label": "positive"}, "relevance": 0.565524, "count": 1}, {"text": "ischemic heart disease", "sentiment": {"score": -0.957113, "label": "negative"}, "relevance": 0.558121, "count": 1}, {"text": "Abbott Laboratories Inc.", "sentiment": {"score": -0.381425, "label": "negative"}, "relevance": 0.553379, "count": 1}, {"text": "Hypertensive heart disease", "sentiment": {"score": -0.935836, "label": "negative"}, "relevance": 0.552782, "count": 1}, {"text": "common types of cerebrovascular disease", "sentiment": {"score": -0.820147, "label": "negative"}, "relevance": 0.550637, "count": 1}, {"text": "anti-dyslipidemics drugs", "sentiment": {"score": -0.888288, "label": "negative"}, "relevance": 0.549581, "count": 1}, {"text": "addition", "sentiment": {"score": 0.506037, "mixed": "1", "label": "positive"}, "relevance": 0.543888, "count": 2}, {"text": "companies", "sentiment": {"score": -0.515029, "label": "negative"}, "relevance": 0.538211, "count": 2}, {"text": "Rheumatic heart disease", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537526, "count": 1}, {"text": "cerebrovascular heart disease", "sentiment": {"score": -0.957113, "label": "negative"}, "relevance": 0.535122, "count": 1}, {"text": "vascular dementia", "sentiment": {"score": -0.820147, "label": "negative"}, "relevance": 0.533922, "count": 1}, {"text": "Europe", "sentiment": {"score": -0.252491, "label": "negative"}, "relevance": 0.532609, "count": 1}, {"text": "coronary heart disease", "sentiment": {"score": -0.809269, "label": "negative"}, "relevance": 0.530572, "count": 1}, {"text": "largest market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530303, "count": 1}, {"text": "high growth rates", "sentiment": {"score": -0.719509, "label": "negative"}, "relevance": 0.530134, "count": 1}, {"text": "high blood pressure", "sentiment": {"score": -0.876595, "label": "negative"}, "relevance": 0.529999, "count": 1}, {"text": "Novartis AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529855, "count": 1}, {"text": "Benicar HCT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529794, "count": 1}, {"text": "Anti-dyslipidemics drug segment", "sentiment": {"score": -0.804171, "label": "negative"}, "relevance": 0.529557, "count": 1}, {"text": "rheumatic fever", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529246, "count": 1}, {"text": "heart failure", "sentiment": {"score": -0.809269, "label": "negative"}, "relevance": 0.528251, "count": 1}, {"text": "subarachnoid hemorrhage", "sentiment": {"score": -0.820147, "label": "negative"}, "relevance": 0.526673, "count": 1}, {"text": "anti-thrombotics drugs", "sentiment": {"score": -0.888288, "label": "negative"}, "relevance": 0.526466, "count": 1}, {"text": "North America", "sentiment": {"score": -0.252491, "label": "negative"}, "relevance": 0.52615, "count": 2}, {"text": "Japan", "sentiment": {"score": 0.321593, "label": "positive"}, "relevance": 0.525905, "count": 1}, {"text": "AstraZeneca PLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525806, "count": 1}, {"text": "major companies", "sentiment": {"score": -0.381425, "label": "negative"}, "relevance": 0.525282, "count": 1}, {"text": "Ischemic heart disease", "sentiment": {"score": -0.608359, "label": "negative"}, "relevance": 0.523595, "count": 1}, {"text": "Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521057, "count": 1}, {"text": "Co-Diovan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521031, "count": 1}, {"text": "Germany", "sentiment": {"score": -0.252491, "label": "negative"}, "relevance": 0.518965, "count": 1}, {"text": "problems", "sentiment": {"score": -0.515029, "label": "negative"}, "relevance": 0.518586, "count": 1}, {"text": "stringent regulations", "sentiment": {"score": -0.867135, "label": "negative"}, "relevance": 0.518303, "count": 1}, {"text": "awareness", "sentiment": {"score": -0.564468, "label": "negative"}, "relevance": 0.518044, "count": 2}, {"text": "Rheumatic fever", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518027, "count": 1}]}, "extracted_metadata": {"sha1": "6e908d2e437fff0c28fd7f0103af46d325d872b1", "filename": "1542647122735.zip-6fd45837f75c493c747c628661f9f20b.xml", "file_type": "json"}, "external_links": ["https://www.persistencemarketresearch.com/samples/3776", "https://www.persistencemarketresearch.com/market-research/cardiovascular-drugs-market.asp", "http://twitter.com/IndustryToday", "https://www.persistencemarketresearch.com/methodology/3776"], "title": "Valuable Foresights on How Cardiovascular Drugs Market will Grow During 2015-2021", "forum_title": "Industry Today"}, {"id": "iTYvvLCFuNqO3qYfDUDcrO9iJLC-wSY2w8p7vmy38P-2Eu5QLVVKZSy1ZKNBDQKT", "result_metadata": {"score": 36.444366}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "United States dollar", "relevance": 0.905949, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.712, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.848414, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.812862, "label": "/finance/bank"}, {"score": 0.647153, "label": "/real estate/buying and selling homes"}], "relations": [{"type": "employedBy", "sentence": "Takeda Pharmaceutical : Announces Pricing of its Unsecured U.S. Dollar Denominated Senior Notes | MarketScreener", "score": 0.670825, "arguments": [{"text": "Dollar Denominated Senior", "location": [64, 89], "entities": [{"type": "Person", "text": "Dollar Denominated Senior"}]}, {"text": "U.S.", "location": [59, 63], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "Takeda Pharmaceutical : Announces Pricing of its Unsecured U.S. Dollar Denominated Senior Notes | MarketScreener", "score": 0.974926, "arguments": [{"text": "Dollar Denominated Senior", "location": [64, 89], "entities": [{"type": "Person", "text": "Dollar Denominated Senior"}]}, {"text": "Notes", "location": [90, 95], "entities": [{"type": "EventCommunication", "text": "Notes"}]}]}], "keywords": [{"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.994409, "count": 1}, {"text": "Pricing", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.805238, "count": 1}, {"text": "Unsecured U.S. Dollar", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.695132, "count": 1}, {"text": "Senior Notes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.197789, "count": 1}, {"text": "MarketScreener", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.059035, "count": 1}]}, "crawl_date": "2018-11-20T01:21:27Z", "url": "https://www.marketscreener.com/TAKEDA-PHARMACEUTICAL-CO-6491073/news/Takeda-Pharmaceutical-Announces-Pricing-of-its-Unsecured-U-S-Dollar-Denominated-Senior-Notes-27635645/", "host": "marketscreener.com", "text": "Attachments Original document Permalink Disclaimer Takeda Pharmaceutical Co.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-20T00:00:00Z", "enriched_text": {"entities": [{"count": 9, "sentiment": {"score": 0.222977, "label": "positive"}, "text": "Takeda", "relevance": 0.777128, "type": "Company"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Singapore Exchange Securities Trading Limited", "relevance": 0.770967, "type": "Company"}, {"count": 18, "sentiment": {"score": -0.118634, "label": "negative"}, "text": "U.S.", "relevance": 0.568927, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 6, "sentiment": {"score": 0.49769, "label": "positive"}, "text": "Takeda", "relevance": 0.539307, "type": "Person"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company", "relevance": 0.514283, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "principal", "relevance": 0.408407, "type": "JobTitle"}, {"count": 7, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.386654, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia", "relevance": 0.3667, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd.", "relevance": 0.365355, "type": "Company"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.357948, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 6, "sentiment": {"score": 0.0777938, "label": "positive"}, "text": "Dealing Disclosures", "relevance": 0.324368, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.294701, "label": "positive"}, "text": "Notes", "relevance": 0.289758, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.2828, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "solicitation", "relevance": 0.278234, "type": "Crime"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.27803, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kazumi Kobayashi", "relevance": 0.22315, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.639078, "label": "positive"}, "text": "Elissa Johnsen", "relevance": 0.222503, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tsuyoshi Tada", "relevance": 0.222394, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "United Kingdom", "relevance": 0.215588, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.215588, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kazumi.Kobayashi@takeda.com", "relevance": 0.215588, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Elissa.Johnsen@takeda.com", "relevance": 0.215588, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tsuyoshi.Tada@takeda.com", "relevance": 0.215588, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "364-Day", "relevance": 0.215588, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "99.580%", "relevance": 0.215588, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "99.936%", "relevance": 0.215588, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "99.937%", "relevance": 0.215588, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "99.960%", "relevance": 0.215588, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "3.800%", "relevance": 0.215588, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "4.000%", "relevance": 0.215588, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "4.400%", "relevance": 0.215588, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "5.000%", "relevance": 0.215588, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1.00%", "relevance": 0.215588, "type": "Quantity"}], "sentiment": {"document": {"score": 0.475933, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "the ' Company ' or ' Takeda ')", "keywords": [{"text": "Takeda"}, {"text": "Company"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " November 19, 2018 (London time) --- Takeda Pharmaceutical Company Limited (TSE: 4502) (the ' Company ' or ' Takeda ') announces that it has today, November 19, 2018 (London time), determined the issue price and other matters in relation to its unsecured U.S. dollar (' US$ ') denominated senior notes (the ' Notes ')for an aggregate amount of US$5,500 million, as outlined below.", "object": {"text": "that it has today, November 19, 2018 (London time), determined the issue price and other matters in relation to its unsecured U.S. dollar (' US$ ') denominated senior notes (the ' Notes ')for an aggregate amount of US$5,500 million, as outlined below", "keywords": [{"text": "unsecured U.S. dollar"}, {"text": "London time"}, {"text": "issue price"}, {"text": "senior notes"}], "entities": [{"type": "Location", "text": "London", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Person", "text": "Notes"}, {"type": "Person", "text": "Notes"}, {"type": "Person", "text": "Notes"}]}, "action": {"verb": {"text": "announce", "tense": "present"}, "text": "announces", "normalized": "announce"}}, {"subject": {"text": "it"}, "sentence": " November 19, 2018 (London time) --- Takeda Pharmaceutical Company Limited (TSE: 4502) (the ' Company ' or ' Takeda ') announces that it has today, November 19, 2018 (London time), determined the issue price and other matters in relation to its unsecured U.S. dollar (' US$ ') denominated senior notes (the ' Notes ')for an aggregate amount of US$5,500 million, as outlined below.", "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "it"}, "sentence": " November 19, 2018 (London time) --- Takeda Pharmaceutical Company Limited (TSE: 4502) (the ' Company ' or ' Takeda ') announces that it has today, November 19, 2018 (London time), determined the issue price and other matters in relation to its unsecured U.S. dollar (' US$ ') denominated senior notes (the ' Notes ')for an aggregate amount of US$5,500 million, as outlined below.", "object": {"text": "the issue price", "keywords": [{"text": "issue price"}]}, "action": {"verb": {"text": "determine", "tense": "past"}, "text": "determined", "normalized": "determine"}}, {"subject": {"text": "senior notes (the ' Notes ')", "keywords": [{"text": "senior notes"}], "entities": [{"type": "Person", "text": "Notes"}]}, "sentence": " November 19, 2018 (London time) --- Takeda Pharmaceutical Company Limited (TSE: 4502) (the ' Company ' or ' Takeda ') announces that it has today, November 19, 2018 (London time), determined the issue price and other matters in relation to its unsecured U.S. dollar (' US$ ') denominated senior notes (the ' Notes ')for an aggregate amount of US$5,500 million, as outlined below.", "object": {"text": "for an aggregate amount of US$5,500 million, as outlined below", "keywords": [{"text": "aggregate"}], "entities": [{"type": "Person", "text": "Notes"}]}, "action": {"verb": {"text": "denominate", "tense": "past"}, "text": "denominated", "normalized": "denominate"}}, {"subject": {"text": "The Notes", "keywords": [{"text": "Notes"}], "entities": [{"type": "Person", "text": "Notes"}]}, "sentence": " The Notes will be issued in order to finance a portion of the funds necessary for the acquisition of Shire plc (the ' Acquisition ') and reduce commitments under the 364-Day Bridge Credit Agreement entered into in connection with the Acquisition on May 8, 2018 (as amended on June 8, 2018 and October 26, 2018) (the ' Bridge Credit Agreement ').", "action": {"verb": {"text": "issue", "tense": "future"}, "text": "will be issued", "normalized": "will be issue"}}, {"subject": {"text": "The Notes", "keywords": [{"text": "Notes"}], "entities": [{"type": "Person", "text": "Notes"}]}, "sentence": " The Notes will be issued in order to finance a portion of the funds necessary for the acquisition of Shire plc (the ' Acquisition ') and reduce commitments under the 364-Day Bridge Credit Agreement entered into in connection with the Acquisition on May 8, 2018 (as amended on June 8, 2018 and October 26, 2018) (the ' Bridge Credit Agreement ').", "object": {"text": "a portion of the funds necessary", "keywords": [{"text": "portion"}, {"text": "funds"}]}, "action": {"verb": {"text": "finance", "tense": "future"}, "text": "to finance", "normalized": "to finance"}}, {"subject": {"text": "commitments", "keywords": [{"text": "commitments"}]}, "sentence": " The Notes will be issued in order to finance a portion of the funds necessary for the acquisition of Shire plc (the ' Acquisition ') and reduce commitments under the 364-Day Bridge Credit Agreement entered into in connection with the Acquisition on May 8, 2018 (as amended on June 8, 2018 and October 26, 2018) (the ' Bridge Credit Agreement ').", "action": {"verb": {"text": "reduce", "tense": "present"}, "text": "reduce", "normalized": "reduce"}}, {"subject": {"text": "the Notes", "keywords": [{"text": "Notes"}], "entities": [{"type": "Person", "text": "Notes"}]}, "sentence": " In accordance with Rule 26 of the City Code on Takeovers and Mergers, a copy of the final offering circular in respect of the Notes will be available to view on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on the business day following the publication thereof.", "object": {"text": "available to view on Takeda's website at www.takeda.com/investors/offer-for-shire", "keywords": [{"text": "Takeda"}, {"text": "website"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be", "normalized": "will be"}}, {"subject": {"text": "by Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Payment of a portion of the cash consideration for the Acquisition and related fees, costs and expenses incurred by Takeda", "object": {"text": "costs and expenses", "keywords": [{"text": "expenses"}, {"text": "costs"}]}, "action": {"verb": {"text": "incur", "tense": "past"}, "text": "incurred", "normalized": "incur"}}, {"subject": {"text": "the U.S., Europe and Asia with registration rights", "keywords": [{"text": "registration rights"}, {"text": "U.S."}, {"text": "Europe"}, {"text": "Asia"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "sentence": " Private offering in foreign markets including the U.S., Europe and Asia with registration rights.", "object": {"text": "Private offering in foreign markets", "keywords": [{"text": "Private offering"}, {"text": "foreign markets"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "The notes", "keywords": [{"text": "notes"}]}, "sentence": " The notes will not be offered or sold within the U.S. or to U.S. persons, except to 'qualified institutional buyers' in reliance on the exemption from registration provided by Rule 144A under the U.S. Securities Act of 1933, as amended (the ' Securities Act ').", "action": {"verb": {"text": "sell", "tense": "future", "negated": true}, "text": "sold", "normalized": "sell"}}, {"subject": {"text": "by Rule 144A", "keywords": [{"text": "Rule 144A"}]}, "sentence": " The notes will not be offered or sold within the U.S. or to U.S. persons, except to 'qualified institutional buyers' in reliance on the exemption from registration provided by Rule 144A under the U.S. Securities Act of 1933, as amended (the ' Securities Act ').", "object": {"text": "registration", "keywords": [{"text": "registration"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "by Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Payment of a portion of the cash consideration for the Acquisition and related fees, costs and expenses incurred by Takeda", "object": {"text": "costs and expenses", "keywords": [{"text": "expenses"}, {"text": "costs"}]}, "action": {"verb": {"text": "incur", "tense": "past"}, "text": "incurred", "normalized": "incur"}}, {"subject": {"text": "the U.S., Europe and Asia with registration rights", "keywords": [{"text": "registration rights"}, {"text": "U.S."}, {"text": "Europe"}, {"text": "Asia"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "sentence": " Private offering in foreign markets including the U.S., Europe and Asia with registration rights.", "object": {"text": "Private offering in foreign markets", "keywords": [{"text": "Private offering"}, {"text": "foreign markets"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "by Rule 144A", "keywords": [{"text": "Rule 144A"}]}, "sentence": " The notes will not be offered or sold within the U.S. or to U.S. persons, except to 'qualified institutional buyers' in reliance on the exemption from registration provided by Rule 144A under the Securities Act.", "object": {"text": "registration", "keywords": [{"text": "registration"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "by Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Payment of a portion of the cash consideration for the Acquisition and related fees, costs and expenses incurred by Takeda", "object": {"text": "costs and expenses", "keywords": [{"text": "expenses"}, {"text": "costs"}]}, "action": {"verb": {"text": "incur", "tense": "past"}, "text": "incurred", "normalized": "incur"}}, {"subject": {"text": "the U.S., Europe and Asia with registration rights", "keywords": [{"text": "registration rights"}, {"text": "U.S."}, {"text": "Europe"}, {"text": "Asia"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "sentence": " Private offering in foreign markets including the U.S., Europe and Asia with registration rights.", "object": {"text": "Private offering in foreign markets", "keywords": [{"text": "Private offering"}, {"text": "foreign markets"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "by Rule 144A", "keywords": [{"text": "Rule 144A"}]}, "sentence": " The notes will not be offered or sold within the U.S. or to U.S. persons, except to 'qualified institutional buyers' in reliance on the exemption from registration provided by Rule 144A under the Securities Act.", "object": {"text": "registration", "keywords": [{"text": "registration"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "by Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Payment of a portion of the cash consideration for the Acquisition and related fees, costs and expenses incurred by Takeda", "object": {"text": "costs and expenses", "keywords": [{"text": "expenses"}, {"text": "costs"}]}, "action": {"verb": {"text": "incur", "tense": "past"}, "text": "incurred", "normalized": "incur"}}, {"subject": {"text": "the U.S., Europe and Asia with registration rights", "keywords": [{"text": "registration rights"}, {"text": "U.S."}, {"text": "Europe"}, {"text": "Asia"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "sentence": " Private offering in foreign markets including the U.S., Europe and Asia with registration rights.", "object": {"text": "Private offering in foreign markets", "keywords": [{"text": "Private offering"}, {"text": "foreign markets"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "by Rule 144A", "keywords": [{"text": "Rule 144A"}]}, "sentence": " The notes will not be offered or sold within the U.S. or to U.S. persons, except to 'qualified institutional buyers' in reliance on the exemption from registration provided by Rule 144A under the Securities Act.", "object": {"text": "registration", "keywords": [{"text": "registration"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "the fiscal year", "entities": []}, "sentence": " 2. Impact on the financial results for the fiscal year ending March 2019", "action": {"verb": {"text": "end", "tense": "present"}, "text": "ending", "normalized": "end"}}, {"subject": {"text": "the commitments under the Bridge Credit Agreement", "keywords": [{"text": "Bridge Credit Agreement"}, {"text": "commitments"}]}, "sentence": " Following receipt of the proceeds of the Notes, the commitments under the Bridge Credit Agreement will be reduced by5,472.37 million U.S. dollars.", "object": {"text": "reduced by5,472.37 million U.S. dollars", "keywords": [{"text": "U.S. dollars"}], "entities": [{"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "the commitments under the Bridge Credit Agreement", "keywords": [{"text": "Bridge Credit Agreement"}, {"text": "commitments"}]}, "sentence": " Following receipt of the proceeds of the Notes, the commitments under the Bridge Credit Agreement will be reduced by5,472.37 million U.S. dollars.", "object": {"text": "by5,472.37 million U.S. dollars", "keywords": [{"text": "U.S. dollars"}], "entities": [{"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "reduce", "tense": "future"}, "text": "will be reduced", "normalized": "will be reduce"}}, {"subject": {"text": "We"}, "sentence": " We will announce the estimated impact that issuing the Notes will have on our business performance promptly once available.", "object": {"text": "the estimated impact that issuing the Notes will have on our business performance promptly once available", "keywords": [{"text": "estimated impact"}, {"text": "business performance"}, {"text": "Notes"}]}, "action": {"verb": {"text": "announce", "tense": "future"}, "text": "will announce", "normalized": "will announce"}}, {"subject": {"text": "the estimated impact", "keywords": [{"text": "estimated impact"}]}, "sentence": " We will announce the estimated impact that issuing the Notes will have on our business performance promptly once available.", "object": {"text": "the Notes", "keywords": [{"text": "Notes"}]}, "action": {"verb": {"text": "issue", "tense": "present"}, "text": "issuing", "normalized": "issue"}}, {"subject": {"text": "This document", "keywords": [{"text": "document"}]}, "sentence": " Note: This document has been prepared to publicly disclose the determination of the terms of the Notes, and does not constitute an offer to sell or a solicitation of an offer to buy any securities in or outside of the U.S. or Japan.", "object": {"text": "prepared to publicly disclose the determination of the terms of the Notes, and does not constitute an offer to sell or a solicitation of an offer to buy any securities in or outside of the U.S. or Japan", "keywords": [{"text": "solicitation"}, {"text": "offer"}, {"text": "determination"}, {"text": "securities"}], "entities": [{"type": "Crime", "text": "solicitation"}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "This document", "keywords": [{"text": "document"}]}, "sentence": " Note: This document has been prepared to publicly disclose the determination of the terms of the Notes, and does not constitute an offer to sell or a solicitation of an offer to buy any securities in or outside of the U.S. or Japan.", "object": {"text": "to publicly disclose the determination of the terms of the Notes, and does not constitute an offer to sell or a solicitation of an offer to buy any securities in or outside of the U.S. or Japan", "keywords": [{"text": "solicitation"}, {"text": "determination"}, {"text": "offer"}, {"text": "securities"}], "entities": [{"type": "Crime", "text": "solicitation"}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "prepare", "tense": "past"}, "text": "prepared", "normalized": "prepare"}}, {"subject": {"text": "This document", "keywords": [{"text": "document"}]}, "sentence": " Note: This document has been prepared to publicly disclose the determination of the terms of the Notes, and does not constitute an offer to sell or a solicitation of an offer to buy any securities in or outside of the U.S. or Japan.", "object": {"text": "the determination of the terms of the Notes", "keywords": [{"text": "determination"}, {"text": "terms"}, {"text": "Notes"}]}, "action": {"verb": {"text": "disclose", "tense": "present"}, "text": "disclose", "normalized": "disclose"}}, {"subject": {"text": "This document", "keywords": [{"text": "document"}]}, "sentence": " Note: This document has been prepared to publicly disclose the determination of the terms of the Notes, and does not constitute an offer to sell or a solicitation of an offer to buy any securities in or outside of the U.S. or Japan.", "object": {"text": "an offer to sell or a solicitation of an offer to buy any securities in or outside of the U.S. or Japan", "keywords": [{"text": "solicitation"}, {"text": "securities"}, {"text": "offer"}, {"text": "U.S."}], "entities": [{"type": "Crime", "text": "solicitation"}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "constitute", "tense": "present", "negated": true}, "text": "constitute", "normalized": "constitute"}}, {"subject": {"text": "any securities", "keywords": [{"text": "securities"}]}, "sentence": " Note: This document has been prepared to publicly disclose the determination of the terms of the Notes, and does not constitute an offer to sell or a solicitation of an offer to buy any securities in or outside of the U.S. or Japan.", "action": {"verb": {"text": "buy", "tense": "future"}, "text": "to buy", "normalized": "to buy"}}, {"subject": {"text": "The securities", "keywords": [{"text": "securities"}]}, "sentence": " The securities set forth above have not been and will not be registered under the Securities Act, and may not be offered or sold in the U.S. absent registration or an applicable exemption from the registration requirements of the Securities Act.", "object": {"text": "registered under the Securities Act", "keywords": [{"text": "Securities Act"}]}, "action": {"verb": {"text": "be", "tense": "future", "negated": true}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The securities", "keywords": [{"text": "securities"}]}, "sentence": " The securities set forth above have not been and will not be registered under the Securities Act, and may not be offered or sold in the U.S. absent registration or an applicable exemption from the registration requirements of the Securities Act.", "action": {"verb": {"text": "register", "tense": "future", "negated": true}, "text": "registered", "normalized": "register"}}, {"subject": {"text": "Takeda Pharmaceutical Company Limited ( TSE: 4502 )", "keywords": [{"text": "Takeda Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Takeda Pharmaceutical Company Limited ( TSE: 4502 ) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "object": {"text": "a global, research and development-driven pharmaceutical company", "keywords": [{"text": "development-driven pharmaceutical company"}, {"text": "research"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "research and development-driven pharmaceutical company", "keywords": [{"text": "development-driven pharmaceutical company"}, {"text": "research"}], "entities": []}, "sentence": " Takeda Pharmaceutical Company Limited ( TSE: 4502 ) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "object": {"text": "better health", "keywords": [{"text": "health"}]}, "action": {"verb": {"text": "bring", "tense": "future"}, "text": "bringing", "normalized": "bring"}}, {"subject": {"text": "research and development-driven pharmaceutical company", "keywords": [{"text": "development-driven pharmaceutical company"}, {"text": "research"}], "entities": []}, "sentence": " Takeda Pharmaceutical Company Limited ( TSE: 4502 ) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "object": {"text": "science", "keywords": [{"text": "science"}]}, "action": {"verb": {"text": "translate", "tense": "present"}, "text": "translating", "normalized": "translate"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation.", "object": {"text": "R&D both", "keywords": [{"text": "R&D"}]}, "action": {"verb": {"text": "conduct", "tense": "present"}, "text": "conducts", "normalized": "conduct"}}, {"subject": {"text": "Innovative products, especially in oncology and gastroenterology, as well as Takeda's presence in emerging markets,", "keywords": [{"text": "Innovative products"}, {"text": "Takeda"}, {"text": "gastroenterology"}, {"text": "oncology"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Innovative products, especially in oncology and gastroenterology, as well as Takeda's presence in emerging markets, are currently fueling the growth of Takeda.", "object": {"text": "currently fueling the growth of Takeda", "keywords": [{"text": "Takeda"}, {"text": "growth"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the growth of Takeda", "keywords": [{"text": "Takeda"}, {"text": "growth"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Innovative products, especially in oncology and gastroenterology, as well as Takeda's presence in emerging markets, are currently fueling the growth of Takeda.", "object": {"text": "Innovative products, especially in oncology and gastroenterology, as well as Takeda's presence in emerging markets,", "keywords": [{"text": "Innovative products"}, {"text": "Takeda"}, {"text": "gastroenterology"}, {"text": "oncology"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "fuel", "tense": "present"}, "text": "fueling", "normalized": "fuel"}}, {"subject": {"text": "Approximately 30,000 Takeda employees", "keywords": [{"text": "Takeda employees"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "object": {"text": "committed to improving quality of life", "keywords": [{"text": "quality"}, {"text": "life"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Approximately 30,000 Takeda employees", "keywords": [{"text": "Takeda employees"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "object": {"text": "to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries", "keywords": [{"text": "health care"}, {"text": "Takeda"}, {"text": "quality"}, {"text": "life"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "commit", "tense": "past"}, "text": "are committed", "normalized": "be commit"}}, {"subject": {"text": "Approximately 30,000 Takeda employees", "keywords": [{"text": "Takeda employees"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "object": {"text": "quality of life", "keywords": [{"text": "quality"}, {"text": "life"}]}, "action": {"verb": {"text": "improve", "tense": "future"}, "text": "improving", "normalized": "improve"}}, {"subject": {"text": "by law or regulation and therefore any person who comes into possession of this announcement should inform themselves about, and comply with, such restrictions", "keywords": [{"text": "possession"}, {"text": "restrictions"}, {"text": "regulation"}, {"text": "announcement"}]}, "sentence": " The distribution of this announcement in jurisdictions outside the United Kingdom or Japan may be restricted by law or regulation and therefore any person who comes into possession of this announcement should inform themselves about, and comply with, such restrictions.", "object": {"text": "The distribution of this announcement in jurisdictions outside the United Kingdom or Japan", "keywords": [{"text": "jurisdictions"}, {"text": "United Kingdom"}, {"text": "announcement"}, {"text": "distribution"}], "entities": [{"type": "Location", "text": "United Kingdom", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "restrict", "tense": "future"}, "text": "may be restricted", "normalized": "may be restrict"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " The distribution of this announcement in jurisdictions outside the United Kingdom or Japan may be restricted by law or regulation and therefore any person who comes into possession of this announcement should inform themselves about, and comply with, such restrictions.", "object": {"text": "into possession of this announcement", "keywords": [{"text": "possession"}, {"text": "announcement"}]}, "action": {"verb": {"text": "come", "tense": "present"}, "text": "comes", "normalized": "come"}}, {"subject": {"text": "any person who comes into possession of this announcement", "keywords": [{"text": "possession"}, {"text": "announcement"}, {"text": "person"}]}, "sentence": " The distribution of this announcement in jurisdictions outside the United Kingdom or Japan may be restricted by law or regulation and therefore any person who comes into possession of this announcement should inform themselves about, and comply with, such restrictions.", "object": {"text": "themselves"}, "action": {"verb": {"text": "inform", "tense": "future"}, "text": "should inform", "normalized": "should inform"}}, {"subject": {"text": "Any failure to comply with such restrictions", "keywords": [{"text": "restrictions"}, {"text": "failure"}]}, "sentence": " Any failure to comply with such restrictions may constitute a violation of the securities laws or regulations of any such relevant jurisdiction.", "object": {"text": "a violation of the securities laws or regulations of any such relevant jurisdiction", "keywords": [{"text": "relevant jurisdiction"}, {"text": "securities laws"}, {"text": "violation"}, {"text": "regulations"}]}, "action": {"verb": {"text": "constitute", "tense": "future"}, "text": "may constitute", "normalized": "may constitute"}}, {"subject": {"text": "a copy of this announcement", "keywords": [{"text": "announcement"}, {"text": "copy"}]}, "sentence": " In accordance with Rule 26.1 of the Code, a copy of this announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on the business day following the date of this announcement.", "object": {"text": "made available (subject to certain restrictions relating to persons resident in restricted jurisdictions", "keywords": [{"text": "certain restrictions"}, {"text": "restricted jurisdictions"}, {"text": "persons resident"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "a copy of this announcement", "keywords": [{"text": "announcement"}, {"text": "copy"}]}, "sentence": " In accordance with Rule 26.1 of the Code, a copy of this announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on the business day following the date of this announcement.", "object": {"text": "available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time)", "keywords": [{"text": "(London time)"}, {"text": "restricted jurisdictions"}, {"text": "certain restrictions"}, {"text": "persons resident"}], "entities": [{"type": "Company", "text": "Takeda"}, {"type": "Location", "text": "London", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "will be made", "normalized": "will be make"}}, {"subject": {"text": "The content of the website", "keywords": [{"text": "content"}, {"text": "website"}]}, "sentence": " The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.", "object": {"text": "to in this announcement", "keywords": [{"text": "announcement"}]}, "action": {"verb": {"text": "refer", "tense": "past"}, "text": "referred", "normalized": "refer"}}, {"subject": {"text": "The content of the website", "keywords": [{"text": "content"}, {"text": "website"}]}, "sentence": " The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.", "object": {"text": "not form part of this announcement", "keywords": [{"text": "announcement"}]}, "action": {"verb": {"text": "do", "tense": "present"}, "text": "does", "normalized": "do"}}], "concepts": [{"text": "Securities Act of 1933", "relevance": 0.979182, "dbpedia_resource": "http://dbpedia.org/resource/Securities_Act_of_1933"}, {"text": "U.S. Securities and Exchange Commission", "relevance": 0.776179, "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.745731, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Stock exchange", "relevance": 0.68431, "dbpedia_resource": "http://dbpedia.org/resource/Stock_exchange"}, {"text": "Offer and acceptance", "relevance": 0.647288, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}], "categories": [{"score": 0.934751, "label": "/real estate/buying and selling homes"}, {"score": 0.90422, "label": "/finance/financial news"}, {"score": 0.840324, "label": "/finance/investing/funds"}], "relations": [{"type": "employedBy", "sentence": "NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION November 19, 2018 (London time) --- Takeda Pharmaceutical Company Limited (TSE: 4502) (the ' Company ' or ' Takeda ') announces that it has today, November 19, 2018 (London time), determined the issue price and other matters in relation to its unsecured U.S. dollar (' US$ ') denominated senior notes (the ' Notes ')for an aggregate amount of US$5,500 million, as outlined below.", "score": 0.392899, "arguments": [{"text": "Takeda", "location": [305, 311], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "Company", "location": [290, 297], "entities": [{"type": "Organization", "text": "Securities Act of"}]}]}, {"type": "basedIn", "sentence": "(h) Pledge None (i) Security None (j) Securities Exchange on which the notes will be listed Singapore Exchange Securities Trading Limited (2)Unsecured US$ Denominated Senior Notes Due 2021 (a) Issue Amount US$1,250 million (b) Coupon 4.000% per annum* (c) Issue Price 99.936% of the principal amount (d) Maturity Date November 26, 2021 (e) Issue Date November 26, 2018 (f) Use of proceeds Payment of a portion of the cash consideration for the Acquisition and related fees, costs and expenses incurred by Takeda (g) Method of Offering Private offering in foreign markets including the U.S., Europe and Asia with registration rights.", "score": 0.958667, "arguments": [{"text": "Exchange Securities Trading Limited", "location": [2335, 2370], "entities": [{"type": "Organization", "text": "Exchange Securities Trading Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Singapore", "location": [2325, 2334], "entities": [{"type": "GeopoliticalEntity", "text": "Singapore", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "(h) Pledge None (i) Security None (j) Securities Exchange on which the notes will be listed Singapore Exchange Securities Trading Limited (3)Unsecured US$ Denominated Senior Notes Due 2023 (a) Issue Amount US$1,500million (b) Coupon 4.400% per annum* (c) Issue Price 99.960% of the principal amount (d) Maturity Date November 26, 2023 (e) Issue Date November 26, 2018 (f) Use of proceeds Payment of a portion of the cash consideration for the Acquisition and related fees, costs and expenses incurred by Takeda (g) Method of Offering Private offering in foreign markets including the U.S., Europe and Asia with registration rights.", "score": 0.93305, "arguments": [{"text": "Exchange Securities Trading Limited", "location": [3180, 3215], "entities": [{"type": "Organization", "text": "Exchange Securities Trading Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Singapore", "location": [3170, 3179], "entities": [{"type": "GeopoliticalEntity", "text": "Singapore", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "(h) Pledge None (i) Security None (j) Securities Exchange on which the notes will be listed Singapore Exchange Securities Trading Limited (4)Unsecured US$ Denominated Senior Notes Due 2028 (a) Issue Amount US$1,750 million (b) Coupon 5.000% per annum* (c) Issue Price 99.580% of the principal amount (d) Maturity Date November 26, 2028 (e) Issue Date November 26, 2018 (f) Use of proceeds Payment of a portion of the cash consideration for the Acquisition and related fees, costs and expenses incurred by Takeda (g) Method of Offering Private offering in foreign markets including the U.S., Europe and Asia with registration rights.", "score": 0.943984, "arguments": [{"text": "Exchange Securities Trading Limited", "location": [4024, 4059], "entities": [{"type": "Organization", "text": "Exchange Securities Trading Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Singapore", "location": [4014, 4023], "entities": [{"type": "GeopoliticalEntity", "text": "Singapore", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "(h) Pledge None (i) Security None (j) Securities Exchange on which the notes will be listed Singapore Exchange Securities Trading Limited * To be increased by up to 1.00% per annum if a registration default occurs.", "score": 0.935217, "arguments": [{"text": "Exchange Securities Trading Limited", "location": [4869, 4904], "entities": [{"type": "Organization", "text": "Exchange Securities Trading Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Singapore", "location": [4859, 4868], "entities": [{"type": "GeopoliticalEntity", "text": "Singapore", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "The notes will not be offered or sold within the U.S. or to U.S. persons, except to 'qualified institutional buyers' in reliance on the exemption from registration provided by Rule 144A under the Securities Act.", "score": 0.839448, "arguments": [{"text": "persons", "location": [2931, 2938], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "U.S.", "location": [2926, 2930], "entities": [{"type": "GeopoliticalEntity", "text": "Securities Act of"}]}]}, {"type": "employedBy", "sentence": "The notes will not be offered or sold within the U.S. or to U.S. persons, except to 'qualified institutional buyers' in reliance on the exemption from registration provided by Rule 144A under the Securities Act.", "score": 0.839448, "arguments": [{"text": "persons", "location": [3775, 3782], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "U.S.", "location": [3770, 3774], "entities": [{"type": "GeopoliticalEntity", "text": "Securities Act of"}]}]}, {"type": "employedBy", "sentence": "The notes will not be offered or sold within the U.S. or to U.S. persons, except to 'qualified institutional buyers' in reliance on the exemption from registration provided by Rule 144A under the Securities Act.", "score": 0.839448, "arguments": [{"text": "persons", "location": [4620, 4627], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "U.S.", "location": [4615, 4619], "entities": [{"type": "GeopoliticalEntity", "text": "Securities Act of"}]}]}, {"type": "partOf", "sentence": "(h) Pledge None (i) Security None (j) Securities Exchange on which the notes will be listed Singapore Exchange Securities Trading Limited (3)Unsecured US$ Denominated Senior Notes Due 2023 (a) Issue Amount US$1,500million (b) Coupon 4.400% per annum* (c) Issue Price 99.960% of the principal amount (d) Maturity Date November 26, 2023 (e) Issue Date November 26, 2018 (f) Use of proceeds Payment of a portion of the cash consideration for the Acquisition and related fees, costs and expenses incurred by Takeda (g) Method of Offering Private offering in foreign markets including the U.S., Europe and Asia with registration rights.", "score": 0.525318, "arguments": [{"text": "Unsecured US$ Denominated Senior Notes Due", "location": [3219, 3261], "entities": [{"type": "Organization", "text": "Unsecured US$ Denominated Senior Notes Due"}]}, {"text": "Exchange Securities Trading Limited", "location": [3180, 3215], "entities": [{"type": "Organization", "text": "Exchange Securities Trading Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "We will announce the estimated impact that issuing the Notes will have on our business performance promptly once available.", "score": 0.861961, "arguments": [{"text": "We", "location": [5202, 5204], "entities": [{"type": "Organization", "text": "Securities Act of"}]}, {"text": "announce", "location": [5210, 5218], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "managerOf", "sentence": "Media and Investor Contacts : Takeda ( Media - inside Japan) Kazumi Kobayashi Kazumi.Kobayashi@takeda.com +81 3 3278 2095 Takeda ( Media - outside Japan) Tsuyoshi Tada Tsuyoshi.Tada@takeda.com +1 617 551 2933 Elissa Johnsen Elissa.Johnsen@takeda.com +1 312 285 3203 About Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited ( TSE: 4502 ) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "score": 0.315032, "arguments": [{"text": "Takeda", "location": [5835, 5841], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "Media -", "location": [5844, 5851], "entities": [{"type": "Organization", "text": "Media -"}]}]}, {"type": "locatedAt", "sentence": "Media and Investor Contacts : Takeda ( Media - inside Japan) Kazumi Kobayashi Kazumi.Kobayashi@takeda.com +81 3 3278 2095 Takeda ( Media - outside Japan) Tsuyoshi Tada Tsuyoshi.Tada@takeda.com +1 617 551 2933 Elissa Johnsen Elissa.Johnsen@takeda.com +1 312 285 3203 About Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited ( TSE: 4502 ) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "score": 0.350646, "arguments": [{"text": "Media -", "location": [5844, 5851], "entities": [{"type": "Organization", "text": "Media -"}]}, {"text": "Japan", "location": [5859, 5864], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Media and Investor Contacts : Takeda ( Media - inside Japan) Kazumi Kobayashi Kazumi.Kobayashi@takeda.com +81 3 3278 2095 Takeda ( Media - outside Japan) Tsuyoshi Tada Tsuyoshi.Tada@takeda.com +1 617 551 2933 Elissa Johnsen Elissa.Johnsen@takeda.com +1 312 285 3203 About Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited ( TSE: 4502 ) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "score": 0.366621, "arguments": [{"text": "Takeda", "location": [5927, 5933], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "Media", "location": [5936, 5941], "entities": [{"type": "Organization", "text": "Media -"}]}]}, {"type": "colleague", "sentence": "Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "score": 0.265518, "arguments": [{"text": "Takeda", "location": [6739, 6745], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "employees", "location": [6746, 6755], "entities": [{"type": "Person", "text": "employees"}]}]}, {"type": "managerOf", "sentence": "Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "score": 0.547182, "arguments": [{"text": "Takeda", "location": [6826, 6832], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "partners", "location": [6835, 6843], "entities": [{"type": "Organization", "text": "partners"}]}]}, {"type": "locatedAt", "sentence": "Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "score": 0.439521, "arguments": [{"text": "partners", "location": [6835, 6843], "entities": [{"type": "Organization", "text": "partners"}]}, {"text": "countries", "location": [6875, 6884], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION November 19, 2018 (London time) --- Takeda Pharmaceutical Company Limited (TSE: 4502) (the ' Company ' or ' Takeda ') announces that it has today, November 19, 2018 (London time), determined the issue price and other matters in relation to its unsecured U.S. dollar (' US$ ') denominated senior notes (the ' Notes ')for an aggregate amount of US$5,500 million, as outlined below.", "score": 0.568752, "arguments": [{"text": "Takeda", "location": [305, 311], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "announces", "location": [315, 324], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "The distribution of this announcement in jurisdictions outside the United Kingdom or Japan may be restricted by law or regulation and therefore any person who comes into possession of this announcement should inform themselves about, and comply with, such restrictions.", "score": 0.669947, "arguments": [{"text": "who", "location": [7405, 7408], "entities": [{"type": "Person", "text": "person"}]}, {"text": "announcement", "location": [7439, 7451], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "partOfMany", "sentence": "The distribution of this announcement in jurisdictions outside the United Kingdom or Japan may be restricted by law or regulation and therefore any person who comes into possession of this announcement should inform themselves about, and comply with, such restrictions.", "score": 0.714252, "arguments": [{"text": "who", "location": [7405, 7408], "entities": [{"type": "Person", "text": "person"}]}, {"text": "themselves", "location": [7466, 7476], "entities": [{"type": "Person", "text": "themselves"}]}]}, {"type": "partOf", "sentence": "Publication on Website In accordance with Rule 26.1 of the Code, a copy of this announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on the business day following the date of this announcement.", "score": 0.576713, "arguments": [{"text": "Rule", "location": [7707, 7711], "entities": [{"type": "Organization", "text": "Code\nUnder Rule"}]}, {"text": "Code", "location": [7724, 7728], "entities": [{"type": "Organization", "text": "Code"}]}]}, {"type": "hasAttribute", "sentence": "If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.", "score": 0.824036, "arguments": [{"text": "Rule", "location": [10641, 10645], "entities": [{"type": "Organization", "text": "Code\nUnder Rule"}]}, {"text": "8.3", "location": [10646, 10649], "entities": [{"type": "Money", "text": "8.3", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "participantIn", "sentence": "Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).", "score": 0.508911, "arguments": [{"text": "persons", "location": [10832, 10839], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "concert", "location": [10850, 10857], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified.", "score": 0.457967, "arguments": [{"text": "whose", "location": [10964, 10969], "entities": [{"type": "Person", "text": "whose"}]}, {"text": "companies", "location": [10940, 10949], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.", "score": 0.457452, "arguments": [{"text": "Panel", "location": [11311, 11316], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "Market Surveillance Unit", "location": [11319, 11343], "entities": [{"type": "Facility", "text": "Market Surveillance Unit"}]}]}, {"type": "agentOf", "sentence": "Attachments Original document Permalink Disclaimer Takeda Pharmaceutical Co. Ltd. published this content on 20 November 2018 and is solely responsible for the information contained herein.", "score": 0.982494, "arguments": [{"text": "Takeda Pharmaceutical Co. Ltd.", "location": [11537, 11567], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "published", "location": [11568, 11577], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "timeOf", "sentence": "Attachments Original document Permalink Disclaimer Takeda Pharmaceutical Co. Ltd. published this content on 20 November 2018 and is solely responsible for the information contained herein.", "score": 0.62975, "arguments": [{"text": "November 2018", "location": [11597, 11610], "entities": [{"type": "Date", "text": "November 2018"}]}, {"text": "published", "location": [11568, 11577], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "affectedBy", "sentence": "The Notes will be issued in order to finance a portion of the funds necessary for the acquisition of Shire plc (the ' Acquisition ') and reduce commitments under the 364-Day Bridge Credit Agreement entered into in connection with the Acquisition on May 8, 2018 (as amended on June 8, 2018 and October 26, 2018) (the ' Bridge Credit Agreement ').", "score": 0.813219, "arguments": [{"text": "Shire plc", "location": [678, 687], "entities": [{"type": "Organization", "text": "Securities Act of"}]}, {"text": "acquisition", "location": [663, 674], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "The Notes will be issued in order to finance a portion of the funds necessary for the acquisition of Shire plc (the ' Acquisition ') and reduce commitments under the 364-Day Bridge Credit Agreement entered into in connection with the Acquisition on May 8, 2018 (as amended on June 8, 2018 and October 26, 2018) (the ' Bridge Credit Agreement ').", "score": 0.533135, "arguments": [{"text": "Acquisition", "location": [811, 822], "entities": [{"type": "Organization", "text": "Acquisition", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [663, 674], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "basedIn", "sentence": "In accordance with Rule 26 of the City Code on Takeovers and Mergers, a copy of the final offering circular in respect of the Notes will be available to view on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on the business day following the publication thereof.", "score": 0.422861, "arguments": [{"text": "Rule", "location": [942, 946], "entities": [{"type": "Organization", "text": "Code\nUnder Rule"}]}, {"text": "City Code", "location": [957, 966], "entities": [{"type": "GeopoliticalEntity", "text": "City Code"}]}]}, {"type": "hasAttribute", "sentence": "1. Outline of the Unsecured US$ Denominated Senior Notes (1)Unsecured US$ Denominated Senior Notes Due 2020 (a) Issue Amount US$1,000million (b) Coupon 3.800% per annum* (c) Issue Price 99.937% of the principal amount (d) Maturity Date November 26, 2020 (e) Issue Date November 26, 2018 (f) Use of proceeds Payment of a portion of the cash consideration for the Acquisition and related fees, costs and expenses incurred by Takeda (g) Method of Offering Private offering in foreign markets including the U.S., Europe and Asia with registration rights.", "score": 0.395531, "arguments": [{"text": "Issue Amount\nUS$", "location": [1532, 1548], "entities": [{"type": "Organization", "text": "Issue Amount\nUS$"}]}, {"text": "1,000million", "location": [1548, 1560], "entities": [{"type": "Money", "text": "1,000million"}]}]}, {"type": "partOf", "sentence": "1. Outline of the Unsecured US$ Denominated Senior Notes (1)Unsecured US$ Denominated Senior Notes Due 2020 (a) Issue Amount US$1,000million (b) Coupon 3.800% per annum* (c) Issue Price 99.937% of the principal amount (d) Maturity Date November 26, 2020 (e) Issue Date November 26, 2018 (f) Use of proceeds Payment of a portion of the cash consideration for the Acquisition and related fees, costs and expenses incurred by Takeda (g) Method of Offering Private offering in foreign markets including the U.S., Europe and Asia with registration rights.", "score": 0.319588, "arguments": [{"text": "Coupon", "location": [1565, 1571], "entities": [{"type": "Organization", "text": "Coupon", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Issue Amount\nUS$", "location": [1532, 1548], "entities": [{"type": "Organization", "text": "Issue Amount\nUS$"}]}]}, {"type": "residesIn", "sentence": "The notes will not be offered or sold within the U.S. or to U.S. persons, except to 'qualified institutional buyers' in reliance on the exemption from registration provided by Rule 144A under the U.S. Securities Act of 1933, as amended (the ' Securities Act ').", "score": 0.640093, "arguments": [{"text": "persons", "location": [2036, 2043], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "U.S.", "location": [2031, 2035], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "(h) Pledge None (i) Security None (j) Securities Exchange on which the notes will be listed Singapore Exchange Securities Trading Limited (2)Unsecured US$ Denominated Senior Notes Due 2021 (a) Issue Amount US$1,250 million (b) Coupon 4.000% per annum* (c) Issue Price 99.936% of the principal amount (d) Maturity Date November 26, 2021 (e) Issue Date November 26, 2018 (f) Use of proceeds Payment of a portion of the cash consideration for the Acquisition and related fees, costs and expenses incurred by Takeda (g) Method of Offering Private offering in foreign markets including the U.S., Europe and Asia with registration rights.", "score": 0.470471, "arguments": [{"text": "Securities Exchange", "location": [2271, 2290], "entities": [{"type": "Organization", "text": "Securities Exchange"}]}, {"text": "Pledge", "location": [2237, 2243], "entities": [{"type": "EventCommunication", "text": "Pledge"}]}]}, {"type": "agentOf", "sentence": "(h) Pledge None (i) Security None (j) Securities Exchange on which the notes will be listed Singapore Exchange Securities Trading Limited (3)Unsecured US$ Denominated Senior Notes Due 2023 (a) Issue Amount US$1,500million (b) Coupon 4.400% per annum* (c) Issue Price 99.960% of the principal amount (d) Maturity Date November 26, 2023 (e) Issue Date November 26, 2018 (f) Use of proceeds Payment of a portion of the cash consideration for the Acquisition and related fees, costs and expenses incurred by Takeda (g) Method of Offering Private offering in foreign markets including the U.S., Europe and Asia with registration rights.", "score": 0.470471, "arguments": [{"text": "Securities Exchange", "location": [3116, 3135], "entities": [{"type": "Organization", "text": "Securities Exchange"}]}, {"text": "Pledge", "location": [3082, 3088], "entities": [{"type": "EventCommunication", "text": "Pledge"}]}]}], "keywords": [{"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": -0.920074, "label": "negative"}, "relevance": 0.718972, "count": 1}, {"text": "U.S. Securities Act", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.667956, "count": 1}, {"text": "senior notes", "sentiment": {"score": -0.920074, "label": "negative"}, "relevance": 0.614691, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0.461522, "mixed": "1", "label": "positive"}, "relevance": 0.609368, "count": 9}, {"text": "Securities Exchange", "sentiment": {"score": -0.447432, "label": "negative"}, "relevance": 0.603985, "count": 4}, {"text": "U.S. persons", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.598172, "count": 4}, {"text": "Disclosure requirements of the Code", "sentiment": {"score": 0.734496, "label": "positive"}, "relevance": 0.593909, "count": 1}, {"text": "securities exchange offeror", "sentiment": {"score": 0.65995, "label": "positive"}, "relevance": 0.581565, "count": 9}, {"text": "Opening Position Disclosure", "sentiment": {"score": 0.501233, "mixed": "1", "label": "positive"}, "relevance": 0.576492, "count": 5}, {"text": "Securities Act", "sentiment": {"score": -0.447432, "label": "negative"}, "relevance": 0.572563, "count": 5}, {"text": "Notes", "sentiment": {"score": 0.375249, "mixed": "1", "label": "positive"}, "relevance": 0.570762, "count": 3}, {"text": "unsecured U.S. dollar", "sentiment": {"score": -0.920074, "label": "negative"}, "relevance": 0.569471, "count": 1}, {"text": "Company", "sentiment": {"score": -0.920074, "label": "negative"}, "relevance": 0.564909, "count": 1}, {"text": "London time", "sentiment": {"score": -0.278873, "mixed": "1", "label": "negative"}, "relevance": 0.563016, "count": 7}, {"text": "VIOLATION OF THE RELEVANT LAWS", "sentiment": {"score": -0.920074, "label": "negative"}, "relevance": 0.562522, "count": 1}, {"text": "Takeda's website", "sentiment": {"score": 0.498984, "label": "positive"}, "relevance": 0.560973, "count": 2}, {"text": "offer", "sentiment": {"score": 0.550268, "label": "positive"}, "relevance": 0.558449, "count": 4}, {"text": "takeda", "sentiment": {"score": 0.498984, "label": "positive"}, "relevance": 0.555354, "count": 2}, {"text": "foreign markets", "sentiment": {"score": 0.322138, "label": "positive"}, "relevance": 0.549771, "count": 4}, {"text": "issue price", "sentiment": {"score": -0.920074, "label": "negative"}, "relevance": 0.547988, "count": 1}, {"text": "registration rights", "sentiment": {"score": 0.322138, "label": "positive"}, "relevance": 0.54687, "count": 4}, {"text": "Singapore Exchange Securities Trading Limited", "sentiment": {"score": -0.447432, "label": "negative"}, "relevance": 0.545006, "count": 4}, {"text": "Rule", "sentiment": {"score": 0.532995, "label": "positive"}, "relevance": 0.544838, "count": 5}, {"text": "acquisition of Shire plc", "sentiment": {"score": 0.496916, "label": "positive"}, "relevance": 0.544492, "count": 1}, {"text": "pharmaceutical company", "sentiment": {"score": 0.830814, "label": "positive"}, "relevance": 0.537327, "count": 1}, {"text": "Dealing Disclosure", "sentiment": {"score": 0.527581, "label": "positive"}, "relevance": 0.53623, "count": 5}, {"text": "announcement", "sentiment": {"score": 0.491758, "mixed": "1", "label": "positive"}, "relevance": 0.534159, "count": 5}, {"text": "portion of the cash consideration", "sentiment": {"score": 0.322138, "label": "positive"}, "relevance": 0.533734, "count": 4}, {"text": "364-Day Bridge Credit Agreement", "sentiment": {"score": 0.496916, "label": "positive"}, "relevance": 0.532967, "count": 1}, {"text": "Acquisition", "sentiment": {"score": 0.510836, "label": "positive"}, "relevance": 0.532795, "count": 7}, {"text": "better health", "sentiment": {"score": 0.830814, "label": "positive"}, "relevance": 0.528324, "count": 1}, {"text": "respect of the Notes", "sentiment": {"score": 0.617682, "label": "positive"}, "relevance": 0.528205, "count": 1}, {"text": "copy of the final offering", "sentiment": {"score": 0.617682, "label": "positive"}, "relevance": 0.52706, "count": 1}, {"text": "offeror", "sentiment": {"score": 0.449517, "mixed": "1", "label": "positive"}, "relevance": 0.526796, "count": 5}, {"text": "portion of the funds", "sentiment": {"score": 0.496916, "label": "positive"}, "relevance": 0.525096, "count": 1}, {"text": "person", "sentiment": {"score": 0.569774, "label": "positive"}, "relevance": 0.52509, "count": 5}, {"text": "Website", "sentiment": {"score": 0.356816, "label": "positive"}, "relevance": 0.524753, "count": 1}, {"text": "US", "sentiment": {"score": -0.920074, "label": "negative"}, "relevance": 0.523878, "count": 1}, {"text": "related fees", "sentiment": {"score": 0.322138, "label": "positive"}, "relevance": 0.523676, "count": 4}, {"text": "Code", "sentiment": {"score": 0.572035, "label": "positive"}, "relevance": 0.522899, "count": 3}, {"text": "City Code", "sentiment": {"score": 0.617682, "label": "positive"}, "relevance": 0.522323, "count": 1}, {"text": "registration", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521723, "count": 4}, {"text": "respect", "sentiment": {"score": 0.734496, "label": "positive"}, "relevance": 0.52166, "count": 1}, {"text": "brighter future", "sentiment": {"score": 0.830814, "label": "positive"}, "relevance": 0.520521, "count": 1}, {"text": "notes", "sentiment": {"score": -0.447432, "label": "negative"}, "relevance": 0.520343, "count": 8}, {"text": "Rule 144A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520015, "count": 4}, {"text": "details of the person", "sentiment": {"score": 0.530035, "label": "positive"}, "relevance": 0.519426, "count": 1}, {"text": "November", "sentiment": {"score": -0.920074, "label": "negative"}, "relevance": 0.519091, "count": 3}, {"text": "impact", "sentiment": {"score": 0.924309, "label": "positive"}, "relevance": 0.518899, "count": 1}, {"text": "Impact", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518899, "count": 1}]}, "extracted_metadata": {"sha1": "cb1ec02d59e3f44d29d23e347469e8386d5f035d", "filename": "1542676887338.zip-76226fa54999955cb38592886c4003c2.xml", "file_type": "json"}, "external_links": ["http://www.publicnow.com/view/61659BFB93B10CA5416B1157EE6CE51460E0D9FF", "https://www.takeda.com/investors/", "https://www.takeda.com/newsroom/newsreleases/2018/takeda-announces-pricing-of-its-unsecured-u.s.-dollar-denominated-senior-notes/", "https://www.takeda.com/investors/offer-for-shire/", "https://www.takeda.com/newsroom/"], "title": "Takeda Pharmaceutical : Announces Pricing of its Unsecured U.S. Dollar Denominated Senior Notes | MarketScreener", "forum_title": "Stock market news - Company News  - MarketScreener.com"}, {"id": "pfmf-zUiDt9DaS1bCe-dWbkgKKi0DLD7dfjVx0-hZQOGjym44JxpFE4tWDZP9USh", "result_metadata": {"score": 34.856438}, "author": "Data Bridge Market Research", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.558418, "label": "negative"}, "text": "Nephron Pharmaceuticals", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.531509, "label": "negative"}, "text": "Unither Pharmaceuticals", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Ltd", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.484928, "label": "positive"}, "text": "Catalent Pharma Solutions", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pharmapack", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Market Forthcoming Developments", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Horizon Pharma", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0.701956, "label": "positive"}}, "semantic_roles": [], "concepts": [{"text": "Pharmacology", "relevance": 0.958983, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pharmacy", "relevance": 0.923989, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.84105, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Pharmaceutical drug", "relevance": 0.806056, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Medicine", "relevance": 0.718597, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}], "categories": [{"score": 0.840167, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.652584, "label": "/health and fitness/drugs"}], "relations": [], "keywords": [{"text": "fill-Seal Market Forthcoming Developments", "sentiment": {"score": 0.701956, "label": "positive"}, "relevance": 0.865062, "count": 1}, {"text": "Nephron Pharmaceuticals", "sentiment": {"score": 0.701956, "label": "positive"}, "relevance": 0.842527, "count": 1}, {"text": "Takeda Pharmaceutical Company Ltd", "sentiment": {"score": 0.701956, "label": "positive"}, "relevance": 0.597632, "count": 1}, {"text": "Unither Pharmaceuticals", "sentiment": {"score": 0.701956, "label": "positive"}, "relevance": 0.534022, "count": 1}, {"text": "Horizon Pharma plc", "sentiment": {"score": 0.701956, "label": "positive"}, "relevance": 0.512144, "count": 1}, {"text": "Catalent Pharma Solutions", "sentiment": {"score": 0.701956, "label": "positive"}, "relevance": 0.321096, "count": 1}, {"text": "CSi packaging", "sentiment": {"score": 0.701956, "label": "positive"}, "relevance": 0.1965, "count": 1}, {"text": "Pharmapack", "sentiment": {"score": 0.701956, "label": "positive"}, "relevance": 0.123621, "count": 1}]}, "crawl_date": "2018-11-20T11:26:24Z", "url": "https://www.openpr.com/news/1385254/Blow-fill-Seal-Market-Forthcoming-Developments-In-2019-To-2025-By-Nephron-Pharmaceuticals-Unither-Pharmaceuticals-Takeda-Pharmaceutical-Company-Ltd-Horizon-Pharma-plc-Catalent-Pharma-Solutions-CSi-packaging-Pharmapack.html", "host": "openpr.com", "text": "Ltd., \u2022 Weiler Engineering Inc., \u2022 Shanghai Sunway International Trade Co.", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-20T11:15:00Z", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.839193, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Wuxi Jingpai Machinery Co. Ltd.", "relevance": 0.617595, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shanghai Sunway International Trade Co. Ltd.", "relevance": 0.58958, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Horizon Pharma", "relevance": 0.55222, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Weiler Engineering Inc.", "relevance": 0.518039, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "360-degree", "relevance": 0.518039, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "5.5%", "relevance": 0.518039, "type": "Quantity"}], "sentiment": {"document": {"score": 0.681388, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Data Bridge Market Research Blow-fill-Seal Market The Blow-fill-Seal Market", "keywords": [{"text": "Research Blow-fill-Seal Market"}, {"text": "Data"}]}, "sentence": "Press release from: Data Bridge Market Research Blow-fill-Seal Market The Blow-fill-Seal Market is segmented in product, application, end-user, and region, which is being used the top players and brands that are dominating the market by their moves like product launches, their researches, joint ventures, merges, and accusations, and as the calculation of historic year base year shows that they are moving in the right direction.This report contains all the recent developments, product launches, joint ventures, merges and accusations by the top brands and players.", "object": {"text": "segmented in product", "keywords": [{"text": "product"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Data Bridge Market Research Blow-fill-Seal Market The Blow-fill-Seal Market", "keywords": [{"text": "Research Blow-fill-Seal Market"}, {"text": "Data"}]}, "sentence": "Press release from: Data Bridge Market Research Blow-fill-Seal Market The Blow-fill-Seal Market is segmented in product, application, end-user, and region, which is being used the top players and brands that are dominating the market by their moves like product launches, their researches, joint ventures, merges, and accusations, and as the calculation of historic year base year shows that they are moving in the right direction.This report contains all the recent developments, product launches, joint ventures, merges and accusations by the top brands and players.", "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "end-user, and region", "keywords": [{"text": "end-user"}, {"text": "region"}]}, "sentence": "Press release from: Data Bridge Market Research Blow-fill-Seal Market The Blow-fill-Seal Market is segmented in product, application, end-user, and region, which is being used the top players and brands that are dominating the market by their moves like product launches, their researches, joint ventures, merges, and accusations, and as the calculation of historic year base year shows that they are moving in the right direction.This report contains all the recent developments, product launches, joint ventures, merges and accusations by the top brands and players.", "object": {"text": "being used the top players", "keywords": [{"text": "players"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "brands", "keywords": [{"text": "brands"}]}, "sentence": "Press release from: Data Bridge Market Research Blow-fill-Seal Market The Blow-fill-Seal Market is segmented in product, application, end-user, and region, which is being used the top players and brands that are dominating the market by their moves like product launches, their researches, joint ventures, merges, and accusations, and as the calculation of historic year base year shows that they are moving in the right direction.This report contains all the recent developments, product launches, joint ventures, merges and accusations by the top brands and players.", "object": {"text": "dominating the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "brands", "keywords": [{"text": "brands"}]}, "sentence": "Press release from: Data Bridge Market Research Blow-fill-Seal Market The Blow-fill-Seal Market is segmented in product, application, end-user, and region, which is being used the top players and brands that are dominating the market by their moves like product launches, their researches, joint ventures, merges, and accusations, and as the calculation of historic year base year shows that they are moving in the right direction.This report contains all the recent developments, product launches, joint ventures, merges and accusations by the top brands and players.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "dominate", "tense": "present"}, "text": "are dominating", "normalized": "be dominate"}}, {"subject": {"text": "the calculation of historic year base year", "keywords": [{"text": "calculation"}, {"text": "historic year base"}]}, "sentence": "Press release from: Data Bridge Market Research Blow-fill-Seal Market The Blow-fill-Seal Market is segmented in product, application, end-user, and region, which is being used the top players and brands that are dominating the market by their moves like product launches, their researches, joint ventures, merges, and accusations, and as the calculation of historic year base year shows that they are moving in the right direction.This report contains all the recent developments, product launches, joint ventures, merges and accusations by the top brands and players.", "object": {"text": "that they are moving in the right direction.This report contains all the recent developments, product launches, joint ventures, merges and accusations by the top brands and players", "keywords": [{"text": "right direction.This report"}, {"text": "product launches"}, {"text": "joint ventures"}, {"text": "recent developments"}]}, "action": {"verb": {"text": "show", "tense": "present"}, "text": "shows", "normalized": "show"}}, {"subject": {"text": "This part"}, "sentence": " This part also sheds light on the gap between supply and consumption.", "object": {"text": "light on the gap between supply and consumption", "keywords": [{"text": "gap"}, {"text": "consumption"}, {"text": "light"}, {"text": "supply"}]}, "action": {"verb": {"text": "shed", "tense": "present"}, "text": "sheds", "normalized": "shed"}}, {"subject": {"text": "Import and export figures", "keywords": [{"text": "Import"}, {"text": "export figures"}]}, "sentence": " Import and export figures are also given in this part.\u2022 Production Analysis: - Production of the Blow-fill-Seal is analyzed with respect to different regions, types and applications.", "action": {"verb": {"text": "give", "tense": "past"}, "text": "given", "normalized": "give"}}, {"subject": {"text": "Production of the Blow-fill-Seal", "keywords": [{"text": "Production"}, {"text": "Blow-fill-Seal"}]}, "sentence": " Import and export figures are also given in this part.\u2022 Production Analysis: - Production of the Blow-fill-Seal is analyzed with respect to different regions, types and applications.", "object": {"text": "analyzed with respect to different regions, types and applications", "keywords": [{"text": "different regions"}, {"text": "respect"}, {"text": "types"}, {"text": "applications"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "price analysis of various Blow-fill-Seal Market key players", "keywords": [{"text": "various Blow-fill-Seal Market"}, {"text": "price analysis"}, {"text": "key players"}]}, "sentence": " Here, price analysis of various Blow-fill-Seal Market key players is also covered.\u2022 Competitors:- In this section, various Blow-fill-Seal industry leading players are studied with respect to their company profile, product portfolio, capacity, price, cost, and revenue.\u2022 Sales and Revenue Analysis: - Both, sales and revenue are studied for the different regions of the Blow-fill-Seal Market.", "object": {"text": "covered.\u2022 Competitors", "keywords": [{"text": "Competitors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "various Blow-fill-Seal industry leading players", "keywords": [{"text": "various Blow-fill-Seal industry"}, {"text": "players"}]}, "sentence": " Here, price analysis of various Blow-fill-Seal Market key players is also covered.\u2022 Competitors:- In this section, various Blow-fill-Seal industry leading players are studied with respect to their company profile, product portfolio, capacity, price, cost, and revenue.\u2022 Sales and Revenue Analysis: - Both, sales and revenue are studied for the different regions of the Blow-fill-Seal Market.", "object": {"text": "with respect to their company profile, product portfolio, capacity, price, cost, and revenue.\u2022 Sales and Revenue Analysis", "keywords": [{"text": "Revenue Analysis"}, {"text": "company profile"}, {"text": "product portfolio"}, {"text": "revenue.\u2022 Sales"}]}, "action": {"verb": {"text": "study", "tense": "past"}, "text": "are studied", "normalized": "be study"}}, {"subject": {"text": "Another major aspect", "keywords": [{"text": "major aspect"}]}, "sentence": " Another major aspect, price, which plays an important part in the revenue generation, is also assessed in this section for the various regions.\u2022 Other Analyses: - Apart from the information, trade and distribution analysis for the Blow-fill-Seal Market.\u2022 A complete and useful guide for new market aspirants\u2022 Forecast information will drive strategic, innovative and profitable business plans and SWOT analysis of players will pave the way for growth opportunities, risk analysis, investment feasibility and recommendationsSpeak To Industry Experts, Request For Details Report At: databridgemarketresearch.com/speak-to-analyst/?dbmr=globa...", "object": {"text": "an important part"}, "action": {"verb": {"text": "play", "tense": "present"}, "text": "plays", "normalized": "play"}}, {"subject": {"text": "players", "keywords": [{"text": "players"}]}, "sentence": " Another major aspect, price, which plays an important part in the revenue generation, is also assessed in this section for the various regions.\u2022 Other Analyses: - Apart from the information, trade and distribution analysis for the Blow-fill-Seal Market.\u2022 A complete and useful guide for new market aspirants\u2022 Forecast information will drive strategic, innovative and profitable business plans and SWOT analysis of players will pave the way for growth opportunities, risk analysis, investment feasibility and recommendationsSpeak To Industry Experts, Request For Details Report At: databridgemarketresearch.com/speak-to-analyst/?dbmr=globa...", "object": {"text": "the way", "keywords": [{"text": "way"}]}, "action": {"verb": {"text": "pave", "tense": "future"}, "text": "will pave", "normalized": "will pave"}}], "concepts": [{"text": "Marketing", "relevance": 0.988099, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Strategic management", "relevance": 0.594659, "dbpedia_resource": "http://dbpedia.org/resource/Strategic_management"}, {"text": "Market research", "relevance": 0.583619, "dbpedia_resource": "http://dbpedia.org/resource/Market_research"}, {"text": "Competitor analysis", "relevance": 0.478522, "dbpedia_resource": "http://dbpedia.org/resource/Competitor_analysis"}, {"text": "Trade", "relevance": 0.444713, "dbpedia_resource": "http://dbpedia.org/resource/Trade"}, {"text": "Revenue", "relevance": 0.424186, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}, {"text": "Region", "relevance": 0.413242, "dbpedia_resource": "http://dbpedia.org/resource/Region"}, {"text": "International trade", "relevance": 0.408397, "dbpedia_resource": "http://dbpedia.org/resource/International_trade"}, {"text": "SWOT analysis", "relevance": 0.380862, "dbpedia_resource": "http://dbpedia.org/resource/SWOT_analysis"}, {"text": "Capacity utilization", "relevance": 0.379428, "dbpedia_resource": "http://dbpedia.org/resource/Capacity_utilization"}, {"text": "Management", "relevance": 0.366279, "dbpedia_resource": "http://dbpedia.org/resource/Management"}, {"text": "Supply and demand", "relevance": 0.359356, "dbpedia_resource": "http://dbpedia.org/resource/Supply_and_demand"}], "categories": [{"score": 0.824314, "label": "/business and industrial/business operations/management/business process"}, {"score": 0.781811, "label": "/finance/financial news"}, {"score": 0.77753, "label": "/finance/investing"}], "relations": [{"type": "memberOf", "sentence": "\u00b7 Competitors:- In this section, various Blow-fill-Seal industry leading players are studied with respect to their company profile, product portfolio, capacity, price, cost, and revenue.", "score": 0.212644, "arguments": [{"text": "their", "location": [1824, 1829], "entities": [{"type": "Person", "text": "players"}]}, {"text": "company", "location": [1830, 1837], "entities": [{"type": "Organization", "text": "Seal Market Report Offers Enlightenment"}]}]}, {"type": "basedIn", "sentence": "\u00b7 A complete and useful guide for new market aspirants\u00b7 Forecast information will drive strategic, innovative and profitable business plans and SWOT analysis of players will pave the way for growth opportunities, risk analysis, investment feasibility and recommendationsSpeak To Industry Experts, Request For Details Report At: databridgemarketresearch.com/speak-to-analyst/?dbmr=globa... Market Key Competitors: \u00b7 Wuxi Jingpai Machinery Co. Ltd., \u00b7 Weiler Engineering Inc., \u00b7 Shanghai Sunway International Trade Co. Ltd., \u00b7 Horizon Pharma plc.,", "score": 0.776483, "arguments": [{"text": "Sunway International Trade Co. Ltd.", "location": [2764, 2799], "entities": [{"type": "Organization", "text": "Sunway International Trade Co. Ltd."}]}, {"text": "Shanghai", "location": [2755, 2763], "entities": [{"type": "GeopoliticalEntity", "text": "Shanghai"}]}]}], "keywords": [{"text": "Data Bridge Market Research Blow", "sentiment": {"score": -0.613864, "label": "negative"}, "relevance": 0.8089, "count": 1}, {"text": "Blow-fill-Seal Market", "sentiment": {"score": 0.644186, "mixed": "1", "label": "positive"}, "relevance": 0.738116, "count": 3}, {"text": "Seal Market", "sentiment": {"score": -0.613864, "label": "negative"}, "relevance": 0.72139, "count": 1}, {"text": "Global Blow-fill-Seal market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.629432, "count": 1}, {"text": "Production Analysis", "sentiment": {"score": 0.759485, "label": "positive"}, "relevance": 0.624779, "count": 1}, {"text": "production capacity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.594124, "count": 1}, {"text": "major aspect", "sentiment": {"score": 0.34503, "label": "positive"}, "relevance": 0.593355, "count": 1}, {"text": "Press release", "sentiment": {"score": -0.613864, "label": "negative"}, "relevance": 0.583507, "count": 1}, {"text": "market", "sentiment": {"score": -0.613864, "label": "negative"}, "relevance": 0.582574, "count": 1}, {"text": "top players", "sentiment": {"score": -0.613864, "label": "negative"}, "relevance": 0.580799, "count": 1}, {"text": "joint ventures", "sentiment": {"score": -0.613864, "label": "negative"}, "relevance": 0.576643, "count": 2}, {"text": "Blow-fill-Seal Market Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.575806, "count": 1}, {"text": "players", "sentiment": {"score": 0.542011, "mixed": "1", "label": "positive"}, "relevance": 0.564407, "count": 2}, {"text": "end-user", "sentiment": {"score": -0.613864, "label": "negative"}, "relevance": 0.562746, "count": 1}, {"text": "country level", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555331, "count": 1}, {"text": "different regions", "sentiment": {"score": 0.759485, "label": "positive"}, "relevance": 0.554503, "count": 1}, {"text": "regional level", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554096, "count": 1}, {"text": "product", "sentiment": {"score": -0.613864, "label": "negative"}, "relevance": 0.553315, "count": 1}, {"text": "Market share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55326, "count": 1}, {"text": "right direction", "sentiment": {"score": -0.613864, "label": "negative"}, "relevance": 0.549193, "count": 1}, {"text": "part", "sentiment": {"score": 0.759485, "label": "positive"}, "relevance": 0.54671, "count": 2}, {"text": "product portfolio", "sentiment": {"score": 0.902832, "label": "positive"}, "relevance": 0.546382, "count": 1}, {"text": "360-degree Blow-fill-Seal overview", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.546127, "count": 1}, {"text": "revenue", "sentiment": {"score": 0.902832, "label": "positive"}, "relevance": 0.545735, "count": 2}, {"text": "way", "sentiment": {"score": 0.99238, "label": "positive"}, "relevance": 0.545423, "count": 2}, {"text": "recent developments", "sentiment": {"score": -0.613864, "label": "negative"}, "relevance": 0.545393, "count": 1}, {"text": "Analyses", "sentiment": {"score": 0.34503, "label": "positive"}, "relevance": 0.544341, "count": 1}, {"text": "Import", "sentiment": {"score": 0.759485, "label": "positive"}, "relevance": 0.544152, "count": 1}, {"text": "price", "sentiment": {"score": 0.672942, "label": "positive"}, "relevance": 0.542151, "count": 2}, {"text": "help of SWOT analysisFor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541908, "count": 1}, {"text": "risk analysis", "sentiment": {"score": 0.99238, "label": "positive"}, "relevance": 0.541081, "count": 1}, {"text": "region", "sentiment": {"score": -0.613864, "label": "negative"}, "relevance": 0.539694, "count": 1}, {"text": "report", "sentiment": {"score": -0.613864, "label": "negative"}, "relevance": 0.535918, "count": 1}, {"text": "section", "sentiment": {"score": 0.672942, "label": "positive"}, "relevance": 0.534902, "count": 3}, {"text": "Industry Experts", "sentiment": {"score": 0.99238, "label": "positive"}, "relevance": 0.533948, "count": 1}, {"text": "information", "sentiment": {"score": 0.34503, "label": "positive"}, "relevance": 0.532365, "count": 1}, {"text": "USD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53228, "count": 1}, {"text": "Sales", "sentiment": {"score": 0.902832, "label": "positive"}, "relevance": 0.532007, "count": 1}, {"text": "various regions", "sentiment": {"score": 0.34503, "label": "positive"}, "relevance": 0.531353, "count": 1}, {"text": "capacity", "sentiment": {"score": 0.902832, "label": "positive"}, "relevance": 0.530101, "count": 1}, {"text": "value", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529405, "count": 1}, {"text": "Wuxi Jingpai Machinery Co. Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529386, "count": 1}, {"text": "moves", "sentiment": {"score": -0.613864, "label": "negative"}, "relevance": 0.529223, "count": 1}, {"text": "Competitors", "sentiment": {"score": 0.902832, "label": "positive"}, "relevance": 0.528585, "count": 1}, {"text": "end", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528009, "count": 1}, {"text": "respect", "sentiment": {"score": 0.83686, "label": "positive"}, "relevance": 0.526534, "count": 2}, {"text": "accusations", "sentiment": {"score": -0.613864, "label": "negative"}, "relevance": 0.525251, "count": 2}, {"text": "Consumption", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524563, "count": 1}, {"text": "consumption", "sentiment": {"score": 0.759485, "label": "positive"}, "relevance": 0.524563, "count": 2}, {"text": "Supply", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524419, "count": 1}]}, "extracted_metadata": {"sha1": "4825f540bf5ad66bf3fb44f2f341da4875594539", "filename": "1542713184130.zip-c9579e9b07c0f7c8c68447e144e217b6.xml", "file_type": "json"}, "external_links": ["https://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-blow-fill-seal-market", "https://databridgemarketresearch.com/request-a-sample/?dbmr=global-blow-fill-seal-market"], "title": "Blow-fill-Seal Market Forthcoming Developments In 2019 To 2025 By: Nephron Pharmaceuticals, Unither Pharmaceuticals, Takeda Pharmaceutical Company Ltd, Horizon Pharma plc, Catalent Pharma Solutions, CSi packaging, Pharmapack,", "forum_title": "openPR.com - New Public Relations: Business, Economy, Finances, Banking & Insurance"}, {"id": "fylMsR524sOo-Tfib4oLcbtY6ml-3IuQFrnS5bp6on9hh3ohI6VcB60OpXjjxuQ1", "result_metadata": {"score": 31.200047}, "author": "Bloomberg News", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.546378, "label": "negative"}, "text": "Takeda", "relevance": 0.33, "type": "Person"}], "sentiment": {"document": {"score": -0.839884, "label": "negative"}}, "semantic_roles": [], "concepts": [{"text": "KILL", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/KILL"}], "categories": [{"score": 0.814193, "label": "/business and industrial/company"}, {"score": 0.778604, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.654385, "label": "/business and industrial/company/earnings"}], "relations": [{"type": "managerOf", "sentence": "Takeda's Dissident Shareholders Keep Trying to Kill Shire Deal", "score": 0.475894, "arguments": [{"text": "Takeda", "location": [0, 6], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Dissident Shareholders", "location": [9, 31], "entities": [{"type": "Organization", "text": "Dissident Shareholders"}]}]}, {"type": "agentOf", "sentence": "Takeda's Dissident Shareholders Keep Trying to Kill Shire Deal", "score": 0.458267, "arguments": [{"text": "Shire", "location": [52, 57], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Kill", "location": [47, 51], "entities": [{"type": "EventViolence", "text": "Kill"}]}]}], "keywords": [{"text": "Takeda's Dissident Shareholders", "sentiment": {"score": -0.839884, "label": "negative"}, "relevance": 0.988041, "count": 1}, {"text": "Shire Deal", "sentiment": {"score": -0.839884, "label": "negative"}, "relevance": 0.011959, "count": 1}]}, "crawl_date": "2018-11-20T00:30:16Z", "url": "https://www.bnn.ca/takeda-s-dissident-shareholders-keep-trying-to-kill-shire-deal-1.1170661", "host": "bnn.ca", "text": "(Bloomberg) -- They have little chance of success, but the shareholder group trying to derail Takeda Pharmaceutical Co.\u2019s $62 billion purchase of U.K.", "main_image_url": "https://www.bnnbloomberg.ca/img/tsn/logos/tsn-logo.png", "country": "CA", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-19T00:00:00-06:00", "enriched_text": {"entities": [{"count": 7, "sentiment": {"score": -0.405404, "label": "negative"}, "text": "Takeda", "relevance": 0.934062, "type": "Person"}, {"count": 4, "sentiment": {"score": 0.0956032, "label": "positive"}, "text": "Takeda", "relevance": 0.84548, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co.", "relevance": 0.550237, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kunio Takeda", "relevance": 0.48857, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.425762, "type": "Organization"}, {"count": 5, "sentiment": {"score": 0.662174, "label": "positive"}, "text": "Christophe Weber", "relevance": 0.347294, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.263958, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.K.-listed Shire Plc", "relevance": 0.257331, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.213174, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.207033, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bloomberg", "relevance": 0.202339, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.599029, "label": "negative"}, "text": "Roche Holding AG", "relevance": 0.191443, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Hoffmann-La Roche", "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann-La_Roche"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jeff Sutherland", "relevance": 0.185662, "type": "Person", "disambiguation": {"subtype": ["ComputerScientist", "MilitaryPerson"], "name": "Jeff Sutherland", "dbpedia_resource": "http://dbpedia.org/resource/Jeff_Sutherland"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Executive Officer", "relevance": 0.181877, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "K. Oanh Ha", "relevance": 0.181296, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "reporter", "relevance": 0.16848, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tokyo", "relevance": 0.1675, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Lisa Du", "relevance": 0.166525, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CEO", "relevance": 0.163158, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ldu31@bloomberg.net", "relevance": 0.124463, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "oha3@bloomberg.net", "relevance": 0.124463, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$30 billion", "relevance": 0.124463, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.124463, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1 percent", "relevance": 0.124463, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "237-year", "relevance": 0.124463, "type": "Quantity"}], "sentiment": {"document": {"score": -0.253301, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "They"}, "sentence": "(Bloomberg) -- They have little chance of success, but the shareholder group trying to derail Takeda Pharmaceutical Co.\u2019s $62 billion purchase of U.K.-listed Shire Plc is making last-minute attempts to win over investors.", "object": {"text": "little chance of success", "keywords": [{"text": "little chance"}, {"text": "success"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "the shareholder group", "keywords": [{"text": "shareholder group"}]}, "sentence": "(Bloomberg) -- They have little chance of success, but the shareholder group trying to derail Takeda Pharmaceutical Co.\u2019s $62 billion purchase of U.K.-listed Shire Plc is making last-minute attempts to win over investors.", "object": {"text": "to derail Takeda Pharmaceutical Co.\u2019s $62 billion purchase of U.K.-listed Shire Plc", "keywords": [{"text": "Takeda Pharmaceutical Co."}, {"text": "U.K.-listed Shire Plc"}, {"text": "purchase"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "U.K.-listed Shire Plc"}, {"type": "Quantity", "text": "$62 billion"}]}, "action": {"verb": {"text": "try", "tense": "present"}, "text": "trying", "normalized": "try"}}, {"subject": {"text": "the shareholder group", "keywords": [{"text": "shareholder group"}]}, "sentence": "(Bloomberg) -- They have little chance of success, but the shareholder group trying to derail Takeda Pharmaceutical Co.\u2019s $62 billion purchase of U.K.-listed Shire Plc is making last-minute attempts to win over investors.", "object": {"text": "Takeda Pharmaceutical Co.\u2019s", "keywords": [{"text": "Takeda Pharmaceutical Co."}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "derail", "tense": "future"}, "text": "trying to derail", "normalized": "try to derail"}}, {"subject": {"text": "Takeda Pharmaceutical Co.", "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": "(Bloomberg) -- They have little chance of success, but the shareholder group trying to derail Takeda Pharmaceutical Co.\u2019s $62 billion purchase of U.K.-listed Shire Plc is making last-minute attempts to win over investors.", "object": {"text": "$62 billion purchase of U.K.-listed Shire Plc", "keywords": [{"text": "U.K.-listed Shire Plc"}, {"text": "purchase"}], "entities": [{"type": "Company", "text": "U.K.-listed Shire Plc"}, {"type": "Quantity", "text": "$62 billion"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "the shareholder group trying to derail Takeda Pharmaceutical Co.\u2019s $62 billion purchase of U.K.-listed Shire Plc", "keywords": [{"text": "Takeda Pharmaceutical Co."}, {"text": "U.K.-listed Shire Plc"}, {"text": "shareholder group"}, {"text": "purchase"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "U.K.-listed Shire Plc"}, {"type": "Quantity", "text": "$62 billion"}]}, "sentence": "(Bloomberg) -- They have little chance of success, but the shareholder group trying to derail Takeda Pharmaceutical Co.\u2019s $62 billion purchase of U.K.-listed Shire Plc is making last-minute attempts to win over investors.", "object": {"text": "making last-minute attempts to win over investors", "keywords": [{"text": "last-minute attempts"}, {"text": "investors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the shareholder group trying to derail Takeda Pharmaceutical Co.\u2019s $62 billion purchase of U.K.-listed Shire Plc", "keywords": [{"text": "Takeda Pharmaceutical Co."}, {"text": "U.K.-listed Shire Plc"}, {"text": "shareholder group"}, {"text": "purchase"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "U.K.-listed Shire Plc"}, {"type": "Quantity", "text": "$62 billion"}]}, "sentence": "(Bloomberg) -- They have little chance of success, but the shareholder group trying to derail Takeda Pharmaceutical Co.\u2019s $62 billion purchase of U.K.-listed Shire Plc is making last-minute attempts to win over investors.", "object": {"text": "last-minute attempts", "keywords": [{"text": "last-minute attempts"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "is making", "normalized": "be make"}}, {"subject": {"text": "The dissident holders", "keywords": [{"text": "dissident holders"}]}, "sentence": " The dissident holders account for only about 1 percent of Takeda\u2019s shares outstanding, but the group is raising its profile as the Japanese drugmaker inches toward completing its largest deal ever.", "object": {"text": "for only about 1 percent of Takeda\u2019s shares outstanding", "keywords": [{"text": "Takeda"}, {"text": "percent"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "Takeda"}, {"type": "Quantity", "text": "1 percent"}]}, "action": {"verb": {"text": "account", "tense": "present"}, "text": "account", "normalized": "account"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " The dissident holders account for only about 1 percent of Takeda\u2019s shares outstanding, but the group is raising its profile as the Japanese drugmaker inches toward completing its largest deal ever.", "object": {"text": "shares outstanding", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "the group", "keywords": [{"text": "group"}]}, "sentence": " The dissident holders account for only about 1 percent of Takeda\u2019s shares outstanding, but the group is raising its profile as the Japanese drugmaker inches toward completing its largest deal ever.", "object": {"text": "raising its profile", "keywords": [{"text": "profile"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the group", "keywords": [{"text": "group"}]}, "sentence": " The dissident holders account for only about 1 percent of Takeda\u2019s shares outstanding, but the group is raising its profile as the Japanese drugmaker inches toward completing its largest deal ever.", "object": {"text": "its profile", "keywords": [{"text": "profile"}]}, "action": {"verb": {"text": "raise", "tense": "present"}, "text": "is raising", "normalized": "be raise"}}, {"subject": {"text": "its largest deal", "keywords": [{"text": "largest deal"}], "entities": []}, "sentence": " The dissident holders account for only about 1 percent of Takeda\u2019s shares outstanding, but the group is raising its profile as the Japanese drugmaker inches toward completing its largest deal ever.", "action": {"verb": {"text": "complete", "tense": "present"}, "text": "completing", "normalized": "complete"}}, {"subject": {"text": "The group", "keywords": [{"text": "group"}]}, "sentence": " The group has put out invitations to shareholders for an emergency meeting after the deal is expected to be approved by Europe on Tuesday in its final major regulatory hurdle.", "object": {"text": "put out invitations to shareholders for an emergency meeting", "keywords": [{"text": "shareholders"}, {"text": "invitations"}, {"text": "emergency meeting"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "the deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " The group has put out invitations to shareholders for an emergency meeting after the deal is expected to be approved by Europe on Tuesday in its final major regulatory hurdle.", "object": {"text": "approved by Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "by Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " The group has put out invitations to shareholders for an emergency meeting after the deal is expected to be approved by Europe on Tuesday in its final major regulatory hurdle.", "object": {"text": "the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "is expected to be approved", "normalized": "be expect to be approve"}}, {"subject": {"text": "The group", "keywords": [{"text": "group"}]}, "sentence": " The group, called \u201cThinking About Takeda\u2019s Future\u201d and formed after the announcement of Takeda\u2019s takeover of Shire, comprises more than 100 former employees and shareholders of the Japanese drugmaker.", "object": {"text": "Thinking About Takeda\u2019s Future", "keywords": [{"text": "Takeda"}, {"text": "Future"}]}, "action": {"verb": {"text": "call", "tense": "past"}, "text": "called", "normalized": "call"}}, {"subject": {"text": "The group", "keywords": [{"text": "group"}]}, "sentence": " The group, called \u201cThinking About Takeda\u2019s Future\u201d and formed after the announcement of Takeda\u2019s takeover of Shire, comprises more than 100 former employees and shareholders of the Japanese drugmaker.", "object": {"text": "About Takeda\u2019s Future", "keywords": [{"text": "Takeda"}, {"text": "Future"}]}, "action": {"verb": {"text": "Thinking", "tense": "present"}, "text": "Thinking", "normalized": "Thinking"}}, {"subject": {"text": "The group", "keywords": [{"text": "group"}]}, "sentence": " The group, called \u201cThinking About Takeda\u2019s Future\u201d and formed after the announcement of Takeda\u2019s takeover of Shire, comprises more than 100 former employees and shareholders of the Japanese drugmaker.", "action": {"verb": {"text": "form", "tense": "past"}, "text": "formed", "normalized": "form"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " The group, called \u201cThinking About Takeda\u2019s Future\u201d and formed after the announcement of Takeda\u2019s takeover of Shire, comprises more than 100 former employees and shareholders of the Japanese drugmaker.", "object": {"text": "takeover of Shire", "keywords": [{"text": "takeover"}, {"text": "Shire"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "the announcement of Takeda\u2019s takeover of Shire,", "keywords": [{"text": "Takeda"}, {"text": "takeover"}, {"text": "announcement"}, {"text": "Shire"}], "entities": [{"type": "Company", "text": "Takeda"}, {"type": "Organization", "text": "Shire"}]}, "sentence": " The group, called \u201cThinking About Takeda\u2019s Future\u201d and formed after the announcement of Takeda\u2019s takeover of Shire, comprises more than 100 former employees and shareholders of the Japanese drugmaker.", "object": {"text": "more than 100 former employees and shareholders of the Japanese drugmaker", "keywords": [{"text": "shareholders"}, {"text": "Japanese drugmaker"}, {"text": "employees"}]}, "action": {"verb": {"text": "comprise", "tense": "present"}, "text": "comprises", "normalized": "comprise"}}, {"subject": {"text": "Some members", "keywords": [{"text": "members"}]}, "sentence": " Some members are part of the founding Takeda family.", "object": {"text": "part of the founding Takeda family", "keywords": [{"text": "founding Takeda family"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The group", "keywords": [{"text": "group"}]}, "sentence": " The group has sent open letters to the company with a list of objections to the takeover, and reportedly has managed to win over the support of Kunio Takeda, the last member of the founding family to run the company.", "object": {"text": "open letters", "keywords": [{"text": "letters"}]}, "action": {"verb": {"text": "send", "tense": "past"}, "text": "has sent", "normalized": "have send"}}, {"subject": {"text": "The group", "keywords": [{"text": "group"}]}, "sentence": " The group has sent open letters to the company with a list of objections to the takeover, and reportedly has managed to win over the support of Kunio Takeda, the last member of the founding family to run the company.", "object": {"text": "managed to win over the support of Kunio Takeda", "keywords": [{"text": "Kunio Takeda"}, {"text": "support"}], "entities": [{"type": "Company", "text": "Kunio Takeda"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The group", "keywords": [{"text": "group"}]}, "sentence": " The group has sent open letters to the company with a list of objections to the takeover, and reportedly has managed to win over the support of Kunio Takeda, the last member of the founding family to run the company.", "object": {"text": "to win over the support of Kunio Takeda, the last member of the founding family to run the company", "keywords": [{"text": "Kunio Takeda"}, {"text": "founding family"}, {"text": "support"}, {"text": "member"}], "entities": [{"type": "Company", "text": "Kunio Takeda"}]}, "action": {"verb": {"text": "manage", "tense": "past"}, "text": "managed", "normalized": "manage"}}, {"subject": {"text": "The group", "keywords": [{"text": "group"}]}, "sentence": " The group has sent open letters to the company with a list of objections to the takeover, and reportedly has managed to win over the support of Kunio Takeda, the last member of the founding family to run the company.", "object": {"text": "over the support of Kunio Takeda, the last member of the founding family to run the company", "keywords": [{"text": "Kunio Takeda"}, {"text": "founding family"}, {"text": "support"}, {"text": "member"}], "entities": [{"type": "Company", "text": "Kunio Takeda"}]}, "action": {"verb": {"text": "win", "tense": "future"}, "text": "has managed to win", "normalized": "have manage to win"}}, {"subject": {"text": "it"}, "sentence": " Although it has some members in common, the group is separate from previous organizations that have been vocal against Takeda\u2019s globalization efforts through acquisitions in the past.", "object": {"text": "some members in common", "keywords": [{"text": "members"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "the group", "keywords": [{"text": "group"}]}, "sentence": " Although it has some members in common, the group is separate from previous organizations that have been vocal against Takeda\u2019s globalization efforts through acquisitions in the past.", "object": {"text": "separate from previous organizations that have been vocal against Takeda\u2019s globalization efforts through acquisitions in the past", "keywords": [{"text": "Takeda\u2019s globalization"}, {"text": "previous organizations"}, {"text": "acquisitions"}, {"text": "efforts"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "separate from previous organizations", "keywords": [{"text": "previous organizations"}]}, "sentence": " Although it has some members in common, the group is separate from previous organizations that have been vocal against Takeda\u2019s globalization efforts through acquisitions in the past.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "have been", "normalized": "have be"}}, {"subject": {"text": "Chief Executive Officer Christophe Weber", "keywords": [{"text": "Officer Christophe Weber"}], "entities": [{"type": "JobTitle", "text": "Chief Executive Officer"}, {"type": "Person", "text": "Christophe Weber"}]}, "sentence": " Chief Executive Officer Christophe Weber, the first non-Japanese to lead the 237-year-old company, has wrestled with factions unhappy with Takeda\u2019s strategy since taking over in 2015.", "object": {"text": "the 237-year-old company", "keywords": [{"text": "237-year-old company"}], "entities": [{"type": "Quantity", "text": "237-year"}]}, "action": {"verb": {"text": "lead", "tense": "future"}, "text": "to lead", "normalized": "to lead"}}, {"subject": {"text": "Chief Executive Officer Christophe Weber, the first non-Japanese to lead the 237-year-old company,", "keywords": [{"text": "Officer Christophe Weber"}, {"text": "237-year-old company"}, {"text": "Chief"}], "entities": [{"type": "JobTitle", "text": "Chief Executive Officer"}, {"type": "Person", "text": "Christophe Weber"}, {"type": "Quantity", "text": "237-year"}]}, "sentence": " Chief Executive Officer Christophe Weber, the first non-Japanese to lead the 237-year-old company, has wrestled with factions unhappy with Takeda\u2019s strategy since taking over in 2015.", "action": {"verb": {"text": "wrestle", "tense": "past"}, "text": "has wrestled", "normalized": "have wrestle"}}, {"subject": {"text": "The dissident group", "keywords": [{"text": "dissident group"}]}, "sentence": " The dissident group is primarily concerned with the financial risk Takeda will take on -- more than $30 billion in additional debt -- the dilution of shares, and the impact on earnings and the company\u2019s dividend.", "object": {"text": "primarily concerned"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "with the financial risk Takeda", "keywords": [{"text": "financial risk Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " The dissident group is primarily concerned with the financial risk Takeda will take on -- more than $30 billion in additional debt -- the dilution of shares, and the impact on earnings and the company\u2019s dividend.", "object": {"text": "The dissident group", "keywords": [{"text": "dissident group"}]}, "action": {"verb": {"text": "concern", "tense": "past"}, "text": "is primarily concerned", "normalized": "be primarily concern"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " The dissident group is primarily concerned with the financial risk Takeda will take on -- more than $30 billion in additional debt -- the dilution of shares, and the impact on earnings and the company\u2019s dividend.", "object": {"text": "dividend", "keywords": [{"text": "dividend"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "about the outlook for Shire\u2019s hemophilia drug, one of the biggest moneymakers in the company\u2019s rare-disease portfolio", "keywords": [{"text": "biggest moneymakers"}, {"text": "rare-disease portfolio"}, {"text": "Shire"}, {"text": "outlook"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": " They are also concerned about the outlook for Shire\u2019s hemophilia drug, one of the biggest moneymakers in the company\u2019s rare-disease portfolio, as it faces challenges from a competing treatment offered by Roche Holding AG.", "object": {"text": "They"}, "action": {"verb": {"text": "concern", "tense": "past"}, "text": "are also concerned", "normalized": "be also concern"}}, {"subject": {"text": "it"}, "sentence": " They are also concerned about the outlook for Shire\u2019s hemophilia drug, one of the biggest moneymakers in the company\u2019s rare-disease portfolio, as it faces challenges from a competing treatment offered by Roche Holding AG.", "object": {"text": "challenges from a competing treatment offered by Roche Holding AG", "keywords": [{"text": "Roche Holding AG"}, {"text": "challenges"}, {"text": "treatment"}], "entities": [{"type": "Company", "text": "Roche Holding AG", "disambiguation": {"subtype": ["Organization", "AwardWinner"], "name": "Hoffmann-La Roche", "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann-La_Roche"}}]}, "action": {"verb": {"text": "face", "tense": "present"}, "text": "faces", "normalized": "face"}}, {"subject": {"text": "by Roche Holding AG", "keywords": [{"text": "Roche Holding AG"}], "entities": [{"type": "Company", "text": "Roche Holding AG", "disambiguation": {"subtype": ["Organization", "AwardWinner"], "name": "Hoffmann-La Roche", "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann-La_Roche"}}]}, "sentence": " They are also concerned about the outlook for Shire\u2019s hemophilia drug, one of the biggest moneymakers in the company\u2019s rare-disease portfolio, as it faces challenges from a competing treatment offered by Roche Holding AG.", "object": {"text": "a competing treatment", "keywords": [{"text": "treatment"}]}, "action": {"verb": {"text": "offer", "tense": "past"}, "text": "offered", "normalized": "offer"}}, {"subject": {"text": "the group", "keywords": [{"text": "group"}]}, "sentence": " Further, the group argues that Takeda\u2019s disclosure of information to investors is too opaque, and is seeking to obtain the minutes of board meetings leading up to the Shire deal.", "object": {"text": "that Takeda\u2019s disclosure of information to investors is too opaque, and is seeking to obtain the minutes of board meetings leading up to the Shire deal", "keywords": [{"text": "Shire deal"}, {"text": "board meetings"}, {"text": "Takeda"}, {"text": "disclosure"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "argue", "tense": "present"}, "text": "argues", "normalized": "argue"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Further, the group argues that Takeda\u2019s disclosure of information to investors is too opaque, and is seeking to obtain the minutes of board meetings leading up to the Shire deal.", "object": {"text": "disclosure of information", "keywords": [{"text": "disclosure"}, {"text": "information"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "board meetings", "keywords": [{"text": "board meetings"}]}, "sentence": " Further, the group argues that Takeda\u2019s disclosure of information to investors is too opaque, and is seeking to obtain the minutes of board meetings leading up to the Shire deal.", "object": {"text": "to the Shire deal", "keywords": [{"text": "Shire deal"}], "entities": []}, "action": {"verb": {"text": "lead", "tense": "present"}, "text": "leading", "normalized": "lead"}}, {"subject": {"text": "They"}, "sentence": " They also object to the scheduling of a Dec. 5 shareholder vote on the deal, saying Takeda is breaking good governance practices by announcing the date with little time for shareholders to prepare.", "object": {"text": "to the scheduling of a Dec. 5 shareholder vote on the deal, saying Takeda is breaking good governance practices by announcing the date with little time for shareholders to prepare", "keywords": [{"text": "good governance practices"}, {"text": "shareholder vote"}, {"text": "little time"}, {"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "object", "tense": "present"}, "text": "object", "normalized": "object"}}, {"subject": {"text": "They"}, "sentence": " They also object to the scheduling of a Dec. 5 shareholder vote on the deal, saying Takeda is breaking good governance practices by announcing the date with little time for shareholders to prepare.", "object": {"text": "Takeda is breaking good governance practices by announcing the date with little time for shareholders to prepare", "keywords": [{"text": "good governance practices"}, {"text": "little time"}, {"text": "Takeda"}, {"text": "shareholders"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "say", "tense": "present"}, "text": "saying", "normalized": "say"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " They also object to the scheduling of a Dec. 5 shareholder vote on the deal, saying Takeda is breaking good governance practices by announcing the date with little time for shareholders to prepare.", "object": {"text": "the date", "keywords": [{"text": "date"}]}, "action": {"verb": {"text": "announce", "tense": "present"}, "text": "announcing", "normalized": "announce"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda\u2019s Reaction", "object": {"text": "Reaction", "keywords": [{"text": "Reaction"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Weber", "keywords": [{"text": "Weber"}], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "sentence": " Weber has said the dissident group has a different vision for Takeda in wanting it to remain a local company instead of becoming more international.", "object": {"text": "said the dissident group has a different vision for Takeda", "keywords": [{"text": "dissident group"}, {"text": "Takeda"}, {"text": "different vision"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Weber", "keywords": [{"text": "Weber"}], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "sentence": " Weber has said the dissident group has a different vision for Takeda in wanting it to remain a local company instead of becoming more international.", "object": {"text": "the dissident group has a different vision for Takeda in wanting it to remain a local company instead of becoming more international", "keywords": [{"text": "dissident group"}, {"text": "different vision"}, {"text": "local company"}, {"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "has said", "normalized": "have say"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Weber has said the dissident group has a different vision for Takeda in wanting it to remain a local company instead of becoming more international.", "object": {"text": "it to remain a local company instead of becoming more international", "keywords": [{"text": "local company"}]}, "action": {"verb": {"text": "want", "tense": "present"}, "text": "wanting", "normalized": "want"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "sentence": " He has been careful to stress that Takeda will keep its Japanese roots even as it becomes a global pharma powerhouse.", "object": {"text": "that Takeda will keep its Japanese roots even as it becomes a global pharma powerhouse", "keywords": [{"text": "global pharma powerhouse"}, {"text": "Japanese roots"}, {"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "stress", "tense": "future"}, "text": "to stress", "normalized": "to stress"}}, {"subject": {"text": "The CEO", "keywords": [{"text": "CEO"}], "entities": [{"type": "JobTitle", "text": "CEO"}]}, "sentence": " The CEO said he will not release the board minutes unless prompted by a court order, saying directors were regularly briefed on takeover talks.", "object": {"text": "he will not release the board minutes unless prompted by a court order, saying directors were regularly briefed on takeover talks", "keywords": [{"text": "takeover talks"}, {"text": "court order"}, {"text": "board"}, {"text": "directors"}], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "sentence": " The CEO said he will not release the board minutes unless prompted by a court order, saying directors were regularly briefed on takeover talks.", "object": {"text": "the board minutes", "keywords": [{"text": "board"}]}, "action": {"verb": {"text": "release", "tense": "future", "negated": true}, "text": "release", "normalized": "release"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Christophe Weber"}]}, "sentence": " The CEO said he will not release the board minutes unless prompted by a court order, saying directors were regularly briefed on takeover talks.", "object": {"text": "directors were regularly briefed on takeover talks", "keywords": [{"text": "takeover talks"}, {"text": "directors"}]}, "action": {"verb": {"text": "say", "tense": "present"}, "text": "saying", "normalized": "say"}}, {"subject": {"text": "directors", "keywords": [{"text": "directors"}]}, "sentence": " The CEO said he will not release the board minutes unless prompted by a court order, saying directors were regularly briefed on takeover talks.", "object": {"text": "on takeover talks", "keywords": [{"text": "takeover talks"}]}, "action": {"verb": {"text": "brief", "tense": "past"}, "text": "briefed", "normalized": "brief"}}], "concepts": [{"text": "Chief executive officer", "relevance": 0.934614, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Stock market", "relevance": 0.860497, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Hoffmann\u2013La Roche", "relevance": 0.834786, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Stock", "relevance": 0.821724, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Shareholder", "relevance": 0.770705, "dbpedia_resource": "http://dbpedia.org/resource/Shareholder"}, {"text": "Share", "relevance": 0.722298, "dbpedia_resource": "http://dbpedia.org/resource/Share_(finance)"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.644805, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Dissident", "relevance": 0.643362, "dbpedia_resource": "http://dbpedia.org/resource/Dissident"}, {"text": "Takeda clan", "relevance": 0.627417, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_clan"}], "categories": [{"score": 0.879637, "label": "/finance/financial news"}, {"score": 0.835176, "label": "/business and industrial/company"}, {"score": 0.798514, "label": "/finance/investing"}], "relations": [{"type": "residesIn", "sentence": "(Bloomberg) -- They have little chance of success, but the shareholder group trying to derail Takeda Pharmaceutical Co.'s $62 billion purchase of U.K.-listed Shire Plc is making last-minute attempts to win over investors.", "score": 0.4368, "arguments": [{"text": "Shire Plc", "location": [158, 167], "entities": [{"type": "Person", "text": "Shire Plc"}]}, {"text": "U.K.", "location": [146, 150], "entities": [{"type": "GeopoliticalEntity", "text": "U.K."}]}]}, {"type": "partOfMany", "sentence": "Some members are part of the founding Takeda family.", "score": 0.509132, "arguments": [{"text": "members", "location": [884, 891], "entities": [{"type": "Person", "text": "members"}]}, {"text": "family", "location": [924, 930], "entities": [{"type": "Person", "text": "family"}]}]}, {"type": "employedBy", "sentence": "Some members are part of the founding Takeda family.", "score": 0.607148, "arguments": [{"text": "family", "location": [924, 930], "entities": [{"type": "Person", "text": "family"}]}, {"text": "Takeda", "location": [917, 923], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "The group has sent open letters to the company with a list of objections to the takeover, and reportedly has managed to win over the support of Kunio Takeda, the last member of the founding family to run the company.", "score": 0.512027, "arguments": [{"text": "group", "location": [936, 941], "entities": [{"type": "Organization", "text": "shareholder group"}]}, {"text": "company", "location": [971, 978], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "The group has sent open letters to the company with a list of objections to the takeover, and reportedly has managed to win over the support of Kunio Takeda, the last member of the founding family to run the company.", "score": 0.623522, "arguments": [{"text": "member", "location": [1099, 1105], "entities": [{"type": "Person", "text": "Kunio Takeda"}]}, {"text": "family", "location": [1122, 1128], "entities": [{"type": "Person", "text": "family"}]}]}, {"type": "memberOf", "sentence": "The group has sent open letters to the company with a list of objections to the takeover, and reportedly has managed to win over the support of Kunio Takeda, the last member of the founding family to run the company.", "score": 0.638068, "arguments": [{"text": "member", "location": [1099, 1105], "entities": [{"type": "Person", "text": "Kunio Takeda"}]}, {"text": "company", "location": [1140, 1147], "entities": [{"type": "Organization", "text": "shareholder group"}]}]}, {"type": "employedBy", "sentence": "Although it has some members in common, the group is separate from previous organizations that have been vocal against Takeda's globalization efforts through acquisitions in the past.", "score": 0.337315, "arguments": [{"text": "Takeda", "location": [1323, 1329], "entities": [{"type": "Person", "text": "Kunio Takeda"}]}, {"text": "organizations", "location": [1280, 1293], "entities": [{"type": "Organization", "text": "organizations"}]}]}, {"type": "affectedBy", "sentence": "Although it has some members in common, the group is separate from previous organizations that have been vocal against Takeda's globalization efforts through acquisitions in the past.", "score": 0.481894, "arguments": [{"text": "organizations", "location": [1280, 1293], "entities": [{"type": "Organization", "text": "organizations"}]}, {"text": "acquisitions", "location": [1362, 1374], "entities": [{"type": "EventBusiness", "text": "acquisitions"}]}]}, {"type": "agentOf", "sentence": "Chief Executive Officer Christophe Weber, the first non-Japanese to lead the 237-year-old company, has wrestled with factions unhappy with Takeda's strategy since taking over in 2015.", "score": 0.789231, "arguments": [{"text": "company", "location": [1478, 1485], "entities": [{"type": "Organization", "text": "shareholder group"}]}, {"text": "wrestled", "location": [1491, 1499], "entities": [{"type": "EventViolence", "text": "wrestled"}]}]}, {"type": "affectedBy", "sentence": "Chief Executive Officer Christophe Weber, the first non-Japanese to lead the 237-year-old company, has wrestled with factions unhappy with Takeda's strategy since taking over in 2015.", "score": 0.796325, "arguments": [{"text": "factions", "location": [1505, 1513], "entities": [{"type": "Person", "text": "factions"}]}, {"text": "wrestled", "location": [1491, 1499], "entities": [{"type": "EventViolence", "text": "wrestled"}]}]}, {"type": "timeOf", "sentence": "Chief Executive Officer Christophe Weber, the first non-Japanese to lead the 237-year-old company, has wrestled with factions unhappy with Takeda's strategy since taking over in 2015.", "score": 0.895769, "arguments": [{"text": "2015", "location": [1566, 1570], "entities": [{"type": "Date", "text": "2015"}]}, {"text": "wrestled", "location": [1491, 1499], "entities": [{"type": "EventViolence", "text": "wrestled"}]}]}, {"type": "employedBy", "sentence": "The dissident holders account for only about 1 percent of Takeda's shares outstanding, but the group is raising its profile as the Japanese drugmaker inches toward completing its largest deal ever.", "score": 0.364007, "arguments": [{"text": "drugmaker", "location": [362, 371], "entities": [{"type": "Person", "text": "drugmaker"}]}, {"text": "its", "location": [334, 337], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "They are also concerned about the outlook for Shire's hemophilia drug, one of the biggest moneymakers in the company's rare-disease portfolio, as it faces challenges from a competing treatment offered by Roche Holding AG.", "score": 0.35559, "arguments": [{"text": "moneymakers", "location": [1894, 1905], "entities": [{"type": "Person", "text": "moneymakers"}]}, {"text": "company", "location": [1913, 1920], "entities": [{"type": "Organization", "text": "shareholder group"}]}]}, {"type": "agentOf", "sentence": "They are also concerned about the outlook for Shire's hemophilia drug, one of the biggest moneymakers in the company's rare-disease portfolio, as it faces challenges from a competing treatment offered by Roche Holding AG.", "score": 0.951048, "arguments": [{"text": "Roche Holding AG", "location": [2008, 2024], "entities": [{"type": "Organization", "text": "Roche Holding AG", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "offered", "location": [1997, 2004], "entities": [{"type": "EventCommunication", "text": "offered"}]}]}, {"type": "participantIn", "sentence": "Further, the group argues that Takeda's disclosure of information to investors is too opaque, and is seeking to obtain the minutes of board meetings leading up to the Shire deal.", "score": 0.632528, "arguments": [{"text": "Takeda", "location": [2057, 2063], "entities": [{"type": "Person", "text": "Kunio Takeda"}]}, {"text": "meetings", "location": [2166, 2174], "entities": [{"type": "EventMeeting", "text": "meetings"}]}]}, {"type": "timeOf", "sentence": "Further, the group argues that Takeda's disclosure of information to investors is too opaque, and is seeking to obtain the minutes of board meetings leading up to the Shire deal.", "score": 0.789549, "arguments": [{"text": "minutes", "location": [2149, 2156], "entities": [{"type": "Duration", "text": "minutes"}]}, {"text": "meetings", "location": [2166, 2174], "entities": [{"type": "EventMeeting", "text": "meetings"}]}]}, {"type": "agentOf", "sentence": "They also object to the scheduling of a Dec. 5 shareholder vote on the deal, saying Takeda is breaking good governance practices by announcing the date with little time for shareholders to prepare.", "score": 0.687613, "arguments": [{"text": "Takeda", "location": [2289, 2295], "entities": [{"type": "Person", "text": "Kunio Takeda"}]}, {"text": "announcing", "location": [2337, 2347], "entities": [{"type": "EventCommunication", "text": "announcing"}]}]}, {"type": "agentOf", "sentence": "Takeda's Reaction Weber has said the dissident group has a different vision for Takeda in wanting it to remain a local company instead of becoming more international.", "score": 0.468464, "arguments": [{"text": "Takeda", "location": [2403, 2409], "entities": [{"type": "Person", "text": "Kunio Takeda"}]}, {"text": "said", "location": [2431, 2435], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "The CEO said he will not release the board minutes unless prompted by a court order, saying directors were regularly briefed on takeover talks.", "score": 0.964799, "arguments": [{"text": "CEO", "location": [2692, 2695], "entities": [{"type": "Person", "text": "Kunio Takeda"}]}, {"text": "said", "location": [2696, 2700], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Takeda's Reaction Weber has said the dissident group has a different vision for Takeda in wanting it to remain a local company instead of becoming more international.", "score": 0.601131, "arguments": [{"text": "Weber", "location": [2421, 2426], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [2431, 2435], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "The CEO said he will not release the board minutes unless prompted by a court order, saying directors were regularly briefed on takeover talks.", "score": 0.910341, "arguments": [{"text": "court", "location": [2760, 2765], "entities": [{"type": "Organization", "text": "court", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "order", "location": [2766, 2771], "entities": [{"type": "EventLegal", "text": "order"}]}]}, {"type": "affectedBy", "sentence": "The CEO said he will not release the board minutes unless prompted by a court order, saying directors were regularly briefed on takeover talks.", "score": 0.682672, "arguments": [{"text": "directors", "location": [2780, 2789], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "saying", "location": [2773, 2779], "entities": [{"type": "EventCommunication", "text": "saying"}]}]}, {"type": "participantIn", "sentence": "The CEO said he will not release the board minutes unless prompted by a court order, saying directors were regularly briefed on takeover talks.", "score": 0.803292, "arguments": [{"text": "directors", "location": [2780, 2789], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "briefed", "location": [2805, 2812], "entities": [{"type": "EventMeeting", "text": "briefed"}]}]}, {"type": "partOfMany", "sentence": "The dissident holders account for only about 1 percent of Takeda's shares outstanding, but the group is raising its profile as the Japanese drugmaker inches toward completing its largest deal ever.", "score": 0.824048, "arguments": [{"text": "drugmaker", "location": [362, 371], "entities": [{"type": "Person", "text": "drugmaker"}]}, {"text": "Japanese", "location": [353, 361], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "The group, called \"Thinking About Takeda's Future\" and formed after the announcement of Takeda's takeover of Shire, comprises more than 100 former employees and shareholders of the Japanese drugmaker.", "score": 0.901448, "arguments": [{"text": "drugmaker", "location": [868, 877], "entities": [{"type": "Person", "text": "drugmaker"}]}, {"text": "Japanese", "location": [859, 867], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "The CEO said he will not release the board minutes unless prompted by a court order, saying directors were regularly briefed on takeover talks.", "score": 0.325148, "arguments": [{"text": "briefed", "location": [2805, 2812], "entities": [{"type": "EventMeeting", "text": "briefed"}]}, {"text": "talks", "location": [2825, 2830], "entities": [{"type": "EventMeeting", "text": "talks"}]}]}, {"type": "agentOf", "sentence": "At the same time, Takeda has become more forthcoming on details of the deal, unveiling a potential debt repayment plan and disclosing progress on integrating the two companies.", "score": 0.865404, "arguments": [{"text": "Takeda", "location": [2850, 2856], "entities": [{"type": "Person", "text": "Kunio Takeda"}]}, {"text": "disclosing", "location": [2955, 2965], "entities": [{"type": "EventCommunication", "text": "disclosing"}]}]}, {"type": "affectedBy", "sentence": "Weber is confident the vote will result in more than the two-thirds required for approval, and analysts say there is only a slim chance the dissidents will have any impact.", "score": 0.401044, "arguments": [{"text": "Weber", "location": [3033, 3038], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "vote", "location": [3056, 3060], "entities": [{"type": "EventElection", "text": "vote"}]}]}, {"type": "agentOf", "sentence": "Weber is confident the vote will result in more than the two-thirds required for approval, and analysts say there is only a slim chance the dissidents will have any impact.", "score": 0.988826, "arguments": [{"text": "analysts", "location": [3128, 3136], "entities": [{"type": "Person", "text": "analysts"}]}, {"text": "say", "location": [3137, 3140], "entities": [{"type": "EventCommunication", "text": "say"}]}]}, {"type": "participantIn", "sentence": "A proposal brought forth by the dissident group at Takeda's annual meeting in June that would require prior approval for major acquisitions was shot down by shareholders, signaling widespread support for the Shire transaction.", "score": 0.623013, "arguments": [{"text": "Takeda", "location": [3257, 3263], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "meeting", "location": [3273, 3280], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "timeOf", "sentence": "A proposal brought forth by the dissident group at Takeda's annual meeting in June that would require prior approval for major acquisitions was shot down by shareholders, signaling widespread support for the Shire transaction.", "score": 0.984115, "arguments": [{"text": "June", "location": [3284, 3288], "entities": [{"type": "Date", "text": "June"}]}, {"text": "meeting", "location": [3273, 3280], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "agentOf", "sentence": "A proposal brought forth by the dissident group at Takeda's annual meeting in June that would require prior approval for major acquisitions was shot down by shareholders, signaling widespread support for the Shire transaction.", "score": 0.574338, "arguments": [{"text": "shareholders", "location": [3363, 3375], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "shot down", "location": [3350, 3359], "entities": [{"type": "EventViolence", "text": "shot down"}]}]}, {"type": "participantIn", "sentence": "The dissident group has conceded it would be an uphill climb to block the deal, acknowledging it has been difficult to meet with investors to argue their case.", "score": 0.89715, "arguments": [{"text": "investors", "location": [3562, 3571], "entities": [{"type": "Person", "text": "dissidents"}]}, {"text": "meet", "location": [3552, 3556], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "timeOf", "sentence": "Meanwhile, the emergency meeting, which was originally scheduled for this week, appears to have been pushed back to next week, according to a sign-up form on the group's website.", "score": 0.784301, "arguments": [{"text": "this week", "location": [3662, 3671], "entities": [{"type": "Date", "text": "this week"}]}, {"text": "meeting", "location": [3618, 3625], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "locatedAt", "sentence": "To contact the reporter on this story: Lisa Du in Tokyo at ldu31@bloomberg.net To contact the editors K. Oanh Ha at oha3@bloomberg.net, Jeff Sutherland", "score": 0.387226, "arguments": [{"text": "Lisa Du", "location": [3811, 3818], "entities": [{"type": "Person", "text": "Lisa Du"}]}, {"text": "Tokyo", "location": [3822, 3827], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "employedBy", "sentence": "The group has put out invitations to shareholders for an emergency meeting after the deal is expected to be approved by Europe on Tuesday in its final major regulatory hurdle.", "score": 0.406417, "arguments": [{"text": "shareholders", "location": [457, 469], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "group", "location": [424, 429], "entities": [{"type": "Organization", "text": "shareholder group"}]}]}, {"type": "locatedAt", "sentence": "To contact the reporter on this story: Lisa Du in Tokyo at ldu31@bloomberg.net To contact the editors K. Oanh Ha at oha3@bloomberg.net, Jeff Sutherland", "score": 0.4267, "arguments": [{"text": "editors", "location": [3866, 3873], "entities": [{"type": "Person", "text": "editors"}]}, {"text": "Tokyo", "location": [3822, 3827], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "partOfMany", "sentence": "To contact the reporter on this story: Lisa Du in Tokyo at ldu31@bloomberg.net To contact the editors K. Oanh Ha at oha3@bloomberg.net, Jeff Sutherland", "score": 0.959843, "arguments": [{"text": "K. Oanh Ha", "location": [3874, 3884], "entities": [{"type": "Person", "text": "K. Oanh Ha"}]}, {"text": "editors", "location": [3866, 3873], "entities": [{"type": "Person", "text": "editors"}]}]}, {"type": "partOfMany", "sentence": "To contact the reporter on this story: Lisa Du in Tokyo at ldu31@bloomberg.net To contact the editors K. Oanh Ha at oha3@bloomberg.net, Jeff Sutherland", "score": 0.525553, "arguments": [{"text": "Jeff Sutherland", "location": [3908, 3923], "entities": [{"type": "Person", "text": "Jeff Sutherland"}]}, {"text": "editors", "location": [3866, 3873], "entities": [{"type": "Person", "text": "editors"}]}]}, {"type": "hasAttribute", "sentence": "To contact the reporter on this story: Lisa Du in Tokyo at ldu31@bloomberg.net To contact the editors K. Oanh Ha at oha3@bloomberg.net, Jeff Sutherland", "score": 0.981786, "arguments": [{"text": "K. Oanh Ha", "location": [3874, 3884], "entities": [{"type": "Person", "text": "K. Oanh Ha"}]}, {"text": "oha3@bloomberg.net", "location": [3888, 3906], "entities": [{"type": "Age", "text": "oha3@bloomberg.net"}]}]}, {"type": "participantIn", "sentence": "The group has put out invitations to shareholders for an emergency meeting after the deal is expected to be approved by Europe on Tuesday in its final major regulatory hurdle.", "score": 0.458887, "arguments": [{"text": "group", "location": [424, 429], "entities": [{"type": "Organization", "text": "shareholder group"}]}, {"text": "meeting", "location": [487, 494], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "participantIn", "sentence": "The group has put out invitations to shareholders for an emergency meeting after the deal is expected to be approved by Europe on Tuesday in its final major regulatory hurdle.", "score": 0.520765, "arguments": [{"text": "shareholders", "location": [457, 469], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "meeting", "location": [487, 494], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "agentOf", "sentence": "The group, called \"Thinking About Takeda's Future\" and formed after the announcement of Takeda's takeover of Shire, comprises more than 100 former employees and shareholders of the Japanese drugmaker.", "score": 0.986483, "arguments": [{"text": "Takeda", "location": [766, 772], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "takeover", "location": [775, 783], "entities": [{"type": "EventPersonnel", "text": "takeover"}]}]}, {"type": "agentOf", "sentence": "The group has sent open letters to the company with a list of objections to the takeover, and reportedly has managed to win over the support of Kunio Takeda, the last member of the founding family to run the company.", "score": 0.706312, "arguments": [{"text": "company", "location": [971, 978], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "takeover", "location": [1012, 1020], "entities": [{"type": "EventPersonnel", "text": "takeover"}]}]}, {"type": "employedBy", "sentence": "The group, called \"Thinking About Takeda's Future\" and formed after the announcement of Takeda's takeover of Shire, comprises more than 100 former employees and shareholders of the Japanese drugmaker.", "score": 0.524432, "arguments": [{"text": "employees", "location": [825, 834], "entities": [{"type": "Person", "text": "employees"}]}, {"text": "Takeda", "location": [766, 772], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "The group, called \"Thinking About Takeda's Future\" and formed after the announcement of Takeda's takeover of Shire, comprises more than 100 former employees and shareholders of the Japanese drugmaker.", "score": 0.566922, "arguments": [{"text": "Shire", "location": [787, 792], "entities": [{"type": "Person", "text": "Shire Plc"}]}, {"text": "takeover", "location": [775, 783], "entities": [{"type": "EventPersonnel", "text": "takeover"}]}]}], "keywords": [{"text": "shareholder group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.797774, "count": 1}, {"text": "Takeda Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.707926, "count": 1}, {"text": "dissident holders", "sentiment": {"score": 0.585978, "label": "positive"}, "relevance": 0.698859, "count": 1}, {"text": "group", "sentiment": {"score": 0.274475, "mixed": "1", "label": "positive"}, "relevance": 0.677354, "count": 6}, {"text": "Chief Executive Officer Christophe Weber", "sentiment": {"score": -0.769365, "label": "negative"}, "relevance": 0.669892, "count": 1}, {"text": "dissidents", "sentiment": {"score": 0.813741, "label": "positive"}, "relevance": 0.623187, "count": 2}, {"text": "emergency meeting", "sentiment": {"score": -0.479652, "label": "negative"}, "relevance": 0.616501, "count": 2}, {"text": "Takeda\u2019s shares", "sentiment": {"score": 0.585978, "label": "positive"}, "relevance": 0.592525, "count": 1}, {"text": "Weber", "sentiment": {"score": 0.933217, "label": "positive"}, "relevance": 0.566227, "count": 1}, {"text": "dissident group", "sentiment": {"score": -0.664014, "label": "negative"}, "relevance": 0.55973, "count": 5}, {"text": "shareholders", "sentiment": {"score": -0.371592, "label": "negative"}, "relevance": 0.555585, "count": 3}, {"text": "slim chance", "sentiment": {"score": 0.933217, "label": "positive"}, "relevance": 0.553055, "count": 1}, {"text": "little chance of success", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.550338, "count": 1}, {"text": "Takeda\u2019s Future", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.546428, "count": 1}, {"text": "proposal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.545204, "count": 1}, {"text": "two-thirds", "sentiment": {"score": 0.933217, "label": "positive"}, "relevance": 0.541521, "count": 1}, {"text": "deal", "sentiment": {"score": -0.424169, "label": "negative"}, "relevance": 0.54131, "count": 3}, {"text": "prior approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540476, "count": 1}, {"text": "largest deal", "sentiment": {"score": 0.467064, "mixed": "1", "label": "positive"}, "relevance": 0.539185, "count": 1}, {"text": "little time", "sentiment": {"score": -0.476277, "label": "negative"}, "relevance": 0.539097, "count": 1}, {"text": "court order", "sentiment": {"score": -0.67327, "label": "negative"}, "relevance": 0.538894, "count": 1}, {"text": "members", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5367, "count": 2}, {"text": "Chances", "sentiment": {"score": 0.933217, "label": "positive"}, "relevance": 0.535166, "count": 1}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532941, "count": 2}, {"text": "week", "sentiment": {"score": -0.577062, "label": "negative"}, "relevance": 0.532732, "count": 1}, {"text": "approval", "sentiment": {"score": 0.933217, "label": "positive"}, "relevance": 0.532356, "count": 1}, {"text": "open letters", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532301, "count": 1}, {"text": "vote", "sentiment": {"score": 0.933217, "label": "positive"}, "relevance": 0.531158, "count": 1}, {"text": "scheduling of a Dec.", "sentiment": {"score": -0.476277, "label": "negative"}, "relevance": 0.53062, "count": 1}, {"text": "last-minute attempts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530308, "count": 1}, {"text": "minutes of board meetings", "sentiment": {"score": -0.526469, "label": "negative"}, "relevance": 0.530094, "count": 1}, {"text": "Shire Plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528861, "count": 1}, {"text": "announcement of Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525426, "count": 1}, {"text": "widespread support", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525297, "count": 1}, {"text": "shareholder vote", "sentiment": {"score": -0.476277, "label": "negative"}, "relevance": 0.524185, "count": 1}, {"text": "analysts", "sentiment": {"score": 0.933217, "label": "positive"}, "relevance": 0.524155, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0.416283, "mixed": "1", "label": "positive"}, "relevance": 0.523884, "count": 5}, {"text": "takeover", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522398, "count": 1}, {"text": "support of Kunio Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522025, "count": 1}, {"text": "CEO", "sentiment": {"score": -0.67327, "label": "negative"}, "relevance": 0.520201, "count": 1}, {"text": "Bloomberg", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520048, "count": 1}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518664, "count": 1}, {"text": "investors", "sentiment": {"score": -0.323384, "mixed": "1", "label": "negative"}, "relevance": 0.518022, "count": 3}, {"text": "invitations", "sentiment": {"score": -0.371592, "label": "negative"}, "relevance": 0.517413, "count": 1}, {"text": "local company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517055, "count": 1}, {"text": "time", "sentiment": {"score": 0.975466, "label": "positive"}, "relevance": 0.514722, "count": 1}, {"text": "June", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514411, "count": 1}, {"text": "outlook", "sentiment": {"score": -0.765722, "label": "negative"}, "relevance": 0.513966, "count": 1}, {"text": "information", "sentiment": {"score": -0.526469, "label": "negative"}, "relevance": 0.513838, "count": 1}, {"text": "sign", "sentiment": {"score": -0.577062, "label": "negative"}, "relevance": 0.51285, "count": 1}]}, "extracted_metadata": {"sha1": "936baac2cc5bf927e6e95a0f847717e2e0b88e2f", "filename": "1542673816216.zip-23d79197e281cb91c224cdd913736675.xml", "file_type": "json"}, "title": "Takeda's Dissident Shareholders Keep Trying to Kill Shire Deal", "forum_title": "News Wire"}, {"id": "0tyhxBUetmOLINXXp8meXihnDOR2OExAbZGFpT6pQ7mGqb-ija80OZCZ0JF7Pc0Q", "result_metadata": {"score": 31.174143}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.955815, "label": "/finance/investing"}, {"score": 0.955815, "label": "/finance/investing/beginning investing"}, {"score": 0.734181, "label": "/finance/financial news"}], "relations": [{"type": "managerOf", "sentence": "Investor advisory firms back Takeda's $62 billion deal for Shire", "score": 0.536213, "arguments": [{"text": "Investor", "location": [0, 8], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "firms", "location": [18, 23], "entities": [{"type": "Organization", "text": "firms", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Investor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.995872, "count": 1}, {"text": "advisory firms", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.983841, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.844727, "count": 1}, {"text": "deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.801703, "count": 1}, {"text": "Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.759902, "count": 1}]}, "crawl_date": "2018-11-20T13:44:44Z", "url": "https://wiky.com/news/articles/2018/nov/20/investor-advisory-firms-back-takedas-62-billion-deal-for-shire/", "host": "wiky.com", "text": "CST FILE PHOTO: The logo of Takeda Pharmaceutical Co.", "main_image_url": "https://radiocms-images.us1.eldarioncloud.com/resize/1200/https://storage.googleapis.com/media.mwcradio.com/mimesis/2018-11/20/2018-11-20T133150Z_1_LYNXNPEEAJ0WR-OUSBS_RTROPTP_3_BUSINESS-US-SHIRE-M-A-INVESTORS.JPG?upscale=False", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-20T13:31:00Z", "enriched_text": {"entities": [{"count": 5, "sentiment": {"score": 0.183675, "label": "positive"}, "text": "Takeda", "relevance": 0.846163, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co", "relevance": 0.637907, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "London-listed Shire", "relevance": 0.338582, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Glass Lewis", "relevance": 0.306796, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Institutional Shareholder Services", "relevance": 0.283208, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0.47335, "label": "positive"}, "text": "Ben Martin", "relevance": 0.271161, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.258007, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.24953, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "drugmaker Shire", "relevance": 0.234785, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.212406, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ISS", "relevance": 0.193021, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Reuters", "relevance": 0.176652, "type": "Company", "disambiguation": {"subtype": [], "name": "Reuters", "dbpedia_resource": "http://dbpedia.org/resource/Reuters"}}, {"count": 1, "sentiment": {"score": 0.35503, "label": "positive"}, "text": "Louise Heavens", "relevance": 0.164116, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tokyo", "relevance": 0.152143, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.152143, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "0.4 percent", "relevance": 0.152143, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "0.6 percent", "relevance": 0.152143, "type": "Quantity"}], "sentiment": {"document": {"score": 0.398607, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Two shareholder advisory firms", "keywords": [{"text": "shareholder advisory firms"}]}, "sentence": " LONDON (Reuters) - Two shareholder advisory firms have backed Takeda Pharmaceutical's <4502.T> $62 billion takeover offer for drugmaker Shire , dealing a blow to a group of investors who hope to block the deal.", "object": {"text": "Takeda Pharmaceutical", "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "back", "tense": "past"}, "text": "have backed", "normalized": "have back"}}, {"subject": {"text": "Glass Lewis both", "keywords": [{"text": "Glass Lewis"}], "entities": [{"type": "Company", "text": "Glass Lewis"}]}, "sentence": " Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "object": {"text": "that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support", "keywords": [{"text": "Takeda vote"}, {"text": "two-thirds support"}, {"text": "pharmaceuticals company"}, {"text": "investor meeting"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "recommend", "tense": "past"}, "text": "recommended", "normalized": "recommend"}}, {"subject": {"text": "the pharmaceuticals company", "keywords": [{"text": "pharmaceuticals company"}]}, "sentence": " Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "object": {"text": "Dec. 5", "keywords": [{"text": "Dec."}]}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "needs to secure", "normalized": "need to secure"}}, {"subject": {"text": "It"}, "sentence": " It is a boost for Takeda, which has faced a campaign by a small group of about 130 retail investors that includes former employees to derail the takeover of London-listed Shire.", "object": {"text": "a boost for Takeda, which has faced a campaign by a small group of about 130 retail investors that includes former employees to derail the takeover of London-listed Shire", "keywords": [{"text": "London-listed Shire"}, {"text": "retail investors"}, {"text": "small group"}, {"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Location", "text": "London-listed Shire", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "former employees to derail the takeover of London-listed Shire", "keywords": [{"text": "London-listed Shire"}, {"text": "takeover"}, {"text": "employees"}], "entities": [{"type": "Location", "text": "London-listed Shire", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " It is a boost for Takeda, which has faced a campaign by a small group of about 130 retail investors that includes former employees to derail the takeover of London-listed Shire.", "object": {"text": "a small group of about 130 retail investors", "keywords": [{"text": "retail investors"}, {"text": "small group"}], "entities": []}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Those shareholders are worried about the significant debt that Takeda is taking on to complete the deal and the risks posed by the scale of the acquisition, which is the largest-ever overseas acquisition by a Japanese company.", "object": {"text": "the significant debt", "keywords": [{"text": "significant debt"}]}, "action": {"verb": {"text": "take", "tense": "present"}, "text": "is taking", "normalized": "be take"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Those shareholders are worried about the significant debt that Takeda is taking on to complete the deal and the risks posed by the scale of the acquisition, which is the largest-ever overseas acquisition by a Japanese company.", "object": {"text": "the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "complete", "tense": "future"}, "text": "to complete", "normalized": "to complete"}}, {"subject": {"text": "by the scale of the acquisition, which is the largest-ever overseas acquisition by a Japanese company", "keywords": [{"text": "largest-ever overseas acquisition"}, {"text": "Japanese company"}, {"text": "scale"}]}, "sentence": " Those shareholders are worried about the significant debt that Takeda is taking on to complete the deal and the risks posed by the scale of the acquisition, which is the largest-ever overseas acquisition by a Japanese company.", "object": {"text": "the risks", "keywords": [{"text": "risks"}]}, "action": {"verb": {"text": "pose", "tense": "past"}, "text": "posed", "normalized": "pose"}}, {"subject": {"text": "the largest-ever overseas acquisition", "keywords": [{"text": "largest-ever overseas acquisition"}]}, "sentence": " Those shareholders are worried about the significant debt that Takeda is taking on to complete the deal and the risks posed by the scale of the acquisition, which is the largest-ever overseas acquisition by a Japanese company.", "object": {"text": "by a Japanese company", "keywords": [{"text": "Japanese company"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "ISS and Glass Lewis", "keywords": [{"text": "Glass Lewis"}, {"text": "ISS"}], "entities": [{"type": "Organization", "text": "Institutional Shareholder Services"}]}, "sentence": " But ISS and Glass Lewis said that investor support for the cash-and-shares transaction was warranted.", "object": {"text": "that investor support for the cash-and-shares transaction was warranted", "keywords": [{"text": "cash-and-shares transaction"}, {"text": "investor support"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "The deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " \"The deal diversifies the company in terms of products and geographies, and provides strong cash flow generation that, combined with divestments, allows for relatively rapid deleveraging, despite maintaining top of the range leverage in the mid-term,\" ISS said in a report to clients.", "object": {"text": "the company", "keywords": [{"text": "company"}]}, "action": {"verb": {"text": "diversify", "tense": "present"}, "text": "diversifies", "normalized": "diversify"}}, {"subject": {"text": "The deal diversifies the company", "keywords": [{"text": "deal"}, {"text": "company"}], "entities": []}, "sentence": " \"The deal diversifies the company in terms of products and geographies, and provides strong cash flow generation that, combined with divestments, allows for relatively rapid deleveraging, despite maintaining top of the range leverage in the mid-term,\" ISS said in a report to clients.", "object": {"text": "strong cash flow generation", "keywords": [{"text": "strong cash flow"}], "entities": []}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "strong cash flow generation", "keywords": [{"text": "strong cash flow"}], "entities": []}, "sentence": " \"The deal diversifies the company in terms of products and geographies, and provides strong cash flow generation that, combined with divestments, allows for relatively rapid deleveraging, despite maintaining top of the range leverage in the mid-term,\" ISS said in a report to clients.", "object": {"text": "with divestments", "keywords": [{"text": "divestments"}]}, "action": {"verb": {"text": "combine", "tense": "past"}, "text": "combined", "normalized": "combine"}}, {"subject": {"text": "strong cash flow generation", "keywords": [{"text": "strong cash flow"}], "entities": []}, "sentence": " \"The deal diversifies the company in terms of products and geographies, and provides strong cash flow generation that, combined with divestments, allows for relatively rapid deleveraging, despite maintaining top of the range leverage in the mid-term,\" ISS said in a report to clients.", "object": {"text": "for relatively rapid deleveraging", "keywords": [{"text": "relatively rapid deleveraging"}]}, "action": {"verb": {"text": "allow", "tense": "present"}, "text": "allows", "normalized": "allow"}}, {"subject": {"text": "top of the range leverage", "keywords": [{"text": "leverage"}, {"text": "range"}]}, "sentence": " \"The deal diversifies the company in terms of products and geographies, and provides strong cash flow generation that, combined with divestments, allows for relatively rapid deleveraging, despite maintaining top of the range leverage in the mid-term,\" ISS said in a report to clients.", "action": {"verb": {"text": "maintain", "tense": "present"}, "text": "maintaining", "normalized": "maintain"}}, {"subject": {"text": "ISS", "keywords": [{"text": "ISS"}], "entities": [{"type": "Organization", "text": "Institutional Shareholder Services"}]}, "sentence": " \"The deal diversifies the company in terms of products and geographies, and provides strong cash flow generation that, combined with divestments, allows for relatively rapid deleveraging, despite maintaining top of the range leverage in the mid-term,\" ISS said in a report to clients.", "object": {"text": "The deal diversifies the company in terms of products and geographies, and provides strong cash flow generation that, combined with divestments, allows for relatively rapid deleveraging, despite maintaining top of the range leverage in the mid-term", "keywords": [{"text": "relatively rapid deleveraging"}, {"text": "strong cash flow"}, {"text": "range leverage"}, {"text": "geographies"}], "entities": []}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Glass Lewis", "keywords": [{"text": "Glass Lewis"}], "entities": [{"type": "Company", "text": "Glass Lewis"}]}, "sentence": " Glass Lewis said in a separate report that \"the strategic case is compelling for Takeda.\"", "object": {"text": "that \"the strategic case is compelling for Takeda", "keywords": [{"text": "Takeda"}, {"text": "strategic case"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "a separate report that \"the strategic case", "keywords": [{"text": "separate report"}, {"text": "strategic case"}]}, "sentence": " Glass Lewis said in a separate report that \"the strategic case is compelling for Takeda.\"", "object": {"text": "compelling for Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Shares in Shire", "keywords": [{"text": "Shire"}, {"text": "Shares"}], "entities": [{"type": "Location", "text": "London-listed Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": " Shares in Shire were up 0.4 percent in London while Takeda closed up 0.6 percent in Tokyo.", "object": {"text": "0.4 percent", "keywords": [{"text": "percent"}], "entities": [{"type": "Quantity", "text": "0.4 percent"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Shares in Shire were up 0.4 percent in London while Takeda closed up 0.6 percent in Tokyo.", "action": {"verb": {"text": "close", "tense": "past"}, "text": "closed", "normalized": "close"}}], "concepts": [{"text": "Stock", "relevance": 0.934224, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Derivative", "relevance": 0.878652, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Stock market", "relevance": 0.859114, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Share", "relevance": 0.83593, "dbpedia_resource": "http://dbpedia.org/resource/Share_(finance)"}, {"text": "Debt", "relevance": 0.803093, "dbpedia_resource": "http://dbpedia.org/resource/Debt"}, {"text": "Corporate finance", "relevance": 0.789723, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_finance"}, {"text": "Shareholder", "relevance": 0.770879, "dbpedia_resource": "http://dbpedia.org/resource/Shareholder"}, {"text": "Leverage", "relevance": 0.764181, "dbpedia_resource": "http://dbpedia.org/resource/Leverage_(finance)"}, {"text": "Finance", "relevance": 0.718698, "dbpedia_resource": "http://dbpedia.org/resource/Finance"}, {"text": "Mergers and acquisitions", "relevance": 0.689139, "dbpedia_resource": "http://dbpedia.org/resource/Mergers_and_acquisitions"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.644805, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Pharmaceutical drug", "relevance": 0.640921, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Risk aversion", "relevance": 0.64015, "dbpedia_resource": "http://dbpedia.org/resource/Risk_aversion"}, {"text": "Takeover", "relevance": 0.627417, "dbpedia_resource": "http://dbpedia.org/resource/Takeover"}, {"text": "Investor", "relevance": 0.626047, "dbpedia_resource": "http://dbpedia.org/resource/Investor"}, {"text": "Stakeholder", "relevance": 0.609679, "dbpedia_resource": "http://dbpedia.org/resource/Stakeholder_(corporate)"}], "categories": [{"score": 0.926216, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.912841, "label": "/finance/investing"}, {"score": 0.912841, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "managerOf", "sentence": "Investor advisory firms back Takeda's $62 billion deal for Shire 7:31 a.m. CST FILE PHOTO: The logo of Takeda Pharmaceutical Co. Japan May 9, 2018.", "score": 0.528589, "arguments": [{"text": "Investor", "location": [0, 8], "entities": [{"type": "Person", "text": "Investor"}]}, {"text": "firms", "location": [18, 23], "entities": [{"type": "Organization", "text": "firms", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.643466, "arguments": [{"text": "Institutional Shareholder Services", "location": [407, 441], "entities": [{"type": "Organization", "text": "Institutional Shareholder Services"}]}, {"text": "ISS", "location": [443, 446], "entities": [{"type": "Facility", "text": "ISS"}]}]}, {"type": "agentOf", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.919245, "arguments": [{"text": "Glass Lewis", "location": [452, 463], "entities": [{"type": "Person", "text": "Glass Lewis"}]}, {"text": "recommended", "location": [469, 480], "entities": [{"type": "EventCommunication", "text": "recommended"}]}]}, {"type": "timeOf", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.975255, "arguments": [{"text": "Tuesday", "location": [484, 491], "entities": [{"type": "Date", "text": "Tuesday"}]}, {"text": "recommended", "location": [469, 480], "entities": [{"type": "EventCommunication", "text": "recommended"}]}]}, {"type": "affectedBy", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.483489, "arguments": [{"text": "shareholders", "location": [497, 509], "entities": [{"type": "Organization", "text": "shareholders", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "recommended", "location": [469, 480], "entities": [{"type": "EventCommunication", "text": "recommended"}]}]}, {"type": "partOf", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.491164, "arguments": [{"text": "shareholders", "location": [497, 509], "entities": [{"type": "Organization", "text": "shareholders", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Takeda", "location": [521, 527], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.473969, "arguments": [{"text": "shareholders", "location": [497, 509], "entities": [{"type": "Organization", "text": "shareholders", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [541, 552], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.592184, "arguments": [{"text": "Takeda", "location": [521, 527], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [541, 552], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.497807, "arguments": [{"text": "Dec. 5", "location": [590, 596], "entities": [{"type": "Date", "text": "Dec. 5"}]}, {"text": "acquisition", "location": [541, 552], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.493241, "arguments": [{"text": "investor", "location": [559, 567], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "meeting", "location": [568, 575], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "timeOf", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.94429, "arguments": [{"text": "Dec. 5", "location": [590, 596], "entities": [{"type": "Date", "text": "Dec. 5"}]}, {"text": "meeting", "location": [568, 575], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "partOf", "sentence": "Investor advisory firms back Takeda's $62 billion deal for Shire 7:31 a.m. CST FILE PHOTO: The logo of Takeda Pharmaceutical Co. Japan May 9, 2018.", "score": 0.654567, "arguments": [{"text": "firms", "location": [18, 23], "entities": [{"type": "Organization", "text": "firms", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Takeda", "location": [29, 35], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "It is a boost for Takeda, which has faced a campaign by a small group of about 130 retail investors that includes former employees to derail the takeover of London-listed Shire.", "score": 0.838826, "arguments": [{"text": "Shire", "location": [842, 847], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "takeover", "location": [816, 824], "entities": [{"type": "EventPersonnel", "text": "takeover"}]}]}, {"type": "agentOf", "sentence": "Those shareholders are worried about the significant debt that Takeda is taking on to complete the deal and the risks posed by the scale of the acquisition, which is the largest-ever overseas acquisition by a Japanese company.", "score": 0.473375, "arguments": [{"text": "Takeda", "location": [912, 918], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [993, 1004], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "Those shareholders are worried about the significant debt that Takeda is taking on to complete the deal and the risks posed by the scale of the acquisition, which is the largest-ever overseas acquisition by a Japanese company.", "score": 0.561392, "arguments": [{"text": "company", "location": [1067, 1074], "entities": [{"type": "Organization", "text": "Institutional Shareholder Services"}]}, {"text": "acquisition", "location": [1041, 1052], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "basedIn", "sentence": "Those shareholders are worried about the significant debt that Takeda is taking on to complete the deal and the risks posed by the scale of the acquisition, which is the largest-ever overseas acquisition by a Japanese company.", "score": 0.991265, "arguments": [{"text": "company", "location": [1067, 1074], "entities": [{"type": "Organization", "text": "Institutional Shareholder Services"}]}, {"text": "Japanese", "location": [1058, 1066], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "But ISS and Glass Lewis said that investor support for the cash-and-shares transaction was warranted.", "score": 0.998091, "arguments": [{"text": "Glass Lewis", "location": [1088, 1099], "entities": [{"type": "Person", "text": "Glass Lewis"}]}, {"text": "said", "location": [1100, 1104], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Glass Lewis said in a separate report that \"the strategic case is compelling for Takeda.", "score": 0.995972, "arguments": [{"text": "Glass Lewis", "location": [1463, 1474], "entities": [{"type": "Person", "text": "Glass Lewis"}]}, {"text": "said", "location": [1475, 1479], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "affectedBy", "sentence": "\"The deal diversifies the company in terms of products and geographies, and provides strong cash flow generation that, combined with divestments, allows for relatively rapid deleveraging, despite maintaining top of the range leverage in the mid-term,\" ISS said in a report to clients.", "score": 0.512031, "arguments": [{"text": "clients", "location": [1454, 1461], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "said", "location": [1434, 1438], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "basedIn", "sentence": "\" Shares in Shire were up 0.4 percent in London while Takeda closed up 0.6 percent in Tokyo.", "score": 0.682993, "arguments": [{"text": "Takeda", "location": [1605, 1611], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "London", "location": [1592, 1598], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "hasAttribute", "sentence": "Investor advisory firms back Takeda's $62 billion deal for Shire 7:31 a.m. CST FILE PHOTO: The logo of Takeda Pharmaceutical Co. Japan May 9, 2018.", "score": 0.510515, "arguments": [{"text": "Takeda", "location": [29, 35], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$62 billion", "location": [38, 49], "entities": [{"type": "Money", "text": "$62 billion"}]}]}, {"type": "basedIn", "sentence": "Investor advisory firms back Takeda's $62 billion deal for Shire 7:31 a.m. CST FILE PHOTO: The logo of Takeda Pharmaceutical Co. Japan May 9, 2018.", "score": 0.362776, "arguments": [{"text": "Takeda Pharmaceutical Co.", "location": [103, 128], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japan", "location": [129, 134], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.817805, "arguments": [{"text": "Takeda", "location": [521, 527], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japan", "location": [513, 518], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "residesIn", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Ben Martin LONDON (Reuters) - Two shareholder advisory firms have backed Takeda Pharmaceutical's <4502.T> $62 billion takeover offer for drugmaker Shire , dealing a blow to a group of investors who hope to block the deal.", "score": 0.829111, "arguments": [{"text": "Ben Martin", "location": [185, 195], "entities": [{"type": "Person", "text": "Ben Martin"}]}, {"text": "LONDON", "location": [196, 202], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "employedBy", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Ben Martin LONDON (Reuters) - Two shareholder advisory firms have backed Takeda Pharmaceutical's <4502.T> $62 billion takeover offer for drugmaker Shire , dealing a blow to a group of investors who hope to block the deal.", "score": 0.525657, "arguments": [{"text": "Ben Martin", "location": [185, 195], "entities": [{"type": "Person", "text": "Ben Martin"}]}, {"text": "Reuters", "location": [204, 211], "entities": [{"type": "Organization", "text": "Reuters", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Ben Martin LONDON (Reuters) - Two shareholder advisory firms have backed Takeda Pharmaceutical's <4502.T> $62 billion takeover offer for drugmaker Shire , dealing a blow to a group of investors who hope to block the deal.", "score": 0.575136, "arguments": [{"text": "Takeda Pharmaceutical", "location": [258, 279], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "<4502.T> $62 billion", "location": [282, 302], "entities": [{"type": "Money", "text": "<4502.T> $62 billion"}]}]}, {"type": "agentOf", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Ben Martin LONDON (Reuters) - Two shareholder advisory firms have backed Takeda Pharmaceutical's <4502.T> $62 billion takeover offer for drugmaker Shire , dealing a blow to a group of investors who hope to block the deal.", "score": 0.632069, "arguments": [{"text": "Takeda Pharmaceutical", "location": [258, 279], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "takeover", "location": [303, 311], "entities": [{"type": "EventPersonnel", "text": "takeover"}]}]}, {"type": "partOfMany", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Ben Martin LONDON (Reuters) - Two shareholder advisory firms have backed Takeda Pharmaceutical's <4502.T> $62 billion takeover offer for drugmaker Shire , dealing a blow to a group of investors who hope to block the deal.", "score": 0.42161, "arguments": [{"text": "group", "location": [360, 365], "entities": [{"type": "Person", "text": "group"}]}, {"text": "investors", "location": [369, 378], "entities": [{"type": "Person", "text": "investors"}]}]}, {"type": "partOfMany", "sentence": "It is a boost for Takeda, which has faced a campaign by a small group of about 130 retail investors that includes former employees to derail the takeover of London-listed Shire.", "score": 0.425426, "arguments": [{"text": "group", "location": [735, 740], "entities": [{"type": "Person", "text": "group"}]}, {"text": "investors", "location": [761, 770], "entities": [{"type": "Person", "text": "investors"}]}]}], "keywords": [{"text": "Glass Lewis", "sentiment": {"score": 0.574175, "label": "positive"}, "relevance": 0.674902, "count": 3}, {"text": "takeover of London", "sentiment": {"score": 0.78421, "label": "positive"}, "relevance": 0.668099, "count": 1}, {"text": "Institutional Shareholder Services", "sentiment": {"score": 0.726087, "label": "positive"}, "relevance": 0.665095, "count": 1}, {"text": "shareholder", "sentiment": {"score": -0.756834, "label": "negative"}, "relevance": 0.657693, "count": 1}, {"text": "Takeda", "sentiment": {"score": -0.249179, "mixed": "1", "label": "negative"}, "relevance": 0.634739, "count": 5}, {"text": "London", "sentiment": {"score": -0.46681, "label": "negative"}, "relevance": 0.622373, "count": 1}, {"text": "shareholders", "sentiment": {"score": 0.456584, "mixed": "1", "label": "positive"}, "relevance": 0.607151, "count": 2}, {"text": "Investor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.605348, "count": 1}, {"text": "deal", "sentiment": {"score": 0.34863, "mixed": "1", "label": "positive"}, "relevance": 0.602538, "count": 4}, {"text": "ISS", "sentiment": {"score": 0.57217, "label": "positive"}, "relevance": 0.598427, "count": 3}, {"text": "retail investors", "sentiment": {"score": 0.78421, "label": "positive"}, "relevance": 0.588398, "count": 1}, {"text": "small group", "sentiment": {"score": 0.78421, "label": "positive"}, "relevance": 0.582772, "count": 1}, {"text": "Reuters", "sentiment": {"score": -0.756834, "label": "negative"}, "relevance": 0.57403, "count": 1}, {"text": "REUTERS", "sentiment": {"score": -0.756834, "label": "negative"}, "relevance": 0.57403, "count": 1}, {"text": "group of investors", "sentiment": {"score": -0.756834, "label": "negative"}, "relevance": 0.569577, "count": 1}, {"text": "Shire", "sentiment": {"score": 0.306305, "mixed": "1", "label": "positive"}, "relevance": 0.56848, "count": 3}, {"text": "strong cash flow generation", "sentiment": {"score": 0.583199, "label": "positive"}, "relevance": 0.564007, "count": 1}, {"text": "term", "sentiment": {"score": 0.583199, "label": "positive"}, "relevance": 0.560141, "count": 1}, {"text": "terms of products", "sentiment": {"score": 0.583199, "label": "positive"}, "relevance": 0.559433, "count": 1}, {"text": "top of the range leverage", "sentiment": {"score": 0.583199, "label": "positive"}, "relevance": 0.553419, "count": 1}, {"text": "cash", "sentiment": {"score": 0.373244, "label": "positive"}, "relevance": 0.550739, "count": 1}, {"text": "report", "sentiment": {"score": 0.583199, "label": "positive"}, "relevance": 0.550176, "count": 1}, {"text": "Japanese company", "sentiment": {"score": 0.243367, "mixed": "1", "label": "positive"}, "relevance": 0.549525, "count": 1}, {"text": "advisory firms", "sentiment": {"score": -0.756834, "label": "negative"}, "relevance": 0.544715, "count": 2}, {"text": "acquisition", "sentiment": {"score": 0.726087, "label": "positive"}, "relevance": 0.542754, "count": 1}, {"text": "boost", "sentiment": {"score": 0.78421, "label": "positive"}, "relevance": 0.541302, "count": 1}, {"text": "Shares", "sentiment": {"score": -0.46681, "label": "negative"}, "relevance": 0.537795, "count": 1}, {"text": "geographies", "sentiment": {"score": 0.583199, "label": "positive"}, "relevance": 0.535656, "count": 1}, {"text": "takeover offer", "sentiment": {"score": -0.756834, "label": "negative"}, "relevance": 0.532845, "count": 1}, {"text": "campaign", "sentiment": {"score": 0.78421, "label": "positive"}, "relevance": 0.531932, "count": 1}, {"text": "rapid deleveraging", "sentiment": {"score": 0.583199, "label": "positive"}, "relevance": 0.530807, "count": 1}, {"text": "company", "sentiment": {"score": 0.583199, "label": "positive"}, "relevance": 0.530245, "count": 1}, {"text": "former employees", "sentiment": {"score": 0.78421, "label": "positive"}, "relevance": 0.529926, "count": 1}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": -0.756834, "label": "negative"}, "relevance": 0.522906, "count": 1}, {"text": "risks", "sentiment": {"score": -0.372454, "label": "negative"}, "relevance": 0.52166, "count": 1}, {"text": "pharmaceuticals company", "sentiment": {"score": 0.726087, "label": "positive"}, "relevance": 0.515977, "count": 1}, {"text": "Japan's Takeda vote", "sentiment": {"score": 0.726087, "label": "positive"}, "relevance": 0.507761, "count": 1}, {"text": "drugmaker Shire", "sentiment": {"score": -0.756834, "label": "negative"}, "relevance": 0.507393, "count": 1}, {"text": "Business", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506209, "count": 1}, {"text": "clients", "sentiment": {"score": 0.589343, "label": "positive"}, "relevance": 0.506209, "count": 1}, {"text": "Tokyo", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506209, "count": 1}, {"text": "investor meeting", "sentiment": {"score": 0.726087, "label": "positive"}, "relevance": 0.503348, "count": 1}, {"text": "significant debt", "sentiment": {"score": -0.372454, "label": "negative"}, "relevance": 0.498779, "count": 1}, {"text": "shares transaction", "sentiment": {"score": 0.373244, "label": "positive"}, "relevance": 0.497433, "count": 1}, {"text": "separate report", "sentiment": {"score": 0.589343, "label": "positive"}, "relevance": 0.484152, "count": 1}, {"text": "FILE PHOTO", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.47896, "count": 1}, {"text": "scale of the acquisition", "sentiment": {"score": -0.372454, "label": "negative"}, "relevance": 0.478107, "count": 1}, {"text": "Ben Martin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.476681, "count": 1}, {"text": "Kim Kyung-Hoon", "sentiment": {"score": -0.756834, "label": "negative"}, "relevance": 0.472219, "count": 1}, {"text": "investor support", "sentiment": {"score": 0.373244, "label": "positive"}, "relevance": 0.468634, "count": 1}]}, "extracted_metadata": {"sha1": "f3174e93292ca110c8b45be3ac5a4fc35d79c7df", "filename": "1542721484539.zip-fbbfc2107a35b3e398b2bfbdfcf02802.xml", "file_type": "json"}, "title": "Investor advisory firms back Takeda's $62 billion deal for Shire", "forum_title": "Business news from wiky.com"}, {"id": "uv3opHZcjhrkblkz-6tmuBLyC4htIZsUUqoY0g3TzNPvB2rrpGeVChIffSIBZbxD", "result_metadata": {"score": 31.169756}, "author": "Asif Suria", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Arbitrage", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Arbitrage"}, {"text": "Risk arbitrage", "relevance": 0.8704, "dbpedia_resource": "http://dbpedia.org/resource/Risk_arbitrage"}], "categories": [{"score": 0.999646, "label": "/business and industrial/company/merger and acquisition"}], "relations": [], "keywords": [{"text": "Merger Arbitrage Mondays", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999186, "count": 1}, {"text": "November", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.880929, "count": 1}]}, "crawl_date": "2018-11-20T14:37:43Z", "url": "https://seekingalpha.com/article/4223508-merger-arbitrage-mondays-november-19-2018", "host": "seekingalpha.com", "text": "(PAAS) $4.10 $3.29 03/31/2019 24.62% 68.08% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $10.85 12/31/2018 24.42% 212.26% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $16.72 10/31/2018 23.21% -445.79% GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd.", "main_image_url": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-20T09:27:00Z", "enriched_text": {"entities": [{"count": 9, "sentiment": {"score": 0, "label": "neutral"}, "text": "NYSE", "relevance": 0.729419, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.488084, "label": "positive"}, "text": "Pan American Silver", "relevance": 0.337796, "type": "Company", "disambiguation": {"subtype": [], "name": "Pan American Silver", "dbpedia_resource": "http://dbpedia.org/resource/Pan_American_Silver"}}, {"count": 2, "sentiment": {"score": 0.546568, "label": "positive"}, "text": "CVR", "relevance": 0.32746, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Forest City", "relevance": 0.29107, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tahoe", "relevance": 0.282961, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tahoe Resources", "relevance": 0.28226, "type": "Company", "disambiguation": {"subtype": [], "name": "Tahoe Resources", "dbpedia_resource": "http://dbpedia.org/resource/Tahoe_Resources"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "athenahealth", "relevance": 0.280373, "type": "Company", "disambiguation": {"subtype": [], "name": "Athenahealth", "dbpedia_resource": "http://dbpedia.org/resource/Athenahealth"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Evergreen", "relevance": 0.24726, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hartford Financial Services Group", "relevance": 0.244534, "type": "Organization", "disambiguation": {"subtype": ["Company"], "name": "The Hartford", "dbpedia_resource": "http://dbpedia.org/resource/The_Hartford"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.240397, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Univar", "relevance": 0.23757, "type": "Company", "disambiguation": {"subtype": [], "name": "Univar", "dbpedia_resource": "http://dbpedia.org/resource/Univar"}}, {"count": 1, "sentiment": {"score": 0.379416, "label": "positive"}, "text": "Forest City Realty Trust", "relevance": 0.23749, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Editor", "relevance": 0.236495, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Reliance Industries Limited", "relevance": 0.232398, "type": "Company", "disambiguation": {"subtype": [], "name": "Reliance Industries", "dbpedia_resource": "http://dbpedia.org/resource/Reliance_Industries"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anchor Bancorp", "relevance": 0.23005, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Apollo Global Management", "relevance": 0.22696, "type": "Company", "disambiguation": {"subtype": [], "name": "Apollo Global Management", "dbpedia_resource": "http://dbpedia.org/resource/Apollo_Global_Management"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "KLA-Tencor Corporation", "relevance": 0.225847, "type": "Company", "disambiguation": {"subtype": [], "name": "KLA Tencor", "dbpedia_resource": "http://dbpedia.org/resource/KLA_Tencor"}}, {"count": 2, "sentiment": {"score": 0.401222, "label": "positive"}, "text": "Nexeo Solutions", "relevance": 0.225046, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GulfMark Offshore", "relevance": 0.225027, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SJW Group", "relevance": 0.224012, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "magicJack", "relevance": 0.222151, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LifePoint Health", "relevance": 0.221729, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "FS Bancorp", "relevance": 0.220906, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teamsport Parent Limited", "relevance": 0.220043, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "IK Healthcare Investment Limited", "relevance": 0.218264, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Finisar", "relevance": 0.217761, "type": "Company", "disambiguation": {"subtype": [], "name": "Finisar", "dbpedia_resource": "http://dbpedia.org/resource/Finisar"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "KMG Chemicals", "relevance": 0.21743, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Connecticut Water Service", "relevance": 0.217424, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "B. Riley Financial", "relevance": 0.211738, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China Oceanwide Holdings Group Co.", "relevance": 0.210714, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tidewater", "relevance": 0.209897, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brookfield Asset Management", "relevance": 0.208053, "type": "Company", "disambiguation": {"subtype": [], "name": "Brookfield Asset Management", "dbpedia_resource": "http://dbpedia.org/resource/Brookfield_Asset_Management"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ConversionPoint Technologies", "relevance": 0.2076, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.256719, "label": "negative"}, "text": "T-Mobile", "relevance": 0.206443, "type": "Company", "disambiguation": {"subtype": [], "name": "T-Mobile USA", "dbpedia_resource": "http://dbpedia.org/resource/T-Mobile_USA"}}, {"count": 1, "sentiment": {"score": 0.475673, "label": "positive"}, "text": "Rockwell Collins", "relevance": 0.206438, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "The Navigators Group", "relevance": 0.203534, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "KMG", "relevance": 0.202761, "type": "Company", "disambiguation": {"subtype": [], "name": "KMG", "dbpedia_resource": "http://dbpedia.org/resource/KMG"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pandora", "relevance": 0.191249, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cabot Microelectronics Corporation", "relevance": 0.189692, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dominion Energy, Inc.", "relevance": 0.183578, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.256719, "label": "negative"}, "text": "US, Inc.", "relevance": 0.168399, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "122 days", "relevance": 0.168399, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1.35 trillion", "relevance": 0.168399, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1.45 billion", "relevance": 0.168399, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5.7 billion", "relevance": 0.168399, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2018 11.69%", "relevance": 0.168399, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2018 14.63%", "relevance": 0.168399, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2018 15.86%", "relevance": 0.168399, "type": "Quantity"}], "sentiment": {"document": {"score": 0.688861, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Merger activity", "keywords": [{"text": "Merger activity"}]}, "sentence": "Merger activity decreased last week with two new deals announced and five pending deals closing.", "action": {"verb": {"text": "decrease", "tense": "past"}, "text": "decreased", "normalized": "decrease"}}, {"subject": {"text": "We"}, "sentence": " We added ATHN as a potential deal to the Deals in the Works section on May 7, 2018 and the price after the news of the potential deal came out was $146.75.", "object": {"text": "ATHN"}, "action": {"verb": {"text": "add", "tense": "past"}, "text": "added", "normalized": "add"}}, {"subject": {"text": "the news of the potential deal", "keywords": [{"text": "potential deal"}, {"text": "news"}], "entities": []}, "sentence": " We added ATHN as a potential deal to the Deals in the Works section on May 7, 2018 and the price after the news of the potential deal came out was $146.75.", "object": {"text": "$146.75", "entities": [{"type": "Quantity", "text": "$146.75"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Tahoe shareholders", "keywords": [{"text": "Tahoe shareholders"}], "entities": [{"type": "Location", "text": "Tahoe", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Under the terms of the agreement, Tahoe shareholders may elect to receive US$3.40 in cash or 0.2403 Pan American shares for each Tahoe share.", "object": {"text": "$3.40 in cash or 0.2403 Pan American shares for each Tahoe share", "keywords": [{"text": "Pan American shares"}, {"text": "Tahoe share"}, {"text": "cash"}], "entities": [{"type": "Quantity", "text": "$3.40"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "may elect to receive", "normalized": "may elect to receive"}}, {"subject": {"text": "Tahoe shareholders", "keywords": [{"text": "Tahoe shareholders"}]}, "sentence": " In addition, Tahoe shareholders will receive contingent consideration in the form of contingent value rights (CVR) that will be exchanged for 0.0497 Pan American shares for each Tahoe share.", "object": {"text": "contingent consideration in the form of contingent value rights (CVR) that will be exchanged for 0.0497 Pan American shares for each Tahoe share", "keywords": [{"text": "contingent value rights"}, {"text": "contingent consideration"}, {"text": "Pan American shares"}, {"text": "Tahoe share"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "will receive", "normalized": "will receive"}}, {"subject": {"text": "We"}, "sentence": " We are treating this as a special conditions deal and are using the value of the CVR when calculating the closing price.", "object": {"text": "treating this as a special conditions deal", "keywords": [{"text": "special conditions"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "We"}, "sentence": " We are treating this as a special conditions deal and are using the value of the CVR when calculating the closing price.", "object": {"text": "this"}, "action": {"verb": {"text": "treat", "tense": "present"}, "text": "are treating", "normalized": "be treat"}}, {"subject": {"text": "We"}, "sentence": " We are treating this as a special conditions deal and are using the value of the CVR when calculating the closing price.", "object": {"text": "the value of the CVR", "keywords": [{"text": "CVR"}, {"text": "value"}], "entities": [{"type": "Organization", "text": "CVR"}]}, "action": {"verb": {"text": "use", "tense": "present"}, "text": "are using", "normalized": "be use"}}, {"subject": {"text": "the discount on the CVR", "keywords": [{"text": "CVR"}, {"text": "discount"}], "entities": [{"type": "Organization", "text": "CVR"}]}, "sentence": " The large spread on the deal reflects the discount on the CVR, as is usually the case in these types of deals.", "object": {"text": "The large spread on the deal", "keywords": [{"text": "large spread"}, {"text": "deal"}], "entities": []}, "action": {"verb": {"text": "reflect", "tense": "present"}, "text": "reflects", "normalized": "reflect"}}, {"subject": {"text": "15, 2018, Forest City Realty Trust (NYSE: FCE.A )", "keywords": [{"text": "Forest City Realty"}, {"text": "FCE.A"}], "entities": [{"type": "Company", "text": "Forest City Realty Trust"}, {"type": "Company", "text": "NYSE"}]}, "sentence": " On November 15, 2018, Forest City Realty Trust (NYSE: FCE.A ) announced that its stockholders approved the acquisition of Forest City by Brookfield Asset Management (NYSE: BAM ).", "object": {"text": "that its stockholders approved the acquisition of Forest City by Brookfield Asset Management (NYSE: BAM )", "keywords": [{"text": "Brookfield Asset Management"}, {"text": "stockholders"}, {"text": "Forest City"}, {"text": "BAM"}], "entities": [{"type": "Company", "text": "Forest City"}, {"type": "Company", "text": "Brookfield Asset Management", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Brookfield Asset Management", "dbpedia_resource": "http://dbpedia.org/resource/Brookfield_Asset_Management"}}, {"type": "Company", "text": "NYSE"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "Forest City", "keywords": [{"text": "Forest City"}], "entities": [{"type": "Company", "text": "Forest City"}]}, "sentence": " Forest City expects that the acquisition will be completed in December on or prior to December 10, 2018.", "object": {"text": "that the acquisition will be completed in December on or prior to December 10, 2018", "keywords": [{"text": "acquisition"}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "expects", "normalized": "expect"}}, {"subject": {"text": "the acquisition", "keywords": [{"text": "acquisition"}]}, "sentence": " Forest City expects that the acquisition will be completed in December on or prior to December 10, 2018.", "action": {"verb": {"text": "complete", "tense": "future"}, "text": "will be completed", "normalized": "will be complete"}}, {"subject": {"text": "The Navigators Group (NASDAQ: NAVG )", "keywords": [{"text": "Navigators Group"}, {"text": "NAVG"}, {"text": "NASDAQ"}], "entities": [{"type": "Company", "text": "The Navigators Group"}]}, "sentence": " On November 16, 2018, The Navigators Group (NASDAQ: NAVG ) announced that, at a special meeting of stockholders, Navigators\u2019 stockholders approved the adoption of the previously announced merger agreement relating to the proposed transaction between Navigators and The Hartford Financial Services Group (NYSE: HIG ).", "object": {"text": "that, at a special meeting of stockholders, Navigators\u2019 stockholders approved the adoption of the previously announced merger agreement relating to the proposed transaction between Navigators and The Hartford Financial Services Group (NYSE: HIG )", "keywords": [{"text": "previously announced merger"}, {"text": "Hartford Financial Services"}, {"text": "stockholders"}, {"text": "special meeting"}], "entities": [{"type": "Organization", "text": "Hartford Financial Services Group", "disambiguation": {"subtype": ["Company"], "name": "The Hartford", "dbpedia_resource": "http://dbpedia.org/resource/The_Hartford"}}, {"type": "Company", "text": "NYSE"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the adoption of the previously announced merger agreement relating to the proposed transaction between Navigators and The Hartford Financial Services Group (NYSE: HIG )", "keywords": [{"text": "previously announced merger"}, {"text": "Hartford Financial Services"}, {"text": "Navigators"}, {"text": "agreement"}], "entities": [{"type": "Organization", "text": "Hartford Financial Services Group", "disambiguation": {"subtype": ["Company"], "name": "The Hartford", "dbpedia_resource": "http://dbpedia.org/resource/The_Hartford"}}, {"type": "Company", "text": "NYSE"}]}, "sentence": " On November 16, 2018, The Navigators Group (NASDAQ: NAVG ) announced that, at a special meeting of stockholders, Navigators\u2019 stockholders approved the adoption of the previously announced merger agreement relating to the proposed transaction between Navigators and The Hartford Financial Services Group (NYSE: HIG ).", "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "merger agreement relating to the proposed transaction between Navigators and The Hartford Financial Services Group (NYSE: HIG )", "keywords": [{"text": "Hartford Financial Services"}, {"text": "merger agreement"}, {"text": "Navigators"}, {"text": "NYSE"}], "entities": [{"type": "Organization", "text": "Hartford Financial Services Group", "disambiguation": {"subtype": ["Company"], "name": "The Hartford", "dbpedia_resource": "http://dbpedia.org/resource/The_Hartford"}}, {"type": "Company", "text": "NYSE"}]}, "sentence": " On November 16, 2018, The Navigators Group (NASDAQ: NAVG ) announced that, at a special meeting of stockholders, Navigators\u2019 stockholders approved the adoption of the previously announced merger agreement relating to the proposed transaction between Navigators and The Hartford Financial Services Group (NYSE: HIG ).", "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "Univar (NYSE: UNVR ) and Nexeo Solutions (NASDAQ: NXEO )", "keywords": [{"text": "Nexeo Solutions"}, {"text": "NYSE"}, {"text": "Univar"}, {"text": "UNVR"}], "entities": [{"type": "Company", "text": "Univar", "disambiguation": {"subtype": [], "name": "Univar", "dbpedia_resource": "http://dbpedia.org/resource/Univar"}}, {"type": "Company", "text": "NYSE"}, {"type": "Company", "text": "Nexeo Solutions"}]}, "sentence": " November 16, 2018: Univar (NYSE: UNVR ) and Nexeo Solutions (NASDAQ: NXEO ) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 , as amended, relating to the previously-announced acquisition of Nexeo Solutions by Univar, expired on November 15, 2018.", "object": {"text": "that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 , as amended, relating to the previously-announced acquisition of Nexeo Solutions by Univar, expired on November 15, 2018", "keywords": [{"text": "Hart-Scott-Rodino Antitrust Improvements"}, {"text": "waiting period"}, {"text": "previously-announced acquisition"}, {"text": "Nexeo Solutions"}], "entities": [{"type": "Company", "text": "Nexeo Solutions"}, {"type": "Company", "text": "Univar", "disambiguation": {"subtype": [], "name": "Univar", "dbpedia_resource": "http://dbpedia.org/resource/Univar"}}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 , as amended, relating to the previously-announced acquisition of Nexeo Solutions by Univar,", "keywords": [{"text": "Hart-Scott-Rodino Antitrust Improvements"}, {"text": "previously-announced acquisition"}, {"text": "Nexeo Solutions"}, {"text": "period"}], "entities": [{"type": "Company", "text": "Nexeo Solutions"}, {"type": "Company", "text": "Univar", "disambiguation": {"subtype": [], "name": "Univar", "dbpedia_resource": "http://dbpedia.org/resource/Univar"}}]}, "sentence": " November 16, 2018: Univar (NYSE: UNVR ) and Nexeo Solutions (NASDAQ: NXEO ) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 , as amended, relating to the previously-announced acquisition of Nexeo Solutions by Univar, expired on November 15, 2018.", "action": {"verb": {"text": "expire", "tense": "past"}, "text": "expired", "normalized": "expire"}}, {"subject": {"text": "2018, Connecticut Water Service (NASDAQ: CTWS )", "keywords": [{"text": "Connecticut Water Service"}, {"text": "CTWS"}, {"text": "NASDAQ"}], "entities": [{"type": "Company", "text": "Connecticut Water Service"}]}, "sentence": " On November 16, 2018, Connecticut Water Service (NASDAQ: CTWS ) announced that its shareholders overwhelmingly voted to approve the company\u2019s proposed merger agreement with SJW Group (NYSE: SJW ).", "object": {"text": "that its shareholders overwhelmingly voted to approve the company\u2019s proposed merger agreement with SJW Group (NYSE: SJW )", "keywords": [{"text": "SJW Group"}, {"text": "merger agreement"}, {"text": "shareholders"}, {"text": "NYSE"}], "entities": [{"type": "Company", "text": "SJW Group"}, {"type": "Company", "text": "NYSE"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "its shareholders", "keywords": [{"text": "shareholders"}]}, "sentence": " On November 16, 2018, Connecticut Water Service (NASDAQ: CTWS ) announced that its shareholders overwhelmingly voted to approve the company\u2019s proposed merger agreement with SJW Group (NYSE: SJW ).", "object": {"text": "to approve the company\u2019s proposed merger agreement with SJW Group", "keywords": [{"text": "merger agreement"}, {"text": "SJW Group"}, {"text": "company"}], "entities": [{"type": "Company", "text": "SJW Group"}]}, "action": {"verb": {"text": "vote", "tense": "past"}, "text": "voted", "normalized": "vote"}}, {"subject": {"text": "its shareholders", "keywords": [{"text": "shareholders"}]}, "sentence": " On November 16, 2018, Connecticut Water Service (NASDAQ: CTWS ) announced that its shareholders overwhelmingly voted to approve the company\u2019s proposed merger agreement with SJW Group (NYSE: SJW ).", "object": {"text": "the company\u2019s proposed merger agreement", "keywords": [{"text": "merger agreement"}, {"text": "company"}]}, "action": {"verb": {"text": "approve", "tense": "future"}, "text": "voted to approve", "normalized": "vote to approve"}}, {"subject": {"text": "proposed merger agreement", "keywords": [{"text": "merger agreement"}]}, "sentence": " On November 16, 2018, Connecticut Water Service (NASDAQ: CTWS ) announced that its shareholders overwhelmingly voted to approve the company\u2019s proposed merger agreement with SJW Group (NYSE: SJW ).", "object": {"text": "with SJW Group (NYSE: SJW )", "keywords": [{"text": "SJW Group"}, {"text": "NYSE"}], "entities": [{"type": "Company", "text": "SJW Group"}, {"type": "Company", "text": "NYSE"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "has", "normalized": "has"}}, {"subject": {"text": "It"}, "sentence": " It took 370 days for this deal to be completed.", "object": {"text": "370 days", "entities": [{"type": "Quantity", "text": "370 days"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "took", "normalized": "take"}}, {"subject": {"text": "this deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " It took 370 days for this deal to be completed.", "object": {"text": "completed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It took 122 days for this deal to be completed.", "object": {"text": "122 days", "entities": [{"type": "Quantity", "text": "122 days"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "took", "normalized": "take"}}, {"subject": {"text": "this deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " It took 122 days for this deal to be completed.", "object": {"text": "completed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It took 122 days for this deal to be completed.", "object": {"text": "122 days", "entities": [{"type": "Quantity", "text": "122 days"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "took", "normalized": "take"}}, {"subject": {"text": "this deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " It took 122 days for this deal to be completed.", "object": {"text": "completed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "by affiliates of Apollo Global Management, LLC", "keywords": [{"text": "Apollo Global Management"}, {"text": "affiliates"}], "entities": [{"type": "Company", "text": "Apollo Global Management", "disambiguation": {"subtype": [], "name": "Apollo Global Management", "dbpedia_resource": "http://dbpedia.org/resource/Apollo_Global_Management"}}]}, "sentence": " The acquisition of LifePoint Health (NASDAQ: LPNT ) by funds managed by affiliates of Apollo Global Management, LLC on November 16, 2018.", "object": {"text": "funds", "keywords": [{"text": "funds"}]}, "action": {"verb": {"text": "manage", "tense": "past"}, "text": "managed", "normalized": "manage"}}, {"subject": {"text": "It"}, "sentence": " It took 116 days for this deal to be completed.", "object": {"text": "116 days", "entities": [{"type": "Quantity", "text": "116 days"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "took", "normalized": "take"}}, {"subject": {"text": "this deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " It took 116 days for this deal to be completed.", "object": {"text": "completed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It took 93 days for this deal to be completed.", "object": {"text": "93 days", "entities": [{"type": "Quantity", "text": "93 days"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "took", "normalized": "take"}}, {"subject": {"text": "this deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " It took 93 days for this deal to be completed.", "object": {"text": "completed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Please"}, "sentence": " Please do your own due diligence before buying or selling any securities mentioned in this article.", "object": {"text": "your own"}, "action": {"verb": {"text": "do", "tense": "present"}, "text": "do", "normalized": "do"}}, {"subject": {"text": "any securities", "keywords": [{"text": "securities"}]}, "sentence": " Please do your own due diligence before buying or selling any securities mentioned in this article.", "action": {"verb": {"text": "mention", "tense": "past"}, "text": "mentioned", "normalized": "mention"}}, {"subject": {"text": "We"}, "sentence": " We do not warrant the completeness or accuracy of the content or data provided in this article.", "object": {"text": "not warrant the completeness or accuracy of the content or data provided in this article", "keywords": [{"text": "completeness"}, {"text": "accuracy"}, {"text": "content"}, {"text": "data"}]}, "action": {"verb": {"text": "do", "tense": "present"}, "text": "do", "normalized": "do"}}, {"subject": {"text": "We"}, "sentence": " We do not warrant the completeness or accuracy of the content or data provided in this article.", "object": {"text": "the completeness or accuracy of the content or data provided in this article", "keywords": [{"text": "completeness"}, {"text": "accuracy"}, {"text": "content"}, {"text": "data"}]}, "action": {"verb": {"text": "warrant", "tense": "present", "negated": true}, "text": "warrant", "normalized": "warrant"}}, {"subject": {"text": "the content or data", "keywords": [{"text": "content"}, {"text": "data"}]}, "sentence": " We do not warrant the completeness or accuracy of the content or data provided in this article.", "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "I am/we"}, "sentence": " Disclosure: I am/we are long FNSR, COL, P, RSYS.", "object": {"text": "long FNSR, COL, P, RSYS", "keywords": [{"text": "COL"}, {"text": "long FNSR"}, {"text": "RSYS"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "I"}, "sentence": " I wrote this article myself, and it expresses my own opinions.", "object": {"text": "myself"}, "action": {"verb": {"text": "write", "tense": "past"}, "text": "wrote", "normalized": "write"}}, {"subject": {"text": "it"}, "sentence": " I wrote this article myself, and it expresses my own opinions.", "object": {"text": "my own opinions", "keywords": [{"text": "opinions"}]}, "action": {"verb": {"text": "express", "tense": "present"}, "text": "expresses", "normalized": "express"}}, {"subject": {"text": "I"}, "sentence": " I am not receiving compensation for it.", "object": {"text": "not receiving compensation for it", "keywords": [{"text": "compensation"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "am", "normalized": "be"}}, {"subject": {"text": "I"}, "sentence": " I am not receiving compensation for it.", "object": {"text": "compensation", "keywords": [{"text": "compensation"}]}, "action": {"verb": {"text": "receive", "tense": "present", "negated": true}, "text": "receiving", "normalized": "receive"}}, {"subject": {"text": "I"}, "sentence": " I have no business relationship with any company whose stock is mentioned in this article.", "object": {"text": "no business relationship with any company whose stock is mentioned in this article", "keywords": [{"text": "business relationship"}, {"text": "company"}, {"text": "stock"}, {"text": "article"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "one or more microcap stocks", "keywords": [{"text": "microcap stocks"}]}, "sentence": " Editor's Note: This article covers one or more microcap stocks.", "object": {"text": "This article", "keywords": [{"text": "article"}]}, "action": {"verb": {"text": "cover", "tense": "present"}, "text": "covers", "normalized": "cover"}}, {"subject": {"text": "the risks", "keywords": [{"text": "risks"}]}, "sentence": " Please be aware of the risks associated with these stocks.", "object": {"text": "with these stocks", "keywords": [{"text": "stocks"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}], "concepts": [{"text": "Stock market", "relevance": 0.975318, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Stock", "relevance": 0.828045, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Shareholder", "relevance": 0.715943, "dbpedia_resource": "http://dbpedia.org/resource/Shareholder"}, {"text": "Share", "relevance": 0.703037, "dbpedia_resource": "http://dbpedia.org/resource/Share_(finance)"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.618682, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Mergers and acquisitions", "relevance": 0.607611, "dbpedia_resource": "http://dbpedia.org/resource/Mergers_and_acquisitions"}, {"text": "Stock exchange", "relevance": 0.564639, "dbpedia_resource": "http://dbpedia.org/resource/Stock_exchange"}, {"text": "Deals", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Deals"}, {"text": "Reliance Industries", "relevance": 0.529617, "dbpedia_resource": "http://dbpedia.org/resource/Reliance_Industries"}, {"text": "Stakeholder", "relevance": 0.52717, "dbpedia_resource": "http://dbpedia.org/resource/Stakeholder_(corporate)"}, {"text": "Economy of New York City", "relevance": 0.5103, "dbpedia_resource": "http://dbpedia.org/resource/Economy_of_New_York_City"}], "categories": [{"score": 0.967417, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.853267, "label": "/finance/financial news"}, {"score": 0.796762, "label": "/finance/investing"}], "relations": [{"type": "hasAttribute", "sentence": "Deal Statistics: Total Number of Deals Closed in 2018 146 Total Number of Deals Not Completed in 2018 14 Total Number of Pending Deals Cash Deals 46 Stock Deals 32 Stock & Cash Deals 15 Special Conditions 8 Total Number of Pending Deals 101 Total Deal Size $1.35 trillion New Deals: The acquisition of athenahealth (NASDAQ: ATHN ) by an affiliate of Veritas and Evergreen for $5.7 billion or $135 per share in cash.", "score": 0.450059, "arguments": [{"text": "Special Conditions 8 Total Number", "location": [283, 316], "entities": [{"type": "Organization", "text": "Special Conditions 8 Total Number"}]}, {"text": "ATHN", "location": [421, 425], "entities": [{"type": "Ticker", "text": "ATHN"}]}]}, {"type": "agentOf", "sentence": "Deal Updates: On November 15, 2018, Forest City Realty Trust (NYSE: FCE.A ) announced that its stockholders approved the acquisition of Forest City by Brookfield Asset Management (NYSE: BAM ).", "score": 0.666391, "arguments": [{"text": "its", "location": [1456, 1459], "entities": [{"type": "Organization", "text": "CVR"}]}, {"text": "acquisition", "location": [1486, 1497], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "partOf", "sentence": "Deal Updates: On November 15, 2018, Forest City Realty Trust (NYSE: FCE.A ) announced that its stockholders approved the acquisition of Forest City by Brookfield Asset Management (NYSE: BAM ).", "score": 0.696419, "arguments": [{"text": "Brookfield Asset Management", "location": [1516, 1543], "entities": [{"type": "Organization", "text": "Brookfield Asset Management"}]}, {"text": "Forest City", "location": [1501, 1512], "entities": [{"type": "Organization", "text": "Forest City"}]}]}, {"type": "hasAttribute", "sentence": "Deal Updates: On November 15, 2018, Forest City Realty Trust (NYSE: FCE.A ) announced that its stockholders approved the acquisition of Forest City by Brookfield Asset Management (NYSE: BAM ).", "score": 0.660281, "arguments": [{"text": "Forest City", "location": [1501, 1512], "entities": [{"type": "Organization", "text": "Forest City"}]}, {"text": "BAM", "location": [1551, 1554], "entities": [{"type": "Ticker", "text": "BAM"}]}]}, {"type": "hasAttribute", "sentence": "Deal Updates: On November 15, 2018, Forest City Realty Trust (NYSE: FCE.A ) announced that its stockholders approved the acquisition of Forest City by Brookfield Asset Management (NYSE: BAM ).", "score": 0.805297, "arguments": [{"text": "Brookfield Asset Management", "location": [1516, 1543], "entities": [{"type": "Organization", "text": "Brookfield Asset Management"}]}, {"text": "BAM", "location": [1551, 1554], "entities": [{"type": "Ticker", "text": "BAM"}]}]}, {"type": "agentOf", "sentence": "Forest City expects that the acquisition will be completed in December on or prior to December 10, 2018.", "score": 0.567569, "arguments": [{"text": "Forest City", "location": [1558, 1569], "entities": [{"type": "Organization", "text": "Forest City"}]}, {"text": "acquisition", "location": [1587, 1598], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "On November 16, 2018, Connecticut Water Service (NASDAQ: CTWS ) announced that its shareholders overwhelmingly voted to approve the company's proposed merger agreement with SJW Group (NYSE: SJW ).", "score": 0.486397, "arguments": [{"text": "company", "location": [2408, 2415], "entities": [{"type": "Organization", "text": "Forest City"}]}, {"text": "merger", "location": [2427, 2433], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "Forest City expects that the acquisition will be completed in December on or prior to December 10, 2018.", "score": 0.759726, "arguments": [{"text": "December", "location": [1620, 1628], "entities": [{"type": "Date", "text": "December"}]}, {"text": "acquisition", "location": [1587, 1598], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "On November 16, 2018, The Navigators Group (NASDAQ: NAVG ) announced that, at a special meeting of stockholders, Navigators' stockholders approved the adoption of the previously announced merger agreement relating to the proposed transaction between Navigators and The Hartford Financial Services Group (NYSE: HIG ).", "score": 0.913878, "arguments": [{"text": "Navigators Group", "location": [1689, 1705], "entities": [{"type": "Organization", "text": "Navigators Group", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "NAVG", "location": [1715, 1719], "entities": [{"type": "Ticker", "text": "NAVG"}]}]}, {"type": "participantIn", "sentence": "On November 16, 2018, The Navigators Group (NASDAQ: NAVG ) announced that, at a special meeting of stockholders, Navigators' stockholders approved the adoption of the previously announced merger agreement relating to the proposed transaction between Navigators and The Hartford Financial Services Group (NYSE: HIG ).", "score": 0.892695, "arguments": [{"text": "stockholders", "location": [1762, 1774], "entities": [{"type": "Person", "text": "stockholders"}]}, {"text": "meeting", "location": [1751, 1758], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "participantIn", "sentence": "On November 16, 2018, The Navigators Group (NASDAQ: NAVG ) announced that, at a special meeting of stockholders, Navigators' stockholders approved the adoption of the previously announced merger agreement relating to the proposed transaction between Navigators and The Hartford Financial Services Group (NYSE: HIG ).", "score": 0.412479, "arguments": [{"text": "The Hartford Financial Services Group", "location": [1928, 1965], "entities": [{"type": "Organization", "text": "The Hartford Financial Services Group", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "merger", "location": [1851, 1857], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "On November 16, 2018, The Navigators Group (NASDAQ: NAVG ) announced that, at a special meeting of stockholders, Navigators' stockholders approved the adoption of the previously announced merger agreement relating to the proposed transaction between Navigators and The Hartford Financial Services Group (NYSE: HIG ).", "score": 0.899849, "arguments": [{"text": "The Hartford Financial Services Group", "location": [1928, 1965], "entities": [{"type": "Organization", "text": "The Hartford Financial Services Group", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "HIG", "location": [1973, 1976], "entities": [{"type": "Ticker", "text": "HIG"}]}]}, {"type": "hasAttribute", "sentence": "Deal Statistics: Total Number of Deals Closed in 2018 146 Total Number of Deals Not Completed in 2018 14 Total Number of Pending Deals Cash Deals 46 Stock Deals 32 Stock & Cash Deals 15 Special Conditions 8 Total Number of Pending Deals 101 Total Deal Size $1.35 trillion New Deals: The acquisition of athenahealth (NASDAQ: ATHN ) by an affiliate of Veritas and Evergreen for $5.7 billion or $135 per share in cash.", "score": 0.564288, "arguments": [{"text": "Pending Deals 101 Total Deal Size", "location": [320, 353], "entities": [{"type": "Organization", "text": "Pending Deals 101 Total Deal Size"}]}, {"text": "ATHN", "location": [421, 425], "entities": [{"type": "Ticker", "text": "ATHN"}]}]}, {"type": "hasAttribute", "sentence": "November 16, 2018: Univar (NYSE: UNVR ) and Nexeo Solutions (NASDAQ: NXEO ) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 , as amended, relating to the previously-announced acquisition of Nexeo Solutions by Univar, expired on November 15, 2018.", "score": 0.910704, "arguments": [{"text": "Univar", "location": [1999, 2005], "entities": [{"type": "Organization", "text": "Univar", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "UNVR", "location": [2013, 2017], "entities": [{"type": "Ticker", "text": "UNVR"}]}]}, {"type": "hasAttribute", "sentence": "November 16, 2018: Univar (NYSE: UNVR ) and Nexeo Solutions (NASDAQ: NXEO ) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 , as amended, relating to the previously-announced acquisition of Nexeo Solutions by Univar, expired on November 15, 2018.", "score": 0.849223, "arguments": [{"text": "Nexeo Solutions", "location": [2024, 2039], "entities": [{"type": "Organization", "text": "Nexeo Solutions", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "NXEO", "location": [2049, 2053], "entities": [{"type": "Ticker", "text": "NXEO"}]}]}, {"type": "foundedOn", "sentence": "November 16, 2018: Univar (NYSE: UNVR ) and Nexeo Solutions (NASDAQ: NXEO ) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 , as amended, relating to the previously-announced acquisition of Nexeo Solutions by Univar, expired on November 15, 2018.", "score": 0.536487, "arguments": [{"text": "Hart-Scott-Rodino Antitrust Improvements Act of", "location": [2100, 2147], "entities": [{"type": "Organization", "text": "Hart-Scott-Rodino Antitrust Improvements Act of"}]}, {"text": "1976", "location": [2148, 2152], "entities": [{"type": "Date", "text": "1976", "disambiguation": {"subtype": ["Starting"]}}]}]}, {"type": "affectedBy", "sentence": "November 16, 2018: Univar (NYSE: UNVR ) and Nexeo Solutions (NASDAQ: NXEO ) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 , as amended, relating to the previously-announced acquisition of Nexeo Solutions by Univar, expired on November 15, 2018.", "score": 0.717252, "arguments": [{"text": "Nexeo Solutions", "location": [2219, 2234], "entities": [{"type": "Organization", "text": "Nexeo Solutions"}]}, {"text": "acquisition", "location": [2204, 2215], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "November 16, 2018: Univar (NYSE: UNVR ) and Nexeo Solutions (NASDAQ: NXEO ) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 , as amended, relating to the previously-announced acquisition of Nexeo Solutions by Univar, expired on November 15, 2018.", "score": 0.628365, "arguments": [{"text": "Univar", "location": [2238, 2244], "entities": [{"type": "Organization", "text": "Univar"}]}, {"text": "acquisition", "location": [2204, 2215], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "November 16, 2018: Univar (NYSE: UNVR ) and Nexeo Solutions (NASDAQ: NXEO ) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 , as amended, relating to the previously-announced acquisition of Nexeo Solutions by Univar, expired on November 15, 2018.", "score": 0.473333, "arguments": [{"text": "November 15, 2018", "location": [2257, 2274], "entities": [{"type": "Date", "text": "November 15, 2018"}]}, {"text": "acquisition", "location": [2204, 2215], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "partOf", "sentence": "November 16, 2018: Univar (NYSE: UNVR ) and Nexeo Solutions (NASDAQ: NXEO ) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 , as amended, relating to the previously-announced acquisition of Nexeo Solutions by Univar, expired on November 15, 2018.", "score": 0.64549, "arguments": [{"text": "Univar", "location": [2238, 2244], "entities": [{"type": "Organization", "text": "Univar"}]}, {"text": "Nexeo Solutions", "location": [2219, 2234], "entities": [{"type": "Organization", "text": "Nexeo Solutions"}]}]}, {"type": "timeOf", "sentence": "On November 16, 2018, Connecticut Water Service (NASDAQ: CTWS ) announced that its shareholders overwhelmingly voted to approve the company's proposed merger agreement with SJW Group (NYSE: SJW ).", "score": 0.631047, "arguments": [{"text": "November 16, 2018", "location": [2279, 2296], "entities": [{"type": "Date", "text": "November 16, 2018"}]}, {"text": "announced", "location": [2340, 2349], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "hasAttribute", "sentence": "On November 16, 2018, Connecticut Water Service (NASDAQ: CTWS ) announced that its shareholders overwhelmingly voted to approve the company's proposed merger agreement with SJW Group (NYSE: SJW ).", "score": 0.905553, "arguments": [{"text": "Connecticut Water Service", "location": [2298, 2323], "entities": [{"type": "Organization", "text": "Connecticut Water Service", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "CTWS", "location": [2333, 2337], "entities": [{"type": "Ticker", "text": "CTWS"}]}]}, {"type": "employedBy", "sentence": "On November 16, 2018, Connecticut Water Service (NASDAQ: CTWS ) announced that its shareholders overwhelmingly voted to approve the company's proposed merger agreement with SJW Group (NYSE: SJW ).", "score": 0.788847, "arguments": [{"text": "shareholders", "location": [2359, 2371], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "its", "location": [2355, 2358], "entities": [{"type": "Organization", "text": "Forest City"}]}]}, {"type": "agentOf", "sentence": "Deal Statistics: Total Number of Deals Closed in 2018 146 Total Number of Deals Not Completed in 2018 14 Total Number of Pending Deals Cash Deals 46 Stock Deals 32 Stock & Cash Deals 15 Special Conditions 8 Total Number of Pending Deals 101 Total Deal Size $1.35 trillion New Deals: The acquisition of athenahealth (NASDAQ: ATHN ) by an affiliate of Veritas and Evergreen for $5.7 billion or $135 per share in cash.", "score": 0.303423, "arguments": [{"text": "Veritas", "location": [447, 454], "entities": [{"type": "Organization", "text": "Veritas", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [384, 395], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "On November 16, 2018, Connecticut Water Service (NASDAQ: CTWS ) announced that its shareholders overwhelmingly voted to approve the company's proposed merger agreement with SJW Group (NYSE: SJW ).", "score": 0.628233, "arguments": [{"text": "SJW Group", "location": [2449, 2458], "entities": [{"type": "Organization", "text": "SJW Group", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "merger", "location": [2427, 2433], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "On November 16, 2018, Connecticut Water Service (NASDAQ: CTWS ) announced that its shareholders overwhelmingly voted to approve the company's proposed merger agreement with SJW Group (NYSE: SJW ).", "score": 0.920536, "arguments": [{"text": "SJW Group", "location": [2449, 2458], "entities": [{"type": "Organization", "text": "SJW Group", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "SJW", "location": [2466, 2469], "entities": [{"type": "Ticker", "text": "SJW"}]}]}, {"type": "timeOf", "sentence": "Closed Deals: The acquisition of magicJack VocalTec (NASDAQ: CALL ) by B. Riley Financial (NASDAQ: RILY ) on November 14, 2018.", "score": 0.889411, "arguments": [{"text": "November 14, 2018", "location": [2582, 2599], "entities": [{"type": "Date", "text": "November 14, 2018"}]}, {"text": "acquisition", "location": [2491, 2502], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "The acquisition of GulfMark Offshore (NYSEMKT: GLF ) by Tidewater (NYSE: TDW ) on November 15, 2018.", "score": 0.4184, "arguments": [{"text": "Tidewater", "location": [2705, 2714], "entities": [{"type": "Organization", "text": "Tidewater", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [2653, 2664], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "The acquisition of GulfMark Offshore (NYSEMKT: GLF ) by Tidewater (NYSE: TDW ) on November 15, 2018.", "score": 0.900569, "arguments": [{"text": "November 15, 2018", "location": [2731, 2748], "entities": [{"type": "Date", "text": "November 15, 2018"}]}, {"text": "acquisition", "location": [2653, 2664], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "partOf", "sentence": "The acquisition of GulfMark Offshore (NYSEMKT: GLF ) by Tidewater (NYSE: TDW ) on November 15, 2018.", "score": 0.273902, "arguments": [{"text": "Tidewater", "location": [2705, 2714], "entities": [{"type": "Organization", "text": "Tidewater", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "GulfMark Offshore", "location": [2668, 2685], "entities": [{"type": "Organization", "text": "GulfMark Offshore"}]}]}, {"type": "hasAttribute", "sentence": "The acquisition of GulfMark Offshore (NYSEMKT: GLF ) by Tidewater (NYSE: TDW ) on November 15, 2018.", "score": 0.455544, "arguments": [{"text": "GulfMark Offshore", "location": [2668, 2685], "entities": [{"type": "Organization", "text": "GulfMark Offshore"}]}, {"text": "TDW", "location": [2722, 2725], "entities": [{"type": "Ticker", "text": "TDW"}]}]}, {"type": "hasAttribute", "sentence": "The acquisition of GulfMark Offshore (NYSEMKT: GLF ) by Tidewater (NYSE: TDW ) on November 15, 2018.", "score": 0.941961, "arguments": [{"text": "Tidewater", "location": [2705, 2714], "entities": [{"type": "Organization", "text": "Tidewater", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "TDW", "location": [2722, 2725], "entities": [{"type": "Ticker", "text": "TDW"}]}]}, {"type": "agentOf", "sentence": "The acquisition of Anchor Bancorp (NASDAQ: ANCB ) by FS Bancorp (NASDAQ: FSBW ) on November 16, 2018.", "score": 0.404095, "arguments": [{"text": "FS Bancorp", "location": [2851, 2861], "entities": [{"type": "Organization", "text": "FS Bancorp", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [2802, 2813], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "The acquisition of Anchor Bancorp (NASDAQ: ANCB ) by FS Bancorp (NASDAQ: FSBW ) on November 16, 2018.", "score": 0.882645, "arguments": [{"text": "November 16, 2018", "location": [2881, 2898], "entities": [{"type": "Date", "text": "November 16, 2018"}]}, {"text": "acquisition", "location": [2802, 2813], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "Deal Statistics: Total Number of Deals Closed in 2018 146 Total Number of Deals Not Completed in 2018 14 Total Number of Pending Deals Cash Deals 46 Stock Deals 32 Stock & Cash Deals 15 Special Conditions 8 Total Number of Pending Deals 101 Total Deal Size $1.35 trillion New Deals: The acquisition of athenahealth (NASDAQ: ATHN ) by an affiliate of Veritas and Evergreen for $5.7 billion or $135 per share in cash.", "score": 0.323343, "arguments": [{"text": "Evergreen", "location": [459, 468], "entities": [{"type": "Organization", "text": "Evergreen", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [384, 395], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "The acquisition of Anchor Bancorp (NASDAQ: ANCB ) by FS Bancorp (NASDAQ: FSBW ) on November 16, 2018.", "score": 0.810991, "arguments": [{"text": "Anchor Bancorp", "location": [2817, 2831], "entities": [{"type": "Organization", "text": "Anchor Bancorp"}]}, {"text": "ANCB", "location": [2841, 2845], "entities": [{"type": "Ticker", "text": "ANCB"}]}]}, {"type": "partOf", "sentence": "The acquisition of Anchor Bancorp (NASDAQ: ANCB ) by FS Bancorp (NASDAQ: FSBW ) on November 16, 2018.", "score": 0.31033, "arguments": [{"text": "FS Bancorp", "location": [2851, 2861], "entities": [{"type": "Organization", "text": "FS Bancorp", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Anchor Bancorp", "location": [2817, 2831], "entities": [{"type": "Organization", "text": "Anchor Bancorp"}]}]}, {"type": "hasAttribute", "sentence": "The acquisition of Anchor Bancorp (NASDAQ: ANCB ) by FS Bancorp (NASDAQ: FSBW ) on November 16, 2018.", "score": 0.934693, "arguments": [{"text": "FS Bancorp", "location": [2851, 2861], "entities": [{"type": "Organization", "text": "FS Bancorp", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "FSBW", "location": [2871, 2875], "entities": [{"type": "Ticker", "text": "FSBW"}]}]}, {"type": "affectedBy", "sentence": "The acquisition of LifePoint Health (NASDAQ: LPNT ) by funds managed by affiliates of Apollo Global Management, LLC on November 16, 2018.", "score": 0.712647, "arguments": [{"text": "LifePoint Health", "location": [2967, 2983], "entities": [{"type": "Organization", "text": "LifePoint Health"}]}, {"text": "acquisition", "location": [2952, 2963], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "The acquisition of LifePoint Health (NASDAQ: LPNT ) by funds managed by affiliates of Apollo Global Management, LLC on November 16, 2018.", "score": 0.463667, "arguments": [{"text": "LLC", "location": [3060, 3063], "entities": [{"type": "Organization", "text": "LLC", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [2952, 2963], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "The acquisition of LifePoint Health (NASDAQ: LPNT ) by funds managed by affiliates of Apollo Global Management, LLC on November 16, 2018.", "score": 0.773178, "arguments": [{"text": "November 16, 2018", "location": [3067, 3084], "entities": [{"type": "Date", "text": "November 16, 2018"}]}, {"text": "acquisition", "location": [2952, 2963], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "The acquisition of LifePoint Health (NASDAQ: LPNT ) by funds managed by affiliates of Apollo Global Management, LLC on November 16, 2018.", "score": 0.784554, "arguments": [{"text": "LifePoint Health", "location": [2967, 2983], "entities": [{"type": "Organization", "text": "LifePoint Health"}]}, {"text": "LPNT", "location": [2993, 2997], "entities": [{"type": "Ticker", "text": "LPNT"}]}]}, {"type": "employedBy", "sentence": "The acquisition of LifePoint Health (NASDAQ: LPNT ) by funds managed by affiliates of Apollo Global Management, LLC on November 16, 2018.", "score": 0.431465, "arguments": [{"text": "affiliates", "location": [3020, 3030], "entities": [{"type": "Person", "text": "affiliates"}]}, {"text": "Apollo Global Management", "location": [3034, 3058], "entities": [{"type": "Organization", "text": "Apollo Global Management", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "The acquisition of KMG Chemicals (NYSE: KMG ) by Cabot Microelectronics Corporation (NASDAQ: CCMP ) on November 16, 2018.", "score": 0.404095, "arguments": [{"text": "Cabot Microelectronics Corporation", "location": [3183, 3217], "entities": [{"type": "Organization", "text": "Cabot Microelectronics Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [3138, 3149], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "The acquisition of KMG Chemicals (NYSE: KMG ) by Cabot Microelectronics Corporation (NASDAQ: CCMP ) on November 16, 2018.", "score": 0.885454, "arguments": [{"text": "November 16, 2018", "location": [3237, 3254], "entities": [{"type": "Date", "text": "November 16, 2018"}]}, {"text": "acquisition", "location": [3138, 3149], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "The acquisition of Tahoe Resources (NYSE: TAHO ) by Pan American Silver (NASDAQ: PAAS ) for $1.45 billion in a cash or stock deal.", "score": 0.538611, "arguments": [{"text": "Pan American Silver", "location": [721, 740], "entities": [{"type": "Organization", "text": "Pan American Silver Corp.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [673, 684], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "The acquisition of KMG Chemicals (NYSE: KMG ) by Cabot Microelectronics Corporation (NASDAQ: CCMP ) on November 16, 2018.", "score": 0.813708, "arguments": [{"text": "KMG Chemicals", "location": [3153, 3166], "entities": [{"type": "Organization", "text": "KMG Chemicals"}]}, {"text": "KMG", "location": [3174, 3177], "entities": [{"type": "Ticker", "text": "KMG"}]}]}, {"type": "partOf", "sentence": "The acquisition of KMG Chemicals (NYSE: KMG ) by Cabot Microelectronics Corporation (NASDAQ: CCMP ) on November 16, 2018.", "score": 0.318298, "arguments": [{"text": "Cabot Microelectronics Corporation", "location": [3183, 3217], "entities": [{"type": "Organization", "text": "Cabot Microelectronics Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "KMG Chemicals", "location": [3153, 3166], "entities": [{"type": "Organization", "text": "KMG Chemicals"}]}]}, {"type": "hasAttribute", "sentence": "The acquisition of KMG Chemicals (NYSE: KMG ) by Cabot Microelectronics Corporation (NASDAQ: CCMP ) on November 16, 2018.", "score": 0.93148, "arguments": [{"text": "Cabot Microelectronics Corporation", "location": [3183, 3217], "entities": [{"type": "Organization", "text": "Cabot Microelectronics Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "CCMP", "location": [3227, 3231], "entities": [{"type": "Ticker", "text": "CCMP"}]}]}, {"type": "partOf", "sentence": "Top 10 deals with largest spreads: Symbol AnnouncedDate AcquiringCompany ClosingPrice LastPrice ClosingDate Profit AnnualizedProfit INUV 11/05/2018 ConversionPoint Technologies, Inc. (N/A) $2.22 $1.18 03/31/2019 88.14% 243.71% TAHO 11/14/2018 Pan American Silver Corp. (PAAS) $4.10 $3.29 03/31/2019 24.62% 68.08% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $10.85 12/31/2018 24.42% 212.26% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $16.72 10/31/2018 23.21% -445.79% GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. (N/A) $5.43 $4.58 12/01/2018 18.56% 564.50% ORBK 03/19/2018 KLA-Tencor Corporation (NASDAQ: KLAC ) $63.09 $54.45 12/31/2018 15.86% 137.82% SCG 01/03/2018 Dominion Energy, Inc. (NYSE: D ) $49.25 $", "score": 0.440167, "arguments": [{"text": "PAAS", "location": [3573, 3577], "entities": [{"type": "Organization", "text": "PAAS"}]}, {"text": "Pan American Silver Corp.", "location": [3546, 3571], "entities": [{"type": "Organization", "text": "Pan American Silver Corp.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Top 10 deals with largest spreads: Symbol AnnouncedDate AcquiringCompany ClosingPrice LastPrice ClosingDate Profit AnnualizedProfit INUV 11/05/2018 ConversionPoint Technologies, Inc. (N/A) $2.22 $1.18 03/31/2019 88.14% 243.71% TAHO 11/14/2018 Pan American Silver Corp. (PAAS) $4.10 $3.29 03/31/2019 24.62% 68.08% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $10.85 12/31/2018 24.42% 212.26% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $16.72 10/31/2018 23.21% -445.79% GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. (N/A) $5.43 $4.58 12/01/2018 18.56% 564.50% ORBK 03/19/2018 KLA-Tencor Corporation (NASDAQ: KLAC ) $63.09 $54.45 12/31/2018 15.86% 137.82% SCG 01/03/2018 Dominion Energy, Inc. (NYSE: D ) $49.25 $", "score": 0.470487, "arguments": [{"text": "EHIC", "location": [3616, 3620], "entities": [{"type": "Organization", "text": "EHIC"}]}, {"text": "04/06/2018", "location": [3621, 3631], "entities": [{"type": "Web", "text": "04/06/2018"}]}]}, {"type": "partOf", "sentence": "Top 10 deals with largest spreads: Symbol AnnouncedDate AcquiringCompany ClosingPrice LastPrice ClosingDate Profit AnnualizedProfit INUV 11/05/2018 ConversionPoint Technologies, Inc. (N/A) $2.22 $1.18 03/31/2019 88.14% 243.71% TAHO 11/14/2018 Pan American Silver Corp. (PAAS) $4.10 $3.29 03/31/2019 24.62% 68.08% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $10.85 12/31/2018 24.42% 212.26% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $16.72 10/31/2018 23.21% -445.79% GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. (N/A) $5.43 $4.58 12/01/2018 18.56% 564.50% ORBK 03/19/2018 KLA-Tencor Corporation (NASDAQ: KLAC ) $63.09 $54.45 12/31/2018 15.86% 137.82% SCG 01/03/2018 Dominion Energy, Inc. (NYSE: D ) $49.25 $", "score": 0.500963, "arguments": [{"text": "Teamsport Parent Limited", "location": [3632, 3656], "entities": [{"type": "Organization", "text": "Teamsport Parent Limited"}]}, {"text": "EHIC", "location": [3616, 3620], "entities": [{"type": "Organization", "text": "EHIC"}]}]}, {"type": "employedBy", "sentence": "Top 10 deals with largest spreads: Symbol AnnouncedDate AcquiringCompany ClosingPrice LastPrice ClosingDate Profit AnnualizedProfit INUV 11/05/2018 ConversionPoint Technologies, Inc. (N/A) $2.22 $1.18 03/31/2019 88.14% 243.71% TAHO 11/14/2018 Pan American Silver Corp. (PAAS) $4.10 $3.29 03/31/2019 24.62% 68.08% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $10.85 12/31/2018 24.42% 212.26% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $16.72 10/31/2018 23.21% -445.79% GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. (N/A) $5.43 $4.58 12/01/2018 18.56% 564.50% ORBK 03/19/2018 KLA-Tencor Corporation (NASDAQ: KLAC ) $63.09 $54.45 12/31/2018 15.86% 137.82% SCG 01/03/2018 Dominion Energy, Inc. (NYSE: D ) $49.25 $", "score": 0.389669, "arguments": [{"text": "KANG", "location": [3703, 3707], "entities": [{"type": "Person", "text": "KANG"}]}, {"text": "IK Healthcare Investment Limited", "location": [3719, 3751], "entities": [{"type": "Organization", "text": "IK Healthcare Investment Limited"}]}]}, {"type": "partOf", "sentence": "Top 10 deals with largest spreads: Symbol AnnouncedDate AcquiringCompany ClosingPrice LastPrice ClosingDate Profit AnnualizedProfit INUV 11/05/2018 ConversionPoint Technologies, Inc. (N/A) $2.22 $1.18 03/31/2019 88.14% 243.71% TAHO 11/14/2018 Pan American Silver Corp. (PAAS) $4.10 $3.29 03/31/2019 24.62% 68.08% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $10.85 12/31/2018 24.42% 212.26% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $16.72 10/31/2018 23.21% -445.79% GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. (N/A) $5.43 $4.58 12/01/2018 18.56% 564.50% ORBK 03/19/2018 KLA-Tencor Corporation (NASDAQ: KLAC ) $63.09 $54.45 12/31/2018 15.86% 137.82% SCG 01/03/2018 Dominion Energy, Inc. (NYSE: D ) $49.25 $", "score": 0.610194, "arguments": [{"text": "Oceanwide Holdings Group Co., Ltd.", "location": [3820, 3854], "entities": [{"type": "Organization", "text": "Oceanwide Holdings Group Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "China", "location": [3814, 3819], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Top 10 deals with largest spreads: Symbol AnnouncedDate AcquiringCompany ClosingPrice LastPrice ClosingDate Profit AnnualizedProfit INUV 11/05/2018 ConversionPoint Technologies, Inc. (N/A) $2.22 $1.18 03/31/2019 88.14% 243.71% TAHO 11/14/2018 Pan American Silver Corp. (PAAS) $4.10 $3.29 03/31/2019 24.62% 68.08% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $10.85 12/31/2018 24.42% 212.26% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $16.72 10/31/2018 23.21% -445.79% GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. (N/A) $5.43 $4.58 12/01/2018 18.56% 564.50% ORBK 03/19/2018 KLA-Tencor Corporation (NASDAQ: KLAC ) $63.09 $54.45 12/31/2018 15.86% 137.82% SCG 01/03/2018 Dominion Energy, Inc. (NYSE: D ) $49.25 $", "score": 0.417812, "arguments": [{"text": "ORBK", "location": [3899, 3903], "entities": [{"type": "Person", "text": "ORBK"}]}, {"text": "KLA-Tencor Corporation", "location": [3915, 3937], "entities": [{"type": "Organization", "text": "KLA-Tencor Corporation"}]}]}, {"type": "hasAttribute", "sentence": "Top 10 deals with largest spreads: Symbol AnnouncedDate AcquiringCompany ClosingPrice LastPrice ClosingDate Profit AnnualizedProfit INUV 11/05/2018 ConversionPoint Technologies, Inc. (N/A) $2.22 $1.18 03/31/2019 88.14% 243.71% TAHO 11/14/2018 Pan American Silver Corp. (PAAS) $4.10 $3.29 03/31/2019 24.62% 68.08% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $10.85 12/31/2018 24.42% 212.26% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $16.72 10/31/2018 23.21% -445.79% GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. (N/A) $5.43 $4.58 12/01/2018 18.56% 564.50% ORBK 03/19/2018 KLA-Tencor Corporation (NASDAQ: KLAC ) $63.09 $54.45 12/31/2018 15.86% 137.82% SCG 01/03/2018 Dominion Energy, Inc. (NYSE: D ) $49.25 $", "score": 0.82548, "arguments": [{"text": "KLA-Tencor Corporation", "location": [3915, 3937], "entities": [{"type": "Organization", "text": "KLA-Tencor Corporation"}]}, {"text": "KLAC", "location": [3947, 3951], "entities": [{"type": "Ticker", "text": "KLAC"}]}]}, {"type": "hasAttribute", "sentence": "The acquisition of Tahoe Resources (NYSE: TAHO ) by Pan American Silver (NASDAQ: PAAS ) for $1.45 billion in a cash or stock deal.", "score": 0.892032, "arguments": [{"text": "Pan American Silver", "location": [721, 740], "entities": [{"type": "Organization", "text": "Pan American Silver Corp.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "PAAS", "location": [750, 754], "entities": [{"type": "Ticker", "text": "PAAS"}]}]}, {"type": "partOf", "sentence": "Top 10 deals with largest spreads: Symbol AnnouncedDate AcquiringCompany ClosingPrice LastPrice ClosingDate Profit AnnualizedProfit INUV 11/05/2018 ConversionPoint Technologies, Inc. (N/A) $2.22 $1.18 03/31/2019 88.14% 243.71% TAHO 11/14/2018 Pan American Silver Corp. (PAAS) $4.10 $3.29 03/31/2019 24.62% 68.08% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $10.85 12/31/2018 24.42% 212.26% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $16.72 10/31/2018 23.21% -445.79% GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. (N/A) $5.43 $4.58 12/01/2018 18.56% 564.50% ORBK 03/19/2018 KLA-Tencor Corporation (NASDAQ: KLAC ) $63.09 $54.45 12/31/2018 15.86% 137.82% SCG 01/03/2018 Dominion Energy, Inc. (NYSE: D ) $49.25 $", "score": 0.485535, "arguments": [{"text": "Dominion Energy, Inc.", "location": [4009, 4030], "entities": [{"type": "Organization", "text": "Dominion Energy, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "SCG", "location": [3994, 3997], "entities": [{"type": "Organization", "text": "SCG"}]}]}, {"type": "hasAttribute", "sentence": "42.96 12/31/2018 14.63% 127.14% S 04/29/2018 T-Mobile US, Inc. (NASDAQ: TMUS ) $7.09 $6.31 06/30/2019 12.38% 20.26% RSYS 07/02/2018 Reliance Industries Limited (N/A) $1.72 $1.54 12/31/2018 11.69% 101.58% SHPG 05/08/2018 Takeda Pharmaceutical Company Limited ( OTCPK:TKPYY ) $194.74 $175.59 01/08/2019 10.91% 79.61% Disclaimer: I hold positions in Finisar ( FNSR ), Rockwell Collins ( COL ), Pandora ( P ) and RadiSys.", "score": 0.912704, "arguments": [{"text": "T-Mobile US, Inc.", "location": [4095, 4112], "entities": [{"type": "Organization", "text": "T-Mobile US, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "TMUS", "location": [4122, 4126], "entities": [{"type": "Ticker", "text": "TMUS"}]}]}, {"type": "employedBy", "sentence": "42.96 12/31/2018 14.63% 127.14% S 04/29/2018 T-Mobile US, Inc. (NASDAQ: TMUS ) $7.09 $6.31 06/30/2019 12.38% 20.26% RSYS 07/02/2018 Reliance Industries Limited (N/A) $1.72 $1.54 12/31/2018 11.69% 101.58% SHPG 05/08/2018 Takeda Pharmaceutical Company Limited ( OTCPK:TKPYY ) $194.74 $175.59 01/08/2019 10.91% 79.61% Disclaimer: I hold positions in Finisar ( FNSR ), Rockwell Collins ( COL ), Pandora ( P ) and RadiSys.", "score": 0.682019, "arguments": [{"text": "SHPG", "location": [4254, 4258], "entities": [{"type": "Person", "text": "SHPG"}]}, {"text": "Takeda Pharmaceutical Company Limited", "location": [4270, 4307], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "I wrote this article myself, and it expresses my own opinions.", "score": 0.996992, "arguments": [{"text": "I", "location": [4713, 4714], "entities": [{"type": "Person", "text": "myself"}]}, {"text": "wrote", "location": [4715, 4720], "entities": [{"type": "EventCommunication", "text": "wrote"}]}]}, {"type": "employedBy", "sentence": "I have no business relationship with any company whose stock is mentioned in this article.", "score": 0.536126, "arguments": [{"text": "whose", "location": [4865, 4870], "entities": [{"type": "Person", "text": "myself"}]}, {"text": "company", "location": [4857, 4864], "entities": [{"type": "Organization", "text": "company"}]}]}, {"type": "residesIn", "sentence": "Under the terms of the agreement, Tahoe shareholders may elect to receive US$3.40 in cash or 0.2403 Pan American shares for each Tahoe share.", "score": 0.66063, "arguments": [{"text": "shareholders", "location": [840, 852], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "Tahoe", "location": [834, 839], "entities": [{"type": "GeopoliticalEntity", "text": "Tahoe Resources"}]}]}, {"type": "residesIn", "sentence": "In addition, Tahoe shareholders will receive contingent consideration in the form of contingent value rights (CVR) that will be exchanged for 0.0497 Pan American shares for each Tahoe share.", "score": 0.596035, "arguments": [{"text": "shareholders", "location": [961, 973], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "Tahoe", "location": [955, 960], "entities": [{"type": "GeopoliticalEntity", "text": "Tahoe Resources"}]}]}, {"type": "timeOf", "sentence": "Deal Updates: On November 15, 2018, Forest City Realty Trust (NYSE: FCE.A ) announced that its stockholders approved the acquisition of Forest City by Brookfield Asset Management (NYSE: BAM ).", "score": 0.808946, "arguments": [{"text": "November 15, 2018", "location": [1382, 1399], "entities": [{"type": "Date", "text": "November 15, 2018"}]}, {"text": "announced", "location": [1441, 1450], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "hasAttribute", "sentence": "Deal Updates: On November 15, 2018, Forest City Realty Trust (NYSE: FCE.A ) announced that its stockholders approved the acquisition of Forest City by Brookfield Asset Management (NYSE: BAM ).", "score": 0.916773, "arguments": [{"text": "Forest City Realty Trust", "location": [1401, 1425], "entities": [{"type": "Organization", "text": "Forest City Realty Trust", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "FCE.A", "location": [1433, 1438], "entities": [{"type": "Ticker", "text": "FCE.A"}]}]}], "keywords": [{"text": "acquisition of athenahealth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.741599, "count": 1}, {"text": "acquisition of Tahoe Resources", "sentiment": {"score": 0.454153, "label": "positive"}, "relevance": 0.625379, "count": 1}, {"text": "new deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.614225, "count": 1}, {"text": "Forest City Realty Trust", "sentiment": {"score": 0.968269, "label": "positive"}, "relevance": 0.608338, "count": 1}, {"text": "NASDAQ", "sentiment": {"score": 0.704476, "label": "positive"}, "relevance": 0.606728, "count": 13}, {"text": "acquisition of Forest City", "sentiment": {"score": 0.968269, "label": "positive"}, "relevance": 0.586769, "count": 1}, {"text": "acquisition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.572761, "count": 1}, {"text": "November", "sentiment": {"score": 0.887532, "label": "positive"}, "relevance": 0.568938, "count": 10}, {"text": "NYSE", "sentiment": {"score": 0.853938, "label": "positive"}, "relevance": 0.56229, "count": 9}, {"text": "Teamsport Parent Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561686, "count": 1}, {"text": "stockholders", "sentiment": {"score": 0.968269, "label": "positive"}, "relevance": 0.560549, "count": 1}, {"text": "Special Conditions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.559719, "count": 1}, {"text": "waiting period", "sentiment": {"score": 0.902689, "label": "positive"}, "relevance": 0.558737, "count": 1}, {"text": "Merger activity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.550158, "count": 1}, {"text": "Navigators Group", "sentiment": {"score": 0.740009, "label": "positive"}, "relevance": 0.549547, "count": 1}, {"text": "Pan American Silver", "sentiment": {"score": 0.454153, "label": "positive"}, "relevance": 0.548456, "count": 1}, {"text": "merger agreement", "sentiment": {"score": 0.740009, "label": "positive"}, "relevance": 0.546743, "count": 2}, {"text": "Forest City", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543747, "count": 1}, {"text": "special meeting of stockholders", "sentiment": {"score": 0.740009, "label": "positive"}, "relevance": 0.543312, "count": 1}, {"text": "deals closing", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542726, "count": 1}, {"text": "Total Number of Deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537623, "count": 2}, {"text": "acquisition of Nexeo Solutions", "sentiment": {"score": 0.902689, "label": "positive"}, "relevance": 0.537026, "count": 1}, {"text": "Nexeo Solutions", "sentiment": {"score": 0.902689, "label": "positive"}, "relevance": 0.535622, "count": 1}, {"text": "acquisition of KMG Chemicals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532622, "count": 1}, {"text": "IK Healthcare Investment Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531423, "count": 1}, {"text": "Tahoe shareholders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531397, "count": 2}, {"text": "acquisition of magicJack VocalTec", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530162, "count": 1}, {"text": "terms of the agreement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528783, "count": 1}, {"text": "acquisition of Anchor Bancorp", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525691, "count": 1}, {"text": "Pan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525432, "count": 3}, {"text": "acquisition of GulfMark Offshore", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524593, "count": 1}, {"text": "Navigators\u2019 stockholders", "sentiment": {"score": 0.740009, "label": "positive"}, "relevance": 0.523053, "count": 1}, {"text": "Navigators", "sentiment": {"score": 0.740009, "label": "positive"}, "relevance": 0.522936, "count": 1}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522438, "count": 2}, {"text": "Hartford Financial Services Group", "sentiment": {"score": 0.740009, "label": "positive"}, "relevance": 0.522274, "count": 1}, {"text": "business relationship", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520218, "count": 1}, {"text": "Total Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519087, "count": 2}, {"text": "Deal Statistics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518598, "count": 1}, {"text": "shareholders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518188, "count": 1}, {"text": "Deals Cash Deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517096, "count": 1}, {"text": "acquisition of LifePoint Health", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51691, "count": 1}, {"text": "Cabot Microelectronics Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51636, "count": 1}, {"text": "Reliance Industries Limited", "sentiment": {"score": 0.763303, "label": "positive"}, "relevance": 0.516329, "count": 1}, {"text": "PAAS", "sentiment": {"score": 0.454153, "label": "positive"}, "relevance": 0.516293, "count": 2}, {"text": "adoption", "sentiment": {"score": 0.740009, "label": "positive"}, "relevance": 0.51609, "count": 1}, {"text": "US", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516075, "count": 1}, {"text": "Connecticut Water Service", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515065, "count": 1}, {"text": "Deals", "sentiment": {"score": 0.633491, "label": "positive"}, "relevance": 0.514522, "count": 3}, {"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": 0.763303, "label": "positive"}, "relevance": 0.514129, "count": 1}, {"text": "KANG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513924, "count": 1}]}, "extracted_metadata": {"sha1": "e02e9a6e847d9d37129366b57d745adde68ae058", "filename": "1542724663378.zip-2fed0247a0dab07842045b53a26ea767.xml", "file_type": "json"}, "external_links": ["http://newsroom.athenahealth.com/phoenix.zhtml?c=253091&p=irol-newsArticle&ID=2376709", "https://www.sec.gov/Archives/edgar/data/1604416/000119312518329139/d659767dex991.htm", "https://www.tahoeresources.com/English/investors/news-releases/press-release-details/2018/Pan-American-Silver-and-Tahoe-Resources-Create-the-Worlds-Premier-Silver-Mining-Company/default.aspx", "https://finance.yahoo.com/news/b-riley-financial-completes-acquisition-150000228.html", "https://www.sec.gov/Archives/edgar/data/276209/000119312518329008/d656196dex991.htm", "https://www.sec.gov/Archives/edgar/data/1028215/000110465918068865/a18-40316_18k.htm", "https://www.sec.gov/Archives/edgar/data/1030749/000119312518329131/d659033d8k.htm", "https://finance.yahoo.com/news/fs-bancorp-inc-completes-merger-110000531.html", "https://www.sec.gov/Archives/edgar/data/1301611/000119312518329058/d654482dex991.htm", "https://www.sec.gov/Archives/edgar/data/793547/000119312518329054/d647438dex991.htm", "https://www.sec.gov/Archives/edgar/data/1647509/000164750918000082/fcrt-form8xkspecialmeeting.htm"], "title": "Merger Arbitrage Mondays - November 19, 2018", "forum_title": "All Articles on Seeking Alpha"}, {"id": "8REdMnrBMhxKvo1OPv8Kwv9zD9-EeyWrPjG4y6lIPu2kYSjDw7GggI09x_lVpLji", "result_metadata": {"score": 31.029066}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.455785, "label": "negative"}, "text": "Takeda", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.455785, "label": "negative"}, "text": "Cardiff University", "relevance": 0.33, "type": "Organization", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Cardiff University", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff_University"}}], "sentiment": {"document": {"score": -0.70996, "label": "negative"}}, "semantic_roles": [], "concepts": [{"text": "Mental disorder", "relevance": 0.930596, "dbpedia_resource": "http://dbpedia.org/resource/Mental_disorder"}], "categories": [{"score": 0.871197, "label": "/health and fitness/disorders"}, {"score": 0.749368, "label": "/health and fitness/disorders/mental disorder/bipolar disorder"}, {"score": 0.707822, "label": "/science/medicine/psychology and psychiatry"}], "relations": [{"type": "partOf", "sentence": "Cardiff University teams up with Takeda to treat psychiatric disorders", "score": 0.823582, "arguments": [{"text": "teams", "location": [19, 24], "entities": [{"type": "Organization", "text": "teams", "disambiguation": {"subtype": ["Sports"]}}]}, {"text": "Cardiff University", "location": [0, 18], "entities": [{"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "educatedAt", "sentence": "Cardiff University teams up with Takeda to treat psychiatric disorders", "score": 0.518491, "arguments": [{"text": "Takeda", "location": [33, 39], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Cardiff University", "location": [0, 18], "entities": [{"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["Educational"]}}]}]}], "keywords": [{"text": "Cardiff University", "sentiment": {"score": -0.70996, "label": "negative"}, "relevance": 0.99999, "count": 1}, {"text": "psychiatric disorders", "sentiment": {"score": -0.70996, "label": "negative"}, "relevance": 0.948538, "count": 1}, {"text": "Takeda", "sentiment": {"score": -0.70996, "label": "negative"}, "relevance": 0.839235, "count": 1}]}, "crawl_date": "2018-11-19T15:14:09Z", "url": "https://www.epmmagazine.com/news/cardiff-university-teams-up-with-takeda/", "host": "epmmagazine.com", "text": "Cardiff University teams up with Takeda to treat psychiatric disorders 19 November 2018 Cardiff University has formed a collaboration with pharmaceutical company Takeda to work on new drugs for treating schizophrenia and other psychiatric disorders. \u00d7 Expand Mental Health The collaboration will combine Cardiff University\u2019s large-scale genomic data and expertise", "main_image_url": "https://www.epmmagazine.com/downloads/6395/download/Mental%20health%20%2816%29.jpg?cb=54d113bcf0ffa86671db32c3d1edcac7&amp;w=-1", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-19T11:45:00Z", "enriched_text": {"entities": [{"count": 6, "sentiment": {"score": -0.196344, "label": "negative"}, "text": "Cardiff University", "relevance": 0.941017, "type": "Organization", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Cardiff University", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff_University"}}, {"count": 4, "sentiment": {"score": -0.542397, "label": "negative"}, "text": "Takeda", "relevance": 0.795485, "type": "Person"}, {"count": 2, "sentiment": {"score": -0.495224, "label": "negative"}, "text": "psychiatric disorders", "relevance": 0.751584, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Mental disorder", "dbpedia_resource": "http://dbpedia.org/resource/Mental_disorder"}}, {"count": 2, "sentiment": {"score": -0.0253449, "label": "negative"}, "text": "Takeda", "relevance": 0.734403, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medical Research Council Centre for Neuropsychiatric Genetics and Genomics", "relevance": 0.5812, "type": "Organization"}, {"count": 3, "sentiment": {"score": -0.508352, "label": "negative"}, "text": "Schizophrenia", "relevance": 0.470478, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Disease"], "name": "Schizophrenia", "dbpedia_resource": "http://dbpedia.org/resource/Schizophrenia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MRC Centre for Neuropsychiatric Genetic and Genomics", "relevance": 0.459833, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0.357295, "label": "positive"}, "text": "Neuroscience and Mental Health Research Institute", "relevance": 0.450502, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cardiff", "relevance": 0.413452, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "WelshPrincipalArea", "City"], "name": "Cardiff", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Neuroscience Drug Discovery Unit", "relevance": 0.394797, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0.50444, "label": "positive"}, "text": "director", "relevance": 0.346942, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Intracranial Neurotherapeutics Unit", "relevance": 0.315679, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "National Centre for Mental Health", "relevance": 0.313785, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Professor Sir Michael Owen", "relevance": 0.305153, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.599304, "label": "positive"}, "text": "Professor Lawrence Wilkinson", "relevance": 0.300187, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.248382, "label": "positive"}, "text": "World Health Organisation", "relevance": 0.286473, "type": "Organization", "disambiguation": {"subtype": [], "name": "World Health Organization", "dbpedia_resource": "http://dbpedia.org/resource/World_Health_Organization"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ceri Davies", "relevance": 0.253894, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "partner", "relevance": 0.243522, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NMHRI", "relevance": 0.227796, "type": "Organization"}], "sentiment": {"document": {"score": -0.332656, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Cardiff University teams up with Takeda to treat psychiatric disorders 19 November 2018 Cardiff University", "keywords": [{"text": "Cardiff University teams"}, {"text": "psychiatric disorders"}, {"text": "Takeda"}], "entities": [{"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Cardiff University", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff_University"}}, {"type": "Person", "text": "Takeda"}, {"type": "HealthCondition", "text": "psychiatric disorders", "disambiguation": {"subtype": ["Disease"], "name": "Mental disorder", "dbpedia_resource": "http://dbpedia.org/resource/Mental_disorder"}}, {"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Cardiff University", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff_University"}}]}, "sentence": "Cardiff University teams up with Takeda to treat psychiatric disorders 19 November 2018 Cardiff University has formed a collaboration with pharmaceutical company Takeda to work on new drugs for treating schizophrenia and other psychiatric disorders.", "object": {"text": "a collaboration with pharmaceutical company Takeda to work on new drugs for treating schizophrenia and other psychiatric disorders", "keywords": [{"text": "pharmaceutical company Takeda"}, {"text": "psychiatric disorders"}, {"text": "new drugs"}, {"text": "schizophrenia"}], "entities": [{"type": "Company", "text": "Takeda"}, {"type": "HealthCondition", "text": "Schizophrenia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Disease"], "name": "Schizophrenia", "dbpedia_resource": "http://dbpedia.org/resource/Schizophrenia"}}]}, "action": {"verb": {"text": "form", "tense": "past"}, "text": "has formed", "normalized": "have form"}}, {"subject": {"text": "Cardiff University", "keywords": [{"text": "Cardiff University"}], "entities": [{"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Cardiff University", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff_University"}}]}, "sentence": " The collaboration will combine Cardiff University\u2019s large-scale genomic data and expertise in psychiatric genetics with Takeda\u2019s drug discovery and clinical development capabilities.", "object": {"text": "large-scale genomic data and expertise in psychiatric genetics with Takeda\u2019s drug discovery and clinical development capabilities", "keywords": [{"text": "large-scale genomic data"}, {"text": "clinical development capabilities"}, {"text": "Takeda\u2019s drug"}, {"text": "psychiatric genetics"}], "entities": []}, "action": {"verb": {"text": "has", "tense": "future"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "the partnership", "keywords": [{"text": "partnership"}]}, "sentence": " Professor Lawrence Wilkinson, scientific director of the Neuroscience and Mental Health Research Institute (NMHRI) who will co-lead the partnership at Cardiff, said: \u201cRecent developments in psychiatric genetics and genomics, combined with advances in neuroscience, mean there is now a real prospect of overcoming the obstacles that have held back progress in developing new drugs for psychiatric disorders.\u201d", "action": {"verb": {"text": "co-lead", "tense": "future"}, "text": "will co-lead", "normalized": "will co-lead"}}, {"subject": {"text": "Professor Lawrence Wilkinson, scientific director of the Neuroscience and Mental Health Research Institute (NMHRI) who will co-lead the partnership at Cardiff,", "keywords": [{"text": "Professor Lawrence Wilkinson"}, {"text": "Mental Health Research"}, {"text": "scientific director"}, {"text": "Neuroscience"}], "entities": [{"type": "Person", "text": "Professor Lawrence Wilkinson"}, {"type": "JobTitle", "text": "director"}, {"type": "Organization", "text": "Neuroscience and Mental Health Research Institute"}, {"type": "Organization", "text": "NMHRI"}, {"type": "Location", "text": "Cardiff", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "WelshPrincipalArea", "CityTown", "City"], "name": "Cardiff", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff"}}]}, "sentence": " Professor Lawrence Wilkinson, scientific director of the Neuroscience and Mental Health Research Institute (NMHRI) who will co-lead the partnership at Cardiff, said: \u201cRecent developments in psychiatric genetics and genomics, combined with advances in neuroscience, mean there is now a real prospect of overcoming the obstacles that have held back progress in developing new drugs for psychiatric disorders.\u201d", "object": {"text": "Recent developments in psychiatric genetics and genomics, combined with advances in neuroscience, mean there is now a real prospect of overcoming the obstacles that have held back progress in developing new drugs for psychiatric disorders", "keywords": [{"text": "psychiatric genetics"}, {"text": "psychiatric disorders"}, {"text": "real prospect"}, {"text": "new drugs"}], "entities": [{"type": "Organization", "text": "Neuroscience and Mental Health Research Institute"}, {"type": "HealthCondition", "text": "psychiatric disorders", "disambiguation": {"subtype": ["Disease"], "name": "Mental disorder", "dbpedia_resource": "http://dbpedia.org/resource/Mental_disorder"}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Recent developments in psychiatric genetics and genomics", "keywords": [{"text": "psychiatric genetics"}, {"text": "Recent developments"}, {"text": "genomics"}]}, "sentence": " Professor Lawrence Wilkinson, scientific director of the Neuroscience and Mental Health Research Institute (NMHRI) who will co-lead the partnership at Cardiff, said: \u201cRecent developments in psychiatric genetics and genomics, combined with advances in neuroscience, mean there is now a real prospect of overcoming the obstacles that have held back progress in developing new drugs for psychiatric disorders.\u201d", "object": {"text": "a real prospect of overcoming the obstacles that have held back progress in developing new drugs for psychiatric disorders", "keywords": [{"text": "real prospect"}, {"text": "psychiatric disorders"}, {"text": "new drugs"}, {"text": "obstacles"}], "entities": [{"type": "HealthCondition", "text": "psychiatric disorders", "disambiguation": {"subtype": ["Disease"], "name": "Mental disorder", "dbpedia_resource": "http://dbpedia.org/resource/Mental_disorder"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Recent developments in psychiatric genetics and genomics", "keywords": [{"text": "psychiatric genetics"}, {"text": "Recent developments"}, {"text": "genomics"}]}, "sentence": " Professor Lawrence Wilkinson, scientific director of the Neuroscience and Mental Health Research Institute (NMHRI) who will co-lead the partnership at Cardiff, said: \u201cRecent developments in psychiatric genetics and genomics, combined with advances in neuroscience, mean there is now a real prospect of overcoming the obstacles that have held back progress in developing new drugs for psychiatric disorders.\u201d", "object": {"text": "the obstacles that have held back progress in developing new drugs for psychiatric disorders", "keywords": [{"text": "psychiatric disorders"}, {"text": "new drugs"}, {"text": "obstacles"}, {"text": "progress"}], "entities": [{"type": "HealthCondition", "text": "psychiatric disorders", "disambiguation": {"subtype": ["Disease"], "name": "Mental disorder", "dbpedia_resource": "http://dbpedia.org/resource/Mental_disorder"}}]}, "action": {"verb": {"text": "overcome", "tense": "future"}, "text": "overcoming", "normalized": "overcome"}}, {"subject": {"text": "new drugs", "keywords": [{"text": "new drugs"}]}, "sentence": " Professor Lawrence Wilkinson, scientific director of the Neuroscience and Mental Health Research Institute (NMHRI) who will co-lead the partnership at Cardiff, said: \u201cRecent developments in psychiatric genetics and genomics, combined with advances in neuroscience, mean there is now a real prospect of overcoming the obstacles that have held back progress in developing new drugs for psychiatric disorders.\u201d", "object": {"text": "for psychiatric disorders", "keywords": [{"text": "psychiatric disorders"}], "entities": [{"type": "HealthCondition", "text": "psychiatric disorders", "disambiguation": {"subtype": ["Disease"], "name": "Mental disorder", "dbpedia_resource": "http://dbpedia.org/resource/Mental_disorder"}}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "Takeda\u2019s expertise in successful drug discovery", "keywords": [{"text": "successful drug discovery"}, {"text": "Takeda"}, {"text": "expertise"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " \u201cTakeda\u2019s expertise in successful drug discovery will enable our ambition to use our research to find better treatments for common brain disorders with high levels of unmet need.\u201d", "object": {"text": "our ambition to use our research to find better treatments for common brain disorders with high levels of unmet need", "keywords": [{"text": "common brain disorders"}, {"text": "unmet need"}, {"text": "better treatments"}, {"text": "high levels"}]}, "action": {"verb": {"text": "enable", "tense": "future"}, "text": "will enable", "normalized": "will enable"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda will be given access to biological psychiatry research across the university, including the MRC Centre for Neuropsychiatric Genetic and Genomics, NMHRI, National Centre for Mental Health, and the Brain Repair and Intracranial Neurotherapeutics Unit.", "object": {"text": "given access to biological psychiatry research across the university, including the MRC Centre for Neuropsychiatric Genetic and Genomics, NMHRI, National Centre for Mental Health, and the Brain Repair and Intracranial Neurotherapeutics Unit", "keywords": [{"text": "Intracranial Neurotherapeutics Unit"}, {"text": "biological psychiatry research"}, {"text": "Neuropsychiatric Genetic"}, {"text": "MRC Centre"}], "entities": [{"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Cardiff University", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff_University"}}, {"type": "Organization", "text": "MRC Centre for Neuropsychiatric Genetic and Genomics"}, {"type": "Organization", "text": "National Centre for Mental Health"}, {"type": "Facility", "text": "Intracranial Neurotherapeutics Unit"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "access to biological psychiatry research across the university, including the MRC Centre for Neuropsychiatric Genetic and Genomics, NMHRI, National Centre for Mental Health, and the Brain Repair and Intracranial Neurotherapeutics Unit", "keywords": [{"text": "Intracranial Neurotherapeutics Unit"}, {"text": "biological psychiatry research"}, {"text": "Neuropsychiatric Genetic"}, {"text": "MRC Centre"}], "entities": [{"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Cardiff University", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff_University"}}, {"type": "Organization", "text": "MRC Centre for Neuropsychiatric Genetic and Genomics"}, {"type": "Organization", "text": "National Centre for Mental Health"}, {"type": "Facility", "text": "Intracranial Neurotherapeutics Unit"}]}, "sentence": " Takeda will be given access to biological psychiatry research across the university, including the MRC Centre for Neuropsychiatric Genetic and Genomics, NMHRI, National Centre for Mental Health, and the Brain Repair and Intracranial Neurotherapeutics Unit.", "object": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "give", "tense": "future"}, "text": "will be given", "normalized": "will be give"}}, {"subject": {"text": "the MRC Centre for Neuropsychiatric Genetic and Genomics, NMHRI, National Centre for Mental Health, and the Brain Repair and Intracranial Neurotherapeutics Unit", "keywords": [{"text": "Intracranial Neurotherapeutics Unit"}, {"text": "Neuropsychiatric Genetic"}, {"text": "MRC Centre"}, {"text": "Mental Health"}], "entities": [{"type": "Organization", "text": "MRC Centre for Neuropsychiatric Genetic and Genomics"}, {"type": "Organization", "text": "National Centre for Mental Health"}, {"type": "Facility", "text": "Intracranial Neurotherapeutics Unit"}]}, "sentence": " Takeda will be given access to biological psychiatry research across the university, including the MRC Centre for Neuropsychiatric Genetic and Genomics, NMHRI, National Centre for Mental Health, and the Brain Repair and Intracranial Neurotherapeutics Unit.", "object": {"text": "biological psychiatry research across the university", "keywords": [{"text": "biological psychiatry research"}], "entities": [{"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Cardiff University", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff_University"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "we"}, "sentence": " \u201cBy working in partnership with world-leading scientific and clinical neuropsychiatric experts at Cardiff University we have a unique opportunity to create a new wave of medicines, that are grounded in the genomic understanding of the disease, for patients suffering from schizophrenia and related psychiatric disorders,\u201d said Ceri Davies, head of the Neuroscience Drug Discovery Unit at Takeda.", "object": {"text": "a unique opportunity to create a new wave of medicines, that are grounded in the genomic understanding of the disease, for patients suffering from schizophrenia and related psychiatric disorders", "keywords": [{"text": "related psychiatric disorders"}, {"text": "genomic understanding"}, {"text": "new wave"}, {"text": "unique opportunity"}], "entities": [{"type": "HealthCondition", "text": "Schizophrenia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Disease"], "name": "Schizophrenia", "dbpedia_resource": "http://dbpedia.org/resource/Schizophrenia"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "we"}, "sentence": " \u201cBy working in partnership with world-leading scientific and clinical neuropsychiatric experts at Cardiff University we have a unique opportunity to create a new wave of medicines, that are grounded in the genomic understanding of the disease, for patients suffering from schizophrenia and related psychiatric disorders,\u201d said Ceri Davies, head of the Neuroscience Drug Discovery Unit at Takeda.", "object": {"text": "a new wave of medicines, that are grounded in the genomic understanding of the disease, for patients suffering from schizophrenia and related psychiatric disorders", "keywords": [{"text": "related psychiatric disorders"}, {"text": "genomic understanding"}, {"text": "new wave"}, {"text": "medicines"}], "entities": [{"type": "HealthCondition", "text": "Schizophrenia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Disease"], "name": "Schizophrenia", "dbpedia_resource": "http://dbpedia.org/resource/Schizophrenia"}}]}, "action": {"verb": {"text": "create", "tense": "future"}, "text": "to create", "normalized": "to create"}}, {"subject": {"text": "a new wave of medicines", "keywords": [{"text": "new wave"}, {"text": "medicines"}]}, "sentence": " \u201cBy working in partnership with world-leading scientific and clinical neuropsychiatric experts at Cardiff University we have a unique opportunity to create a new wave of medicines, that are grounded in the genomic understanding of the disease, for patients suffering from schizophrenia and related psychiatric disorders,\u201d said Ceri Davies, head of the Neuroscience Drug Discovery Unit at Takeda.", "object": {"text": "grounded in the genomic understanding of the disease", "keywords": [{"text": "genomic understanding"}, {"text": "disease"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "in the genomic understanding of the disease, for patients suffering from schizophrenia and related psychiatric disorders,\u201d said Ceri Davies, head of the Neuroscience Drug Discovery Unit at Takeda", "keywords": [{"text": "related psychiatric disorders"}, {"text": "Neuroscience Drug Discovery"}, {"text": "Ceri Davies"}, {"text": "genomic understanding"}], "entities": [{"type": "HealthCondition", "text": "Schizophrenia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Disease"], "name": "Schizophrenia", "dbpedia_resource": "http://dbpedia.org/resource/Schizophrenia"}}, {"type": "Person", "text": "Ceri Davies"}, {"type": "Organization", "text": "Neuroscience Drug Discovery Unit"}, {"type": "Company", "text": "Takeda"}]}, "sentence": " \u201cBy working in partnership with world-leading scientific and clinical neuropsychiatric experts at Cardiff University we have a unique opportunity to create a new wave of medicines, that are grounded in the genomic understanding of the disease, for patients suffering from schizophrenia and related psychiatric disorders,\u201d said Ceri Davies, head of the Neuroscience Drug Discovery Unit at Takeda.", "object": {"text": "a new wave of medicines", "keywords": [{"text": "new wave"}, {"text": "medicines"}]}, "action": {"verb": {"text": "ground", "tense": "past"}, "text": "are grounded", "normalized": "be ground"}}, {"subject": {"text": "Ceri Davies, head of the Neuroscience Drug Discovery Unit at Takeda", "keywords": [{"text": "Ceri Davies"}, {"text": "Neuroscience Drug Discovery"}, {"text": "Takeda"}, {"text": "head"}], "entities": [{"type": "Person", "text": "Ceri Davies"}, {"type": "Organization", "text": "Neuroscience Drug Discovery Unit"}, {"type": "Company", "text": "Takeda"}]}, "sentence": " \u201cBy working in partnership with world-leading scientific and clinical neuropsychiatric experts at Cardiff University we have a unique opportunity to create a new wave of medicines, that are grounded in the genomic understanding of the disease, for patients suffering from schizophrenia and related psychiatric disorders,\u201d said Ceri Davies, head of the Neuroscience Drug Discovery Unit at Takeda.", "object": {"text": "By working in partnership with world-leading scientific and clinical neuropsychiatric experts at Cardiff University we have a unique opportunity to create a new wave of medicines, that are grounded in the genomic understanding of the disease, for patients suffering from schizophrenia and related psychiatric disorders", "keywords": [{"text": "clinical neuropsychiatric experts"}, {"text": "related psychiatric disorders"}, {"text": "Cardiff University"}, {"text": "genomic understanding"}], "entities": [{"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Cardiff University", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff_University"}}, {"type": "HealthCondition", "text": "Schizophrenia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Disease"], "name": "Schizophrenia", "dbpedia_resource": "http://dbpedia.org/resource/Schizophrenia"}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Schizophrenia", "keywords": [{"text": "Schizophrenia"}], "entities": [{"type": "HealthCondition", "text": "Schizophrenia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Disease"], "name": "Schizophrenia", "dbpedia_resource": "http://dbpedia.org/resource/Schizophrenia"}}]}, "sentence": " Schizophrenia affects around 23 million people worldwide and typically begins in early adulthood, according the World Health Organisation (WHO).", "object": {"text": "23 million people worldwide", "keywords": [{"text": "people"}]}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affects", "normalized": "affect"}}, {"subject": {"text": "Schizophrenia", "keywords": [{"text": "Schizophrenia"}], "entities": [{"type": "HealthCondition", "text": "Schizophrenia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Disease"], "name": "Schizophrenia", "dbpedia_resource": "http://dbpedia.org/resource/Schizophrenia"}}]}, "sentence": " Schizophrenia affects around 23 million people worldwide and typically begins in early adulthood, according the World Health Organisation (WHO).", "object": {"text": "the World Health Organisation (WHO)", "keywords": [{"text": "World Health Organisation"}], "entities": [{"type": "Organization", "text": "World Health Organisation", "disambiguation": {"subtype": [], "name": "World Health Organization", "dbpedia_resource": "http://dbpedia.org/resource/World_Health_Organization"}}]}, "action": {"verb": {"text": "accord", "tense": "present"}, "text": "according", "normalized": "accord"}}, {"subject": {"text": "Professor Sir Michael Owen, director of the Medical Research Council Centre for Neuropsychiatric Genetics and Genomics", "keywords": [{"text": "Sir Michael Owen"}, {"text": "Neuropsychiatric Genetics"}, {"text": "Medical Research Council"}, {"text": "Genomics"}], "entities": [{"type": "Person", "text": "Professor Sir Michael Owen"}, {"type": "JobTitle", "text": "director"}, {"type": "Organization", "text": "Medical Research Council Centre for Neuropsychiatric Genetics and Genomics"}]}, "sentence": " Professor Sir Michael Owen, director of the Medical Research Council Centre for Neuropsychiatric Genetics and Genomics said: \u201cTherapeutic progress for these conditions has been limited by a lack of understanding of their primary causes, however major genetic advances in the last decade, many of which have been led by Cardiff University, have provided new and reliable insights into their biological causation.", "object": {"text": "Therapeutic progress for these conditions has been limited by a lack of understanding of their primary causes, however major genetic advances in the last decade, many of which have been led by Cardiff University, have provided new and reliable insights into their biological causation", "keywords": [{"text": "major genetic advances"}, {"text": "Therapeutic progress"}, {"text": "reliable insights"}, {"text": "biological causation"}], "entities": [{"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Cardiff University", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff_University"}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Therapeutic progress for these conditions", "keywords": [{"text": "Therapeutic progress"}, {"text": "conditions"}]}, "sentence": " Professor Sir Michael Owen, director of the Medical Research Council Centre for Neuropsychiatric Genetics and Genomics said: \u201cTherapeutic progress for these conditions has been limited by a lack of understanding of their primary causes, however major genetic advances in the last decade, many of which have been led by Cardiff University, have provided new and reliable insights into their biological causation.", "object": {"text": "limited"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "we"}, "sentence": " With our partner Takeda we have an unprecedented opportunity to develop novel therapeutic approaches for neuropsychiatric disorders.\u201d Tags", "object": {"text": "an unprecedented opportunity to develop novel therapeutic approaches for neuropsychiatric disorders.\u201d Tags", "keywords": [{"text": "novel therapeutic approaches"}, {"text": "unprecedented opportunity"}, {"text": "neuropsychiatric disorders."}, {"text": "Tags"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}], "concepts": [{"text": "Psychiatry", "relevance": 0.985313, "dbpedia_resource": "http://dbpedia.org/resource/Psychiatry"}, {"text": "Genetics", "relevance": 0.873423, "dbpedia_resource": "http://dbpedia.org/resource/Genetics"}, {"text": "Medicine", "relevance": 0.750602, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Mental disorder", "relevance": 0.699459, "dbpedia_resource": "http://dbpedia.org/resource/Mental_disorder"}, {"text": "Pharmacology", "relevance": 0.568259, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Psychology", "relevance": 0.523512, "dbpedia_resource": "http://dbpedia.org/resource/Psychology"}, {"text": "Neuropsychiatry", "relevance": 0.464805, "dbpedia_resource": "http://dbpedia.org/resource/Neuropsychiatry"}, {"text": "Drug discovery", "relevance": 0.456661, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Biology", "relevance": 0.438574, "dbpedia_resource": "http://dbpedia.org/resource/Biology"}, {"text": "Gene", "relevance": 0.417345, "dbpedia_resource": "http://dbpedia.org/resource/Gene"}, {"text": "Genomics", "relevance": 0.41663, "dbpedia_resource": "http://dbpedia.org/resource/Genomics"}, {"text": "Neurology", "relevance": 0.406923, "dbpedia_resource": "http://dbpedia.org/resource/Neurology"}, {"text": "Mental health", "relevance": 0.397271, "dbpedia_resource": "http://dbpedia.org/resource/Mental_health"}, {"text": "Medical research", "relevance": 0.394065, "dbpedia_resource": "http://dbpedia.org/resource/Medical_research"}, {"text": "Bioinformatics", "relevance": 0.382863, "dbpedia_resource": "http://dbpedia.org/resource/Bioinformatics"}, {"text": "Medical Research Council", "relevance": 0.382482, "dbpedia_resource": "http://dbpedia.org/resource/Medical_Research_Council_(UK)"}, {"text": "Clinical trial", "relevance": 0.38111, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Neuroscience", "relevance": 0.379577, "dbpedia_resource": "http://dbpedia.org/resource/Neuroscience"}, {"text": "Genome", "relevance": 0.37658, "dbpedia_resource": "http://dbpedia.org/resource/Genome"}, {"text": "Francis Crick", "relevance": 0.371702, "dbpedia_resource": "http://dbpedia.org/resource/Francis_Crick"}, {"text": "Schizophrenia", "relevance": 0.370629, "dbpedia_resource": "http://dbpedia.org/resource/Schizophrenia"}, {"text": "Pharmaceutical industry", "relevance": 0.349722, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Pharmaceutical drug", "relevance": 0.34515, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Drug", "relevance": 0.337361, "dbpedia_resource": "http://dbpedia.org/resource/Drug"}, {"text": "Influenza", "relevance": 0.335313, "dbpedia_resource": "http://dbpedia.org/resource/Influenza"}, {"text": "Drug development", "relevance": 0.327381, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "James D. Watson", "relevance": 0.310829, "dbpedia_resource": "http://dbpedia.org/resource/James_D._Watson"}, {"text": "Greek loanwords", "relevance": 0.31075, "dbpedia_resource": "http://dbpedia.org/resource/Greek_loanwords"}, {"text": "Clinical psychology", "relevance": 0.309404, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_psychology"}, {"text": "Pre-clinical development", "relevance": 0.306972, "dbpedia_resource": "http://dbpedia.org/resource/Pre-clinical_development"}, {"text": "Human Genome Project", "relevance": 0.304623, "dbpedia_resource": "http://dbpedia.org/resource/Human_Genome_Project"}, {"text": "Mental health professional", "relevance": 0.304339, "dbpedia_resource": "http://dbpedia.org/resource/Mental_health_professional"}, {"text": "Psychiatrist", "relevance": 0.30251, "dbpedia_resource": "http://dbpedia.org/resource/Psychiatrist"}, {"text": "Brain", "relevance": 0.278529, "dbpedia_resource": "http://dbpedia.org/resource/Brain"}, {"text": "World Health Organization", "relevance": 0.272009, "dbpedia_resource": "http://dbpedia.org/resource/World_Health_Organization"}, {"text": "Adult", "relevance": 0.271122, "dbpedia_resource": "http://dbpedia.org/resource/Adult"}, {"text": "Biological psychiatry", "relevance": 0.269288, "dbpedia_resource": "http://dbpedia.org/resource/Biological_psychiatry"}, {"text": "Cardiff", "relevance": 0.26775, "dbpedia_resource": "http://dbpedia.org/resource/Cardiff"}, {"text": "Adulthood", "relevance": 0.266082, "dbpedia_resource": "http://dbpedia.org/resource/Adulthood"}, {"text": "Drugs", "relevance": 0.265844, "dbpedia_resource": "http://dbpedia.org/resource/Drugs"}, {"text": "Drug addiction", "relevance": 0.263841, "dbpedia_resource": "http://dbpedia.org/resource/Drug_addiction"}, {"text": "Human brain", "relevance": 0.263409, "dbpedia_resource": "http://dbpedia.org/resource/Human_brain"}, {"text": "Mental status examination", "relevance": 0.262822, "dbpedia_resource": "http://dbpedia.org/resource/Mental_status_examination"}, {"text": "Genetic disorder", "relevance": 0.259895, "dbpedia_resource": "http://dbpedia.org/resource/Genetic_disorder"}, {"text": "Psychiatric medication", "relevance": 0.257096, "dbpedia_resource": "http://dbpedia.org/resource/Psychiatric_medication"}, {"text": "Psychosis", "relevance": 0.257094, "dbpedia_resource": "http://dbpedia.org/resource/Psychosis"}, {"text": "Psychopathology", "relevance": 0.256688, "dbpedia_resource": "http://dbpedia.org/resource/Psychopathology"}, {"text": "Model organism", "relevance": 0.256643, "dbpedia_resource": "http://dbpedia.org/resource/Model_organism"}, {"text": "Family therapy", "relevance": 0.254954, "dbpedia_resource": "http://dbpedia.org/resource/Family_therapy"}, {"text": "Edward Mellanby", "relevance": 0.254614, "dbpedia_resource": "http://dbpedia.org/resource/Edward_Mellanby"}], "categories": [{"score": 0.969688, "label": "/health and fitness/disorders"}, {"score": 0.958916, "label": "/science/medicine/psychology and psychiatry"}, {"score": 0.934462, "label": "/science/medicine/genetics"}], "relations": [{"type": "partOf", "sentence": "Cardiff University teams up with Takeda to treat psychiatric disorders 19 November 2018 Cardiff University has formed a collaboration with pharmaceutical company Takeda to work on new drugs for treating schizophrenia and other psychiatric disorders.", "score": 0.797524, "arguments": [{"text": "teams", "location": [19, 24], "entities": [{"type": "Organization", "text": "teams", "disambiguation": {"subtype": ["Sports"]}}]}, {"text": "Cardiff University", "location": [0, 18], "entities": [{"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "hasAttribute", "sentence": "\" \"Takeda's expertise in successful drug discovery will enable our ambition to use our research to find better treatments for common brain disorders with high levels of unmet need.", "score": 0.663087, "arguments": [{"text": "our", "location": [945, 948], "entities": [{"type": "Person", "text": "their"}]}, {"text": "brain disorders", "location": [995, 1010], "entities": [{"type": "HealthCondition", "text": "brain disorders"}]}]}, {"type": "partOf", "sentence": "\" Takeda will be given access to biological psychiatry research across the university, including the MRC Centre for Neuropsychiatric Genetic and Genomics, NMHRI, National Centre for Mental Health, and the Brain Repair and Intracranial Neurotherapeutics Unit.", "score": 0.530235, "arguments": [{"text": "university", "location": [1117, 1127], "entities": [{"type": "Organization", "text": "Neuropsychiatric Genetics and Genomics"}]}, {"text": "MRC Centre for Neuropsychiatric Genetic and Genomics", "location": [1143, 1195], "entities": [{"type": "Organization", "text": "MRC Centre for Neuropsychiatric Genetic and Genomics"}]}]}, {"type": "employedBy", "sentence": "\"By working in partnership with world-leading scientific and clinical neuropsychiatric experts at Cardiff University we have a unique opportunity to create a new wave of medicines, that are grounded in the genomic understanding of the disease, for patients suffering from schizophrenia and related psychiatric disorders,\" said Ceri Davies, head of the Neuroscience Drug Discovery Unit at Takeda.", "score": 0.365009, "arguments": [{"text": "experts", "location": [1388, 1395], "entities": [{"type": "Person", "text": "experts"}]}, {"text": "Cardiff University", "location": [1399, 1417], "entities": [{"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "partOf", "sentence": "\"By working in partnership with world-leading scientific and clinical neuropsychiatric experts at Cardiff University we have a unique opportunity to create a new wave of medicines, that are grounded in the genomic understanding of the disease, for patients suffering from schizophrenia and related psychiatric disorders,\" said Ceri Davies, head of the Neuroscience Drug Discovery Unit at Takeda.", "score": 0.509416, "arguments": [{"text": "we", "location": [1418, 1420], "entities": [{"type": "Organization", "text": "Neuroscience Drug Discovery Unit"}]}, {"text": "Cardiff University", "location": [1399, 1417], "entities": [{"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "hasAttribute", "sentence": "\"By working in partnership with world-leading scientific and clinical neuropsychiatric experts at Cardiff University we have a unique opportunity to create a new wave of medicines, that are grounded in the genomic understanding of the disease, for patients suffering from schizophrenia and related psychiatric disorders,\" said Ceri Davies, head of the Neuroscience Drug Discovery Unit at Takeda.", "score": 0.806244, "arguments": [{"text": "patients", "location": [1549, 1557], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "schizophrenia", "location": [1573, 1586], "entities": [{"type": "HealthCondition", "text": "schizophrenia"}]}]}, {"type": "hasAttribute", "sentence": "\"By working in partnership with world-leading scientific and clinical neuropsychiatric experts at Cardiff University we have a unique opportunity to create a new wave of medicines, that are grounded in the genomic understanding of the disease, for patients suffering from schizophrenia and related psychiatric disorders,\" said Ceri Davies, head of the Neuroscience Drug Discovery Unit at Takeda.", "score": 0.832845, "arguments": [{"text": "patients", "location": [1549, 1557], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "psychiatric disorders", "location": [1599, 1620], "entities": [{"type": "HealthCondition", "text": "neuropsychiatric disorders"}]}]}, {"type": "agentOf", "sentence": "\"By working in partnership with world-leading scientific and clinical neuropsychiatric experts at Cardiff University we have a unique opportunity to create a new wave of medicines, that are grounded in the genomic understanding of the disease, for patients suffering from schizophrenia and related psychiatric disorders,\" said Ceri Davies, head of the Neuroscience Drug Discovery Unit at Takeda.", "score": 0.864164, "arguments": [{"text": "Ceri Davies", "location": [1628, 1639], "entities": [{"type": "Person", "text": "Ceri Davies"}]}, {"text": "said", "location": [1623, 1627], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "employedBy", "sentence": "\"By working in partnership with world-leading scientific and clinical neuropsychiatric experts at Cardiff University we have a unique opportunity to create a new wave of medicines, that are grounded in the genomic understanding of the disease, for patients suffering from schizophrenia and related psychiatric disorders,\" said Ceri Davies, head of the Neuroscience Drug Discovery Unit at Takeda.", "score": 0.489049, "arguments": [{"text": "head", "location": [1641, 1645], "entities": [{"type": "Person", "text": "Ceri Davies"}]}, {"text": "Neuroscience Drug Discovery Unit", "location": [1653, 1685], "entities": [{"type": "Organization", "text": "Neuroscience Drug Discovery Unit"}]}]}, {"type": "employedBy", "sentence": "\"By working in partnership with world-leading scientific and clinical neuropsychiatric experts at Cardiff University we have a unique opportunity to create a new wave of medicines, that are grounded in the genomic understanding of the disease, for patients suffering from schizophrenia and related psychiatric disorders,\" said Ceri Davies, head of the Neuroscience Drug Discovery Unit at Takeda.", "score": 0.713121, "arguments": [{"text": "Takeda", "location": [1689, 1695], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Neuroscience Drug Discovery Unit", "location": [1653, 1685], "entities": [{"type": "Organization", "text": "Neuroscience Drug Discovery Unit"}]}]}, {"type": "agentOf", "sentence": "Professor Sir Michael Owen, director of the Medical Research Council Centre for Neuropsychiatric Genetics and Genomics said: \"Therapeutic progress for these conditions has been limited by a lack of understanding of their primary causes, however major genetic advances in the last decade, many of which have been led by Cardiff University, have provided new and reliable insights into their biological causation.", "score": 0.858633, "arguments": [{"text": "Sir Michael Owen", "location": [1852, 1868], "entities": [{"type": "Person", "text": "Sir Michael Owen"}]}, {"text": "said", "location": [1961, 1965], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "hasAttribute", "sentence": "Cardiff University teams up with Takeda to treat psychiatric disorders 19 November 2018 Cardiff University has formed a collaboration with pharmaceutical company Takeda to work on new drugs for treating schizophrenia and other psychiatric disorders.", "score": 0.847881, "arguments": [{"text": "Takeda", "location": [33, 39], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "psychiatric disorders", "location": [49, 70], "entities": [{"type": "HealthCondition", "text": "neuropsychiatric disorders"}]}]}, {"type": "hasAttribute", "sentence": "With our partner Takeda we have an unprecedented opportunity to develop novel therapeutic approaches for neuropsychiatric disorders.", "score": 0.514003, "arguments": [{"text": "Takeda", "location": [2271, 2277], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "neuropsychiatric disorders", "location": [2359, 2385], "entities": [{"type": "HealthCondition", "text": "neuropsychiatric disorders"}]}]}, {"type": "managerOf", "sentence": "Professor Sir Michael Owen, director of the Medical Research Council Centre for Neuropsychiatric Genetics and Genomics said: \"Therapeutic progress for these conditions has been limited by a lack of understanding of their primary causes, however major genetic advances in the last decade, many of which have been led by Cardiff University, have provided new and reliable insights into their biological causation.", "score": 0.520565, "arguments": [{"text": "director", "location": [1870, 1878], "entities": [{"type": "Person", "text": "Sir Michael Owen"}]}, {"text": "Medical Research Council Centre", "location": [1886, 1917], "entities": [{"type": "Organization", "text": "Medical Research Council Centre"}]}]}, {"type": "partOf", "sentence": "Professor Sir Michael Owen, director of the Medical Research Council Centre for Neuropsychiatric Genetics and Genomics said: \"Therapeutic progress for these conditions has been limited by a lack of understanding of their primary causes, however major genetic advances in the last decade, many of which have been led by Cardiff University, have provided new and reliable insights into their biological causation.", "score": 0.839674, "arguments": [{"text": "Medical Research Council Centre", "location": [1886, 1917], "entities": [{"type": "Organization", "text": "Medical Research Council Centre"}]}, {"text": "Neuropsychiatric Genetics and Genomics", "location": [1922, 1960], "entities": [{"type": "Organization", "text": "Neuropsychiatric Genetics and Genomics"}]}]}, {"type": "parentOf", "sentence": "With our partner Takeda we have an unprecedented opportunity to develop novel therapeutic approaches for neuropsychiatric disorders.", "score": 0.301866, "arguments": [{"text": "partner", "location": [2263, 2270], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "our", "location": [2259, 2262], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "participantIn", "sentence": "Cardiff University teams up with Takeda to treat psychiatric disorders 19 November 2018 Cardiff University has formed a collaboration with pharmaceutical company Takeda to work on new drugs for treating schizophrenia and other psychiatric disorders.", "score": 0.703501, "arguments": [{"text": "Takeda", "location": [33, 39], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "collaboration", "location": [120, 133], "entities": [{"type": "EventMeeting", "text": "collaboration"}]}]}, {"type": "participantIn", "sentence": "Cardiff University teams up with Takeda to treat psychiatric disorders 19 November 2018 Cardiff University has formed a collaboration with pharmaceutical company Takeda to work on new drugs for treating schizophrenia and other psychiatric disorders.", "score": 0.499172, "arguments": [{"text": "Takeda", "location": [162, 168], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "collaboration", "location": [120, 133], "entities": [{"type": "EventMeeting", "text": "collaboration"}]}]}, {"type": "agentOf", "sentence": "Cardiff University teams up with Takeda to treat psychiatric disorders 19 November 2018 Cardiff University has formed a collaboration with pharmaceutical company Takeda to work on new drugs for treating schizophrenia and other psychiatric disorders.", "score": 0.537094, "arguments": [{"text": "Cardiff University", "location": [88, 106], "entities": [{"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["Educational"]}}]}, {"text": "collaboration", "location": [120, 133], "entities": [{"type": "EventMeeting", "text": "collaboration"}]}]}, {"type": "employedBy", "sentence": "Cardiff University teams up with Takeda to treat psychiatric disorders 19 November 2018 Cardiff University has formed a collaboration with pharmaceutical company Takeda to work on new drugs for treating schizophrenia and other psychiatric disorders.", "score": 0.512991, "arguments": [{"text": "Takeda", "location": [162, 168], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "pharmaceutical company", "location": [139, 161], "entities": [{"type": "Organization", "text": "pharmaceutical company", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "\u00d7 Expand Mental Health The collaboration will combine Cardiff University's large-scale genomic data and expertise in psychiatric genetics with Takeda's drug discovery and clinical development capabilities.", "score": 0.427401, "arguments": [{"text": "Takeda", "location": [393, 399], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Cardiff University", "location": [304, 322], "entities": [{"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "agentOf", "sentence": "Professor Lawrence Wilkinson, scientific director of the Neuroscience and Mental Health Research Institute (NMHRI) who will co-lead the partnership at Cardiff, said: \"Recent developments in psychiatric genetics and genomics, combined with advances in neuroscience, mean there is now a real prospect of overcoming the obstacles that have held back progress in developing new drugs for psychiatric disorders.", "score": 0.518452, "arguments": [{"text": "Lawrence Wilkinson", "location": [466, 484], "entities": [{"type": "Person", "text": "Lawrence Wilkinson"}]}, {"text": "said", "location": [616, 620], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "employedBy", "sentence": "Professor Lawrence Wilkinson, scientific director of the Neuroscience and Mental Health Research Institute (NMHRI) who will co-lead the partnership at Cardiff, said: \"Recent developments in psychiatric genetics and genomics, combined with advances in neuroscience, mean there is now a real prospect of overcoming the obstacles that have held back progress in developing new drugs for psychiatric disorders.", "score": 0.432166, "arguments": [{"text": "scientific director", "location": [486, 505], "entities": [{"type": "Person", "text": "Lawrence Wilkinson"}]}, {"text": "Mental Health Research Institute", "location": [530, 562], "entities": [{"type": "Organization", "text": "Mental Health Research Institute"}]}]}, {"type": "educatedAt", "sentence": "Professor Lawrence Wilkinson, scientific director of the Neuroscience and Mental Health Research Institute (NMHRI) who will co-lead the partnership at Cardiff, said: \"Recent developments in psychiatric genetics and genomics, combined with advances in neuroscience, mean there is now a real prospect of overcoming the obstacles that have held back progress in developing new drugs for psychiatric disorders.", "score": 0.407811, "arguments": [{"text": "who", "location": [571, 574], "entities": [{"type": "Person", "text": "Lawrence Wilkinson"}]}, {"text": "Cardiff", "location": [607, 614], "entities": [{"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["Educational"]}}]}]}], "keywords": [{"text": "Cardiff University", "sentiment": {"score": -0.524302, "mixed": "1", "label": "negative"}, "relevance": 0.802998, "count": 4}, {"text": "psychiatric disorders", "sentiment": {"score": -0.416298, "mixed": "1", "label": "negative"}, "relevance": 0.678798, "count": 3}, {"text": "Takeda", "sentiment": {"score": -0.767853, "label": "negative"}, "relevance": 0.622378, "count": 3}, {"text": "Professor Lawrence Wilkinson", "sentiment": {"score": 0.494988, "label": "positive"}, "relevance": 0.602242, "count": 1}, {"text": "new drugs", "sentiment": {"score": -0.344548, "mixed": "1", "label": "negative"}, "relevance": 0.58962, "count": 2}, {"text": "unique opportunity", "sentiment": {"score": -0.927143, "label": "negative"}, "relevance": 0.583211, "count": 1}, {"text": "Mental Health Research Institute", "sentiment": {"score": 0.494988, "label": "positive"}, "relevance": 0.577614, "count": 1}, {"text": "pharmaceutical company Takeda", "sentiment": {"score": -0.54109, "label": "negative"}, "relevance": 0.574156, "count": 1}, {"text": "Neuropsychiatric Genetic", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.569435, "count": 1}, {"text": "research", "sentiment": {"score": 0.541848, "label": "positive"}, "relevance": 0.567014, "count": 1}, {"text": "Cardiff University\u2019s large-scale", "sentiment": {"score": -0.54109, "label": "negative"}, "relevance": 0.56523, "count": 1}, {"text": "scientific director of the Neuroscience", "sentiment": {"score": 0.494988, "label": "positive"}, "relevance": 0.563821, "count": 1}, {"text": "Cardiff", "sentiment": {"score": 0.494988, "label": "positive"}, "relevance": 0.562729, "count": 1}, {"text": "university", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.560819, "count": 1}, {"text": "schizophrenia", "sentiment": {"score": -0.767853, "label": "negative"}, "relevance": 0.559581, "count": 2}, {"text": "collaboration", "sentiment": {"score": -0.54109, "label": "negative"}, "relevance": 0.555764, "count": 2}, {"text": "genomics", "sentiment": {"score": 0.494988, "label": "positive"}, "relevance": 0.554651, "count": 1}, {"text": "Genomics", "sentiment": {"score": -0.430193, "label": "negative"}, "relevance": 0.554651, "count": 2}, {"text": "Takeda\u2019s drug discovery", "sentiment": {"score": -0.54109, "label": "negative"}, "relevance": 0.552198, "count": 1}, {"text": "National Centre", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.551177, "count": 1}, {"text": "neuroscience", "sentiment": {"score": 0.494988, "label": "positive"}, "relevance": 0.549937, "count": 1}, {"text": "psychiatric genetics", "sentiment": {"score": -0.344548, "mixed": "1", "label": "negative"}, "relevance": 0.549139, "count": 2}, {"text": "Recent developments", "sentiment": {"score": 0.494988, "label": "positive"}, "relevance": 0.54381, "count": 1}, {"text": "advances", "sentiment": {"score": 0.494988, "label": "positive"}, "relevance": 0.54351, "count": 1}, {"text": "Professor Sir Michael Owen", "sentiment": {"score": -0.430193, "label": "negative"}, "relevance": 0.543355, "count": 1}, {"text": "early adulthood", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540851, "count": 1}, {"text": "Schizophrenia", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539826, "count": 1}, {"text": "genomic understanding of the disease", "sentiment": {"score": -0.927143, "label": "negative"}, "relevance": 0.539539, "count": 1}, {"text": "expertise", "sentiment": {"score": -0.54109, "label": "negative"}, "relevance": 0.538236, "count": 1}, {"text": "partnership", "sentiment": {"score": -0.6318, "mixed": "1", "label": "negative"}, "relevance": 0.535986, "count": 2}, {"text": "November", "sentiment": {"score": -0.54109, "label": "negative"}, "relevance": 0.53561, "count": 1}, {"text": "neuropsychiatric disorders", "sentiment": {"score": 0.562674, "label": "positive"}, "relevance": 0.53398, "count": 1}, {"text": "World Health Organisation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529175, "count": 1}, {"text": "Therapeutic progress", "sentiment": {"score": -0.430193, "label": "negative"}, "relevance": 0.528369, "count": 1}, {"text": "Mental Health", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527831, "count": 1}, {"text": "genomic data", "sentiment": {"score": -0.54109, "label": "negative"}, "relevance": 0.526575, "count": 1}, {"text": "lack of understanding of their primary causes", "sentiment": {"score": 0.291301, "mixed": "1", "label": "positive"}, "relevance": 0.526351, "count": 1}, {"text": "conditions", "sentiment": {"score": -0.430193, "label": "negative"}, "relevance": 0.526208, "count": 1}, {"text": "world", "sentiment": {"score": -0.927143, "label": "negative"}, "relevance": 0.522702, "count": 1}, {"text": "patients", "sentiment": {"score": -0.927143, "label": "negative"}, "relevance": 0.522104, "count": 1}, {"text": "MRC Centre", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521977, "count": 1}, {"text": "access", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521529, "count": 1}, {"text": "\u00d7 Expand Mental Health", "sentiment": {"score": -0.54109, "label": "negative"}, "relevance": 0.520433, "count": 1}, {"text": "ambition", "sentiment": {"score": 0.541848, "label": "positive"}, "relevance": 0.51892, "count": 1}, {"text": "obstacles", "sentiment": {"score": 0.494988, "label": "positive"}, "relevance": 0.518792, "count": 1}, {"text": "people", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518433, "count": 1}, {"text": "clinical neuropsychiatric experts", "sentiment": {"score": -0.927143, "label": "negative"}, "relevance": 0.512, "count": 1}, {"text": "new wave of medicines", "sentiment": {"score": -0.927143, "label": "negative"}, "relevance": 0.507679, "count": 1}, {"text": "biological psychiatry research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507399, "count": 1}, {"text": "major genetic advances", "sentiment": {"score": 0.533292, "label": "positive"}, "relevance": 0.505542, "count": 1}]}, "extracted_metadata": {"sha1": "a7a58c255ac9fa17a5410aac90bbf8a25ddc50e8", "filename": "1542640449239.zip-2924f06d958ca5b37daf59d07b22c972.xml", "file_type": "json"}, "external_links": ["http://www.facebook.com/2008/fbml", "http://www.who.int/news-room/fact-sheets/detail/mental-disorders"], "title": "Cardiff University teams up with Takeda to treat psychiatric disorders", "forum_title": "European Pharmaceutical Manufacturer Magazine - News for the pharma and drugs industry"}, {"id": "RrYbpxaKTzB1FltrSEpSglT_R37UuiIxnBk5TlfRY3O73921VqWpLqCaI-uu861R", "result_metadata": {"score": 30.977888}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management UK", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.92115, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.607673, "label": "/finance/investing/brokerages"}, {"score": 0.605701, "label": "/finance/investing/funds/mutual funds"}, {"score": 0.597169, "label": "/finance/bank"}], "relations": [{"type": "agentOf", "sentence": "Daiwa Asset Management UK Regulatory Announcement: Form 8.3 - Takeda Pharmaceutical Company Limited", "score": 0.991221, "arguments": [{"text": "Daiwa Asset Management UK Regulatory", "location": [0, 36], "entities": [{"type": "Organization", "text": "Daiwa Asset Management UK Regulatory", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Announcement", "location": [37, 49], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}], "keywords": [{"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.741197, "count": 1}, {"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.711277, "count": 1}, {"text": "Daiwa Asset Management UK Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.466409, "count": 1}]}, "crawl_date": "2018-11-20T12:07:59Z", "url": "https://www.businesswire.com/news/home/20181119005948/en/Daiwa-Asset-Management-UK-Regulatory-Announcement-Form", "host": "businesswire.com", "text": "Ltd.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-20T07:00:00-06:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management Co. Ltd", "relevance": 0.73398, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management", "relevance": 0.645192, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management Europe", "relevance": 0.626669, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.569229, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.546351, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.250646, "label": "positive"}, "text": "Erich Berner", "relevance": 0.530653, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.502247, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.498168, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.491578, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.491578, "type": "Quantity"}], "sentiment": {"document": {"score": 0.48122, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "19 November 2018 (f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " 19 November 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Details, including nature of the rights concerned and relevant percentages: N/A", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "increasing/reducing a long/short position", "keywords": [{"text": "long/short position"}]}, "sentence": " Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position", "object": {"text": "e.g. opening/closing a long/short position", "keywords": [{"text": "long/short position"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit - - - - - - - - (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit - - - - - (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " None (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020-7597-7056 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "020-7597-7056 Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "*If the discloser", "keywords": [{"text": "discloser"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "a natural person", "keywords": [{"text": "natural person"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a natural person, a telephone number", "keywords": [{"text": "natural person"}, {"text": "telephone number"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "provided to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "provided contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "has been provided", "normalized": "have be provide"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: Daiwa Asset Management Category Code: RET Sequence Number: 659636 Time of Receipt (offset from UTC): 20181120T010141+0000 Contacts Daiwa Asset Management", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.945778, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Offer and acceptance", "relevance": 0.507067, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Call option", "relevance": 0.503676, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.486225, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Contract", "relevance": 0.448837, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.408328, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Grammatical number", "relevance": 0.399664, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Bond", "relevance": 0.393056, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Unit type", "relevance": 0.372346, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Option contract", "relevance": 0.371859, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Balance sheet", "relevance": 0.367195, "dbpedia_resource": "http://dbpedia.org/resource/Balance_sheet"}, {"text": "Security", "relevance": 0.36273, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Stock", "relevance": 0.362044, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.351963, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Uniform Commercial Code", "relevance": 0.34602, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Legal person", "relevance": 0.33923, "dbpedia_resource": "http://dbpedia.org/resource/Legal_person"}, {"text": "Security", "relevance": 0.338856, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}], "categories": [{"score": 0.921232, "label": "/real estate/buying and selling homes"}, {"score": 0.834144, "label": "/finance/financial news"}, {"score": 0.708277, "label": "/finance/investing/day trading"}], "relations": [{"type": "populationOf", "sentence": "LONDON- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.504392, "arguments": [{"text": "8.3", "location": [13, 16], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "basedIn", "sentence": "Short Name: Daiwa Asset Management Category Code: RET Sequence Number: 659636 Time of Receipt (offset from UTC): 20181120T010141+0000 Contacts Daiwa Asset Management", "score": 0.434823, "arguments": [{"text": "UTC", "location": [5797, 5800], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [5776, 5783], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}, {"type": "managerOf", "sentence": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Company Limited (the Offeror) (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 19 November 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "score": 0.463222, "arguments": [{"text": "manager", "location": [700, 707], "entities": [{"type": "Person", "text": "manager"}]}, {"text": "Takeda Pharmaceutical Company Limited", "location": [626, 663], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "(a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit ORD Sale 10,700 4438.8663 JPY ORD Purchase 800 4293 JPY ORD Purchase 300 4441.9766 JPY (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit - - - - - (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit - - - - - -", "score": 0.787954, "arguments": [{"text": "i", "location": [3278, 3279], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [3281, 3288], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "- - (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit - - - - - (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) - - - - 4.", "score": 0.591687, "arguments": [{"text": "Price", "location": [3904, 3909], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3914, 3918], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4286, 4292], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4303, 4310], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 20 November 2018 Contact name: Erich Berner (Daiwa Asset Management Europe) Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.545365, "arguments": [{"text": "Erich Berner", "location": [5122, 5134], "entities": [{"type": "Person", "text": "Erich Berner"}]}, {"text": "Daiwa Asset Management Europe", "location": [5136, 5165], "entities": [{"type": "Organization", "text": "Daiwa Asset Management Europe", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 20 November 2018 Contact name: Erich Berner (Daiwa Asset Management Europe) Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.842228, "arguments": [{"text": "Rule 8", "location": [5225, 5231], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5239, 5243], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5306, 5330], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5298, 5303], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.", "score": 0.83842, "arguments": [{"text": "Market Surveillance Unit", "location": [5585, 5609], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5577, 5582], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5641, 5646], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5660, 5687], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.755009, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.683417, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.622792, "count": 2}, {"text": "relevant securities", "sentiment": {"score": 0.685089, "label": "positive"}, "relevance": 0.617484, "count": 3}, {"text": "Full name of discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.606406, "count": 1}, {"text": "Short positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.604662, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.578589, "count": 3}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.574715, "count": 1}, {"text": "PERSON", "sentiment": {"score": 0.54238, "label": "positive"}, "relevance": 0.572446, "count": 2}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.571342, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.567184, "count": 2}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.565643, "count": 1}, {"text": "Telephone number", "sentiment": {"score": -0.908997, "label": "negative"}, "relevance": 0.563113, "count": 1}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561852, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.556005, "count": 1}, {"text": "unit ORD Sale", "sentiment": {"score": 0.865913, "label": "positive"}, "relevance": 0.549482, "count": 1}, {"text": "Details", "sentiment": {"score": 0.704735, "label": "positive"}, "relevance": 0.547743, "count": 1}, {"text": "natural person", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.544022, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.541685, "count": 1}, {"text": "November", "sentiment": {"score": -0.908997, "label": "negative"}, "relevance": 0.540924, "count": 2}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.540636, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.704735, "label": "positive"}, "relevance": 0.540636, "count": 1}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.540581, "count": 2}, {"text": "disclosure", "sentiment": {"score": 0.814317, "label": "positive"}, "relevance": 0.540169, "count": 4}, {"text": "options", "sentiment": {"score": 0.343063, "mixed": "1", "label": "positive"}, "relevance": 0.540163, "count": 4}, {"text": "Code", "sentiment": {"score": -0.612444, "mixed": "1", "label": "negative"}, "relevance": 0.539165, "count": 3}, {"text": "Owner", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.538366, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.537974, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.537784, "count": 1}, {"text": "unit", "sentiment": {"score": 0.478033, "mixed": "1", "label": "positive"}, "relevance": 0.537505, "count": 4}, {"text": "Purchases", "sentiment": {"score": 0.865913, "label": "positive"}, "relevance": 0.536726, "count": 1}, {"text": "person", "sentiment": {"score": 0.814317, "label": "positive"}, "relevance": 0.536415, "count": 4}, {"text": "telephone number", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.535777, "count": 1}, {"text": "Sequence Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533061, "count": 1}, {"text": "offer", "sentiment": {"score": 0.618287, "mixed": "1", "label": "positive"}, "relevance": 0.5323, "count": 3}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53216, "count": 1}, {"text": "arrangements", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.530939, "count": 3}, {"text": "currency of all prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529414, "count": 1}, {"text": "sale Number of securities Price", "sentiment": {"score": 0.865913, "label": "positive"}, "relevance": 0.529289, "count": 1}, {"text": "voting rights", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.529029, "count": 1}, {"text": "Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527826, "count": 1}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527354, "count": 1}, {"text": "agreement", "sentiment": {"score": 0.814317, "label": "positive"}, "relevance": 0.527087, "count": 2}, {"text": "understandings", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.527077, "count": 3}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.526895, "count": 1}, {"text": "DISCLOSURE", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.526811, "count": 2}, {"text": "Class of relevant security", "sentiment": {"score": 0.704735, "label": "positive"}, "relevance": 0.526485, "count": 2}, {"text": "derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526361, "count": 2}, {"text": "state", "sentiment": {"score": -0.5347, "label": "negative"}, "relevance": 0.526057, "count": 1}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525857, "count": 1}]}, "extracted_metadata": {"sha1": "a80592236f0288d9e4540312b8397dede31328ec", "filename": "1542715679076.zip-acdc8fcd9fa4a86cf180dd3b9a10d240.xml", "file_type": "json"}, "title": "Daiwa Asset Management UK Regulatory Announcement: Form 8.3 - Takeda Pharmaceutical Company Limited", "forum_title": "All News | Business Wire"}]}